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Background: Gestational diabetes mellitus (GDM) is associated with a higher risk of important adverse
outcomes. Practice varies and the best strategy for identifying and treating GDM is unclear.
Aim: To estimate the clinical effectiveness and cost-effectiveness of strategies for identifying and treating
women with GDM.
Methods: We analysed individual participant data (IPD) from birth cohorts and conducted systematic
reviews to estimate the association of maternal glucose levels with adverse perinatal outcomes; GDM
prevalence; maternal characteristics/risk factors for GDM; and the effectiveness and costs of treatments.
The cost-effectiveness of various strategies was estimated using a decision tree model, along with a value
of information analysis to assess where future research might be worthwhile. Detailed systematic searches
of MEDLINE® and MEDLINE In-Process & Other Non-Indexed Citations®, EMBASE, Cumulative Index to
Nursing and Allied Health Literature Plus, Cochrane Central Register of Controlled Trials, Cochrane
Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Health Technology
Assessment database, NHS Economic Evaluation Database, Maternity and Infant Care database and the
Cochrane Methodology Register were undertaken from inception up to October 2014.
Results: We identified 58 studies examining maternal glucose levels and outcome associations. Analyses
using IPD alone and the systematic review demonstrated continuous linear associations of fasting and
post-load glucose levels with adverse perinatal outcomes, with no clear threshold below which there is no
increased risk. Using IPD, we estimated glucose thresholds to identify infants at high risk of being born
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large for gestational age or with high adiposity; for South Asian (SA) women these thresholds were fasting
and post-load glucose levels of 5.2 mmol/l and 7.2 mmol/l, respectively and for white British (WB) women
they were 5.4 and 7.5 mmol/l, respectively. Prevalence using IPD and published data varied from 1.2% to
24.2% (depending on criteria and population) and was consistently two to three times higher in SA women
than in WB women. Lowering thresholds to identify GDM, particularly in women of SA origin, identifies
more women at risk, but increases costs. Maternal characteristics did not accurately identify women with
GDM; there was limited evidence that in some populations risk factors may be useful for identifying low-risk
women. Dietary modification additional to routine care reduced the risk of most adverse perinatal
outcomes. Metformin (Glucophage,® Teva UK Ltd, Eastbourne, UK) and insulin were more effective than
glibenclamide (Aurobindo Pharma – Milpharm Ltd, South Ruislip, Middlesex, UK). For all strategies to
identify and treat GDM, the costs exceeded the health benefits. A policy of no screening/testing or
treatment offered the maximum expected net monetary benefit (NMB) of £1184 at a cost-effectiveness
threshold of £20,000 per quality-adjusted life-year (QALY). The NMB for the three best-performing
strategies in each category (screen only, then treat; screen, test, then treat; and test all, then treat) ranged
between –£1197 and –£1210. Further research to reduce uncertainty around potential longer-term benefits
for the mothers and offspring, find ways of improving the accuracy of identifying women with GDM, and
reduce costs of identification and treatment would be worthwhile.
Limitations: We did not have access to IPD from populations in the UK outside of England. Few
observational studies reported longer-term associations, and treatment trials have generally reported only
perinatal outcomes.
Conclusions: Using the national standard cost-effectiveness threshold of £20,000 per QALY it is not
cost-effective to routinely identify pregnant women for treatment of hyperglycaemia. Further research to
provide evidence on longer-term outcomes, and more cost-effective ways to detect and treat GDM, would
be valuable.
Study registration: This study is registered as PROSPERO CRD42013004608.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
When a woman is pregnant, hormonal changes cause blood glucose (sugar) levels to increase so thather infant can grow and develop. For some women glucose levels become too high; this is called
gestational diabetes mellitus (GDM). The babies of these women can grow excessively, be larger and
fatter at birth, and therefore have more complications during birth. Doctors, midwives and researchers are
worried that babies of these mothers might be fatter and at greater risk of diabetes and heart disease later
in life. It is not clear how GDM should be diagnosed or treated to try and prevent these problems.
Therefore, we undertook research to find out the best way of diagnosing and treating GDM.
We found that the risk of having a larger baby and having complications around the time of birth increased
with each greater level of blood glucose in the mother. We showed that more babies at risk of being too
large and having problems at birth would be identified if a lower level of glucose was used to diagnose
GDM. This was particularly the case for South Asian women. Once a woman is diagnosed with GDM,
changing her diet, and treatment with a tablet called metformin or insulin injections will all reduce the risk
of having a large baby and pregnancy complications. However, the identification and treatment of women
with GDM using the currently recommended cost-effectiveness threshold is not the best-performing
strategy. So far there have not been any large studies that have looked at whether or not GDM really does
cause longer-term problems for children, and, if so, whether or not treatments will help reduce these
problems. Further research is needed to evaluate the longer-term effects of identifying and treating GDM.
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Scientific summary
Background
Gestational diabetes mellitus (GDM) is associated with an increased risk of important adverse perinatal
outcomes, including macrosomia and birth injury, and there is limited evidence that longer-term health of
women and their offspring may also be compromised.
Over recent years there has been considerable debate about the relative effectiveness of different methods
for identifying women with GDM. The identification of a treatment threshold for GDM has proved
challenging. In 2010, using data from the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study,
which reported graded linear associations of fasting and post-load glucose levels with the majority of adverse
primary and secondary outcomes, the International Association of Diabetes and Pregnancy Study Groups
(IADPSG) recommended new thresholds for diagnosing GDM. The aim of these new glucose thresholds is to
identify obesity risk by identifying infants who are large for gestational age (LGA), have more adipose tissue
at birth, and who have high cord blood C-peptide levels (as opposed to identifying women at risk of type 2
diabetes). In 2013, the World Health Organization (WHO), whose previous criteria for diagnosing GDM have
been widely adopted, endorsed the IADPSG criteria thresholds. The shift in the aim of diagnosing GDM from
one of identifying women at risk of type 2 diabetes to one of identifying risk of future offspring obesity is
particularly important for South Asian (SA) women, as their infants, in comparison with white Europeans,
have markedly lower birthweight (BW) and reduced risk of LGA, but this lower BW masks a propensity to
greater adiposity and associated cardiometabolic risk. It is unclear whether the association of glucose levels
with perinatal outcomes is the same for SA and white British (WB) women or if the IADPSG criteria for
diagnosing GDM should also be the same in SA women, who are at higher risk of GDM than white
Europeans. HAPO was a large well designed study; however, it is unclear to what extent the association
between glucose levels and adverse outcomes has been investigated by other studies, and, if there are other
studies, whether or not these provide additional evidence that can be used to inform criteria.
Changing or lowering diagnostic thresholds will influence the prevalence of GDM in a given population.
Prevalence estimates are also influenced by the screening strategy used (selective or universal), and, if
selective, the method of selecting women for testing (e.g. the number and/or type of risk factor) and also
the characteristics of the population being screened. It is unclear what the prevalence of GDM is in the UK
and Ireland when different criteria are applied and whether or not prevalence differs by ethnicity. Certain
maternal characteristics/risk factors, including advancing age and obesity, are associated with increased risk
of GDM. The performance of these characteristics has been questioned over recent years, with some
clinical guidelines recommending universal testing for GDM. Universal testing, however, might incur
increased health service costs with little additional health benefit over selective testing, and so it is
therefore important to examine the performance of risk factors [the UK National Institute for Health and
Care Excellence (NICE) recommended screening strategy] to identify those at increased risk of GDM.
Treatment of GDM aims to reduce associated risks by reducing hyperglycaemia. Treatment seems to reduce
the risk of adverse perinatal outcomes, although the effects on longer-term health are more uncertain.
There are various treatment options available, including diet modification and pharmacological interventions
[metformin (hydrochloride) (Glucophage,® Teva UK Ltd, Eastbourne, UK), glibenclamide (Aurobindo Pharma –
Milpharm Ltd, South Ruislip, Middlesex, UK) and insulin], with, currently, no clear indication as to which
treatment strategy is most effective. A key issue surrounding GDM is determining the most clinically
effective and cost-effective strategy for identification and treatment of hyperglycaemia.
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Aim
The overall aim of this research was to estimate the cost and clinical effectiveness of strategies for identifying
and treating women with GDM in order to improve the associated adverse health outcomes for mothers
and their infants. Our specific objectives were to determine (1) the risk of adverse outcomes associated with
graded increases in maternal glucose level and derive thresholds for diagnosing GDM in SA and WB women;
(2) the prevalence of GDM in the UK and Ireland; (3) the effectiveness (sensitivity, specificity, acceptability
and costs) of maternal characteristics to accurately identify women at risk of GDM; (4) the most effective
treatments for GDM for reducing the risk of adverse perinatal outcomes; and (5) the most cost-effective and
clinically effective strategy for identifying and treating GDM.
Methods
Data sources used to address these objectives were:
1. Individual participant data (IPD) from (1) the Born in Bradford (BiB) study, a large cohort of SA and WB
women; (2) the Atlantic Diabetes in Pregnancy (Atlantic DIP) study; and (3) Warwick/Coventry hospitals.
2. Summary results from detailed systematic searches of MEDLINE® and MEDLINE In-Process & Other
Non-Indexed Citations®, EMBASE, Cumulative Index to Nursing and Allied Health Literature Plus,
Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Database of
Abstracts of Reviews of Effects, Health Technology Assessment database, NHS Economic Evaluation
Database, Maternity and Infant Care database and the Cochrane Methodology Register, from inception
up to October 2014.
Multivariable logistic regression was used to examine potential differences between SA and WB women
in the associations of fasting and post-load glucose levels with adverse perinatal outcomes. The IADPSG
methods were used to determine diagnostic thresholds in the two groups. Systematic reviews were
conducted using standard methods to identify relevant studies examining associations of fasting and
post-load glucose levels with adverse perinatal and longer-term outcomes, GDM prevalence, risk factors
for GDM, treatments and costs. Meta- and network-analyses were conducted when appropriate.
A decision tree model was developed to evaluate the cost-effectiveness of alternative strategies of combined
screening, diagnosis and treatment of hyperglycaemia during pregnancy following the perspective of the UK
NHS and Personal and Social Services for both costs and outcomes [quantified as quality-adjusted life-years
(QALYs)]. Discounting was not applied to the base-case analysis, given that the time horizon was < 1 year
(3 months). Future costs and QALYs accrued after 1 year, included in sensitivity analysis, were discounted at
3.5% annual rate. Probabilistic sensitivity analysis and scenario analysis were performed to characterise and
incorporate uncertainty in the analysis. Subgroup analysis was conducted for two subgroups: SA and
other ethnicity.
Results
Associations of gestational fasting and post-load glucose levels in women without
existing or gestational diabetes with perinatal and longer-term outcomes
Our systematic review identified 58 eligible studies; 38 were included in meta-analyses (including the BiB
study and Atlantic DIP study), 28 examined at least three glucose levels and associated risk of adverse
perinatal outcomes, 20 examined two glucose level ranges, and five studies reported associations with
longer-term outcomes. In analyses from the BiB study alone and the systematic review we found evidence
of graded linear associations of fasting and post-load glucose levels with adverse perinatal outcomes.
Associations between glucose levels and outcomes were broadly similar for SA and WB women, although
the association with LGA appeared stronger in SA than WB women. The frequency of ‘LGA’ was greater for
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WB women than for SA women; however, ‘sum of skinfolds > 90th percentile’ and ‘Caesarean section’
were similar. Associations were stronger for fasting glucose levels than for 2-hour post-load glucose levels.
For example, from the systematic review (combining fasting glucose results from both the 75-g and 100-g
studies), for macrosomia the odds ratio (OR) for every 1-mmol/l increase in fasting glucose level (six studies)
was 2.06 [95% confidence interval (CI) 1.86 to 2.28], whereas for the 2-hour glucose level (combining
post-load glucose results from both the 75-g and 100-g studies) (seven studies) the OR was 1.21 (95% CI
1.16 to 1.26). There was no robust evidence for a non-linear association between glucose level and log OR
of any outcome, and therefore there was no clear threshold below which there was no increased risk.
Three published studies examined longer-term infant outcomes: one study, diabetes between the ages
of 2 and 24 years (552 participants); one study, childhood obesity between the ages of 5 and 7 years
(9439 participants); and one study, overweight and obesity at age 2 years (1165 participants).
In the BiB study, our analyses demonstrated no clear threshold below which there was no increase in risk
of an adverse outcome. Using the methods operated by the IADPSG we produced glucose thresholds to
identify infants at risk of being LGA or with high levels of adiposity {OR of 1.75 above mean maternal
glucose levels [at oral glucose tolerance test (OGTT) for these outcomes]}. Irrespective of ethnicity, these
thresholds were as follows: fasting glucose level of 5.3 mmol/l and 2-hour post-load glucose level of
7.5 mmol/l, and corresponding ethnic-specific thresholds of 5.2 and 7.2 mmol/l for SA women,
and 5.4 and 7.5 mmol/l for WB women.
Prevalence of gestational diabetes
In the BiB study, we applied six different criteria that have been proposed for diagnosing GDM, including
the criteria we derived, those recently suggested by NICE, and the IADPSG criteria. Prevalence varied from
1.2% to 8.7% in WB women and from 4.1% to 24.2% in SA women, prevalence being consistently two
to three times higher in SA women than in WB women. Consistent with these findings in the systematic
review/meta-analyses the prevalence in UK/Ireland varied between 1% and 24% depending on maternal
characteristics (including ethnicity) and the criteria used to define GDM.
Maternal characteristics (risk factors) to identify women at increased risk of
gestational diabetes
Two IPD cohorts and 29 published studies were included. Studies examined individual risk factors, risk
prediction models and guideline recommendations. None of these accurately predicted GDM. Performance
varied by risk factor; for example, in the BiB study the sensitivity and specificity of GDM in a previous
pregnancy was 6.0% and 99.3%, respectively. However, this risk factor identifies fewer women because
the incidence is lower than that in, for example, women from an ethnic group with a high prevalence of
GDM (sensitivity and sensitivity using BiB study data 76.3% and 40.6%, respectively). There was some
evidence that in some populations characteristics/risk factors could identify low-risk women accurately and
in those populations risk factors might be useful for identifying women who do not require diagnostic
tests.
Treatments for gestational diabetes
Forty-eight trials were included. Dietary modification (possibly alongside glucose monitoring and
supplemental insulin if needed) compared with routine antenatal care was effective in reducing the risk of
the majority of reported adverse outcomes. For example, macrosomia (nine trials) relative risk (RR) of 0.46
[95% CI 0.36 to 0.60 (I2 = 33%)] and Caesarean section (eight trials) RR of 0.86 [CI 0.77 to 0.95 (I2 = 3%)].
Metformin appeared as effective as insulin at reducing the risk of most adverse outcomes, and for some
outcomes, macrosomia for example, was more effective [RR 0.75, 95% CI 0.57 to 0.96 (I2 = 0%)]. From the
network meta-analyses, both insulin and metformin appeared to be more effective than glibenclamide
(macrosomia: glibenclamide vs. insulin OR 3.43, 95% CI 1.32 to 8.91; and glibenclamide vs. metformin OR
5.36, 95% CI 1.86 to 15.59), although the small number of trials for these comparisons means that the CIs
are wide and include the null value for most effect estimates. We found similar effectiveness when differing
insulin preparations were compared. Few trials included reported negative treatment effects, such as
satisfaction or side effects.
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Cost-effectiveness of screening, diagnosis and treatment of gestational diabetes
Our economic evaluation showed that for all strategies to identify and treat GDM, the costs exceeded
the health benefits. A policy of no screening/testing or treatment offered the maximum expected net
monetary benefit (NMB) of –£1184 at a cost-effectiveness threshold of £20,000. The NMB for the three
best-performing strategies in each category (screen only then treat; screen, test, then treat; and test all,
then treat) ranged between –£1197 and –£1210.
Results were robust to sensitivity analysis. Because longer-term health benefits within the model are estimated
with considerable uncertainty, the higher cost-effectiveness threshold of £30,000 might not be applicable.
Limitations
Studies and trials included in our systematic reviews and meta-analyses varied considerably in terms of
size, population, inclusion criteria, treatments and outcomes reported and we found evidence of statistical
heterogeneity, with the I2 value varying from 0% to 77% in different meta-analyses. Criteria thresholds
used to diagnose GDM varied and therefore trial populations included women with varying degrees of
hyperglycaemia, potentially influencing treatment effects, prevalence and risk factor performance estimates.
Some comparisons included few trials and/or participants and therefore results may be imprecisely estimated.
Conclusions
There is a graded positive association of glucose level with adverse perinatal outcomes in different
populations, including both SA and WB women. Our findings suggest that applying lower thresholds for
identifying GDM – particularly in women of SA origin – than those in current practice in the UK will increase
prevalence, but would identify more of those at risk of adverse perinatal outcomes. Maternal risk factors do
not accurately identify those at risk of GDM, but may be valuable for predicting those at very low risk,
who do not require diagnostic testing, in some populations. Treatment of GDM with diet (with glucose
monitoring and supplemental insulin if needed) reduces the risk of most adverse outcomes, and metformin
or insulin is effective at reducing the risk of most adverse perinatal outcomes. These findings support the
‘step-up’ approach, for which, in most cases, lifestyle modification is the first-line treatment, with metformin
and/or insulin added as required.
The aim of diagnosing GDM has shifted from identifying women at risk of type 2 diabetes to identifying
offspring who are at future risk of longer-term greater adiposity and cardiometabolic ill health. Our research
shows an absence of evidence to support the assumption that treatment will reduce any longer-term effects.
There is a balance between costs and improved perinatal and any longer-term health impacts from the
application of different diagnostic criteria and treatments. We found that at a cost-effectiveness threshold of
£20,000 per QALY it is not cost-effective to identify women for treatment for hyperglycaemia, even in the
scenario in which longer-term outcomes are incorporated into the model. It is only with the inclusion of longer-
term health outcomes and at cost-effectiveness thresholds of > £24,000 per QALY that net health benefits are
improved by intervening. Given the uncertainty surrounding the estimation of longer-term outcomes, and that
only when these are incorporated into our economic model are health benefits improved, further research in
this area would be useful to help determine the potential cost-effectiveness of intervening in GDM.
Study registration
This study is registered as PROSPERO CRD42013004608.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Normal pregnancy is associated with insulin resistance that is similar to that found in type 2 diabetes.Physiological resistance to insulin action during pregnancy becomes apparent in the second trimester,
and insulin resistance increases progressively to term. These changes facilitate transport of glucose across
the placenta to ensure normal fetal growth and development. Transfer of glucose across the placenta
stimulates fetal pancreatic insulin secretion, and insulin acts as an essential growth hormone. However, if
resistance to maternal insulin action becomes too pronounced then maternal hyperglycaemia occurs and
gestational diabetes mellitus (GDM) may be diagnosed.
Associated risks
Gestational diabetes mellitus is associated with an increased risk of adverse perinatal outcomes, including
large-for-gestational-age (LGA) birthweight (BW), macrosomia (defined as BW of > 4 kg) and Caesarean
section (C-section).1 There is also limited evidence that GDM is associated with increased risk of longer-term
ill health outcomes in the mother (e.g. type 2 diabetes and cardiovascular disease)2,3 and offspring
(e.g. obesity and associated cardiometabolic risk).4,5
Recently, the Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study6 examined the association
between gestational fasting and post-load glucose levels in women without diabetes. These findings have
been used by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) to inform
their criteria to diagnose GDM. The HAPO study6 reported graded linear increases in the odds of four
primary outcomes (BW of > 90th centile for gestational age, primary C-section, diagnosed neonatal
hypoglycaemia and cord blood C-peptide of > 90th percentile) across the whole distribution of fasting and
post-load glucose levels, illustrating no clear threshold below which there is no increase in risk. There were
also graded monotonic associations with a majority of secondary outcomes, including preterm birth,
shoulder dystocia and pre-eclampsia. However, there were limited numbers of South Asian (SA) women
included and no SA centres. In Chapters 2 and 3 we report analyses (using similar methods to those used by
the HAPO study6) using individual participant data (IPD) and data from published studies to determine the
risk of adverse outcomes associated with graded increases in maternal glucose levels, in the BiB study,7
to determine the differences in risk between SA and white British (WB) women, and, in IPD and published
studies, combined, for all women.
Screening
An important question regarding the diagnosis of GDM is what glucose thresholds (fasting or post load)
are most clinically effective and cost-effective. Appropriate identification of women who develop GDM is
essential so that treatment can be provided to reduce the associated risks. However, diagnosis is complex
and there are a number of different criteria with different thresholds used internationally and nationally
(Table 1). This lack of a clear threshold to signify increased risk means that somewhat arbitrary thresholds
need to be used to define GDM, an issue that is similar to the diagnosis of type 2 diabetes, hypertension
and dyslipidaemia [which, like GDM, are diagnoses made to indicate risk of later disease (cardiovascular
disease for these exposures) that might be prevented by appropriate intervention (lifestyle change and
medication)]. In Chapters 2–4 we report details of our derived thresholds using IPD and published data for
diagnosing GDM and prevalences using past and current criteria.
There are two main strategies to identify women with GDM: (1) universal testing, through which all women
are offered a diagnostic test [usually an oral glucose tolerance test (OGTT)]; or (2) selective testing, through
which those women identified as having an increased risk of developing GDM are offered a diagnostic test.
The second strategy is closer to the more usual screening model described by the UK National Screening
Committee (NSC).17
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Once risk is identified (in universal screening/selective testing), those at high risk (however defined) will be
offered a diagnostic test (usually an OGTT) and, depending on those results, will be given advice and/or
medical treatment or not.17 Screening is therefore undertaken to (1) identify those women at greatest risk,
to prevent unnecessary diagnostic testing of those women unlikely to develop GDM, and (2) reduce costs
associated with universal diagnostic testing.
Several health-care agencies including the UK National Institute for Health and Care Excellence (NICE)18
recommend that pregnant women should have their risk evaluated by assessment of maternal characteristics
(risk factors) (see Table 14). Those with one or more risk factor should be offered a diagnostic OGTT.
Chapter 5 of this report examines the accuracy of maternal characteristics as risk factors for the identification of
women who are most likely to develop GDM. We have examined the performance of maternal characteristics,
first using IPD, and second using published data. Maternal risk factors for GDM include advanced maternal
age, high body mass index (BMI), previous GDM, previous macrosomic infant, family history of type 2 diabetes
or GDM (in a previous pregnancy), and ethnicity with a high associated prevalence of diabetes. We have
chosen to focus on maternal characteristics (and not to include invasive screening tests, including blood tests)
because this strategy is recommended for use by several agencies including NICE.19
Diagnostic testing
Gestational diabetes mellitus is generally diagnosed using an OGTT. The OGTT is normally conducted in
the morning following an overnight fast. A baseline plasma glucose sample is obtained; the woman then
consumes a drink containing typically 75 g or 100 g of glucose and then at hourly intervals plasma glucose
level is measured. The frequency of measurement depends on the glucose load and local policy. Women
with an ‘elevated’ glucose level at one or two or more measurements are classified as having GDM.
There are some limitations to the OGTT as a diagnostic test, however: (1) a negative OGTT does not mean a
woman will not develop GDM later in pregnancy, because as gestation progresses, insulin resistance may
increase, therefore repeat glucose testing may be required; (2) glucose thresholds for diagnosis are arbitrary
cut-off points and vary depending on the recommending agencies (see Table 1); and (3) the reproducibility of
the OGTT is only around 75%20,21 (we have not examined the performance of the OGTT within this report).
TABLE 1 Current and previous criteria recommended to diagnose GDM (plasma glucose levels in mmol/l)
Criteria Fasting 1-hour post load 2-hour post load 3-hour post load
75-g OGTT (plasma glucose)
aIADPSG8 (2010), ADIPS9 (2013), WHO10 (2013) ≥ 5.1 ≥ 10.0 ≥ 8.5 –
aWHO11 (1999) ≥ 6.1 – ≥ 7.8 –
aADA12 (2006) ≥ 5.3 ≥ 10.0 ≥ 8.6
aADIPS13 (1998) ≥ 5.5 – ≥ 8.0 –
100-g OGTT (plasma or serum glucose)
bACOG14/C&C ≥ 5.3 ≥ 10.0 ≥ 8.6 ≥ 7.8
bNDDG15 ≥ 5.8 ≥ 10.6 ≥ 9.2 ≥ 8.0
bO’Sullivan16 ≥ 5.0 ≥ 9.2 ≥ 8.1 ≥ 6.9
ACOG, American College of Obstetricians and Gynecologists; ADA, American Diabetes Association; ADIPS, Australasian
Diabetes in Pregnancy Society; C&C, Carpenter and Coustan; OGTT, oral glucose tolerance test; NDDG, National Diabetes
Data Group; WHO, World Health Organization.
a One threshold should be met or exceeded for GDM to be diagnosed.
b Two thresholds should be met or exceeded for GDM to be diagnosed.
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Treatments for gestational diabetes
Treatment of GDM aims to reduce hyperglycaemia and, in doing so, reduce the risk of adverse outcomes.
Diet/lifestyle modification is often used as first-line treatment; if this does not adequately reduce and
control glucose levels or if glucose level is substantially elevated then pharmacological interventions [e.g.
metformin (hydrochloride) (Glucophage,® Teva UK Ltd, Eastbourne, UK) and/or insulin] may also be given.
Oral agents, including metformin and glibenclamide (Aurobindo Pharma – Milpharm Ltd, South Ruislip,
Middlesex, UK), present a possible alternative to injected insulin and may be as effective, with the added
benefit of being more acceptable to women.
Chapter 6 reports a systematic review investigating the effectiveness of different treatments for GDM to
improve maternal and infant health outcomes. Meta- and network-analyses have been carried out
where appropriate.
Economic evaluation
Chapter 7 details an economic evaluation of screening and diagnostic tests to identify and treat women
with GDM. Current evidence on the cost-effectiveness of identifying and treating women with GDM is
limited; the increasing prevalence of GDM, however, along with increasing demands on health service
budgets, makes this evaluation central to the future planning of care pathways and resource allocation.
We also report analyses in this chapter that examine the value of undertaking further research to
understand the effects of treatments of GDM.
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3

Chapter 2 Hyperglycaemia and the risk of adverse
perinatal outcomes in South Asian and white British
women: the Born in Bradford cohort
This chapter presents the methods and results of a study to determine the nature of the associationbetween maternal pregnancy glucose levels and risk of perinatal outcomes using IPD from the Born in
Bradford (BiB) study.22 This study7 compares the associations of gestational glucose level with risk of
adverse perinatal outcomes between SA and WB women (unless shown within the text sections, figures
and tables are shown in the appendices and referred to within the text). A version of this chapter has been
published in Farrar et al.7 This is an Open Access article under the terms of the Creative Commons
Attribution License (CC BY), which permits use, distribution and reproduction, provided the original work is
properly cited (https://creativecommons.org/licenses/by/4.0/).
Introduction
Gestational diabetes increases the risk of several adverse perinatal outcomes.1 In recent years, there has
been much debate about how GDM should be diagnosed. In 2010, IADPSG recommended new thresholds
for the diagnosis of the disease, which aimed to reduce obesity risk by identifying infants who were LGA,
with high adiposity at birth, and who had high concentrations of cord blood C-peptide.8 In 2013, the World
Health Organization (WHO),10 whose previous criteria for diagnosing GDM have been widely used, endorsed
the IADPSG criteria. The IADPSG criteria were produced with results from the HAPO study,6 which aimed to
establish the association between maternal glucose concentrations that did not meet criteria for overt
diabetes (pre-existing diabetes or GDM) and risk of adverse perinatal outcomes. The HAPO study6 found
graded linear associations of fasting and post-load maternal glucose level with LGA, high adiposity and
high concentrations of cord blood C-peptide, and similar linear associations with several other perinatal
outcomes. In view of the absence of any clear threshold of glucose concentration at which risk of adverse
outcomes increased, the IADPSG reached a consensus on how to calculate the new criteria. They decided
that the thresholds for diagnosing GDM would be the glucose values at which the odds ratios (ORs)
reached 1.75 for BW of > 90th percentile, per cent infant body fat (based on skinfolds) > 90th percentile,8
and concentration of cord C-peptide > 90th percentile. Although in most populations the application of the
IADPSG criteria increases the number of women diagnosed with GDM compared with most previously
used criteria (Table 2),24 they might not identify women at risk who have a high 2-hour post-load glucose
result but which is still below that specified by the IADPSG criteria.6
TABLE 2 Different criteria used for diagnosing GDM in recent years
Criteria
Glucose thresholds (mmol/l)a
Criteria Coverage of useFasting
1-hour
post load
2-hour
post load
HAPO exclusion11 5.8 11.1 2002 Some US cities
WHO (previous)11 7.0 7.8 1999–2013 Widespread globally
WHO (previous, modified)23 6.1 7.8 1999 to current UK
NICE18 5.6 7.8 2015 UK
IADPSG and WHO (current)8,10 5.1 10.8 8.5 2010/2013 to present Widespread globally
a All values are for a glucose tolerance test undertaken at ≈ 26–28 weeks of gestation.
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It is unclear whether or not the association between maternal glucose level and perinatal outcomes and the
IADPSG criteria for diagnosing GDM should be the same in SA women, who are at higher risk of GDM than
white European women.25 The shift in the aim of diagnosing GDM from one of identifying women at risk
of type 2 diabetes to one of identifying risk of future offspring obesity is especially important for SAs,
because SA women, on average, have infants of markedly lower BW and a reduced risk of LGA than white
European women.18,24 However, lower BW of SA infants masks a propensity to greater adiposity and
associated cardiometabolic risk in later life.26–32 High maternal pregnancy glucose level is an important
mediator of greater birth adiposity in SA compared with white European infants.23 Although findings of the
HAPO study6 showed similar associations across different geographical centres, there were no SA centres,
and too few SA participants to assess the association between maternal glycaemia and perinatal outcomes.
We aimed to establish whether or not the IADPSG criteria for diagnosis of GDM are appropriate for SA
women and to assess how the prevalence of GDM varies when different criteria for its diagnosis are used in
SA and WB women. Our specific objectives were to establish the nature of the association of fasting and
post-load glucose levels with adverse perinatal outcomes in a large cohort of SA women and compare those
findings with a similarly sized cohort of WB women; to use our results to identify appropriate thresholds for
diagnosing GDM in SA and WB women; and to compare the prevalence of GDM in these two groups with
different criteria. We hypothesised that the association between fasting and post-load glucose levels, and
BW and infant adiposity, and the thresholds used to diagnose GDM, would differ between SA and WB
women. Furthermore, we predicted that prevalence of GDM would be greater in SA women than WB
women irrespective of criteria used. Our findings should inform clinical practice for diagnosing GDM.
Methods
Study design and participants
‘Born in Bradford’ is a prospective birth cohort study22 of women who delivered a live singleton baby at the
Bradford Royal Infirmary, Bradford, UK. Figure 1 shows full inclusion and exclusion of women from the
Total number of pregnancies
(n = 13,773; 12,450 women)
Potentially eligible cohort
(n = 13,061)
Available analysis cohort
(N = 10,353)
• WB, n = 4088
• SA, n = 5408
• Other, n = 857
Exclusion
• Other ethnicity, n = 800
Exclusion
• GDM, n = 844
Exclusions
Comparing GDM prevalence analyses
(N = 9496)
Main analysis (comparison of relationship of gestational
glucose to perinatal outcomes, estimating
diagnostic criteria)
(N = 9509)
• WB, n = 3888
• SA, n = 4821
• Other, n = 800
• Did not deliver at BRI, n = 412
• Multiple pregnancy, n = 162
• Stillbirth, n = 71
• Existing diabetes, n = 67
Missing data
• Did not complete baseline questionnaire,
   n = 2243
• Did not complete OGTT, n = 444
• Missing data on ethnicity, n = 21
• WB, n = 4088
• SA, n = 5408
FIGURE 1 Study sample flow chart. The criteria used in the hospital in which study participants were recruited to
diagnose GDM (and hence exclude them from the analyses presented here) was either fasting glucose level of
≥ 6.1 mmol/l or 2-hour post-load glucose level of ≥ 7.8 mmol/l. BRI, Bradford Royal Infirmary.
THE BORN IN BRADFORD COHORT
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BiB study22 in this study. Women were excluded from all analyses if they did not complete a baseline
questionnaire or the OGTT or had missing data for ethnic origin. For the main analyses of the association of
gestational glucose level with perinatal outcomes and development of GDM diagnostic criteria, we excluded
women who were diagnosed with GDM. GDM was defined according to modified WHO criteria operating at
the time (either fasting glucose level of ≥ 6.1 mmol/l or 2-hour post-load glucose level of ≥ 7.8 mmol/l).11,23
The cohort is broadly representative of the obstetric population in Bradford.22 All women booked for
delivery in Bradford are offered a 75-g OGTT (comprising fasting and 2-hour post-load samples) at around
26–28 weeks’ gestation, and women were recruited mainly at their OGTT appointment. At recruitment,
women had their height and weight measured, completed an interviewer-administered questionnaire, and
provided written consent for information to be abstracted from their medical records. Interviews were
undertaken in English or in SA languages (including Urdu and Mirpuri). The analysis of glucose samples was
carried out using a Siemens Advia 2400 analyser from the ADVIA® 2400 Clinical Chemistry System (Siemens
Healthcare Ltd, Camberley, UK). The coefficients of variation range between 1.73% at 3.2 mmol/l and
0.64% at 19.1 mmol/l. Ethics approval was obtained from the Bradford Research Ethics Committee
(07/H1302/112). All participants provided informed written consent.
Participants completed a morning OGTT after fasting overnight. A baseline venous blood sample was
taken. Participants then consumed a standard solution containing the equivalent of 75 g of anhydrous
glucose over 5 minutes. After 2 hours a second sample was taken. Fasting and post-load plasma glucose
assays were undertaken immediately using a glucose oxidase method. The analyses were undertaken using
the Siemens Advia 2400 analyser following a standard protocol. The coefficients of variation range
between 1.73% at 3.2 mmol/l and 0.64% at 19.1 mmol/l.
We assessed associations of maternal glucose concentrations with:
l three primary outcomes – LGA (defined as BW of > 90th percentile for gestational age), infant
adiposity (defined as sum of skinfolds > 90th percentile for gestational age) and C-section
l five secondary outcomes – pre-eclampsia, preterm delivery, shoulder dystocia, instrumental vaginal
delivery and admission to the neonatal unit.
These outcomes are established clinical complications of GDM, and similar to the primary and secondary
outcomes in the HAPO study.6 We did not have information about cord blood C-peptide or neonatal
hypoglycaemia in our cohort. We were unable to calculate percentage body fat from skinfolds as done in
the HAPO study6 because no equivalent formulae exist for SA infants; thus, we used a cut-off of > 90th
percentile for the sum of skinfolds. We included C-section in our analyses as, although it is not used to
predict future risk of adiposity and ill health, it is an important perinatal outcome and is associated with
LGA, greater infant adiposity and increased health service costs.33
Birthweight, mode of delivery (normal vaginal, instrumented vaginal or C-section), gestational age,
pre-eclampsia, shoulder dystocia and admission to the neonatal unit were obtained from hospital records.
C-section was compared with all vaginal deliveries. Pre-eclampsia was defined as new-onset proteinuria
(> 300 g in 24 hours) together with blood pressure (BP) of ≥ 140/90 mmHg after 20 weeks’ gestation on
more than one occasion. BWs were converted into standard deviation (SD) scores standardised for
gestational age and gender relative to the UK-WHO growth standard.34,35 Infants were then categorised as
either being > 90th percentile or not.27 The UK-WHO growth standards are based on data from six
counties (USA, Norway, Oman, Brazil, India and Ghana) and describe the optimum pattern of growth for
all children, rather than the prevailing pattern in the UK.35 Skinfold thickness (triceps and subscapular)
were summed and the 90th percentile was established from quantile regression using six gender–ethnic
groups [combining gender and ethnic origin (WB, SA, and other)] and adjusted for parity (0, 1, 2, 3+).36
The intra-rate and inter-rate technical error of measurements for the skinfold thicknesses were,
respectively, 0.22–0.35 mm and 0.15–0.54 mm for triceps, and 0.14–0.25 mm and 0.17–0.63 mm for
subscapular skinfolds.37
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Statistical analyses
Associations of fasting and post-load glucose levels with outcomes were assessed by categories, and with
glucose as a continuous variable (per SD). We used multivariable logistic regression with clustered sandwich
estimators38 (to account for some women in the cohort having more than one pregnancy) to assess
associations of fasting and post-load glucose levels with each outcome. We followed the analytical protocol
used in the HAPO study6 as closely as possible, with fasting and post-load glucose concentrations divided
into seven categories (see the Table 3 footnotes for definition of categories). In order to explore any extreme
threshold effects, the top two categories for fasting and post-load glucose levels included about 1% and 3%
of women, respectively. Models were adjusted for gestational age at OGTT, presence or absence of family
history of diabetes, family history of hypertension, previous GDM, previous macrosomia, smoking status,
alcohol consumption during pregnancy, maternal age and BMI, maternal education, baby gender and parity.
Models for all women were additionally adjusted for ethnic origin. Models for SA women were not adjusted
for alcohol consumption during pregnancy because most reported never drinking alcohol. Additionally,
preterm delivery was adjusted for squared maternal BMI because of evidence of a quadratic relationship of
BMI with preterm delivery. Shoulder dystocia models were not adjusted for previous GDM because of small
numbers. Ethnicity was categorised as WB, SA and other ethnicity according to UK Office for National
Statistics criteria.39 Education was equivalised to UK standard attainments, and participants were included in
one of five mutually exclusive categories (< 5 GCSE equivalent, 5+ GCSE equivalent, A level equivalent,
higher than A level, other).23 Parity was categorised as 0 or ≥ 1 previous pregnancies. Smoking was
categorised as never, past (not during this index pregnancy), current (during this pregnancy) and alcohol as
consumed during this pregnancy or not.
Maternal BMI was calculated from height measured at the time of recruitment and from weight measured
at booking antenatal clinic, which was obtained from electronic hospital records. Expected date of birth
(40 weeks) was estimated from a gestation ultrasound scan at ≈ 10 weeks then, using the date of OGTT
and date of birth, gestational age at OGTT and birth were calculated. Infant gender was obtained from
electronic hospital records, and family history of diabetes and hypertension were abstracted from paper
hospital records.
We established fasting and post-load glucose thresholds for BW of > 90th percentile and standardised
sum of skinfolds of > 90th percentile that equated to an OR of 1.75, using the methods of IADPSG.8
We estimated the ORs of these outcomes at mean glucose levels and the ORs at 0.1-mmol/l intervals
across the full range of fasting and 2-hour post-load glucose levels. We then plotted this range of ORs
and used the plots to estimate the thresholds of fasting, and 2-hour post-load glucose that were
closest to ORs for each outcome of 1.75 in both ethnic groups. These analyses were carried out with
adjustment for the same potential confounders as in all multivariable regression analyses. All analyses
were undertaken separately in WB and SA women, and we tested for differences in associations by
including an interaction term between glucose and ethnic origin. Because women of SA origin were mainly
Pakistani, we undertook a sensitivity analysis in which we repeated analyses including only Pakistani
women. To maximise statistical power and minimise bias that might occur if women with missing data
were excluded from analyses, we used multivariate multiple imputation with chained equations to impute
missing values40 (see Appendix 1, Table 50). We repeated all analyses with the complete data cohort
for comparison.
Levels of missing data range from 0% to 32% for the different variables (see Appendix 1, Table 50), and
5056 (53%) had complete data on all variables included in any analyses. To maximise statistical power and
minimise bias due to excluding those with any missing data, we used multivariate multiple imputation, with
chained equations to impute missing values for covariables and outcomes for the main analyses.40 We
generated 50 imputed data sets and combined these using Rubin’s rules, using the ‘mi’ commands in Stata
13 (StataCorp LP, College Station, TX, USA). Distributions of variables from pooling of the data sets with
imputed variables were similar to those for observed variables (see Appendix 1, Table 50). We repeated all
analyses with the complete data cohort for comparison.
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Results
Women were recruited to the BiB study22 between March 2007 and November 2010; investigators collected
detailed information from 12,450 women (13,773 pregnancies resulting in 13,818 births). After exclusions,
9509 women (4821 SA and 3888 WB) were included in the main analyses looking at associations of fasting
and post-load glucose levels with adverse perinatal outcomes. A total of 844 women with GDM who were
excluded from main analyses were included in the analyses that compared the prevalence of GDM with
different criteria. Table 3 shows characteristics of the women and infants in the eligible cohort: 51%
were SA, 41% were WB and 8% were of other ethnic origin. Median fasting and post-load glucose
concentrations were slightly higher in SA than WB women. WB infants were almost three times more
likely than SA infants to have a BW of > 90th percentile, but the frequency of sum of skinfolds of > 90th
percentile was similar in WB and SA infants. Characteristics were similar in the larger cohort of eligible
women to those that were included in the main analysis cohort (see Appendix 1, Table 51).
Associations of fasting and post-load glucose levels with primary outcomes
Figure 2 shows the unadjusted percentage of women in each group who had each of the three primary
outcomes by categories of fasting and 2-hour post-load glucose level by ethnicity and for all women.
Generally, the frequency of each of the three primary outcomes increased across the seven categories of
fasting and post-load glucose levels, with no evidence of a threshold at which risk markedly increases,
except for the association of fasting glucose level with C-section in SA women. The higher prevalence of
BW of > 90th percentile in WB infants than in SA infants is consistent across all glucose categories.
Combining data for all women (i.e. including 99% of the cohort) showed monotonic relationships of
fasting and post-load glucose levels up to the sixth category (see Appendix 1, Figures 45 and 46).
TABLE 3 Maternal and infant characteristics for all pregnancies and by ethnic origin. Analyses are based on
complete data for each characteristic (numbers vary by characteristic and are provided in the table)
Outcome N
All women:
mean (SD),
median (IQR)
or n (%) N
WB: mean
(SD), median
(IQR) or n (%) N
SA: mean
(SD), median
(IQR) or n (%) N
Other: mean
(SD), median
(IQR) or n (%)
Primary outcomes
BW of > 90th
percentilea
9508 592 (6.2) 3887 361 (9.3) 4821 164 (3.4) 800 67 (8.4)
Sum of skinfolds of
> 90th percentileb
6458 687 (10.6) 2510 270 (10.8) 3409 365 (10.7) 539 52 (9.7)
Caesarean delivery 9509 1983 (20.9) 3888 870 (22.4) 4821 907 (18.8) 800 206 (25.8)
Secondary outcomes
Pre-eclampsia 9120 229 (2.5) 3724 97 (2.6) 4629 115 (2.5) 767 17 (2.2)
Preterm delivery
(< 37 weeks)
9509 471 (5.0) 3888 204 (5.3) 4821 227 (4.7) 8000 40 (5.0)
Shoulder dystociac 7526 105 (1.4) 3018 42 (1.4) 3914 50 (1.3) 594 13 (2.2)
Instrumental vaginal
deliveryc
7519 930 (12.4) 3015 417 (13.8) 3913 417 (10.7) 591 96 (16.2)
Intensive neonatal
care
9509 412 (4.3) 3888 166 (4.3) 4821 213 (4.4) 800 33 (4.1)
Glucose levels
Fasting 9509 4.4 (4.2–4.7) 3888 4.3 (4.1–4.6) 4821 4.5 (4.2–4.8) 800 4.4 (4.1–4.6)
Two-hour post load 9509 5.4 (4.7–6.1) 3888 5.3 (4.5–6.0) 4821 5.4 (4.8–6.2) 800 5.3 (4.6–6.0)
continued
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TABLE 3 Maternal and infant characteristics for all pregnancies and by ethnic origin. Analyses are based on
complete data for each characteristic (numbers vary by characteristic and are provided in the table) (continued )
Outcome N
All women:
mean (SD),
median (IQR)
or n (%) N
WB: mean
(SD), median
(IQR) or n (%) N
SA: mean
(SD), median
(IQR) or n (%) N
Other: mean
(SD), median
(IQR) or n (%)
Maternal and infant characteristics
Maternal age at
delivery (years)
9509 27.3 (5.5) 3888 26.8 (6.1) 4821 27.7 (5.0) 800 27.4 (5.7)
Aged ≥ 35 years 1092 (11.5) 487 (12.5) 503 (10.4) 102 (12.8)
BMI (at booking) 9073 25.8 (5.6) 3708 26.7 (5.9) 4596 25.2 (5.3) 769 25.7 (5.5)
Obese (BMI
≥ 30 kg/m2)
1808 (19.9) 899 (24.2) 768 (16.7) 141 (18.3)
Maternal education 9383 3847 4755 781
< 5 GCSEs 2024 (21.6) 788 (20.5) 1140 (24.0) 96 (12.3)
≥ 5 GCSEs 2954 (31.5) 1336 (34.7) 1453 (30.6) 165 (21.1)
A level 1389 (14.8) 652 (17.0) 639 (13.4) 98 (12.6)
Higher than A
level
2402 (25.6) 739 (19.2) 1352 (28.4) 311 (39.8)
Other 614 (6.5) 332 (8.6) 171 (3.6) 111 (14.2)
Smoking status 9494 3886 4809 799
Never 6518 (68.7) 1589 (40.9) 4428 (92.1) 501 (62.7)
Before pregnancy 1359 (14.3) 973 (25.0) 227 (4.7) 159 (19.9)
In pregnancy 1617 (17.0) 1324 (34.1) 154 (3.2) 139 (17.4)
Any alcohol during
pregnancy
9477 1950 (20.6) 3875 1715 (44.3) 4805 40 (0.8) 797 195 (24.5)
Primiparity 9151 3813 (41.7) 3762 1821 (48.4) 4623 1566 (33.9) 766 426 (55.6)
Family history of
diabetes
9212 2313 (25.1) 3782 508 (13.4) 4660 1657 (35.6) 770 148 (19.2)
Family history of
hypertension
9203 2519 (27.4) 3774 909 (24.1) 4654 1412 (30.3) 775 198 (25.6)
Previous GDMd 5338 56 (1.1) 1941 19 (1.0) 3057 35 (1.1) 340 2 (0.6)
Previous macrosomia
(≥ 4 kg)d
4464 359 (8.0) 1662 212 (12.8) 2523 124 (4.9) 279 23 (8.2)
Gestational age at
OGTT (weeks)
9509 26.3 (1.9) 3888 26.2 (1.9) 4821 26.3 (1.9) 800 26.4 (1.7)
Gestational age at
delivery (weeks)
9509 39.7 (1.7) 3888 39.8 (1.8) 4821 39.6 (1.7) 800 39.7 (1.7)
Male gender 9509 4884 (51.4) 3888 2006 (51.6) 4821 2464 (51.1) 800 414 (51.8)
IQR, interquartile range.
For maternal age, maternal BMI, gestational age at OGTT, gestational age at delivery and BW, the values are mean (SD); for
maternal gestational fasting and post-load glucose levels, values are median (IQR); for all other variables (that are categorical)
the values are numbers (%).
a The 90th centile using the UK-WHO growth standard.
b Internal standardisation by ethnicity and gender.
c These analyses exclude women who had a C-section, therefore N = 7526.
d Percentages relate to multiparous women only (N = 5345).
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Regression analyses confirmed monotonic associations of glucose level with each of the primary outcomes, in
each group, without (see Appendix 1, Table 52) and with adjustment for confounders (Table 4). In view of
the monotonic nature of the associations, we focused our comparisons on results with fasting or post-load
glucose level as a continuous variable (per 1 SD). Although there was not strong statistical evidence of
differences, the point estimates suggested stronger associations of fasting and post-load glucose levels
with all three outcomes, except for those of fasting glucose level with LGA and post-load glucose level with
C-section. However, there was no strong statistical evidence that the associations differed between the two
groups for any primary outcome (p interaction of ≥ 0.2 for all associations).
TABLE 4 Confounder-adjusted association of gestational fasting and 2-hour post-load glucose level with
primary outcomes
Outcome
All women (N= 9509) WB (n= 3888) SA (n= 4821)
p-interactionaOR 95% CI OR 95% CI OR 95% CI
By fasting glucose categoryb and per 1 SD
BW of > 90th percentile
1 (reference) 1.00 – 1.00 – 1.00 – 0.39
2 1.18 0.90 to 1.54 1.15 0.83 to 1.59 1.07 0.59 to 1.94
3 1.35 1.04 to 1.74 1.38 1.01 to 1.90 1.10 0.65 to 1.88
4 1.42 1.02 to 1.97 1.57 1.04 to 2.37 1.05 0.56 to 1.98
5 1.90 1.35 to 2.67 1.59 0.97 to 2.62 2.12 1.20 to 3.76
6 3.10 2.00 to 4.79 2.21 1.07 to 4.54 3.35 1.72 to 6.51
7 2.60 1.35 to 5.04 2.09 0.80 to 5.48 3.25 1.29 to 8.21
Per 1 SD 1.31 1.20 to 1.43 1.22 1.08 to 1.38 1.43 1.23 to 1.67
Sum of skinfolds of > 90th percentile
1 (reference) 1.00 – 1.00 – 1.00 – 0.98
2 1.11 0.88 to 1.40 1.04 0.74 to 1.46 1.29 0.92 to 1.82
3 1.40 1.14 to 1.72 1.35 0.96 to 1.88 1.56 1.15 to 2.13
4 1.61 1.24 to 2.09 1.69 1.09 to 2.62 1.70 1.18 to 2.45
5 2.02 1.54 to 2.64 2.05 1.26 to 3.36 2.15 1.49 to 3.10
6 3.23 2.29 to 4.56 3.20 1.52 to 6.74 3.18 2.01 to 5.02
7 2.73 1.53 to 4.87 2.71 0.97 to 7.58 3.06 1.44 to 6.51
Per 1 SD 1.35 1.25 to 1.45 1.35 1.18 to 1.54 1.35 1.23 to 1.49
Caesarean delivery
1 (reference) 1.00 – 1.00 – 1.00 – 0.47
2 0.98 0.84 to 1.13 1.03 0.83 to 1.27 0.99 0.79 to 1.24
3 1.11 0.96 to 1.28 1.06 0.86 to 1.32 1.20 0.97 to 1.49
4 1.17 0.97 to 1.41 1.11 0.81 to 1.51 1.33 1.03 to 1.73
5 1.20 0.98 to 1.48 1.18 0.83 to 1.69 1.18 0.88 to 1.56
6 1.14 0.84 to 1.55 1.42 0.83 to 2.45 1.02 0.67 to 1.56
7 2.14 1.34 to 3.41 1.25 0.57 to 2.77 2.88 1.58 to 5.25
Per 1 SD 1.09 1.03 to 1.15 1.06 0.97 to 1.16 1.11 1.02 to 1.20
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TABLE 4 Confounder-adjusted association of gestational fasting and 2-hour post-load glucose level with primary
outcomes (continued )
Outcome
All women (N= 9509) WB (n= 3888) SA (n= 4821)
p-interactionaOR 95% CI OR 95% CI OR 95% CI
By 2-hour post-load glucose categoryb and per 1 SD
BW of > 90th percentile
1 (reference) 1.00 – 1.00 – 1.00 – 0.60
2 0.95 0.74 to 1.23 1.00 0.73 to 1.37 0.96 0.56 to 1.66
3 1.08 0.83 to 1.39 0.98 0.71 to 1.36 1.04 0.61 to 1.76
4 1.29 0.92 to 1.80 1.20 0.78 to 1.84 1.39 0.72 to 2.66
5 1.58 1.14 to 2.19 1.18 0.76 to 1.82 2.12 1.15 to 3.93
6 1.71 1.04 to 2.81 1.74 0.90 to 3.36 1.66 0.69 to 3.98
7 1.29 0.65 to 2.60 1.27 0.50 to 3.26 1.64 0.54 to 5.05
Per 1 SD 1.17 1.07 to 1.29 1.10 0.98 to 1.24 1.28 1.06 to 1.55
Sum of skinfolds of > 90th percentile
1 (reference) 1.00 – 1.00 – 1.00 – 0.23
2 1.02 0.81 to 1.29 1.24 0.88 to 1.73 0.96 0.68 to 1.35
3 1.32 1.05 to 1.65 1.13 0.78 to 1.63 1.51 1.10 to 2.07
4 1.84 1.40 to 2.41 1.76 1.12 to 2.76 1.94 1.33 to 2.83
5 1.94 1.47 to 2.55 1.79 1.13 to 2.82 2.22 1.52 to 3.25
6 2.29 1.54 to 3.39 2.63 1.35 to 5.14 2.13 1.25 to 3.64
7 2.53 1.53 to 4.17 1.80 0.68 to 4.77 3.13 1.71 to 5.74
Per 1 SD 1.31 1.21 to 1.42 1.26 1.11 to 1.42 1.38 1.23 to 1.54
Caesarean delivery
1 (reference) 1.00 – 1.00 – 1.00 – 0.54
2 0.95 0.82 to 1.10 0.89 0.72 to 1.11 1.06 0.84 to 1.32
3 1.07 0.92 to 1.24 1.09 0.87 to 1.37 1.01 0.80 to 1.27
4 1.11 0.91 to 1.36 0.96 0.70 to 1.32 1.19 0.89 to 1.60
5 1.00 0.81 to 1.23 1.03 0.76 to 1.42 0.97 0.71 to 1.33
6 1.31 0.96 to 1.79 1.12 0.68 to 1.85 1.35 0.88 to 2.07
7 1.15 0.76 to 1.74 0.86 0.43 to 1.72 1.29 0.72 to 2.29
Per 1 SD 1.05 0.99 to 1.11 1.02 0.94 to 1.10 1.05 0.96 to 1.14
FPG, fasting plasma glucose.
a Testing the null hypothesis that the associations of glucose categories with outcome do not differ between WB and
SA women.
b Glucose categories are defined as follows: FPG level – category 1, < 4.3 mmol/l; category 2, 4.3–4.4 mmol/l; category 3,
4.5–4.7 mmol/l; category 4, 4.8–4.9 mmol/l; category 5, 5.0–5.2 mmol/l; category 6, 5.3–5.6 mmol/l; category 7,
5.7–6.0 mmol/l. Post-load plasma glucose level – category 1, < 4.7 mmol/l; category 2, 4.7–5.4 mmol/l; category 3,
5.5–6.2 mmol/l; category 4, 6.3–6.6 mmol/l; category 5, 6.7–7.2 mmol/l; category 6, 7.3–7.5 mmol/l; category 7,
7.6–7.7 mmol/l.
Models adjusted for gestational age at OGTT, presence or absence of family history of diabetes, family history of
hypertension, previous GDM, previous macrosomia, smoking status, alcohol during pregnancy, mother’s age and mother’s
BMI, mother’s education, baby gender and parity. Models for all women additionally adjusted for ethnicity. Models for SA
women not adjusted for alcohol during pregnancy because the vast majority reported never drinking alcohol. BW of > 90th
percentile and sum of skinfolds > 90th percentile additionally adjusted for squared maternal BMI because of evidence of a
quadratic association of it with these outcomes.
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Associations of fasting and post-load glucose levels with secondary outcomes
Associations with secondary outcomes were similar in the two ethnic groups [see Appendix 1, Table 53
(unadjusted) and Table 54 (confounder adjusted)]. The frequency of pre-eclampsia, shoulder dystocia and,
with a weaker magnitude, instrumental delivery, also increased across each glucose category, especially
with fasting glucose level (see Appendix 1, Figures 45 and 46). Neither fasting nor post-load glucose
concentrations were clearly associated with preterm delivery or admission to the neonatal unit.
Criteria for diagnosing gestational diabetes mellitus
Table 5 shows the thresholds of fasting and glucose that would result in an OR of 1.75 for BW of
> 90th percentile, and sum of skinfolds of > 90th percentile in each group. Fasting and post-load glucose
thresholds based on the average of BW and skinfolds of > 90th percentile for all women irrespective of
ethnic origin were 5.3 mmol/l and 7.5 mmol/l, respectively. Fasting glucose thresholds based on BW or the
average of BW and skinfolds of > 90th percentile were higher for WB women than for SA women (see Table 5);
with skinfolds of > 90th percentile alone as the outcome, the fasting glucose threshold was the same in
both ethnic groups. There was no 2-hour post-load threshold that reached an OR of 1.75 for BW of
> 90th percentile in either ethnic group. A threshold for sum of skinfolds of > 90th percentile was found
only in SA women (see Table 5).
Table 6 shows GDM prevalence by past and present diagnostic criteria, and the criteria derived from our
data. For our study criteria, we show prevalences with the same thresholds in both ethnic groups (the
thresholds derived for all women) and also ethnic-specific thresholds. Prevalence of GDM was about
twice as high in SA women using any criteria range (4.1–17.4%) than in WB women (1.2–8.7%) for all
non-ethnic specific criteria. Prevalence was greater in both ethnic groups with the recently derived IADPSG,
NICE and our criteria than the 1999 WHO criteria. Of the three recent criteria, the NICE criteria resulted in
the lowest prevalences in WB women and our criteria the highest. In SA women, the NICE criteria resulted
in the lowest prevalence. If we applied criteria derived in our study for all women (i.e. not taking account of
ethnic origin) to the SA women, the prevalence of GDM was the same using either IADPSG/WHO or our
criteria. However, when we applied our ethnic-specific criteria, prevalence in SA women was nearly three
times that in WB women (see Table 6).
Additional sensitivity analyses
The number of missing data ranged from 0% to 32% for the different variables (see Appendix 1, Table 50)
and 5056 of the 9509 (53%) had complete data on all variables for the main analyses. Distributions of any
variable with missing data were the same in the imputation data sets (see Table 4 and Appendix 1, Table 54)
and for observed complete case data (see Appendix 1, Tables 56 and 57). There was no strong evidence for
a quadratic curvilinear association between fasting or post-load glucose level and any of the primary or
secondary outcomes (see Appendix 1, Table 55). The results of analyses restricted to Pakistani women did
not differ from those presented for all SA women (see Appendix 1, Tables 58 and 59).
TABLE 5 Thresholds of fasting and post-load glucose levels (mmol/l) that would identify an OR of ≈ 1.75 for BW of
> 90th centile and sum of skinfolds of > 90th centile
Outcomes
All women (N= 10,356) WB women (n= 4105) SA women (n= 5445)
Fasting
2-hour
post load Fasting
2-hour
post load Fasting
2-hour
post load
BW of > 90th percentile 5.3 NP 5.6 NP 5.1 NP
Sum skinfolds of > 90th percentile 5.2 7.5 5.2 NP 5.2 7.2
Average glucose level for both BW and
sum of skinfolds of > 90th percentile
5.3 7.5 5.4 NP 5.2 7.2
NP, not possible to determine a threshold because within our study none of the women reached a threshold that gave an
OR of 1.75 or greater (the IADPSG consensus minimal OR considered to be of clinical importance).
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Discussion
We recorded graded monotonic associations of fasting and 2-hour post-load glucose level with LGA and
high adiposity (as assessed by skinfold thickness) across most of the glucose distribution in both SA and WB
women. The associations of glucose level with LGA appeared stronger in SA than WB women, but there
was no statistical evidence of an interaction with ethnic origin. Applying the same method as the IADPSG
to our data, we estimated fasting and post-load glucose thresholds for diagnosing GDM that are lower in
SA women than in WB women. For WB women, our criteria included a fasting glucose threshold that
was slightly higher, and a 2-hour glucose threshold that was markedly lower, than those recommended by
IADPSG and WHO. Our results support a lower threshold for both fasting and 2-hour post-load glucose
level for diagnosing GDM than is currently recommended by NICE in both WB and SA women. NICE
supports higher fasting glucose thresholds to those proposed by the IADPSG and WHO in WB and SA
women, but lower 2-hour post-load glucose thresholds. Using existing criteria, the prevalence of GDM in
our cohort was about twice as high in SA than in WB women; when we applied the ethnic-specific criteria
derived from our data, the prevalence was three times higher in SA women, and identified about 25% of
SA women as having GDM.
Overall patterns of associations in our study, for both primary and secondary outcomes, were similar to
those seen in the HAPO study,6 especially for fasting glucose levels.6 Because of differences between ours
and the HAPO study6 in the post-load glucose threshold used to exclude women from the study cohort,
our highest 2-hour post-load category (category 7) was similar to category 4 in the HAPO study.6 As a result,
for some outcomes, the linear relationship seems to flatten at the upper end of the 2-hour post-load
glucose categories.
TABLE 6 Prevalence of GDM in SA and WB women using different criteria (all values expressed in mmol/l)
Criteria
Criteria (all define GDM as the
presence of having glucose levels at or
above one or more of the following)
Prevalence in our study population:
% (95% CI)
Fasting
glucose
1-hour
post-load
glucose
2-hour
post-load
glucose WB SA
Older, used in recent past
Exclusion in HAPO exclusiona 5.8 – 11.1 1.2 (0.9 to 1.5) 4.1 (3.6 to 4.7)
WHO (previous)b 7.0 – 7.8 4.7 (4.1 to 5.4) 10.4 (9.6 to 11.2)
WHO (previous, modifiedc 6.1 – 7.8 4.9 (4.3 to 5.6) 10.8 (10.0 to 11.7)
Recently proposed
NICEd 5.6 – 7.8 5.9 (5.2 to 6.6) 12.5 (11.7 to 13.4)
IADPSG/WHO (current)e 5.1 10.8 8.5 7.6 (6.8 to 8.5) 17.3 (16.3 to 18.3)
Our study
Same criteria for all womenf 5.3 – 7.5 8.7 (7.9 to 9.6) 17.4 (16.4 to 18.4)
For WB 5.4 – 7.5 8.3 (7.5 to 9.2) –
For SA 5.2 – 7.2 – 24.2 (23.1 to 25.3)
a Used in the HAPO study6 to exclude women with GDM.
b Used by WHO up to 2013.
c Criteria used for all pregnant women in Bradford (and in other populations) at the time that women were recruited for
the BiB study22 and used here to exclude those with GDM.
d Criteria in current UK guidelines.41
e Criteria were developed using HAPO study6 data and were adopted by WHO in 2013.
f Criteria developed in this study.
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
Compared with the IADPSG, who used data from the HAPO study,6 we could not identify a 2-hour post-load
threshold: there was no threshold that reached an OR of 1.75 for BW of > 90th percentile, and only SA
women reached a threshold for this OR for sum of skinfolds of > 90th percentile. The IADPSG consensus
panel chose 1.75 to represent the lowest level of clinically important risk; a lower OR was not considered
clinically important. GDM was diagnosed in our study using a lower 2-hour post-load glucose threshold than
in the HAPO study;6 both studies excluded women with GDM as it would be unethical not to treat them.
If we had applied the same high 2-hour post-load glucose threshold as in the HAPO study6 to diagnose GDM
and to exclude women from the main analysis, we would have been more likely to identify an OR of 1.75,
because women with higher glucose concentrations and greater associated risk of the primary outcomes
would have been included in our analyses. The 2-hour post-load glucose level used to exclude women with
GDM in the HAPO study6 was much higher than that recommended by WHO, and also by other criteria
recommended at the time that the HAPO study6 began, including the Australasian Diabetes in Pregnancy
Society criteria. Thus, the 2-hour post-load glucose threshold used to define GDM in the IADPSG and WHO
criteria is higher than that suggested by our study (see Table 1). Because the diagnostic criteria for GDM in
our study meant that we excluded women from the main analyses with a much lower post-load glucose
threshold than was the case in the HAPO study,6 we had difficulty identifying a glucose threshold that
reached an OR of 1.75 for sum of skinfolds of > 90th percentile in WB women. Therefore, our GDM
diagnostic criteria for this group are mainly driven by results of the associations with LGA.
Consistent with other studies,42–45 we have shown that using any criteria the prevalence of GDM is greater
in SA women than in WB women. When we used the same criteria for both ethnic groups, the criteria
derived from our study resulted in a higher prevalence of GDM than the NICE criteria for both WB women
and SA women, but broadly similar prevalences for both groups to those found with the IADPSG/WHO
criteria. When we used ethnic group-specific criteria, the prevalences for WB women remained higher than
the NICE criteria, but were similar to IADPSG/WHO criteria, whereas those for SA women became higher for
both of these other two criteria. Our study cohort is large and well characterised. The broad consistency of
our findings with the results of the HAPO study,6 and the fact that our results were unchanged when we
limited the analyses in SAs to those of Pakistani origin, suggests that the results might be generalisable to
all white Europeans and SAs. Some participants had missing data for some variables, but the distribution
of recorded variables and those from the pooled multiple imputed data sets were similar, as were the
association results. We did not collect data for 1-hour post-load glucose concentrations, which were
measured in the HAPO study,6 and a 1-hour post-load glucose threshold is included in IADPSG/WHO criteria
for GDM. Although the HAPO study6 found linear associations of 1-hour post-load glucose levels with
adverse perinatal outcomes, none of the randomised trials that have shown the effect of treatments on
adverse perinatal outcomes had used this to define GDM. Furthermore, it is unclear how many additional
women in different populations are identified by this additional glucose measurement. Thus, the benefit of
this additional measurement remains somewhat unclear. We do not have data for cord blood C-peptide
concentrations or neonatal hypoglycaemia. High cord blood C-peptide concentrations were one of the
criteria used by the IADPSG in the development of their diagnostic criteria; this additional information might
have affected our results. However, the similar prevalences of GDM in WB women using the IADPSG/WHO
criteria or our study criteria suggest that including these data would not have markedly changed our results.
Concerns have been raised about the increased prevalence of GDM and hence the cost to health services if
the IADPSG criteria are used worldwide in place of the previously widely used 1999 WHO criteria.25,46,47
Until the late 1990s, the main aim of diagnosing GDM was to identify women at risk of subsequent type 2
diabetes.48 By contrast, the outcomes used to develop the IADPSG criteria, which we also used, were
chosen to identify offspring at risk of future high adiposity and cardiometabolic risk.48 Although there is
evidence that GDM causes greater adiposity in offspring in later life,48,49 there is still debate about the
validity of that evidence.50 Thus, the extent to which the IADPSG or our criteria will accurately predict future
adverse offspring health remains to be established. Conversely, in view of the graded association of
maternal glucose concentrations with adverse perinatal outcomes, lowering the thresholds used to
diagnose GDM would identify more pregnancies at risk of these outcomes. Because effective, safe, and
cheap treatments are available for GDM (e.g. lifestyle advice, metformin and insulin) that reduce glucose
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level across its distribution and help prevent adverse perinatal outcomes,51,52 applying the IADPSG/WHO
2013 or our criteria in place of the WHO 1999 criteria, and also in place of the recently suggested NICE
criteria, might improve perinatal outcomes. Because the NICE 2015 criteria recommend higher thresholds of
fasting and post-load glucose levels than the IADPSG/WHO or our newly defined criteria, their use will
identify fewer women who are at increased risk of adverse outcomes.53
To conclude, our data support the use of lower fasting and post-load glucose thresholds in SA women than
in WB women. They also suggest that compared with our criteria or those of the IADPSG/WHO, the criteria
recommended by NICE might underestimate the prevalence of GDM, especially in SA women. The use of
our ethnic-specific thresholds for diagnosing GDM in SA women, and of either our – or the IASPSG/WHO –
criteria for white European women might reduce the occurrence of adverse perinatal outcomes, in particular
LGA, as more at-risk women would be treated. However, the effect of applying any of the recently
proposed criteria on later life adiposity and associated cardiometabolic health in offspring are unknown and
require further investigation. Furthermore the effectiveness of identifying and treating women with GDM at
different cost-effectiveness thresholds, together with the use of varying glucose level thresholds, is also
unclear. Our comprehensive analysis detailed in Chapter 7 of this report examines this area and provides
information about uncertainties and the value of further research evidence.
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Chapter 3 Associations of gestational fasting and
post-load glucose levels in women without existing or
gestational diabetes with perinatal and longer-term
outcomes: a systematic review
Introduction
This chapter presents a systematic review and meta-analyses to determine the association between graded
increases in glucose level and risk of perinatal and longer-term outcomes. A version of this chapter has
been published in Farrar et al.54 This is an Open Access article distributed in accordance with the terms
of the Creative Commons Attribution (CC BY 3.0) license, which permits others to distribute, remix,
adapt and build upon this work, for commercial use, provided the original work is properly cited. See:
http://creativecommons.org/licenses/by/3.0/.
Previous systematic reviews
To our knowledge, this is the first comprehensive systematic review and meta-analyses examining the
association of gestational glucose level with risk of perinatal and longer-term outcomes. We have previously
undertaken a review as part of a master’s degree dissertation.55 In that dissertation, a systematic search
was undertaken to identify studies that investigated the association between gestational glucose levels
[measured using the OGTT or oral glucose challenge test (OGCT)] and adverse outcomes. The findings
of that review suggested strong associations between fasting glucose categories and both LGA and
macrosomia and these associations were weaker for 2-hour post-load glucose categories. However, that
review included only studies that had been published up to March 2013, and we are aware of additional
studies since then. Furthermore, there was no attempt to explore sources of heterogeneity between studies.
The aim in this study was to expand and update the previous search and analyses in order to determine
associations between fasting and post-load glucose levels, and both perinatal and longer-term maternal
and offspring outcomes. This section is reported in accordance with PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guidelines.56
Methods
Search
The original (master’s dissertation) searches were undertaken in March 2013.55 The search strategies
including interfaces and search terms used, and how they were combined, are shown in Appendix 7
(see Tables 83 and 84). Although no date or language restrictions were placed on the searches, only
studies with an English language title and/or an abstract were screened for inclusion. The same search
strategy (as in March 2013) was used for updating this review, with repeat searches undertaken in
September 2013 and October 2014. The following databases were searched: MEDLINE® and MEDLINE
In-Process & Other Non-Indexed Citations,® EMBASE, Cumulative Index to Nursing and Allied Health
Literature (CINAHL) Plus, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database
of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE), Health Technology
Assessment (HTA) database, NHS Economic Evaluation Database (NHS EED) and the Cochrane
Methodology Register (CMR).
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The search results were downloaded into an EndNote (Thomson Reuters, CA, USA) library and duplicates
were removed. All records (title, publication details and abstracts if available) were screened for eligibility,
independently, by two reviewers. We had previously screened the records identified by the March 2013
search; however, we rescreened these again to ensure that the screening standard was high and consistent
across all searches. All studies identified as potential ‘includes’ were checked by a second reviewer.
Disagreements were resolved by discussion or by a third reviewer. The reference lists of all of the included
studies and any related systematic reviews identified were checked for further possible inclusions.
Inclusion and exclusion criteria
All studies reporting the association of fasting or post-load glucose level (obtained from an OGTT or
OGCT) with perinatal and longer-term health outcomes in mother or offspring were potentially eligible.
Associations in women diagnosed with GDM, however defined, were excluded. The included studies had
to have the following characteristics.
Types of studies
All published and ongoing cohort studies and control (placebo or no active treatment) arms of randomised
trials were considered for inclusion.
Types of participants
Pregnant women who had undergone assessment of glucose tolerance using an OGTT or OGCT were
included. Women with pre-existing diabetes and those diagnosed with GDM and treated (to reduce
glycaemic levels) were excluded, by excluding either whole studies (when it was impossible to exclude
those with pre-existing diabetes or treated GDM from the study results) or subgroups of studies in which
those with pre-existing diabetes or treated GDM had been included, if results were presented in such a
way that we were able to exclude those with pre-existing diabetes or treated GDM. For the latter, we used
the within-study definition of GDM and recorded that definition. Although, a priori, we assumed that
GDM would have been diagnosed differently in different studies, and our preliminary review confirmed
this, it is appropriate to use the within-study definition. Excluding women with treated GDM is appropriate
because the reason for excluding these women is that treatment would affect the natural association of
glucose levels with adverse outcomes.
Types of tests
The OGTT, including the 75-g and 100-g tests, and the 50-g OGCT. Studies of intravenous glucose testing
were excluded. Each included study had to report at least two glucose categories for comparison, following
exclusion of any treated group. Diagnostic criteria and threshold for treatment differed between studies.
Types of outcomes
Outcome data had to be reported as numbers of events in each of two or more defined glucose
categories, as ORs or risk ratios in each category relative to a specified baseline category, or as ORs or risk
ratios per SD or per 1 mmol/l of glucose. Studies reporting only correlations were excluded. Studies had to
report at least one of the following outcomes.
Perinatal maternal outcomes
C-section (elective or emergency).
Induction of labour.
Instrumental (assisted delivery) (ventouse or forceps).
Pregnancy-induced hypertension (PIH) (however defined).
Pre-eclampsia (however defined).
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Perinatal infant outcomes
Macrosomia (BW of ≥ 4.0 kg).
LGA (BW of ≥ 90th percentile, or however defined).
Preterm birth (< 37 weeks’ gestation).
l Birth injury/trauma:
¢ shoulder dystocia
¢ Erb’s palsy
¢ fractured clavicle.
Admission to special care or higher-care facility.
Neonatal hypoglycaemia.
Longer-term maternal or offspring outcomes
Type 2 diabetes (offspring or mother).
Cardiovascular disease (offspring or mother).
Obesity (offspring or mother) (however defined).
Quality assessment
The risk of bias in the included published studies was assessed using a modified version of the Critical
Appraisal Skills Programme57 (CASP) and Quality in Prognosis Studies (QUIPS) quality assessment tool.58
These tools are designed to aid the assessment of observational studies of association and prediction.
The following quality criteria were considered:
l representative nature of included population
l loss to follow-up
l consistency of glucose measurement and outcome assessment
l blinding of participants and medical practitioners to glucose level
l blinding of outcome assessors to glucose level
l selective reporting of outcomes
l adjustment of results for key confounding variables.
Each criterion was classified as being at low, high or unclear risk of bias. One reviewer performed the
quality assessment; all assessments were then checked by a second reviewer.
Data extraction
Data were extracted from each publication on the following:
l glucose test used:
¢ OGCT or OGTT
¢ glucose load (50 g, 75 g or 100 g)
¢ timing (fasting, 1-, 2- or 3-hour post load)
l glucose levels in each defined glucose category (when reported)
¢ in millimoles per litre; levels presented as milligrammes per decilitre were converted to millimoles
per litre
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l numbers of women in each glucose category
l for each outcome reported:
¢ definition of outcome
¢ number of outcome events in each glucose category
¢ relative risk (RR) or OR of outcomes in each glucose category relative to baseline category
(if reported)
¢ RR or OR per millimole per litre of glucose or per SD of glucose (if reported)
l whether women with pre-existing diabetes and GDM were excluded
l study location
l how GDM was defined
l which potential confounding factors were adjusted for
l each quality criterion.
When presented, RR or ORs adjusted for key confounding factors (such as age, BMI, parity) were extracted
for each glucose category or type of glucose measure.
One reviewer performed the data extraction. A second reviewer checked the accuracy of the data
extraction for all included studies, but did not independently extract data.
Contact with authors and individual participant data
Having identified all relevant published studies that fulfilled our inclusion criteria, and, given that a goal of
this project was to understand GDM within a contemporary UK population, we searched for recently
recruited cohorts in the UK. We identified four eligible cohorts with IPD: two had sufficiently complete case
data: the BiB study22 (data provided by John Wright, Bradford Institute for Health Research, September 2013)
and the Atlantic Diabetes in Pregnancy cohort (Atlantic DIP59) (data provided by Fidelma Dunne, Department
of Medicine, National University of Ireland, September 2013), one cohort had insufficient complete case
data and was not included (Warwick/Coventry: P Saravanan, Warwick Medical School, 2013, personal
communication60) and we were unable to secure data from one other (UK HAPO cohort6); however, we have
included the published estimates from the whole HAPO cohort6 wherever possible.
Both the BiB and Atlantic DIP cohorts22,59 include fasting and 2-hour post-load glucose levels, obtained
as part of a 75-g OGTT. When outcomes were not reported explicitly in the data set they were derived
from available data if possible. For example, macrosomia, LGA and preterm birth were calculated from BW
and gestational age data.
Statistical analyses
General approach
Statistical analyses were based on the number of women, and number of outcome events in each glucose
category in each study. It should be noted that using these raw numbers means that these analyses are
not adjusted for potential confounding factors. For the BiB and Atlantic DIP cohorts,22,59 glucose levels were
divided into seven categories, with equal numbers of women in each category; for other published eligible
studies we used whatever categories were used in the study. Studies that did not report outcomes by
glucose categories were not included in these unadjusted analyses of outcome risk by glucose category.
Within each glucose category we calculated the risk by dividing the number of outcome events by the total
number of women in that category. With one exception,61 it was possible to do this for all of the published
studies. In this one exception,61 only adjusted ORs were presented in each category (not numbers of
events). For that study,61 numbers of each outcome were estimated, given the number of women in each
glucose category (which was provided) and the ORs, using an exhaustive search approach to find numbers
of outcomes that reproduced the reported ORs and their standard errors (SEs) as closely as possible. For
each study that we were able to calculate risk per glucose category, we graphed these risks against the
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categories to assess the shape of the association and see if results looked generally linear (as in Chapter 2
for the BiB cohort), before modelling the identified associations and pooling results from studies. In studies
that reported adjusted ORs or risk ratios for each glucose category, these results were similarly plotted to
check the shape of the association and identify any divergence from results using unadjusted data.
Studies reporting odds ratios or risk ratios per standard deviation or 1 mmol/l of glucose
The aim of this analysis was to identify trends in outcomes with changes in glucose levels, so results
reporting the trend as ORs per 1 mmol/l of glucose per SD in glucose level would be the preferred data.
However, only the HAPO study6 reported such results, so no meta-analyses could be performed. The
reported ORs per SD of glucose were converted into ORs per 1 mmol/l using the reported SDs. These were
then compared with ORs obtained from the IPD cohorts.
Studies reporting three or more glucose categories
For each study the risk of each GDM-related outcome along with its 95% confidence interval (CI) was
calculated for each glucose category. For each outcome, and for each study, this risk was plotted against
the level of glucose in each category, to visually inspect the trends in risk with glucose level.
Studies reporting results from only two glucose groups were excluded from these analyses because they
did not report sufficient data to reliably estimate median glucose levels in each glucose category.
After inspecting risk of outcome across glucose categories for as many outcomes as possible, and in as
many studies as possible, we felt that it was reasonable to assume a log–linear relationship between
fasting or post-load glucose levels and all outcomes. Associations of fasting or post-load glucose levels
(per 1 mmol/l) were therefore modelled separately for each study, outcome and glucose test (based on
timing and load), using the following logistic regression model:
log
pi jkl
1− pi jkl
 !
= ɸi jkl + θi jklGi jkl, (model 1)
where i indicates study, j glucose test (e.g. 100-g OGTT fasting level), k the outcome of interest (e.g.
macrosomia) and l the glucose category. Then pijkl is the probability of having the outcome in the relevant
glucose category, Gijkl is the estimated median glucose level in that category, so ɸijkl is the baseline log
odds of the outcome and θijkl is the association between glucose level and outcome, in terms of the log
odds of outcome per 1-mmol/l increase in glucose level.
Estimates of association between outcome and glucose level, with their 95% CI, were pooled across
studies using DerSimonian and Laird random-effects meta-analysis to account for any potential
heterogeneity in the trends across studies.62 Studies were combined in meta-analyses if there were two or
more studies for the specified outcome and glucose test. Heterogeneity was examined using the I2-statistic
and its 95% CI.63
To increase the number of studies and participants in each comparison, studies were pooled if they
included relevant glucose levels (fasting and/or post load) from either the 75-g or 100-g OGTT. This
assumes that the trends in outcome incidence with glucose level were the same for the two OGTTs. We
used a ‘one-stage’ version of model 1, above, with all studies combined in a single regression model. This
model includes random intercept (ɸ) and slope (θ) terms to account for heterogeneity in the baseline odds
of the outcome (i.e. the odds of each outcome in the lowest glucose category) and association between
glucose levels and outcome between studies.
This analysis differs slightly from that in Chapter 2, for which results were summarised as the odds per SD.
In this chapter, odds per 1 mmol/l glucose are used. This is because the SD in glucose levels varies across
studies and was not generally reported; using odds per 1 mmol/l glucose permits a consistent approach to
analysis across studies.
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For studies that reported an adjusted OR for each outcome relative to a baseline glucose category,
including the two studies for which we had IPD,22,59 we examined adjusted results. The adjusted ORs
with their 95% CIs were plotted against the level of glucose in each category, so that a visual inspection
of trends in risk across glucose levels could be undertaken. However, we were unable to perform
meta-analyses of these results because of the limited number of studies presenting adjusted ORs.
Linearity
Following a visual inspection of figures of associations and to test the validity of our assumption of a
log–linear association between outcome and glucose level (based on evidence from the HAPO6 and BiB22
studies), model 1 – presented above – was fitted again with an additional glucose-squared term (i.e. a term
γ i jklG
2
i jkl). A statistically significant association with glucose squared would suggest a quadratic–curvilinear
relationship. Therefore, a lack of evidence suggests the relationship is not likely to be quadratic and
suggests, along with the visual evidence, that there is a possibility that the relationship may be linear.
Studies reporting only two glucose categories
Several studies examined associations between perinatal outcomes and glucose levels following a 50-g
OGCT. The OGCT was undertaken to determine whether women should (or should not) go on to have a
diagnostic OGTT. Outcomes were then compared between those who did not meet the criteria for having
an OGTT with those who did meet those criteria but who were not diagnosed with GDM [i.e. two groups
were compared: < 130 mg/dl vs. ≥ 130 mg/dl post-challenge glucose or (for some studies) < 140 mg/dl vs.
≥ 140 mg/dl post-challenge glucose].14 The glucose categories in millimoles per litre (values expressed as
milligrammes per decilitre were converted to millimoles per litre) in each of these two comparisons were
abstracted, as were the numbers of women in each category and the number of these with outcomes in
each category.
Some studies compared outcomes in women whose glucose levels were all ‘normal’ at any OGTT time
point (i.e. fasting and 1, 2 or 3 hours post load, depending on which tests was undertaken) to women
who had one elevated glucose level; these comparisons were undertaken in populations using criteria that
required at least two elevated levels for a diagnosis of GDM to be made.
For both of these types of study, the numbers of outcomes in each group was used to calculate ORs for
outcomes. The ORs for each group (lower risk vs. higher risk) were pooled across studies for each outcome
using DerSimonian and Laird random-effects meta-analysis.62
Analyses of the individual participant data cohorts
In order to perform analyses that were not possible with published data, in particular to perform adjusted
analyses, further analyses of the two IPD cohorts were performed. To maintain consistency, the statistical
modelling approach used was broadly similar to that used in the analyses of published studies. To maintain
a consistent approach to analyses of the two cohorts the data sets were cleaned using the same rules and
analyses undertaken as described below.
The shape of the association between outcomes and glucose levels were viewed. Following this assessment
and to model these associations a log–linear relationship between risk and outcome was assumed; the
model was adjusted for age, BMI and ethnicity (these were the potential confounders reported across both
cohorts). Women with GDM according to the WHO criteria11 were excluded from analysis, as they were
offered treatment (fasting ≥ 6.1 mmol/l and/or 2-hour post-load ≥ 7.8 mmol/l). This association was modelled
separately for each cohort, outcome and time of glucose measurement. Formally, the models had the form:
log
pi j
1− pi j
 !
= ɸi + θiGi j + βXi j, (model 2)
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with parameters as in model 1, above, except that Xij is a matrix of the adjusting factors (age, BMI,
ethnicity). The model was fitted using logistic regression. For each cohort outcome, for both fasting and
post-load glucose model results were used to calculate the estimated odds of outcome at increasing
glucose levels, and the absolute risk of an outcome at increasing glucose levels, to examine the trend in
risk with glucose.
The results from model 2, above, for each cohort were used to predict the OR of having an outcome
relative to the mean glucose level across the full range of fasting and post-load glucose levels. This makes
the assumption that the log OR increases linearly with glucose levels.
A further ‘one-stage’ model was considered, pooling the two cohorts together in a single model. The same
model structure as in model 1, above, was used, but assuming that the association between glucose level
and outcome was subject to a random effect across the two cohorts, that is:
θi ∼N(θ, τ2), (model 3)
where θ is the summary association between glucose level and outcome across both cohorts and τ2 is the
heterogeneity in effect. To test the validity of the assumption of a log–linear association between outcome
and glucose level the model presented above was fitted again with an additional glucose-squared term.
Results
Included studies
The search from the unpublished review55 and the updated searches together identified 11,219 potentially
relevant studies following removal of duplicates. After title and abstract screening 125 publications were
obtained for full-text review. After full-text screening, 57 studies (see Tables 7–9) were included in the
review and 37 in the meta-analysis (including the two studies22,59 for which we had IPD) (see Appendix 2,
Table 62 for excluded studies with reasons). Figure 3 shows the identification of these studies.
Several publications reported data from the same cohort. Four of the included publications used data from
the HAPO cohort,6 but reported different outcomes. One of these publications (Pettitt et al.41) was not
included in the analyses because it reported associations with outcomes in a subset of participants that
had been previously reported in the whole cohort. For the remaining publications, data from the most
recent and comprehensive publication for each outcome were used. Two publications61,64 used data from
the same cohort: Figueroa et al.64 examined glucose levels at OGCT and risk of adverse outcomes, whereas
Landon et al.61 examined glucose levels at OGTT and risk of adverse outcomes. Data from both
publications are therefore included in analyses.
Characteristics of eligible studies are described in Tables 7–9. The studies fall into four categories: (1) 28
studies (including BiB and Atlantic DIP)6,61,64–87 reported associations between glucose levels (from OGTT or
OGCT) split into three or more categories and adverse perinatal outcomes (see Table 7); (2) 20 studies88–107
reported associations between glucose levels (from OGTT or OGCT) split into two categories with adverse
perinatal outcomes (see Table 8) – these studies were mostly comparisons of women with lower glucose
levels at OGCT [typically < 140 mg/dl (7.8 mmol/l)] compared with women with higher glucose levels at
OGCT; (3) five studies36,41,65,108,109 reported longer-term outcomes in either mother or offspring (see Table 9)
(it was not possible to pool studies reporting longer-term outcomes because they were too diverse); and
(4) the remaining five studies110–113 did not present numerical data that were suitable for analysis and
therefore could not be included in any of the meta-analyses (see Appendix 2, Table 63). One study114 used
a 75-g OGTT in a non-fasted population. As there were no other studies that had used this test in this
way, and post-load glucose levels from a non-fasted group are likely to differ to those from a fasted
group, we did not include results from this study in any meta-analyses.
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Quality assessment
The results of the quality assessment of the included studies are shown in Appendix 2, Table 60. In general
most studies were at low risk of bias. Most studies recruited any pregnant women, without any further
inclusion/exclusion criteria, so that the study population would be more representative of the whole
‘general’ obstetric population. The majority of studies were in western populations from high-income
countries, with a small number from other populations, for example the Pima Indian population of
Arizona. There was little loss to follow-up in most studies. Fasting and post-load glucose levels were
assessed using OGCT and/or OGTT, and most outcomes were measured using standard definitions.
The main potential risk of bias was due to lack of blinding. Blinding of participants, clinicians, research
staff and those assessing outcomes to glucose levels is possible; however, all staff may have been aware
that glucose levels did not indicate GDM (study defined) requiring treatment. Many studies were
retrospective, and in these cases it is likely that participants and medical staff were aware of the
glucose levels.
Consequently, it is possible that associations of glucose levels with perinatal outcomes were ‘confounded
by indication’. Women and health practitioners may have been influenced by glucose results. For example,
in those women who had levels just below the thresholds for GDM diagnosis, monitoring and treatment
may have differed from those whose levels were lower. Those with higher levels might have been given
lifestyle advice aimed at reducing their levels, they may have been monitored more closely and there may
have been a greater likelihood of intervening during labour, such as electing for C-section.
Potentially relevant
records identified through
database searching
(n = 15,916)
Records after duplicates
removed
(n = 11,219)a
Records screened
(n = 11,241)
Records excluded on title
and abstract
(n = 11,116)
Full-text articles excluded,
with reasons
(n = 70)
Additional records identified
through other sources such
as previous systematic
reviews
(n = 22)
Cohorts with IPD
(n = 2)
Articles excluded because
data were not appropriate
for the meta-analyses
(n = 20)
Full-text articles assessed
for eligibility
(n = 125)
Studies included in
qualitative synthesis
(n = 57)
Studies included in
meta-analyses
(n = 37)
FIGURE 3 The search process. a, Includes 7947 from the March 2013 search, 808 from the September 2013 search,
and 2464 from the October 2014 search.
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Studies generally reported all outcomes listed in their methods sections, but no single study reported data
on all of our included outcomes. The studies were necessarily observational (randomisation to a given
glucose level is not possible). In addition to confounding by indication, it is possible that other characteristics
might have confounded the associations that we have examined. Only a minority of studies reported
associations that were adjusted for what we considered to be key confounding factors (maternal age,
BMI/other measure of adiposity and previous GDM).
The two cohorts for which we had IPD were judged – like most other studies described in Appendix 2,
Table 60 – to be at low risk of bias. For these we had the added advantage that we were able to adjust
for key confounders, although as with other studies we cannot rule out confounding by indication or
residual confounding by characteristics that were unmeasured or poorly measured in those studies.
Analyses of individual participant data cohorts
The frequencies of each adverse outcome across seven fasting and 2-hour post-load glucose categories in
the BiB study22 and Atlantic DIP59 are shown in Appendix 2, Figure 47. We have not included skinfolds
of > 90th percentile as an outcome or any other measure of infant adiposity because it was not available
in the Atlantic DIP cohort59 and in relation to the BiB study22 it has been reported in Chapter 2. For
comparison we have included the HAPO study6 point estimates in the analyses presented in Appendix 2,
Figures 48 and 49 (we were unable to secure IPD from the UK centres of the HAPO study6) because the
results from that study6 have recently been used to develop new criteria thresholds for GDM diagnosis.
Across all categories of fasting and post-load glucose levels the frequencies of C-section, instrumental
birth, LGA, macrosomia and pre-eclampsia are greater in the Atlantic DIP cohort59 than in the BiB study.22
Preterm birth is similar in both studies, and numbers for shoulder dystocia are too few to draw conclusions.
The ORs per 1-mmol/l increase in fasting and post-load glucose levels for the BiB, Atlantic DIP and HAPO
studies6,22,59 are shown in Appendix 2, Figures 48 and 49, respectively. For most outcomes the cohorts
show similar results, with increases in outcome incidence as glucose levels increase, although results were
not always statistically significant in the smaller Atlantic DIP cohort.59 There are some exceptions to this.
For instrumental delivery, the BiB study22 shows a positive association between outcome and glucose level,
but no such association was found in the Atlantic DIP study.59 For the Atlantic DIP study,59 risk of preterm
birth reduced as fasting glucose level increased, but increased as post-load glucose level increased.
This may be a chance finding and related to the low incidence of preterm birth in the Atlantic DIP
study59 (3%). Associations were stronger for fasting glucose levels than 2-hour post-load glucose levels.
Meta-analyses provided significant results for ORs per 1-mmol/l increases in glucose level and the majority
of outcomes, with the exception of instrumental and preterm birth, for fasting glucose level.
In Appendix 2, Figures 50 and 51 show the ORs for each outcome with increasing fasting and post-load
glucose categories, respectively, relative to the mean glucose level for each outcome in each of the cohorts.
The dashed vertical lines show the thresholds for diagnosing GDM using the IADPSG and WHO (1999)
criteria (fasting glucose levels of 5.1 mmol/l and 6.1 mmol/l; post-load glucose levels of 7.8 mmol/l and
8.5 mmol/l, respectively) and the horizontal dashed line an OR of 1.75 (the OR recommended by the
IADPSG for applying GDM diagnostic thresholds).
The estimated ORs illustrated in Appendix 2, Figure 50, which are greater than the WHO fasting threshold
of 6.0 mmol/l, and in Appendix 2, Figure 51, which are greater than the post-load threshold of 7.7 mmol/l,
are predictions assuming that the linear trend continues at higher glucose levels (if women are not
treated), and are not based on the data from the cohorts (because in both cohorts women were offered
treatment if their glucose levels were greater and therefore have been excluded). For fasting glucose level,
the two cohorts give similar results for C-section, LGA, macrosomia, pre-eclampsia and shoulder dystocia.
For macrosomia, LGA and shoulder dystocia the IADPSG diagnostic threshold of 5.1 mmol/l corresponds
reasonably closely with an OR for outcomes relative to average fasting glucose level of between 1.5 and
1.75 mmol/l. The WHO thresholds are associated with a higher OR for adverse outcome.
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Trends in perinatal outcome risk with glucose levels
This section examines 28 studies presenting data on perinatal outcomes in three or more glucose
categories using either an OGCT or OGTT (see Table 7). This section presents a series of figures for which
the risk of a specified outcome is plotted against glucose levels. Studies are categorised according to
the timing of the glucose test (fasting, 1-hour post load, 2-hour post load) and the glucose load used
(50-g OGCT, 75-g OGTT, 100-g OGTT).
Appendix 2, Figure 52, shows the trend for macrosomia, and Appendix 2, Figure 53, for LGA. For both
outcomes the analyses suggest the risk increases as glucose levels increase, the association seems stronger
for fasting glucose level compared with post-load glucose level. The relationship appears to be linear,
with no sudden increase in risk. There is considerable heterogeneity across studies in the underlying risk
of macrosomia and LGA, but the trends (i.e. the slopes of the lines) appear reasonably consistent across
studies. Although there are differences in the actual glucose levels according to the glucose test used,
there is no evidence that the trend in risk with glucose level is different for the different glucose tests.
In Appendix 2, Figure 54 shows the trends for pre-eclampsia and increasing glucose levels; Figure 55,
C-section, Figure 56 instrumental birth; and Figure 57, induction of labour and increasing glucose levels.
Risk of pre-eclampsia and C-section seems to increase with increasing glucose level similarly to macrosomia
and LGA. Data on assisted delivery (forceps and ventouse) and induced labour are too few to draw any
meaningful conclusions.
Furthermore, in Appendix 2, Figure 58 shows the trends for shoulder dystocia; Figure 59 the trends for
preterm birth; and Figure 60 the trends for neonatal hypoglycaemia. Although data for all three outcomes
are limited, these outcomes do not seem to be associated with increasing glucose levels. The risk of
shoulder dystocia appears to increase only at the higher levels of glucose (e.g. > 6 mmol/l at 2 hours post
load), although this observation is driven primarily by one study.61
Association between 1-mmol/l increases in fasting and post-load glucose
levels and risk of adverse perinatal outcomes
This section examines the trends in adverse perinatal outcomes (see Appendix 2, Figures 52–60) and
increasing glucose levels represented as ORs for each outcome per 1-mmol/l increase in glucose level,
calculated using the logistic regression models described above (see Methods). Each glucose load/test is
considered separately, and when there are sufficient studies for any outcome, results are combined in
meta-analyses.
50-g oral glucose challenge test
Figure 4 shows the OR per 1-mmol/l increase in 1-hour post-load glucose for outcomes using the 50-g
OGCT. The associations between C-section, LGA, macrosomia, neonatal hypoglycaemia, pre-eclampsia and
shoulder dystocia are statistically significantly associated with 1-mmol/l increases in glucose level. Preterm
birth does not seem to be associated with increases in glucose level, or does PIH/pre-eclampsia (some
studies combine these two outcomes).
75-g oral glucose tolerance test
Figure 5 shows the OR per 1-mmol/l increase in fasting glucose for all outcomes. The risk of the majority of
adverse outcomes increases with increasing fasting glucose level, with statistically significant associations
for LGA, macrosomia, pre-eclampsia, C-section, induced labour and neonatal hypoglycaemia. There is no
evidence of increasing odds with increasing glucose levels for shoulder dystocia or instrumental birth
(forceps and ventouse). There seems to be a negative association between increasing fasting glucose levels
and preterm birth, suggesting that, as glucose levels increase, the odds of a preterm birth reduces by 23%
(OR 0.77, 95% CI 0.62 to 0.96).
Appendix 2, Figure 61, shows the OR per 1-mmol/l increase in 1-hour post-load glucose for reported
outcomes without meta-analysis because of the limited number of studies included. The HAPO study6
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Pooled
LGA
Cheng 200768
Figueroa 201364
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Pooled
Macrosomia
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Yee 201087
Pooled
Neonatal hypoglycaemia
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Pre-eclampsia
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Cheng 200768
Lurie 199875
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Yee 201087
Pooled
Preterm birth
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Pooled
Shoulder dystocia
Cheng 200768
Yee 201087
Pooled
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1.20 (1.14 to 1.27)
1.18 (1.10 to 1.26)
1.35 (1.23 to 1.49)
 
0.93 (0.46 to 1.88)
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1.14 (1.04 to 1.24)
 
1.39 (1.24 to 1.57)
1.24 (1.10 to 1.40)
1.68 (1.29 to 2.19)
1.22 (1.12 to 1.33)
1.32 (1.19 to 1.46)
 
1.19 (1.09 to 1.31)
1.18 (1.05 to 1.32)
1.11 (1.08 to 1.14)
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1.11 (1.00 to 1.24)
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1.31 (1.07 to 1.20)
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1.23 (1.10 to 1.36)
1.15 (1.04 to 1.28)
1.25 (1.13 to 1.39)
 
1.04 (1.00 to 1.08)
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1.06 (0.96 to 1.17)
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Study Effect (95% Cl)
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OR per 1-mmol/l increase in glucose
increased riskReduced risk
FIGURE 4 Odds ratio for 1-mmol/l increases in 1-hour post-load glucose for 50-g OGCT and adverse outcomes.
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FIGURE 5 Odds ratio for 1-mmol/l increases in fasting glucose level for 75-g OGTT and adverse outcomes.
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reports BW of > 90th percentile and Pettitt et al.41 report LGA; however, Pettitt et al. report results for a
subset of participants from the whole HAPO study.6 The analyses suggest that the 2-hour post-load
glucose (Figure 6) associations are weaker than the fasting glucose associations (see Figure 5), and the
statistically significant associations between increasing fasting glucose and reduced odds of preterm birth
and increased odds of C-section are lost.
100-g oral glucose challenge test
Figure 7 shows the OR per 1-mmol/l increase in fasting glucose for all outcomes using the 100-g OGTT,
and Figure 8 shows the results for 2-hour post-load glucose without meta-analysis because of the limited
number of studies. Only one study61 reported 1-hour 100-g results for outcomes including cord C-peptide
and LGA. One study80 performed the OGTT at 9 weeks rather than at the more usual 26–28 weeks.
Fasting results (the only levels reported by this study80) seem consistent with the fasting glucose results
reported at the more conventional 26–28 weeks.83
It is difficult to draw conclusions from the results reported by these studies, given the limited data, but the
findings are similar to the post-load associations of the 75-g test results. Fasting glucose and associated
outcomes should not be affected by the subsequent glucose load; however, differences in glucose load
and subsequent post-load glucose associations may be.
Combining 75-g and 100-g glucose test results
To increase the number of studies and participants included in the comparisons, we combined the results
for the 75-g and 100-g OGTTs. We therefore assumed that the association between outcomes and
increases in glucose were the same for both tests. The results of meta-analyses combining these tests are
shown in Figure 9.
Combined results (75-g and 100-g OGTT) are similar to those for the 75-g OGTT alone. For fasting glucose
there are statistically significant increases in risk of C-section, LGA, macrosomia, pre-eclampsia, neonatal
hypoglycaemia, induction (of labour) and shoulder dystocia. Glucose levels do not appear to be associated
with preterm birth or assisted (instrumental) delivery. The increase in odds can be substantial, with a more
than doubling in odds per 1-mmol/l increase in fasting glucose level for pre-eclampsia and for LGA.
The results for the 2-hour post-load glucose levels are weaker than fasting associations, although CIs are
narrower, particularly for preterm birth and pre-eclampsia, The association of increasing 2-hour post-load
glucose levels with C-section just misses significance (OR 1.10, 95% CI 0.96 to 1.25).
The associations are weaker when the 75-g and 100-g test results are combined compared with the 75-g
test results alone, reflecting the weaker associations when the 100-g test is administered.
Testing the linearity assumption
We viewed the shape of the associations between the log odds of outcomes and increasing glucose levels
or categories for fasting and 2-hour OGTT (combining 75-g and 100-g tests) and for the 1-hour OGCT,
for each outcome, these associations appeared generally linear. We tested the assumption of a linear
association by including a squared term for the glucose levels in the regression models (see Methods).
If the associations were quadratic curvilinear (rather than linear) we would expect there to be a statistically
significant association between outcome risk and the square of the glucose level. The results of this
analysis for all outcomes for the fasting and 2-hour 75-g OGTT and the OGCT are presented in Appendix 2,
Table 61. Data were too limited to repeat this analysis for the 100-g OGTT alone.
The small number of studies limits the ability to draw conclusions; however, for the majority of outcomes,
the association between outcome and the square of glucose was not statistically significant – it is therefore
reasonable that, given the visual evidence (see Appendix 2, Figures 52–60), the association between glucose
levels and outcomes is linear. There were, however, statistically significant curvilinear associations between
fasting and 2-hour post-load glucose levels (75-g OGTT) and 1-hour post-load glucose level (50-g OGCT) and
PIH/pre-eclampsia, but two of these associations were negative, suggesting that the odds of pre-eclampsia
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FIGURE 6 Odds ratio for 1-mmol/l increases in 2-hour post-load glucose level for 75-g OGTT and adverse outcomes.
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‘levels off’ slightly at higher glucose levels rather than continuing to increase, and one association (fasting
glucose, 75-g OGTT) was positive. This inconsistency in direction suggests that these may be chance findings,
and therefore caution is advised when considering these results. There was a positive association with fasting
glucose (75-g OGTT) and neonatal hypoglycaemia and preterm birth, but few studies were included, and,
again, these results should be interpreted with caution (see Appendix 2, Table 61).
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FIGURE 8 Odds ratio for 1-mmol/l increases in 2-hour post-load glucose for 100-g OGTT and adverse outcomes.
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FIGURE 7 Odds ratio for 1-mmol/l increases in fasting glucose for 100-g OGTT and adverse outcomes.
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Analyses of adjusted odds ratios
Of the included studies, 106,61,64,66,68–70,72,80,82 reported ORs for outcomes adjusted for potential confounding
factors such as maternal BMI and previous GDM. This section presents these ORs relative to the baseline
glucose category for macrosomia64,70,80 LGA6,61,64,72,82 C-section6,68,80,82 and pre-eclampsia66,68,69 which were
the only outcomes reported across studies.
Appendix 2, Figure 62, shows the results for macrosomia; Figure 63, LGA; Figure 64, C-section; and
Figure 65, pre-eclampsia. The limited data make drawing conclusions difficult; however, there seems to
be a general trend of increasing odds (when results are adjusted for selected potentially confounding
variables) of each adverse perinatal outcome with each 1-mmol/l increase in glucose level. Compared with
post-load glucose level, fasting is more strongly associated with odds of a perinatal outcome. For example
the odds of LGA doubles with each 1-mmol/l increase in fasting glucose level, whereas the odds of LGA
doubles with each 3 mmol/l increase in 2-hour post-load glucose level.
Meta-analysis of studies with two oral glucose challenge test or oral glucose
tolerance test categories
Fifteen studies reported associations between two glucose categories and adverse perinatal outcomes.
The characteristics of these studies are presented in Table 8. Ten of these studies examined associations
between glucose levels following a 50-g OGCT and perinatal outcomes. Outcomes were compared
between those who did not meet the criteria for having an OGTT to those who did meet those criteria,
but who were not diagnosed with GDM, that is, two groups were compared [< 130 mg/dl vs. ≥ 130 mg/dl
post challenge glucose level or (for some studies) < 140 mg/dl vs. ≥ 140 mg/dl post challenge glucose
level]. Three studies compared lower levels of glucose with higher levels 2 hours after a 75-g or 100-g
OGTT, whereas two other studies compared women with no elevated glucose levels at any time following
an OGTT, with women with one elevated glucose level. For all of these comparisons, the numbers of
outcomes in the two groups were used to calculate ORs for outcomes comparing one group with a
perceived lower risk with another group with a perceived higher risk.
0.50 0.75 1.50 3.00
Odds ratio per 1 mmol/l increase in glucose
increased riskReduced risk
Morbidity Timing Number of studies Effect (95% CI)
C-section6,22,59,71,80,83
Induction22,71
Instrumental birth22,59,71
LGA6,22,59,61,65,71,72
Macrosomia22,59,71,80,81,83
Pre-eclampsia22,59,69,83
Preterm birth22,59,71
Shoulder dystocia22,59,61,71
Neonatal hypoglycemia71,76
PIH/Pre-eclampsia61,71,81
C-section6,61
LGA6,61
Pre-eclampsia61,69
C-section6,22,59,71,73,77,79,83,106
Induction22,71
Instrumental birth22,59,71,77
LGA6,22,59,61,65,71–74,77,79
Macrosomia22,59,71,73,81,83,85
Pre-eclampsia22,59,69,83
Preterm birth22,59,71,73,79,85
Shoulder dystocia22,59,61,71,74
Neonatal hypoglycemia71,74,76
PIH/Pre-eclampsia61,71,81
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
Fasting
1 hour
1 hour
1 hour
2 hours
2 hours
2 hours
2 hours
2 hours
2 hours
2 hours
2 hours
2 hours
2 hours
6
2
3
7
6
4
3
4
2
3
2
2
2
9
2
4
11
7
4
6
5
3
3
1.59 (1.49 to 1.70)
1.31 (1.14 to 1.50)
0.99 (0.87 to 1.13)
2.11 (1.73 to 2.58)
2.06 (1.86 to 2.28)
2.15 (1.45 to 3.19)
0.77 (0.62 to 0.96)
1.97 (1.36 to 2.85)
1.37 (1.20 to 1.57)
1.91 (1.49 to 2.43)
1.18 (1.15 to 1.20)
1.24 (1.20 to 1.27)
1.19 (1.15 to 1.24)
1.10 (0.96 to 1.25)
1.10 (1.04 to 1.16)
1.07 (1.03 to 1.12)
1.22 (1.19 to 1.25)
1.21 (1.16 to 1.26)
1.23 (1.18 to 1.29)
1.07 (0.99 to 1.15)
1.38 (1.22 to 1.56)
1.13 (1.09 to 1.18)
1.19 (1.08 to 1.30)
FIGURE 9 Combined 75-g and 100-g OGTT fasting glucose, 1-hour glucose levels, 2-hour glucose levels and
adverse outcomes.
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
39
The results of these meta-analyses are shown in Figures 10 and 11. Women in the group with higher
glucose levels following an OGCT have a statistically significant increased risk of C-section, LGA,
macrosomia and pre-eclampsia than women with lower glucose levels. Other outcomes were reported in
only one or two studies; therefore, these associations are less clear (see Figure 10).
Results from studies comparing lower levels of glucose with higher levels at 2 hours following a 75-g or
100-g OGTT, and results from studies comparing women with no elevated glucose levels at any time after
an OGTT to women with one elevated glucose level, were not pooled in meta-analyses. This was because of
the differences in the glucose tests used and the timings of the glucose measurements. Generally, however,
there was a suggestion that women with one elevated glucose level at OGTT are at higher risk of C-section
and macrosomia than women with no elevated glucose levels, although the CIs are wide and often include
the null value. There was no evidence of a difference between groups in the odds of preterm birth.
Studies of longer-term and anthropometric outcomes
Six studies22,36,41,65,108,109 reported longer-term and/or anthropometric outcomes, either measures of
adiposity or incidence of diabetes. The characteristics of these studies are presented in Table 9.
Three studies7,36,65 (see Chapter 2) reported neonatal obesity (skinfold thickness and percentage body fat
of > 90th centile), one study41 reported obesity at age 2 year and one study108 reported obesity at age
5–7 years. One study,109 in Pima Indians, reported longer-term incidence of diabetes in offspring.
The associations of glucose levels with each outcome for each study are shown in Figure 12. Data from
one study115 were presented only as ORs of association, so this study could not be included in this figure.
Data are too few to perform a meta-analysis; however, the HAPO36 (2009) model II results (model II, adjusted
for age, BMI, BMI2, height, mean arterial BP, gestational age at OGTT, smoking, alcohol use, hospitalisation
prior to delivery, and any family history of diabetes) suggest a strong association between glucose levels and
sum of skinfolds (flank, triceps and subscapular) of > 90th centile (fasting OR per SD 1.39, 95% CI, 1.33
to 1.47; 1-hour post-load glucose level OR 1.42, 95% CI 1.35 to1.49); 2-hour post-load glucose level OR
1.36, 95% CI 1.30 to 1.43) and body fat of > 90th centile (fasting OR 1.35, 95% CI 1.28 to 1.42; 1-hour
post-load glucose level OR 1.44, 95% CI 1.37 to 1.52; 2-hour post-load glucose level OR 1.35, 95% CI 1.29
to 1.42). Aris et al.65 and the BiB study7 (see Chapter 2) report a linear association between skinfold thickness
or body fat percentage of > 90th percentile with increasing glucose levels (fasting and 2-hour post load).
There is limited evidence of an association between increasing maternal glucose levels and longer-term
child obesity and overweight. Hillier et al.108 report the risk of childhood obesity and overweight is greater
for infants of women with the highest OGCT glucose levels than for those with the lowest, and that risk is
greater for infants of women with GDM than infants of women without GDM (child weight > 95th centile,
OR 1.82, 95% CI 1.15 to 2.88). Pettitt et al.41 found no evidence of an association between glucose levels
and overweight and obesity at the age of 2 years.41
Pettitt et al.109 reported a strong association between increasing maternal glucose level and increased risk
of offspring diabetes, but this was in an unusual population (Pima Indians) therefore the results may not
generalise to European populations.
Other identified studies not included in the meta-analyses
Several studies could not be included in the analyses: one study110 reported the association between
fasting, 1-hour and 2-hour OGTT glucose levels and outcomes only as an OR per SD. The study110 reports
statistically significant increases in risk of LGA, C-section, preterm birth, shoulder dystocia and gestational
hypertension with increasing glucose levels.
One study111 examined the incidence of type 2 diabetes in Pima Indians (similarly to Pettitt et al.,109 and
possibly for the same cohort, so is excluded) and concluded that diabetes incidence in offspring increases
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FIGURE 10 Meta-analysis for ORs of outcomes comparing those with OGCT negative results with those with OGCT
positive results.
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as maternal glucose levels increase, the 2-hour post-load OGTT glucose level was used, diabetes was
recorded at ages from 10 to 25 years.
One study71 reported preliminary results, so it was excluded because it was superseded by a later
publication included in the analyses.112 The earlier study71 reported 2-hour post-load 75-g OGTT glucose
levels and incidence of LGA, shoulder dystocia, C-section and preterm birth.
One study114 reported a significant association between the 2-hour post-load glucose level following a 75-g
non-fasted OGCT and macrosomia. The study114 was excluded because the 75-g OGCT is a glucose load not
normally used in a non-fasted state and there were no other studies using this test in this way.
One study113 compared the risk of outcomes in women without elevated glucose levels to those with a single
elevated glucose level at either 1, 2 or 3 hours following a 100-g OGTT. The study113 reported that, compared
with women without an elevated glucose level, women with one elevated glucose level were at higher risk of
adverse outcomes including C-section, pre-eclampsia and neonatal hypoglycaemia. The associations were
stronger for women with an elevated glucose level at 1-hour post-load compared with 2 or 3 hours. There
were no women with an elevated fasting glucose level and normal post-load glucose level.
Discussion
We identified 57 eligible studies examining the association between maternal glucose levels at OGTT and
OGCT and risk of adverse maternal and infant outcomes. The data reported by five studies71,110,111,113,114
were insufficient to allow inclusion in any meta-analyses.
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FIGURE 11 Meta-analysis for ORs of outcomes comparing those with one OGTT elevated glucose level with those
with no elevated OGTT glucose levels.
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Studies examining the association between three or more graded increases
in glucose level and risk of perinatal adverse outcomes
There was a positive association between LGA, macrosomia, C-section plus pre-eclampsia and increasing
glucose levels. There was evidence for an increase in risk in shoulder dystocia, neonatal hypoglycaemia,
instrumental (assisted) birth and induced labour, although data were more limited for these outcomes.
There was no evidence of an association between preterm birth and increasing maternal glucose levels.
The associations, in terms of OR per 1-mmol/l increase in glucose level, were stronger for fasting glucose
levels than post-load glucose levels.
Fewer studies examining glucose levels and adverse outcomes used the 100-g OGTT than the 75-g OGTT;
however, our findings suggest that associations are similar for the two tests. Equally, the post-load
glucose results for the 1-hour 50-g OGCT were broadly consistent with the post-load glucose results of
the 75-g and 100-g OGTT. We combined the fasting results from the 75-g and 100-g OGTT together
and the results from the 2-hour post-load 75-g and 100-g OGTT. Combining results for fasting glucose
measurements is reasonable, because fasting glucose levels will not be affected by subsequent glucose
load. The validity of combining results for post-load glucose level is more uncertain, as it assumes that the
association of risk between adverse outcomes and glucose level is independent of the test’s glucose load.
Our analysis generally suggests the odds of an adverse outcome increases linearly with glucose levels.
Therefore, there appears to be a continuum of risk across glucose levels, with no sudden increase in risk at
any glucose level, suggesting that there is no glucose level below which there is no increased risk, and no
clear glucose threshold that can distinguish between women at low risk from those at a substantially
increased risk of having an adverse outcome.
We excluded women from our analysis with diagnosed GDM, however defined, because these women
would have been offered treatment and treatment to reduce hyperglycaemia will influence the natural
association between glucose level and outcome risk (see Chapter 2).
Most of the analyses were based on unadjusted raw numbers of women with outcomes in different
categories. The risks may therefore be over or underestimated because of potential confounding. For
example, the risk of macrosomia is recognised as being higher for obese women than ‘normal’ weight
women irrespective of glucose levels.116 In the few studies presenting adjusted analyses to correct for
possible confounding, there was evidence that risk of adverse outcomes increased (similarly to unadjusted
analyses) as glucose levels increased, and we have also shown this using the BiB study data,22 as described
in Chapter 2. However, we cannot rule out confounding by indication or residual confounding by
characteristics that were unmeasured or poorly measured in studies.
Studies examining the association between graded increases in glucose level
and risk of longer-term adverse outcomes
There were few studies investigating longer-term outcomes for the mother or infant. Two studies41,108
examined glucose levels and risk of offspring obesity and reported variable results. One study109 reported
an association with diabetes in childhood; however, the women were Pima Indians, who are at greater risk
of diabetes, and therefore these results may not generalise to a European population.
Studies examining the association between two categories of glucose level
and risk of adverse outcomes
Several studies present glucose levels at OGCT divided into two categories (typically women considered to
have OGCT positive results vs. OGCT negative results). Our analyses showed that elevated OGCT levels
(those indicating an OGTT should be offered) compared with ‘normal’ OGCT results were associated with
an increased risk of C-section, LGA, macrosomia and pre-eclampsia, suggesting that this test does identify
women at increased risk of these adverse outcomes. A limited number of studies presented results for the
OGTT with just two glucose groups, but data were too few to draw any firm conclusions.
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Strengths and limitations
We identified a large number of high-quality studies examining associations between maternal glucose levels
and adverse perinatal outcomes; most studies included > 1000 women. Studies tended to report similar
adverse outcomes and therefore we were able to pool estimates in meta-analyses. We were able to examine
(because they were available and reported) a variety of outcomes including macrosomia, LGA, C-section,
pre-eclampsia, neonatal hypoglycaemia and shoulder dystocia, across the whole glucose spectrum.
Included studies were necessarily observational (randomisation to a given glucose level is not possible),
therefore it is conceivable that other characteristics might have confounded the associations that we have
examined and may be responsible for the results we present.
Unfortunately, five studies71,110,111,113,114 did not include sufficient data or information to allow inclusion in
the meta-analyses and therefore our estimates may have been different if these studies were able to be
included. However, as most studies suggest a positive relationship between increasing glucose level and
adverse outcome, the inclusion of these studies would be unlikely to change results.
Five studies36,41,65,108,109 examined maternal glucose level and longer-term outcomes, although they
investigated diabetes and adiposity, the timing of the measurements and methods of assessment varied,
preventing pooling of estimates. Data for the 100-g OGTT, and particularly the 1-hour post-load measure,
were more limited than the 75-g OGTT, therefore less confidence should be placed on these results.
Conclusion
Our meta-analyses suggest an increasing risk for the majority of reported adverse perinatal outcomes
including macrosomia, LGA, C-section, pre-eclampsia, neonatal hypoglycaemia and shoulder dystocia,
across the whole spectrum of glucose levels. Associations between risk of an outcome and graded increases
in glucose level seem to apply to all glucose loads (50-g, 75-g and 100-g) and at all measurement times
(fasting, and 1-hour and 2-hour post load), although the strength of these associations varies. Associations
were stronger for fasting glucose levels than post-load glucose levels and for the 75-g OGTT compared with
the 100-g OGTT.
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Chapter 4 Prevalence of gestational diabetes in
the UK and Republic of Ireland: a systematic review
Introduction
Prevalence of GDM is influenced by (1) population characteristics, for example Asian or Middle Eastern
ethnicity and obesity;44,117–120 (2) criteria used for GDM diagnosis, because lower glucose level thresholds
will identify greater numbers of women with GDM;121–123 and (3) screening and testing strategy, because
the application of universal – rather than selective – glucose tolerance testing leads to greater numbers of
women tested, leading to increased numbers identified.124
Prevalence of GDM is increasing alongside rising levels of obesity and inactivity, which can increase insulin
resistance,125 mirroring the increasing rate of type 2 diabetes in the non-pregnant population.
The shift from identifying women at future risk of type 2 diabetes, to trying to predict risk of perinatal and
longer-term ill-health outcomes in the infants of women who have had GDM, has prompted changes to
diagnostic criteria. Criteria with lower thresholds will identify more women at risk, thus increasing
prevalence and if treatment strategies remain unchanged, costs will increase. However, providing
treatment to more women may reduce the risk of perinatal and longer-term ill health, potentially saving
money for the UK NHS (and the individual). Chapter 7 details a cost-effectiveness analysis that examines
alternative identification and treatment strategies.
We have estimated the prevalence of GDM using different criteria for WB and SA women in the BiB
cohort,22 described in Chapter 2 of this report. In this chapter, however, we report a systematic review to
determine the prevalence of GDM in the UK and Irish obstetric population, using identified and eligible
published reports. We also derive and compare estimates from three IPD cohorts (including that of the BiB
study22). This section is reported in accordance with PRISMA guidelines.56
Methods
Search strategy
Searches were undertaken in July 2014 in MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations,
EMBASE, the Maternity and Infant Care database and CENTRAL. No date restrictions were applied to the
searches; citations were restricted to English language only (see Appendix 7, Table 84).
Title and abstract screening and full-text screening were performed in duplicate by two reviewers with
disagreements resolved by consensus or by a third reviewer.
Three cohort studies were eligible and provided data at the individual participant level:
l the BiB study22 (John Wright, Bradford Institute for Health Research, September 2013)
l the Atlantic DIP study59 from the Irish Atlantic seaboard (Fidelma Dunne, Department of Medicine,
National University of Ireland, September 2013)
l the Warwick/Coventry cohort,60 unpublished data from Warwick Hospital, George Eliot Hospital,
Nuneaton and University Hospital Coventry (Ponnusamy Saravanan, Warwick Medical School,
September 2013).
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Because IPD were available from an Irish cohort (Atlantic DIP59), we have considered prevalence of GDM in
the UK and Ireland together.
Inclusion/exclusion criteria
This review sought to identify all cohorts of pregnant women in whole, or in part, in the UK or Republic of
Ireland who were assessed for GDM.
The included studies had to have the following characteristics.
Population
Pregnant women from the UK or Republic of Ireland without pre-existing diabetes.
Diagnostic test
All women had to receive an OGTT (75 g or 100 g) in pregnancy to diagnose GDM using recognised
diagnostic criteria, or with criteria reported in the paper.
Outcomes
Studies had to report numbers of women, with and without GDM, according to the diagnostic test used or
the prevalence of GDM.
Study design
All published, unpublished and ongoing observational cohort studies, or cross-sectional studies reporting
data for women resident in the UK or Republic of Ireland. Only studies published in English were included.
When multiple publications reported prevalence estimates for the same cohort of women only the most
recent and comprehensive publication was included.
Quality assessment
We assessed the characteristics of all of the publication/study criteria (including the population, location
and publication year) that were used to diagnose GDM and derive prevalence estimates.
Data extraction
The following data were extracted from each publication:
l year of publication
l location of the study
l details of the population characteristics, for example ethnicity, age, BMI distribution (if reported)
l details of the OGTT methods and diagnostic criteria used
l total number of women with and without GDM, or the prevalence of GDM
l prevalence of GDM in participant subgroups, such as ethnic group or BMI group.
For the IPD, the prevalence of GDM was calculated, based on the reported OGTT glucose measurements,
with GDM diagnosed according to a range of diagnostic criteria as described earlier in Table 1. Prevalence
was also calculated by ethnic group (white, SA or ‘Other’) and by age categories using the modified WHO
1999 criteria11 (fasting glucose level of ≥ 6.1 mmol/l and 2-hour post-load glucose level of ≥ 7.8 mmol/l).
Synthesis methods
Prevalences of GDM, along with their 95% CI, were estimated from the data for each study. These
prevalence estimates are shown on forest plots. Studies were categorised by GDM diagnostic criteria and
year of publication, in order to investigate the effect of these factors (see Figures 14 and 15).
Meta-analyses of the prevalence data were considered, but not performed because of the heterogeneity
across the studies, particularly the diversity of diagnostic criteria used to diagnose GDM.
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Results
The database searches identified 1591 references for checking (1196 following deduplication). After title
and abstract screening, 92 publications were retrieved for full-text screening (17 of which were potentially
relevant for the systematic review on risk factors and so kept for that review). The main reasons for
exclusion were that the study was published only as a conference abstract and data reported were
insufficient, or the study did not include a UK or Irish population. The full list of excluded citations with
reasons is contained in Appendix 3, Table 64.
Of the 92 publications, 12 were potentially eligible for inclusion. We also identified three cohorts with IPD
(the Atlantic DIP study,59 Warwick/Coventry60 and the BiB study22), reporting GDM prevalence for a UK
or Irish cohort.42,44,118,126–134 After data extraction, two publications128,134 were excluded because they
reported data from the same cohort. One additional paper (on the HAPO cohort6) was included, having
been identified for another review undertaken as part of this project (see Chapter 3).131 One publication135
was excluded because it reported prevalence for the Atlantic DIP cohort59 for which IPD were available.
After including the IPD cohorts, a total of 13 studies with 16 cohorts of women (see Table 10) defined
either by criteria used to define GDM or by location (for multisite studies) were included. Full details of the
identification process are presented in Figure 13.
Quality assessment and included studies
A summary of GDM diagnostic criteria are presented in the introduction to this report (see Table 1). Table 10
summarises the 10 published studies42,44,118,127–129,131–133 and the three IPD cohorts included in this review.
Potentially eligible records
identified
(n = 1590)
Potentially eligible records
identified after deduplication
(n = 1195)
Full-text records
assessed for eligibility
(n = 91)
Additional articles identified
 (n = 1)
Individual participant (IPD) 
cohort data sets 
(n = 3)
Records excluded
(n = 1104)
Full-text articles
excluded with reasons
(n = 79)
Duplicate studies
excluded
(n = 3)
Published studies
and IPD cohorts included
(n = 13)
FIGURE 13 The search process.
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Prevalence of gestational diabetes mellitus by year the study was undertaken and
gestational diabetes mellitus criteria used
Figure 14 shows prevalence by year and GDM criteria used by each study. Using data from the three IPD
cohorts we calculated GDM prevalence according to the most commonly used GDM diagnostic criteria
presented in Table 1; 1-hour post-load glucose levels (75-g OGTT) were not available for the BiB,22 Atlantic
DIP59 and Warwick/Coventry cohorts,60 therefore prevalences may be underestimated for criteria that
include a 1-hour glucose level [American Diabetes Association (ADA), IADPSG, NDDG (National Diabetes
Data Group)]. These prevalence estimates are shown in Figure 15. The Atlantic DIP study59 has higher
prevalence estimates for all diagnostic criteria. NDDG criteria are the most conservative, having the highest
glucose thresholds. The WHO 1980, WHO 1999, ADA and Australasian Diabetes in Pregnancy Society
(ADIPS) criteria produce similar prevalence estimates, despite their different glucose threshold criteria. The
IADPSG criteria give the highest prevalence estimates for the IPD cohorts, similarly to published estimates,
as a result of the lower fasting glucose threshold.
TABLE 10 Summary of included studies and cohortsa
Study
Publication
year Location
GDM diagnostic
criteria No. of women No. with GDM
Prevalence
of GDM (%)
Ali126 2013 Dublin NDDG 1375 139 10.1
IADPSG 1679 221 13.2
Atlantic DIP59 IPD Ireland WHO 1999b 6105 622 10.2
BiB22 IPD Bradford WHO 1999b 10,432 850 8.1
Warwick/
Coventry60c
IPD Warwick/
Coventry
WHO 1999b 6569 570 8.7
Dornhost44 1992 London
(St Mary’s)
Reported in
paperd
11,035 170 1.5
Gregory127 1998 Cambridge WHO 1980b 3316 67 2.0
Griffin133 2000 Dublin NDDG 1299 35 2.7
Janghorbani128 2006 Plymouth WHO 1980b 4942 90 1.8
Khalifeh129 2014 Dublin WHO 1999b 68,494 888 1.2
Dublin WHO 1999b 112,138 2016 1.8
Koukkou118 1995 London –
St Thomas’
EASDe 6887 136 2.0
Makgoba42 2012 London –
St Mary’s
Variedf 174,320 1688 1.0
Sacks131 2012 Manchester IADPSG 2376 577 24.3
Belfast IADPSG 1671 286 17.1
Samanta132 1989 Leicester WHO 1980 12,005 128 1.1
AUC, area under curve; NDDG, National Diabetes Data Group.
a Studies may include more than one defined cohort.
b Either 1980 or 1999 criteria, depending on year data were generated.
c P Saravanan, Warwick/Coventry individual participant data, Warwick Medical School, University of Warwick, 2013,
personal communication.60
d All women without pre-existing diabetes screened at booking and then those with risk factors rescreened using
‘modified’ O’Sullivan screening test, which was a 50-g OGCT followed by OGTT if level > 7.8 mmol/l. GDM diagnosed
with 3-hour 100-g OGTT if AUC ≥ 4.3 units.
e European Association for the Study of Diabetes 75-g OGTT. GDM diagnosed if 2-hour plasma glucose level ≥ 9mmol/l.
f Only primiparous women included. No ‘common’ screening test was used: as pregnancies were included from 1998 and
2000, different criteria could have been used.
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Prevalence of gestational diabetes mellitus by ethnicity
Two published studies44,118 report prevalence of GDM by ethnicity (Table 11). Both of these studies44,118
were undertaken when recommended criteria thresholds were higher (1992 and 1995) than those now
suggested by the IADPSG and consequently report lower GDM prevalence than would be expected today.
Both studies,44,118 however, report differing GDM prevalence by ethnicity, with women of Asian and SA
origin having the highest rates. Koukkou et al.118 do not provide more information on the origin of the
Asian women in their study (they were recruited from an inner-city London hospital), so they could be of
any number of Asian ethnicities.
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FIGURE 14 Prevalence of GDM by year the study was undertaken and GDM criteria used. DPSG (EASD), Diabetic
Pregnancy Study Group (of the European Association for the Study of Diabetes).
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FIGURE 15 Estimated prevalence according to different GDM criteria in the IPD cohorts. See Table 1 for
criteria thresholds.
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Prevalence of GDM by ethnicity was calculated using the three IPD cohorts. These data are summarised in
Table 12.
Prevalence of gestational diabetes mellitus by age
The published studies provided insufficient data to estimate prevalence by age, but we have been able
to calculate estimates using the IPD cohorts. The results are summarised in Table 13. GDM prevalence
appears to increase as age category increases in all three cohorts. A logistic regression confirmed this, with
a statistically significant increase in odds of GDM of 1.08, 95% CI 1.08 to 1.10 per year.
Prevalence of gestational diabetes mellitus by timing of oral glucose
tolerance test
The BiB22 IPD included information on the timing of the OGTT, in terms of gestational age.
We examined results (numbers in parenthesis) by the following gestational age categories (in weeks
plus days): < 25 (438), 25–25 plus 6 days (1733), 26–26 plus 6 days (5695), 27–27 plus 6 days (1133),
TABLE 13 Prevalence of GDM by age, as a percentage (95% CI) [no. with GDM/total no.], in the IPD cohortsa
Cohort
Age (years) group
< 20 20–25 25–30 30–35 35–40 > 40
Atlantic DIP59 5.0 (0 to 23)
[6/119]
4.0 (0 to 13)
[19/472]
8.7 (3 to 14)
[103/1179]
12.6 (8 to 17)
[234/1858]
15.8 (11 to 21)
[195/1238]
21.3 (10 to 32)
[51/240]
BiB22 3.4 (0 to 9)
[36/1050]
4.0 (1 to 8)
[121/2989]
8.0 (5 to 11)
[269/3346]
12.3 (8 to 16)
[250/2028]
17.2 (11 to 23)
[153/888]
16.0 (0 to 31)
[21/131]
Warwick/
Coventry60
4.4 (0 to 14)
[16/364]
5.2 (0 to 11)
[65/1245]
7.6 (3 to 12)
[151/1976]
10.0 (6 to 14)
[177/1771]
12.5 (7 to 18)
[122/974]
16.3 (5 to 28)
[39/239]
a Estimates based on WHO criteria and used at the time these data were collected: fasting glucose ≥ 6.1 mmol/l and
2-hour post-load glucose ≥ 7.8 mmol/l.
TABLE 11 Prevalence of GDM reported in published studies by ethnicity
Study Year
Prevalence: percentage (n)
White European African/Afro-Caribbean South-East Asian SA Asian
Dornhorst44 1992 0.4 (6279) 1.5 (1953) 3.5 (386) 4.4 (1159) –
Koukkou118 1995 1.2 (315) 2.7 (300) – – 5.8 (49)
Estimates were derived using various criteria. The WHO 1999 criteria were used at the time of recruitment to
diagnose GDM.
TABLE 12 Prevalence of GDM by ethnicity, as a percentage (95% CI) [no. with GDM/total no.], in the IPD cohortsa
Cohort White SA Other
Atlantic DIP59 8.6 (6.1 to 11.1) [481/5613] 39.1 (28 to 50) [77/197] 21.7 (12 to 32) [64/295]
BiB22 4.9 (1.9 to 7.9) [201/4105] 10.8 (8.1 to 13.4) [512/4745] 8.7 (4.0 to 13.4) [137/1582]
Warwick/Coventry60 8.1 (5.2 to 11.0) [336/4167] 10.8 (5.1 to 16.5) [113/1046] 8.9 (3.8 to 14.0) [121/1356]
a Estimates based on modified WHO 1999 criteria, used at the time these data were collected: fasting glucose level
≥ 6.1 mmol/l and 2-hour post-load glucose ≥ 7.8 mmol/l.
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28–28 plus 6 days (529), 29–29 plus 6 days (276), 30–30 plus 6 days (263) and ≥ 31 (364). A logistic
regression analysis found no evidence that the prevalence of GDM changed according to the timing of the
test (OR 1.00, 95% CI 0.96 to 1.04).
Discussion
Studies in this review demonstrate a wide range of GDM prevalences. The differences in prevalence are
partly explained by the differing criteria and thresholds used to diagnose GDM. Prior to 2010, the WHO
criteria11 were used widely in the UK and Ireland, and GDM prevalence was consistently estimated at
between 1% and 3% across cohorts. Since 2010, however, variation in estimates are wider (8–24%).
The IADPSG criteria8 (published in 2010 and used in several later studies) produced the highest prevalences
because of their lower (than previous criteria) fasting glucose threshold. Given the linear monotonic
association across the whole spectrum of glucose levels and adverse outcomes, using lower thresholds
(as recommended by the IADPSG) will increase the number of women identified who are at increased risk
of an adverse outcome. Treatment aims to reduce glucose levels with the goal of reducing the associated
increased risks. Treatment trials,51,52 however, have used diagnostic criteria with higher glucose level
thresholds than those recommended by the IADPSG and now endorsed by the WHO (or those derived
using the BiB data,22 detailed in Chapter 2), therefore the degree to which treatments will improve
outcomes for women identified by these criteria using lower glucose level thresholds is unknown.
Several criteria recommend that women have their risk of GDM evaluated either by assessment of
maternal characteristics/risk factors (including ethnicity and weight) or by administration of the 50-g OGCT,
those that are classified as ‘high risk’ are offered diagnostic testing usually using the OGTT. Some criteria
(including the IADPSG), however, recommend universal testing. Criteria recommending that all women are
offered testing, rather than only ‘high-risk’ women, will increase the prevalence of GDM irrespective of
glucose level thresholds used.124
Differing population characteristics explain some of the diversity in prevalence estimates. In the BiB study,22
GDM prevalence in SA women was two- to threefold greater than in WB women (see Tables 4 and 12).
Other characteristics also influence prevalence, including advanced maternal age or increasing maternal
weight. We have shown that timing of OGTT does not seem to influence prevalence of GDM, however we
had few women undergoing OGTT below 25 or above 30 weeks’ gestation. Women who are tested
outside the usual 26–28 week range may have specific high-risk status, including previous GDM or
symptoms/clinical indications such as polyhydramnios or ultrasound indication of a LGA fetus, therefore the
population characteristics of studies with a wider range of OGTT timings should be examined carefully.
Strengths and limitations
We identified 13 studies22,42,44,59,60,118,126–129,131–133 undertaken over 25 years in varied areas of England and
Ireland. We were able to demonstrate how prevalence changed over these 25 years and how participant
characteristics and criteria influence prevalence. The studies were large, all included > 1000 women and all
reported their inclusion and GDM criteria. Our IPD provided valuable information that was not available
from published estimates, and showed that, even in contemporary cohorts, GDM prevalence can vary
considerably between groups with varying maternal characteristics, including ethnicity.
Few published studies included populations at high risk of GDM because of their ethnicity therefore the
inclusion of the BiB cohort22 is extremely valuable. Estimates of prevalence for SA women in the Atlantic
DIP cohort59 are uncertain because there were few women of SA ethnicity in that cohort, and even fewer
with diagnosed GDM. We undertook several subgroup comparisons; however, these results should be
interpreted cautiously given that the studies were not designed or powered to detect differences in
prevalence across subgroups. The prevalence of GDM in WB women in the BiB study22 is lower (5%) than
that in the Atlantic DIP59 (9%) and the Warwick/Coventry60 (8%) cohorts, even although all used the same
diagnostic criteria. The Atlantic DIP study59 (like the BiB study22) universally offered an OGTT, whereas the
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Warwick/Coventry studies60 selectively tested their population, but both cohorts59,60 had similar and higher
GDM prevalence in their white populations than the BiB study,22 and it is unclear why this is so.
We did not identify any eligible studies that included Scottish or Welsh cohorts, therefore, although we
intended to present data on UK prevalence of GDM, our data represent England, Northern Ireland and the
Republic of Ireland (as we were able to include the Atlantic DIP cohort59).
Conclusions
The prevalence of GDM is increasing in the UK; the offer of an OGTT to all women, the lowering of
diagnostic thresholds, and increases in the proportion of women at risk, either because of their ethnicity
or increasing weight or age, are all contributing factors (which is examined in the Chapter 5). Within a
narrow gestational time frame we have demonstrated that timing of OGTT does not seem to influence
prevalence; however, we had few women tested at < 25 or > 31 weeks of gestation and therefore caution
should be taken when interpreting these findings. We showed that populations of older women or
women whose ethnicity conveys a high risk of diabetes will have higher GDM prevalence.
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Chapter 5 Maternal characteristics (risk factors) to
identify women at increased risk of gestational
diabetes: a systematic review
Introduction
In this chapter we first examine maternal characteristics/risk factor screening performance using IPD from
the BiB22 and Atlantic DIP59 studies. Second, we report the findings from a systematic review of published
literature on maternal characteristics/risk factor screening for GDM. Within this review we investigate
whether or not multiple risk factor screening strategies represent a useful approach to screening for GDM.
We examine the degree to which these approaches detect cases of GDM and whether or not they reduce
the number of OGTTs performed.
Screening identifies apparently healthy women who are at increased risk of having or developing GDM.
Once a woman is identified as having an increased risk she can be given information and advice and
further tests. Treatment can be started following a definitive diagnosis of GDM (usually using the OGTT).
Screening is therefore undertaken to (1) identify those women at greatest risk in order to prevent
unnecessary testing of those women who are unlikely to develop GDM and (2) reduce the costs associated
with universal diagnostic testing.
Diagnostic testing can be undertaken in either the whole obstetric population, by offering all women an
OGTT (universal testing), or in a selected population, by offering an OGTT to only those women at
increased risk of developing GDM (selective testing).
Screening options
There are two ‘screening’ methods generally used to identify women who are at increased risk of
developing GDM; (1) the 50-g OGCT, which is similar to the OGTT, but does not require an overnight fast:
one plasma glucose level is obtained 1 hour following the consumption of a 50-g glucose drink – women
with a positive test (above a predefined glucose level) are offered an OGTT; and (2) maternal characteristics/
risk factor assessment, which involves the assessment of maternal characteristics to identify increased risk of
GDM: family history of diabetes; being of an ethnicity with a high prevalence of diabetes; previous history
of having a macrosomic infant or GDM; or BMI of ≥ 30 kg/m2 are risk factors recommended for use by
NICE18 – when one or more risk factors are identified then NICE recommends that an OGTT is offered.
Diagnostic testing
Gestational diabetes mellitus is generally diagnosed using an OGTT. The OGTT is normally conducted in
the morning following an overnight fast. A baseline plasma glucose sample is obtained, the woman then
consumes a drink containing, typically, 75 g or 100 g of glucose, and then at hourly intervals plasma
glucose is measured. The frequency of measurement depends on the glucose load and local policy.
Women with an ‘elevated’ glucose level at one or more measurements are classified as having GDM.
There are some limitations to the OGTT as a diagnostic test: (1) a negative OGTT result does not mean a
woman will not develop GDM later in pregnancy – because, as gestation progresses, insulin resistance may
increase, repeat glucose testing therefore may be required; (2) the linear positive graded association across
the whole spectrum of maternal glucose and risk of adverse outcomes has made the identification of clear
diagnostic glucose level thresholds for GDM difficult;6,7 and (3) the reproducibility of the OGTT is around
only 75%.20,21
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The accuracy of a screening or diagnostic test relates to its ability to distinguish between those with the
condition (GDM) and those who do not have the condition; this can be presented in terms of a test’s
sensitivity and specificity, predictive values, likelihood ratios, and the area under the receiver operating
characteristic (ROC) curve.
Several health-care agencies, including NICE and the ADIPS (see Table 14), have recommended that
pregnant women should have their risk of GDM evaluated by assessment of maternal characteristics/risk
factors. Those with one or more maternal characteristics/risk factors should be offered a diagnostic OGTT
(or alternative test: see Table 14, ADA entry).
Table 14 shows a selection of the risk factors recommended for use to guide diagnostic testing.
TABLE 14 Recommended risk factors by organisation
Agency Nature of screening strategy
NICE (UK)
201518
Offer OGTT only to women with at least one of:
l BMI ≥ 30 kg/m2
l Previous macrosomic baby (> 4.5 kg)
l Previous GDM
l Family history of diabetes
l Family minority ethnic origin with a high prevalence of diabetes
ADA 2014136 Testing at first antenatal visit should be undertaken to identify undiagnosed type 2 diabetes
(universal OGTT testing is recommended at 24–28 weeks) in all pregnant women who are overweight
(BMI≥ 25 kg/m2) and have additional risk factors:
l physical inactivity
l first-degree relative with diabetes
l high-risk race/ethnicity (e.g. African American, Latino, Native American, Asian American, Pacific Islander)
l women who delivered a baby weighing > 9 lb or were diagnosed with GDM
l hypertension (≥ 140/90 mmHg or on therapy for hypertension)
l HDL cholesterol level < 35mg/dl (0.90 mmol/l) and/or a triglyceride level > 250mg/dl (2.82 mmol/l)
l women with polycystic ovarian syndrome
l A1C test result of ≥ 5.7%, IGT or IFG on previous testing
l other clinical conditions associated with insulin resistance (e.g. severe obesity, acanthosis nigricans)
l history of CVD
ADIPS 20139 Women who are from a high-risk ethnic background or have a BMI of 25–35 kg/m2 as their only risk factor
should be considered as ‘moderate risk’, and should initially be screened with either a random or a fasting
glucose test in early pregnancy, followed by an OGTT if clinically indicated. ADIPS suggests that the
thresholds for further action are not clear at present and clinical judgement should be exercised
Women at ‘high risk’ of GDM (one high-risk factor or two moderate risk factors) should be offered a 75-g
OGTT, with venous plasma samples taken: fasting, 1 hour and 2 hours, at the first opportunity after conception
Women at moderate or high risk with normal glucose should be offered an OGTT at 24–28 weeks
Moderate risk factors for GDM
l Ethnicity: Asian, Indian subcontinent, Aboriginal, Torres Strait Islander, Pacific Islander, Maori, Middle
Eastern, non-white African
l BMI of 25–35 kg/m2
High risk factors for GDM
l Previous GDM
l Previously elevated blood glucose level
l Maternal age ≥ 40 years
l Family history of diabetes mellitus (first-degree relative with diabetes or a sister with GDM)
l BMI of > 35 kg/m2
l Previous macrosomia (BW of > 4500 g or of > 90th centile)
l Polycystic ovarian syndrome
l Medications: corticosteroid drugs, antipsychotic drugs
A1C, glycated haemoglobin (a retrospective estimate of blood glucose levels); CVD, cardiovascular disease; IFG, impaired
fasting glucose; IGT, impaired glucose tolerance.
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Recommended risk factors vary considerably; however, all strategies suggest that early pregnancy (first
trimester) screening and testing for GDM or previously undiagnosed type 2 diabetes in those women classified
as being at particularly high risk. NICE recommends that first trimester testing is offered to women who have
had previous GDM, whereas the ADA and ADIPS recommend early testing of women with a variety of risk
factors. Of these three institutions, the ADA recommends that all of those not identified as having GDM
(or previously undiagnosed diabetes) in the first trimester should be tested in the third trimester.136 NICE and
ADIPS recommend universal risk factor screening and selective OGTT in the third trimester.9,18
Risk factor screening: individual participant data cohorts
Methods
Two cohorts with IPD were eligible and agreed to share their data:
l The BiB cohort (John Wright, Bradford Institute for Health Research, September 2013) At the time of
recruitment to the BiB study,22 all women planning to give birth at the Bradford Royal Infirmary were
offered a 75-g OGTT (irrespective of risk factors). The WHO 199911 (modified) criteria were used to
diagnose GDM (fasting glucose level of ≥ 6.1 mmol/l, 2-hour post-load glucose level of ≥ 7.8 mmol/l).
l The Atlantic DIP Cohort59 (Fidelma Dunne, Department of Medicine, National University of Ireland,
September 2013) Women at participating hospitals in the south-west of Ireland were all offered a 75-g
OGTT (irrespective of risk factors) and, as with the BiB study,22 the WHO 1999 (modified) criteria11 were
used to diagnose GDM (fasting glucose level of ≥ 6.1 mmol/l, 2-hour post-load glucose level of
≥ 7.8 mmol/l).
An OGTT was offered to all women in both cohorts. Uptake of the offer varied between the two cohorts
[63% (the BiB study22) vs. 58% (the Atlantic DIP study59)].124,137
We have examined the following characteristics because they are associated with a greater risk of GDM
development, and their use as indicators for OGTT is recommended by institutions including NICE18 and
the ADA.136
l age
l obesity, measured by BMI
l parity (multiparous vs. primiparous)
l ethnicity (white, SA or other)
l family history of diabetes
l GDM in previous pregnancy
l macrosomic baby (≥ 4 kg) in previous pregnancy.
Age was examined yearly from 20 to 40 years and BMI at every 1.0-kg/m2 unit increase from 15.0 to
40.0 kg/m2. For age and BMI combined, however, we present results for age ≥ 25 years and ≥ 30 years
and BMI of ≥ 25 kg/m2 and ≥ 30 kg/m2.
Ethnicity was coded as white, SA or other [the majority of women were either of white European (in the
BiB22 and Atlantic DIP59 studies) or SA ethnicity (the BiB22 study)] and parity was coded as primiparous
(first pregnancy) or multiparous (second or subsequent pregnancy).
Statistical analyses
For each risk factor the following were calculated with their SEs and 95% CIs:
l Sensitivity:
¢ The proportion of women with GDM who had the risk factor (i.e. proportion of GDM cases
correctly identified by the test).
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l Specificity:
¢ The proportion of women without GDM who did not have the risk factor.
l Positive rate:
¢ The proportion of women with the risk factor (i.e. proportion who would be offered an OGTT).
Most existing GDM screening guidelines recommend offering an OGTT to any woman who has at least
one risk factor from a set of risk factors (see Table 14). To investigate the screening potential of this
approach we considered the risk factors in the list above, with age ≥ 25 years or ≥ 30 years, and ≥ BMI
25 kg/m2 or ≥ 30 kg/m2. For each of the 287 possible combinations of these risk factors we calculated
whether or not each woman had at least one of the risk factors, and then estimated the sensitivity,
specificity and positive rate associated with having one or more risk factors.
From this set of 287 possible combinations of risk factors we removed those that were ‘dominated’ by
others. A screening test is dominated if there is at least one other ‘test’ with both higher sensitivity and
specificity, which would be preferred to the dominated test. Sensitivity and positive rate for the remaining
non-dominated tests were plotted in ROC space.
We examined screening based on a predicted risk of GDM, similar to screening strategies used to identify
those at risk of cardiovascular disease.138 A logistic regression model was fitted to the data from both
cohorts, regressing GDM incidence against the risk factors. The resulting log ORs from this regression model
were used to calculate a predicted risk of GDM for each woman in the data set. The sensitivity and positive
rate for predicting GDM at each percentage point of risk from 1% to 80% was calculated and plotted in
ROC space. The same analyses were conducted on the separate and pooled data sets for comparison.
Results
Risk factor sensitivities, specificities and positive rates
A total of 14,103 women (Atlantic DIP59 4164/6105, BiB22 9939/10,432) with complete data on all risk
factors were included. Table 15 presents performance characteristics (sensitivities, specificities and positive
rates) for predicting GDM using the presence of a maternal characteristic/risk factor by cohort.
Only age and BMI achieve a sensitivity of > 50% in both cohorts (i.e. detect more than half of all
GDM cases).
Risk factors as predictors for gestational diabetes mellitus
We next consider risk factor screening, by which women are offered an OGTT if they have at least one
positive maternal characteristic/risk factor among a set. The results for these analyses are provided in
Figure 16, which shows the percentage of GDM cases identified (sensitivity) against the percentage of
women offered an OGTT (positive rate) for all of the sets of risk factors that were not ‘dominated’ by others.
Figure 16 shows that in order to identify 80% of women with GDM (80% sensitivity) then approximately
60% of women would have to be offered an OGTT (40% specificity). To identify 90% of women with
GDM, about 70% of women would need to be offered an OGTT, and for 95%, 80% of women need to
be offered an OGTT. Therefore, most women would need to be tested to identify the majority of women
with GDM using risk factors to identify those at higher risk. Figure 16 shows that strategies that identify
one risk factor or one out of two risk factors seem to detect < 60% of GDM cases. To detect ≥ 90% of
GDM cases requires that at least three or four risk factors are considered (in Figure 16, ‘Number of risk
factors’ refers to the following: 1 = one risk factor; 2 = at least one risk factor out of two; 3 = at least one
risk factor out of three; and 4 = at least one risk factor out of four).
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Both cohorts have similar estimates of sensitivity and specificity across the range of possible risk factor
screening strategies, that is, the points in Figure 16 all lie on approximately the same curve for both
cohorts. Importantly, however, the risk factors used to achieve, for example, a sensitivity of 90% differs
between cohorts. Table 16 provides examples of risk factors, included in screening strategies, with
sensitivity of between 90% and 95% (so they detect almost all cases of GDM) for the two cohorts,
separately and combined. Age and BMI are the most commonly occurring risk factors, with family history
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FIGURE 16 Screening performance of one or more risk factor for identifying GDM. Colour indicates the number of
risk factors in each set. ●= results for the Atlantic DIP study;59 ▲ = results for the BiB study.22
TABLE 15 Screening performance for the prediction of GDM using a single risk factor
Risk factor
Cohort
BiB22 Atlantic DIP59
Sensitivitya (%) Specificitya (%)
Positive
rate (%) Sensitivityb (%) Specificityb (%)
Positive
rate (%)
Age ≥ 25 years 85.5 33.7 67.7 96.5 11.8 89.0
Age ≥ 30 years 57.0 66.6 35.1 80.2 36.0 65.7
BMI ≥ 25 kg/m2 69.8 51.2 50.3 85.6 39.1 63.4
BMI ≥ 30 kg/m2 37.0 80.0 21.3 55.2 76.0 27.2
Ethnicity: non-white 76.3 40.6 60.6 24.1 93.3 8.5
Multiparity 42.4 68.6 29.9 30.0 73.1 26.3
Family history of
diabetes
38.9 74.4 25.7 31.4 71.2 28.5
Previous GDMc 6.0 99.3 1.0 – – –
Previous macrosomiac 7.9 86.3 4.8 – – –
a Sensitivity accurate to ± 3%; specificity accurate to ± 2%.
b Sensitivity accurate to ± 8%; specificity accurate to ± 2%.
c Not available in the Atlantic DIP study.59
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of diabetes, prior GDM and non-white ethnicity also common. In the BiB cohort22 offering an OGTT to
anyone either aged ≥ 25 years or with a BMI of ≥ 30 kg/m2 detects 92% of all GDM cases (because the
majority of women in the BiB cohort are aged > 25 years of age or have a BMI of > 30 kg/m2), including
other factors, does not substantially increase the detection rate, but there are few women left to test and
only an 8% increase was needed to achieve a 100% detection rate.
Risk prediction models
The association between each risk factor and GDM, in terms of the OR, is shown in Table 17. All risk
factors, except multiparity, were statistically significantly associated with GDM. The results were generally
consistent across the two cohorts. Having GDM in a previous pregnancy is the most dominant risk factor,
associated with a five-fold increase in the odds of GDM development in the current pregnancy. Non-white
ethnicity is also a strong indicator of risk. Multiparity was associated with lower risk (see Table 17).
The ROC curve of sensitivity against positive rate using predicted risk to screen for GDM is shown in
Figure 17 for both the BiB22 and Atlantic DIP59 cohorts. Both cohorts provide similar results. To detect 90%
of GDM cases based on a risk model requires that 70% of pregnant women undergo an OGTT.
TABLE 16 Performance of age and BMI categories for the identification of GDM
Risk factors included Sensitivity Specificity Positive rate
BiB cohort22
Aged ≥ 25 years, BMI ≥ 30 kg/m2 90.4 28.7 72.7
Aged ≥ 25 years, BMI ≥ 30 kg/m2, prior GDM 90.4 28.6 72.8
Aged ≥ 25 years, BMI ≥ 30 kg/m2, diabetes 91.6 23.2 77.7
Aged ≥ 25 years, BMI ≥ 30 kg/m2, diabetes, prior GDM 91.6 23.1 77.7
Aged ≥ 30 years, BMI ≥ 30 kg/m2, non-white 94.3 21.3 79.8
Aged ≥ 30 years, BMI ≥ 30 kg/m2, non-white, prior GDM 94.3 21.3 79.9
Aged ≥ 25 years, BMI ≥ 25 kg/m2, diabetes 94.4 16.9 83.8
Aged ≥ 25 years, BMI ≥ 25 kg/m2, diabetes, prior GDM 90.4 28.7 72.7
Atlantic DIP cohort59
BMI ≥ 25 kg/m2, non-white 90.1 36.8 66.0
Aged ≥ 30 years, BMI ≥ 30 kg/m2 90.8 28.6 73.4
Aged ≥ 30 years, BMI ≥ 30 kg/m2, non-white 93.9 26.0 76.0
Cohorts combined
Aged ≥ 30 years, BMI ≥ 30 kg/m2, diabetes 90.0 24.6 76.4
Aged ≥ 30 years, BMI ≥ 25 kg/m2, diabetes, prior GDM 90.3 24.6 76.5
BMI ≥ 25 kg/m2, non-white 92.0 24.0 77.3
BMI ≥ 25 kg/m2, non-white, prior GDM 92.1 24.0 77.3
Aged ≥ 25 years, BMI ≥ 30 kg/m2 93.2 23.3 78.0
Aged ≥ 25 years, BMI ≥ 30 kg/m2, prior GDM 93.2 23.3 78.1
Aged ≥ 30 years, BMI ≥ 30 kg/m2, non-white 94.1 22.7 78.7
Aged ≥ 30 years, BMI ≥ 30 kg/m2, non-white, prior GDM 94.1 22.7 78.7
Aged ≥ 25 years, BMI ≥ 25 kg/m2 95.9 16.5 84.5
Aged ≥ 25 years, BMI ≥ 25 kg/m2 prior GDM 95.9 16.5 84.5
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Figure 18 compares the screening performance of the risk prediction model with screening performance
based on age alone and based on oral glucose tolerance testing of anyone with at least one risk factor
using data from the BiB cohort22 only. Figure 18 shows that using a risk prediction model to screen for
GDM generally provides improved performance compared with screening based on counting positive risk
factors alone. This is because the sensitivity is generally higher at all specificities and positive rates, so the
number of women who would be offered an OGTT could be reduced while detecting the same number of
GDM cases. However, at high specificities (where most GDM cases are detected) there is little performance
difference between using a risk prediction model and counting risk factors.
Risk factor screening: a systematic review
We have undertaken a systematic review to identify studies examining risk factors to identify women with
GDM and have conducted analyses where appropriate. This section is reported in accordance with
PRISMA guidelines.56
TABLE 17 Odds ratio for the association between risk factors and GDM
Risk factor
BiB22 Atlantic DIP59
OR 95% CI OR 95% CI
Age (per year) 1.09 1.08 to 1.1 1.10 1.07 to 1.12
BMI (per kg/m2) 1.06 1.05 to 1.08 1.13 1.11 to 1.15
Ethnicity (non-white) 2.32 1.90 to 2.83 5.16 3.85 to 6.91
Multiparity 0.89 0.73 to 1.08 0.74 0.58 to 0.96
Family history of diabetes 1.36 1.14 to 1.63 1.42 1.17 to 1.80
Previous macrosomia 1.54 1.12 to 2.13 – –
Previous GDM 5.90 3.78 to 9.22 – –
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FIGURE 17 Sensitivity and positive rate when using a risk prediction model to predict GDM.
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Methods
Search strategy
Searches were undertaken in June 2014 in MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations,
EMBASE, Maternity and Infant Care database and CENTRAL (see Appendix 7, Table 85). No date or other
restrictions were applied to the searches, however, because of logistical constraints the results were
restricted to English language only. In addition to database searches, reference checking of included journal
articles and related systematic reviews was undertaken. Title and abstract screening and then full-text
screening was performed in duplicate by two reviewers, with disagreements resolved by consensus or by a
third reviewer.
Inclusion/exclusion criteria
This review took a broad approach to identifying publications related to risk factors for GDM by seeking to
identify any study that measured the association or predictive value of the following risk factors:
l age
l obesity and/or BMI
l ethnicity (where applicable to the UK)
l parity
l previous GDM, macrosomia or other GDM-related morbidity
l family history of diabetes.
Only risk factors that were likely to be recorded in medical records without the need for further
measurement were considered. Specifically, OGCT, fasting plasma glucose (FPG), vitamin D and genetic
factors were excluded.
The included studies had to have the following characteristics.
Population
Pregnant women without pre-existing diabetes.
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FIGURE 18 Screening performance using risk prediction compared with having one positive risk factor, or using
age alone.
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Screening test
Any risk factor listed above was eligible.
Diagnostic test
All women had to receive a diagnostic test (usually 75-g or 100-g OGTT) to diagnose GDM by recognised
diagnostic criteria, or with criteria reported in the paper.
Outcomes
Numbers of women with and without GDM, according to the results of the diagnostic test (usually OGTT).
Studies had to report numbers of women with each risk factor, or the sensitivity and specificity (screening
performance) of the risk factor to identify GDM, or data from which those statistics could be calculated.
Study design
All published, unpublished and ongoing observational studies, cohort studies, case–control studies or
cross-sectional studies. Only studies published in English were considered.
Individual participant data cohorts (the BiB22 and Atlantic DIP59 studies) were not eligible for inclusion
because these cohorts did not use maternal characteristics/risk factors to identify high-risk women, but
offered all women an OGTT.
Studies reporting only ethnicity outside the UK were excluded to focus on ethnicity risk relevant only to the
UK population. Studies not reporting on at least one of the risk factors listed above were excluded.
Quality assessment
No formal quality assessment process was planned or undertaken for this review because of the lack of
any validated quality assessment tool for screening studies, and the diversity of type of study included.
Data extraction
The following data were extracted from each publication:
l year of publication
l location in which study was performed
l details of the population, such as ethnicity, age, BMI distribution (if the study was not performed on
the general population of pregnant women)
l details of the diagnostic criteria used
l details of the maternal characteristics/risk factors and cut-off levels applied to risk factors if appropriate
l total number of women with and without GDM
l number of women with and without GDM according to diagnostic test results
l screening performance statistics (sensitivity and specificity, if reported).
Synthesis methods
The following screening performance statistics were calculated from the data presented for each study:
l sensitivity (proportion of GDM cases correctly identified as high risk by screening)
l specificity (proportion of women without GDM correctly identified as low risk)
l positive rate (proportion of women who would be offered an OGTT).
These statistics were plotted across studies in ROC space by plotting detection rate against positive rate.
The general performance of risk factor screening was then summarised and the conclusions of each
study considered.
Meta-analysis methods for pooling of screening studies [such as the hierarchical summary receiver operator
curves (HSROC) model] were considered, but not performed because of the considerable diversity across
studies in terms of screening strategies and included risk factors.
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Results
Included studies
The database searches identified 5867 citations (3140 after deduplication). After title and abstract screening
181 publications were retrieved for full-text screening; 47 of these were excluded (see Appendix 4, Table 65).
Ninety-seven studies reported associations between risk factors and GDM incidence, but did not consider
multiple risk factor screening, and eight studies examined the effect of screening based on a single risk factor
(although some studies reported more than one risk factor, they were not considered in combination).
Because the analysis in the first section of this chapter suggests that single risk factor screening is not the
most efficient strategy, these studies have not been included and they are not considered further. Five
publications were identified through reference checking of related reviews and eight from other searches
conducted for this report.
One hundred and thirty-four studies reported the association between maternal characteristics/risk factors
and GDM, and 29 of these reported data on risk factors, 24 of which had sufficient data to allow inclusion
in the analyses. Details of the identification process are presented in Figure 19.
Quality assessment and risk of bias
All included studies were observational, consisting of a mix of prospective and retrospective cohort studies.
All studies used an OGTT to diagnose GDM, and all specified the diagnostic criteria used. Criteria varied
between studies therefore there are differences in the thresholds used to define GDM. As discussed in
Chapters 2–4 of this report; different criteria thresholds can influence GDM prevalence. All of the risk
factors examined in this review are simple observable maternal characteristics/risk factors; the assessment
of whether or not a risk factor is present therefore is unlikely to be subject to substantial measurement or
reporting error or bias.
Studies were diverse in their included populations (see Table 18). This heterogeneity limits the ability to
draw conclusions across studies and generalise findings.
Potentially relevant records identified
through database searching
(n = 5867)
Records after duplicates removed
(n = 3140)
Records screened
(n = 3153)
Records excluded
(n = 2972)
Studies included
(n = 29)
Full-text articles assessed for
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Association
studies
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through reference
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and prevalence
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Full-text articles
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(n = 47)
FIGURE 19 The search process.
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Studies of multiple risk factor screening
Of the 29 included studies,93,122,139–165 24 provided sufficient data for screening performance (sensitivity,
specificity) to be calculated; these 24 studies are summarised in Table 18. The studies were conducted in a
variety of countries and used different criteria for diagnosing GDM; therefore different studies will produce
different GDM prevalences. Six studies93,122,139,143,146,157 assessed the screening performance of existing
guideline recommendations [NICE, ADA, American College of Obstetricians and Gynecologists (ACOG),
TABLE 18 Characteristics of included multiple risk factor studies
Study Year Country
GDM diagnosis
criterion
Total
women
No. with
GDM
Risk factor screening
strategy
Avalos122 2013 Ireland IADPSG 5500 681 Irish guideline
recommendations
Caliskan142 2004 Turkey NDDG 422 14 Number of risk factors
Cosson143 2013 France WHO 18,755 2710 French guideline
recommendations
Cypryk144 2008 Poland WHO 2180 510 Number of risk factors
Danilenko-Dixon146 1999 USA NDDG 18,504 564 ADA guideline
recommendations
Jensen145 2003 Denmark DPSG 2992a 83 Number of risk factors
Jiménez-Moleón93 2002 Spain NDDG 1962 65 ADA and ACOG guideline
recommendations
Marquette147 1985 USA C&C 434 12 Number of risk factors
Moses148 1998 Australia ADIPS 2907 183 Age, BMI, ethnicity
Nanda149 2011 UK WHO 11,464 297 Risk model
Naylor164 1997 US NDDG or C&C 1571 69 Risk score
Ostlund150 2003 Sweden WHO 3616 61 ‘Traditional risk factors’
Phaloprakam151 2009 Thailand C&C 469 127 Risk score
Pintaudi152 2014 Italy IADPSG 1015 113 ‘Standard risk factors’
Sacks153 1987 USA ADA 4116 138 Number of risk factors
Savona-Ventura165 2013 Mediterranean ADA 1368 119 Based on age, BMI and
diastolic BP
Shamsuddin154 2001 Malaysia OGTT levels
reported
768 191 Number of risk factors
Shirazian155 2009 Iran ADA 924 68 Risk score
Sunsaneevithayakul156 2003 Thailand Not reported 9325 235 Number of risk factors
Teh157 2011 Australia ADIPS 2426 250 NICE, ADA and ADIPS
guideline recommendations
Van Leeuwen141 (A) 2010 Netherlands OGTT/GCT levels
reported
995 24 Risk model
Van Leeuwen140 (B) 2009 Netherlands WHO 1266 47 Risk score
Williams158 1999 US NDDG 25,118 148 Based on age, BMI,
ethnicity, family history
Yang139 2002 China WHO 9471 171 ADA guideline
C&C, Carpenter and Coustan; GCT, glucose challenge test.
a A total of 5235 women were included in the study; 2992 had an OGTT performed. DPSG, Diabetic Pregnancy
Study Group.
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ADIPS, Irish, French]. Seven studies93,122,139,142,143,146,157 counted the number of risk factors for each woman.
Six studies140,141,149,151,155,164 used a risk prediction model or a risk score to determine the results of risk factor
screening and five studies148,150,152,158,165 examined various risk factors.
Figure 20 shows the estimates of sensitivity and positive rate for the studies in Table 18 plotted against
each other in ROC space. In Figure 20 (see also Figure 21) the shape of the points indicates the type of
screening method used (● = existing guidelines; ▲ = counting numbers of risk factors; + = use of a risk
prediction model or score; and ▪ = other methods).
Figure 21 presents the results for studies93,122,139,143,146,157 reporting the performance of current screening
guidelines. The vertical lines here show the 95% CIs for sensitivity and positive rate.
Figure 22 shows the sensitivity and specificity for those studies140,141,149,151,155,164 evaluating risk prediction
models or risk scores. Each study has multiple points because the studies reported results at various levels
of risk. Results are reasonably consistent across studies, with all points lying approximately on a common
ROC curve, suggesting that no specific risk scoring method is superior to another. Increasing sensitivity
reduces specificity, for example to achieve a sensitivity of 80%, specificity is approximately 45%; to achieve
a sensitivity of 90%, the specificity is approximately 35%. So to identify greater numbers of women with
GDM requires offering an OGTT to increasing numbers.
Conclusions reported by the study authors
We examined the conclusions drawn by the authors for each included paper to determine whether or not
the study authors recommended maternal characteristics/risk factor (selective) testing or universal testing
(with OGTT). Appendix 4, Table 66, presents a summary of the conclusions for all included studies.
This includes the 24 studies included in the analyses above and the five remaining studies that did not
have extractable data. The conclusions of the study authors are varied, with 11 favouring universal
diagnostic testing and 10 supporting some form of maternal characteristic/risk factor screening (universal
screening and selective testing). Eight of the study authors made no firm recommendations. Of those
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FIGURE 20 Screening performance (sensitivity and positive rate) for the included studies.
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studies that investigated current screening guideline recommendations (eight studies), seven did not
recommend risk factor screening, three favoured universal diagnostic testing and four were undecided.
Studies without extractable data
Five studies159–163 considered multiple risk factor screening, but reported insufficient data to be included.
These studies are briefly described below.
l Corcoy et al.159 (2004, Spain) examined the presence of multiple ‘low’ risk factors (e.g. ethnicity and
BMI of < 25 kg/m2) in a general pregnancy cohort and in a cohort of women with GDM. Women with
GDM were less likely to have known ‘low’ risk factors for GDM than women with GDM (7% vs. 1.3%).
Although selective screening seems to reliably identify low-risk women, only 7% of women in this
population would not require screening.
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FIGURE 21 Screening performance of existing risk factor screening guidelines.
100
0
10
20
30
40
50
60
70
80
90
100
90 80 70 60 50 40 30 20 10
Specificity (%)
Se
n
si
ti
vi
ty
 (
%
) Author
     Nanda149
     Naylor164
     Phaloprakam151
     Shirazian155
     Van Leeuwen A141
     Van Leeuwen B140
FIGURE 22 Screening performance of risk prediction or scoring models.
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l Cosson et al.163 (2006, France) compared two different strategies in different time periods for
identifying GDM: selective and universal testing using a 75-g OGTT. Risk factors were reported by year
and adverse outcomes were reported for the women with GDM by year, but not for the whole
population.
l Crete and Anaste160 (2012, USA) examined age, BMI, ethnicity, family history of diabetes and prior
GDM, and previous macrosomic infant, and reported that age 30–34 years and BMI of > 30 kg/m2
doubled the risk of GDM; risk increased fourfold in those with previous GDM. Women who were both
older and heavier had a higher risk than women with a single risk factor, but not significantly so.
l Davey and Hamblin161 (2001, Australia) compared risk factor prevalence of women with GDM to those
without, and presented percentages and ORs for these two groups.
l Göbl et al.162 (2012, Austria) presented results for risk screening in combination with FPG, and
concluded that the combination may be useful in screening for GDM.
Discussion
Risk factor screening aims to identify as many ‘at risk’ women as possible so that diagnostic testing can be
offered to those most likely to test positive, while preventing unnecessary testing in those least likely to
test positive. A screening test with high sensitivity and specificity is therefore beneficial. Screening for GDM
based on risk factors can take a variety of forms, including offering an OGTT to women with just one risk
factor important in that population, or with one or more risk factors out of a set, which is the approach
recommended by several institutions providing guidance, including NICE,19 or by calculating a predicted
risk or risk score. This review identified 29 eligible studies, 93,122,139–165 which were methodologically diverse.
We were unable to demonstrate superiority of any one strategy over another.
Certain risk factors are increasing in the pregnant population (e.g. obesity and advanced maternal age)
therefore in the future it may be that the majority of women will have at least one risk factor and fulfil
many criteria for diagnostic testing. Risk factor screening in such a population would require most women
to be tested, but a proportion of women with hyperglycaemia/GDM would still be missed. Screening
women for risk factors makes additional demands on consultation time and risk factors may not be
recognised; however, even although they may be relatively easy to identify. Generally, the risk factor
screening strategies examined in this review use only maternal characteristics; occasionally, however, as in
the Nanda et al. study149 biochemical markers are included; these may increase screening complexity and
costs, without necessarily improving case detection rates.
Performance of risk factors
We found that all of the risk factors we examined, excluding multiparity, were associated with increased
odds of GDM. Multiparity does not seem to be linked to increased insulin resistance during pregnancy, but
is associated with GDM through the mediation of progressive ageing and weight gain.167 The BiB study22
has relatively fewer older women included – 11.5% aged ≥ 35 years at delivery (see Tables 3 and 13) –
therefore for the BiB population this mediated effect seems to have been lost, although we have not
examined this formally. Regardless of the method used, risk factors to identify GDM generally have poor
screening performance. Unfortunately, if risk factor sensitivity is high, specificity is low; therefore, to identify
> 50% of GDM cases, > 50% of women need to be offered an OGTT; to identify 80% of women with
GDM, around 60% need to be offered an OGTT; and to identify 90% of women, around 70% need to be
offered an OGTT. These numbers may vary, depending on the prevalence of GDM in the population, but
our analyses using IPD suggests not significantly so. Our analyses using IPD also suggests that offering an
OGTT to everyone aged > 25 years will identify 86% of GDM cases, but nearly 68% of women will receive
the test. Although 68% is a considerable proportion of women to test, this strategy would avoid testing in
32% of the population and this may equate to a considerable cost saving. Our results were consistent
across the IPD cohorts and the included published studies. Risk factor screening could therefore avoid the
need for an OGTT in 20–30% of women at lowest risk of GDM. Using this strategy would lead to some
women with GDM not being identified; these women would therefore not benefit from treatment.
Considering other risk factors, other than age or BMI category, such as previous macrosomia or family
history of diabetes, adds little value, because their addition does not seem to identify additional GDM cases.
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The magnitude of risk associated with GDM in a subsequent pregnancy following a pregnancy
complicated by GDM suggests that all women with a previous pregnancy complicated by GDM should be
offered an OGTT. This would not increase the number of women being offered an OGTT substantially
because the prevalence of this risk factor is relatively low, although numbers are increasing. Our results
suggest that the use of age or BMI category to identify those at increased risk is as effective as using
multiple risk factors and the use of this latter strategy may overcomplicate the screening process. Offering
all women an OGTT may avoid missed cases through selection; however, the uptake of a universal offer
of OGTT is between 63% and 75% depending on population and, therefore, a universal offer will also
miss cases.124,137,150 Furthermore, offering an OGTT to all women may unnecessarily ‘medicalise’ some
pregnancies at relatively lower risk, and this may adversely affect the woman’s experience and possibly
increase the risk of medical interventions such as induction of labour and C-section.
Performance of different guideline recommendations
Analysis examining the performance of guideline recommendations was unable to demonstrate superiority of
one set of recommendations over another, although the number of included studies was few. Screening
performance of recommendations varies across studies. For example, if the ADA guideline recommendations
are used to selectively screen in the third trimester they would identify between 86% and 100% of GDM
cases, but between 66% and 96% of women would be offered an OGTT (depending on population
characteristics). How recommendations are implemented in practice will also affect performance. For
example, the ADA recommend selective screening using risk factors in the first trimester, but suggest that an
OGTT should be offered in the third trimester to all women not identified as having diabetes in the first
trimester. Therefore, all women are offered an OGTT at some point in pregnancy. Guideline performance
varies, some identifying more cases than others. Those with higher case identification generally require that
greater numbers of women are tested. Depending on the guideline used, the strategy adopted and the
population characteristics, detection can be anything from 65% to 100% of GDM cases.
Performance of risk prediction models
We presented a model in Table 16 that could be used to calculate the odds of having GDM for any woman
provided her characteristics are known (i.e. age, BMI, family history of diabetes). These estimated odds can
be converted into an estimated risk of GDM. This risk could be used to screen for GDM, by offering an OGTT
to any woman with a risk score above a prespecified threshold, for example 5%. Using a low risk cut-off will
identify more GDM cases, but will also lead to more women having an OGTT. A higher threshold will reduce
the number of OGTTs performed, but will identify fewer GDM cases. Of the 10 studies that recommended
risk factor screening, six were studies140,141,149,151,155,164 that proposed a new risk prediction model or scoring
system (using risk factors). However, our analysis using IPD suggests that using a risk algorithm or prediction
score does not substantially improve performance compared with identifying one or two risk factors, and is
similar to using multiple risk factors (over one or two risk factors). The extra complexity of the risk prediction
model may therefore complicate screening while adding little to performance.
Conclusions
Our analyses suggest that no single method of risk factor screening is better overall. Risk factor screening
based on having one or more risk factors and methods based on risk prediction or scoring performed
similarly, suggesting that if risk factor screening is to be used, the simpler approach of offering an OGTT if
at least one risk factor is present may be preferable and this is the recommended approach of several
institutions including NICE.18
The potential benefits of offering universal testing must be weighed against any adverse effects and costs.
Taken in this context the most efficient method of identifying women with GDM is likely to differ between
populations. For high-risk populations in which the majority of women have a risk factor, especially a BMI
of > 30 kg/m2 or advanced maternal age, universal testing may be most beneficial. For a young population
of women with few risk factors, selective testing may be best; the use of risk factors in this population
could be used to identify those at low risk who do not need testing and those remaining would be
therefore offered an OGTT.
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Chapter 6 Treatments for gestational diabetes:
a systematic review
Introduction
As discussed throughout this report GDM is associated with an increased risk of several important perinatal
adverse outcomes, including C-section and macrosomia (BW of > 4 kg) and there is growing evidence
that longer-term health of both mother and infant may also be adversely affected.
Treatment of GDM aims to control hyperglycaemia, which, in turn, aims to reduce the risk of adverse
outcomes. Diet and lifestyle modification may be used as first-line treatment and if partly or wholly
unsuccessful, or where women have substantially elevated glucose level at diagnosis, pharmaceutical
interventions (metformin, glibenclamide and/or insulin) may also be given. Certain oral hypoglycaemic
agents including metformin and glibenclamide present a possible alternative to injected insulin and
may be as effective with the added benefit of being more acceptable to women.
This chapter reports a systematic review investigating the effectiveness of treatments for GDM to improve
maternal and infant health outcomes.
Methods
Search strategy
This review updates five existing systematic reviews of treatments for GDM: Alwan et al. (Cochrane
review),168 Hartling et al. (Annals of Internal Medicine 2013),1 Horvath et al. (BMJ 2010),169 Falavigna
(Diabetes, Research and Clinical Practice 2012)170 and Gui et al. (PLOS ONE).171 The search strategies of all
five reviews1,168–171 included randomised controlled trials (RCTs), one review also included observational
studies which were ineligible in our review and therefore these studies were not considered.1 One review
compared the effects of metformin with insulin only,171 the four remaining reviews compared any treatment
for GDM. It is likely that search strategies and assessment of eligibility differed between the reviews (these
details are not published); however, the reviews seemed to take a broad approach to potential inclusion
(RCTs, women with GDM and any treatments) and generally excluded and included the same trials,
although there were slight variation when multiple publications of the same trial were identified.
The search strategies (see Appendix 7, Table 86) were designed to identify records of RCTs added to
search sources since the most recent search date of the review by Alwan et al.168 (July 2011). Strategies
were developed using a combination of subject indexing terms and free-text search terms in the title
and abstract fields, to identify relevant trials related to GDM and impaired glucose tolerance (IGT) in
pregnancy. Where database functionality allowed, results were limited to records added to the database
since 2011, using appropriate fields such as the entry date field in MEDLINE. Searches were first
conducted in September 2013 and updated in October 2014 using the same search strategies. The
databases searched were MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations, EMBASE,
and CENTRAL. Results of the searches were downloaded into EndNote X7 bibliographic management
software and duplicate records were removed using several algorithms. In addition to database searches,
reference checking of included journal articles and related systematic reviews were undertaken. For full
details of all database search strategies, including interfaces used, search dates and result numbers,
see Appendix 7, Table 86.
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All trials included in the existing systematic reviews were obtained. Title and abstract screening and then
full-text screening were performed by two reviewers with disagreements resolved by consensus, or by a
third reviewer.
Inclusion/exclusion criteria
This review identified RCTs in which a treatment designed to lower blood glucose in women with GDM
was examined in comparison with routine or standard antenatal care or an alternative treatment designed
to lower blood glucose. The other inclusion criteria were as follows.
Population
Pregnant women diagnosed with GDM or IGT using any threshold definition and women with pre-existing
diabetes were excluded.
Intervention
The treatment could be any one or more of the following:
l insulin
l metformin
l glibenclamide
l dietary advice and diet modification with or without additional lifestyle modification (e.g. exercise)
or monitoring
l any combination of the above.
Comparator
The comparison group could receive ‘standard/routine obstetric care’ (however defined by the trial) or any
of the above treatments.
Outcomes
Trials had to report incidence of adverse outcomes, for example RRs, ORs or mean differences (MDs) for
outcomes compared across treatment groups for at least one of the following, which could be defined
variously by the trials:
l gestational age at birth
l BW
l macrosomia (BW of ≥ 4 kg)
l LGA (BW of > 90th centile)
l shoulder dystocia
l preterm birth < 37 weeks’ gestation)
l neonatal hypoglycaemia
l admission to neonatal intensive care unit (NICU)
l C-section (elective or emergency)
l pre-eclampsia
l PIH
l induced labour
l instrumental birth (forceps or vacuum/ventouse)
l Apgar score at 5 minutes
l negative treatment effects (e.g. gastrointestinal upset, well-being).
Trials
Only RCTs were eligible. Blinding of clinicians or researchers (to the intervention) or those assessing
outcome data was not part of the inclusion criteria. Conference abstracts of RCTs and letters to journals
were eligible for inclusion if they reported sufficient information.
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Quality assessment
The risk of bias of the included trials was assessed using the Cochrane risk of bias tool,172 which considers
the following characteristics:
l sequence generation
l allocation concealment
l blinding of participants and medical staff to treatment allocation
l blinding of the assessors of outcomes to the treatment allocation
l completeness of outcome reporting (e.g. loss to follow-up)
l selective reporting of outcomes
l Other sources of bias (not addressed by the above domains).
Each criterion was classified as being at low, high or unclear risk of bias. One reviewer performed the
quality assessment, which was checked by a second.
Data extraction
Data were extracted from each publication on the following:
l maternal age at randomisation
l gestational age at randomisation and/or oral glucose tolerance testing
l ethnicity
l BMI
l what test, and diagnostic criteria were used to diagnose GDM
l details of treatment and control used.
Statistical data for each reported outcome were extracted, when reported:
l numbers of women in treatment and control groups
l numbers of morbidities in each group
l OR or RR for comparison between groups (with 95% CIs)
l mean and SD for the outcome in each group.
One reviewer performed the data extraction, which was checked by a second reviewer.
Synthesis methods
Meta-analyses
For the statistical analysis, the included trials were divided into the following categories according to the
included treatments:
l insulin vs. metformin
l insulin vs. glibenclamide
l metformin vs. glibenclamide
l diet or dietary advice and or lifestyle vs. pharmacological (glibenclamide, metformin or insulin)
treatment
l diet or dietary advice and/or glucose monitoring and/or insulin use vs. routine antenatal care.
The results of trials comparing different types of insulin and different types of diet were not pooled
because of their diversity and were reviewed narratively.
For dichotomous outcomes the RR for each outcome comparing each trial arm, with its 95% CI, was
calculated from the numbers of women with the outcome. For continuous outcomes the MD between trial
arms, with its 95% CI, was calculated from the mean and SD of the outcome.
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For each outcome, and within each of the four treatment categories listed above, RRs or mean differences
were pooled in random-effects DerSimonian and Laird meta-analyses. Heterogeneity was assessed using
Higgins I2-statistic. Subgroup analyses were performed to investigate differences across varying definitions
of GDM.
Network meta-analysis
This review examines a number of different treatments for GDM. Rather than comparing just two
treatments, as in the meta-analyses undertaken in previous reviews, network meta-analysis was used to
combine information across multiple treatments simultaneously. Information on the effectiveness of a
treatment can be obtained directly, for example by comparing glibenclamide and metformin in those trials
that included these treatments, or indirectly, for example by examining the effects of insulin compared with
metformin, and insulin compared with glibenclamide in order to compare glibenclamide and metformin.
Network meta-analysis combines this direct and indirect evidence to improve the estimation of the
effectiveness of treatments.173 Formally, analyses were conducted for each dichotomous outcome using a
Bayesian approach, based on the models originally created by Lu and Ades,174 using the OpenBUGS
software: www.openbugs.net/w/FrontPage (last accessed January 2015). Each model generated a
comparison between treatments, expressed as an OR and a probability that each treatment was the best
treatment to reduce the incidence of the outcome.
Network meta-analysis was performed to compare insulin versus metformin versus glibenclamide.
Results
Existing reviews
This review updates five existing systematic reviews (see Chapter 5, Methods). Here we present a short
summary of the existing reviews.
Alwan et al. 2009
This Cochrane review168 included RCTs examining any treatment for GDM, including diet and lifestyle
modification and drug treatments (such as metformin and insulin) in addition to routine antenatal care,
against any treatment or routine care. A range of outcomes were considered, including all of those included
in our review. The Cochrane risk of bias tool was used to assess trial quality and trials were synthesised in
meta-analyses. Database searches were most recently performed in 2011; these trials are still awaiting
classification. This Cochrane treatments review168 has now been divided into separate intervention
comparisons and these separate reviews are now being conducted.
The current review, however, includes eight trials, involving 1418 women, of which five are included in
our review. This Cochrane review concluded that treatments, including dietary advice and insulin were
effective in lowering the incidence of a range of outcomes (pre-eclampsia, macrosomia, LGA and shoulder
dystocia) compared with routine antenatal care. Induction of labour was more common in the treated
group than in those having only routine antenatal care. The review found evidence of a reduction in the
risk of C-section for women receiving oral hypoglycaemic agents compared with insulin. The review
suggested that conclusions may change when the review is updated to incorporate the 29 citations
awaiting classification. Ten of the trials awaiting classification have been included in our review and are
indicated by the solid black triangles in Table 14.
Hartling et al. 2013
Five RCTs involving 2945 women and six observational studies involving 3110 women were included in this
review1 comparing diet and lifestyle modification, glucose monitoring and insulin as needed to routine
antenatal care. Database searches were performed in 2012. All five trials were included in our update
review (see Table 14). The Cochrane risk of bias tool was used to assess trial quality, and trials were
synthesised in meta-analyses. The review found that treatment lowered the risk of pre-eclampsia, shoulder
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dystocia and macrosomia, but data were too limited to be confident about the effects on gestational
weight gain and longer-term health outcomes.
Horvath et al. 2010
Five trials were included, involving 2999 women, comparing a specific treatment, which included diet and
lifestyle modification and insulin as needed to routine antenatal care. All five trials were included in our
review (see Table 14). This review169 also included 13 observational studies (not included in our review)
comparing more intensive specific treatment to less-intensive specific treatment; this comparison was not
considered in our review. Database searches were performed in 2009. The Cochrane risk of bias tool was
used to assess trial quality, and trials were synthesised in meta-analyses. The review found that treatment
was effective in lowering the risk of shoulder dystocia and LGA.
Falavigna et al. 2012
Seven trials were included involving 3157 women, comparing diet and lifestyle modification and insulin as
needed to routine antenatal care. Six of these trials were included in our review (see Table 14). Database
searches were performed in 2012. The Cochrane risk of bias tool was used to assess trial quality and trials
were synthesised in meta-analyses. The review170 reported that treatment lowered the risk of LGA,
macrosomia, pre-eclampsia and shoulder dystocia.
Gui et al. 2013
Five trials, involving 1270 women, were included comparing metformin to insulin; all were included in our
review (see Table 14). Database searches were performed in 2012. The Cochrane risk of bias tool was
used to assess trial quality and trials were synthesised in meta-analyses. The review171 found that
gestational weight gain and gestational age at birth were lower and PIH occurred significantly less often,
but preterm birth occurred more often for women who were treated with metformin than in those treated
with insulin.
Included trials
Trial publications from the five identified systematic reviews1,168–171 were obtained for screening. The two
searches in September 2013 and October 2014 identified 6450 citations (2985 and 3555 citations,
respectively). Following deduplication of titles (and abstracts where available), 3645 citations were
reviewed (including citations of trials included in the previous reviews). Of these, 158 were judged
potentially eligible based on title and abstract. After obtaining the full text and assessing eligibility, 48 trials
were included (46 in the meta-analyses: two trials reported insufficient data to allow inclusion) and 110
were excluded (see Appendix 5, Table 67). The full details of the search process are presented in the flow
chart (Figure 23).
Of the included trials, 23175–195 compared drug treatments: 10 trials175–183,196 compared metformin with insulin,
eight trials184–191 compared glibenclamide with insulin, two trials192,193 compared glibenclamide with metformin,
one trial compared a metformin–glibenclamide combination with insulin195 and one trial194 compared
glibenclamide in addition to diet therapy with placebo in addition to diet therapy. Ten trials51,52,197–203 compared
combinations of diet modification, glucose monitoring and insulin use to routine obstetric care. Five trials204–208
compared different insulin formulations. Of the remaining nine trials,200–202,209–214 five trials201,202,211–213 were
comparisons of different diets. One trial200 compared types of dietary education, one trial214 compared diet to
insulin, one trial210 compared exercise to insulin, and one trial209 compared exercise to diet. None of these nine
trials200–202,209–214 was included in any meta-analysis because of trial diversity. The included trials are summarised
in Table 19.
The trials included women with GDM who were diagnosed following a 75-g or 100-g OGTT, a variety of
threshold criteria were used, including the Carpenter and Coustan criteria (C&C) or those of the NDDA,14
WHO,11 ADA136 and local guidelines (criteria were specified in the publications).177,182 Inclusion criteria for
women in the dietary modification trials were more varied. Some of these trials included women with a
positive OGCT, but negative OGTT (therefore not diagnosed as GDM by usual criteria); some included
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women with ‘mild or borderline’ GDM (usually defined as having fasting glucose below the threshold, but
post-load glucose above the threshold for diagnosing GDM) and women defined as having ‘IGT’ (although
current diagnostic criteria would consider these women to have GDM).
Quality assessment
The quality assessment results are provided in Appendix 5, Table 68. In general, reporting of many aspects
of trial quality was poor. The randomisation procedure was rarely described, and so its quality could often
not be assessed, although all trials were described in the publications as being ‘randomised’ trials. Blinding
of participants and medical staff was generally not reported, but as most of these trials include some
administration of insulin, it is probable that most clinicians could not be blinded. Most trials had reasonably
complete outcome data and loss to follow-up was low. Most trials presented results for all their
prespecified outcomes; therefore selective reporting was assessed as minimal. The large number of
possible outcomes, however, means that the possibility that some trials collected data on outcomes, but
did not report them, cannot be ruled out.
Trials comparing metformin and insulin
There were 10 trials that compared metformin with insulin.175–183,196 In general, women were eligible if they
were unable to achieve glycaemic control with dietary and lifestyle modification. Therefore, there is the
possibility that those included may have more severe insulin resistance or may be less compliant or find
adhering to lifestyle interventions more difficult than those requiring only dietary intervention outside of a
trial. The specific criteria for the addition of insulin are not reported in most trials, although some trials do
report that supplemental insulin was prescribed if glycaemic control was not achieved by participants
receiving metformin. It is possible that thresholds for what is defined as ‘good’ control differed between trials
and between sites in multicentre trials. Included trials are summarised in Table 20. Criteria for diagnosing
GDM vary across trials as does the screening strategy used; these differences should be considered when
interpreting the results from the meta-analyses. Meta-analyses are shown by outcome; not all trials report
each outcome.
Records after duplicates
removed
(n = 3645)
Records identified through database searching
(n = 6450)
Records screened
(n = 3648)
Additional records
identified through other
sources such as previous
systematic reviews
(n = 3)
Records excluded
on title and abstract
(n = 3490)
Full-text articles
excluded,
with reasons
(n = 111)
Trials included in
review
(n = 47)
Trials included in
quantitative synthesis
(n = 45)
Full-text articles
assessed for eligibility
(n = 158)
FIGURE 23 Flow chart of the search process.
TREATMENTS FOR GESTATIONAL DIABETES: A SYSTEMATIC REVIEW
NIHR Journals Library www.journalslibrary.nihr.ac.uk
98
Because of the large volume of treatments and outcome comparisons, we have generally combined trials
and presented pooled estimates in forest plots. We have provided an example of one outcome (usually
macrosomia) and treatment comparison by individual trials (results across trials of all outcomes are
available from the contact author on request).
Figure 24 shows the results of the meta-analysis of trials comparing metformin and insulin treatment and
risk of macrosomia. There was no evidence of heterogeneity in this analysis (I2 = 2%).
Figure 25 shows the results of the meta-analysis of trials for all dichotomous perinatal outcomes reported.
There is a significantly reduced risk of macrosomia, neonatal hypoglycaemia and PIH (although for PIH this is
marginal) for women given metformin compared with those who were given insulin. There is a suggestion
that those who were given metformin rather than insulin are less likely to develop pre-eclampsia or have a
baby admitted to the NICU, although results were not statistically significant. Metformin use was associated
with a statistically significantly increased risk of instrumental birth (vaginal delivery by forceps or ventouse)
compared with insulin use.
Heterogeneity varied across these analyses but was generally low to moderate (I2 = 0–60%); however, trials
reporting C-section had high heterogeneity (I2 = 71%).
Figure 26 shows the results of the meta-analysis of trials for all continuous outcomes: gestational age at
birth, BW and 5-minute Apgar score for metformin vs. insulin treatment. All outcomes were similar
between the two groups. Heterogeneity across trials was low.
TABLE 20 Trials comparing metformin and insulin
Reference Year Location Population
Criteria used to
diagnose GDM Screening strategya
Hague176 2003 Australia 30 ADIPS Risk based
Hassan175 2012 Pakistan 150 WHO 50-g OGCT
Ijäs177 2010 Finland 100 Reported in paperb Risk based
Mesdaghinia178 2013 Iran 200 ADA 50-g OGCT
Moore179 2007 USA 63 NDDG 50-g OGCT
Niromanesh196 2012 Iran 160 C&C 50-g OGCT
Rowan180 2008 Australia/NZ 751 ADIPS Risk based
Spaulonci181 2013 Brazil 94 ADA Universal OGTT
Tertti182 2013 Finland 217 Finnish criteriac
(changed during trial)
Risk-based screening then OGTT
or universal OGTT testing
Zinnat183 2013 Bangladesh 450 Not reportedd Not reportedd
NZ, New Zealand.
a It is assumed that, unless otherwise reported, the screening strategy as advocated by the criteria used was adhered to.
b Criteria did not correspond to any standard diagnostic criteria. GDM was diagnosed using 2-hour 75-g OGTT after an
overnight fast if one or more capillary plasma glucose thresholds 5.3 (fasting), 11.0 (1 hour) and 9.6 (2 hours) mmol/l
was equalled or exceeded.
c The diagnostic cut-off values of plasma glucose up to December 2008 were the following: fasting ≥ 4.8 mmol/l, 1-hour
≥ 10.0 mmol/l and 2-hour ≥ 8.7 mmol/l, and thereafter ≥ 5.3, ≥ 10.0 and ≥ 8.6 mmol/l, respectively.
d Conference abstract.
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Trials comparing glibenclamide and insulin
Eight trials compared glibenclamide to insulin.184–191 Details of these trials are given in Table 21.
Figure 27 shows the results of the meta-analysis of trials for all dichotomous perinatal outcomes for
glibenclamide compared with insulin treatment. The analysis suggests that insulin is more effective in
reducing the odds of an adverse outcome compared with glibenclamide (LGA, macrosomia, neonatal
hyperglycaemia and pre-eclampsia) or has similar effects (NICU admission, preterm birth and C-section);
however, the increases were not statistically significant and the CIs were wide.
Pooled
Hague 2003176
Hassan 2012175
Ijäs 2011177
Mesdaghinia 2013178
Moore 2007179
Niromanesh 2012196
Spaulonci 2013181
Tertti 2012182
Zinnat 2013183
0.75 (0.57 to 0.98)
Trial Effect (95% Cl)
0.88 (0.14 to 5.42)
0.57 (0.25 to 1.28)
0.82 (0.37 to 1.80)
0.61 (0.30 to 1.23)
0.58 (0.15 to 2.23)
0.37 (0.10 to 1.36)
0.14 (0.01 to 2.69)
1.34 (0.74 to 2.40)
0.70 (0.42 to 1.15)
0.1 0.2 0.5 1.0 2.0 4.0
RR
insulin betterMetformin better
FIGURE 24 Metformin vs. insulin: macrosomia.
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LGA177,178,180–182,196
Macrosomia175–179,181–183,196
NICU admission175–178,180,182,183,196
Shoulder dystocia178,183,196
Neonatal hypoglycaemia175,177–179,181,182,196
Preterm birth178,180,182,196
Apgar score of < 7 at 5 minutes178,180
Maternal
C-section175–177,182,196
Pre-eclampsia176,180,182,196
PIH180,182,196
Instrumental birth177,182,183
Induction175–177,182
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1.66 (1.37 to 2.01)
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Outcome Number
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0.81 (0.62 to 1.05)
0.75 (0.57 to 0.98)
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FIGURE 25 Metformin vs. insulin: dichotomous outcomes.
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Outcome
GA at birth176,177,180–182,196
BW175–182,196
Apgar score of < 7 at 
5 minutes175,177,179,181,182,196
Number of trials
6
9
6
I2 (%)
0
32
30
MD (95% Cl)
– 0.16 (– 0.69 to 0.36)
– 0.04 (– 0.39 to 0.31)
0.02 (– 0.55 to 0.59)
insulin betterMetformin better
–1.0 – 0.5 0.5 1.00.0
MD
FIGURE 26 Metformin vs. insulin: continuous outcomes. GA, gestational age.
TABLE 21 Trials comparing glibenclamide and insulin
Reference Year Location Population
Criteria used to
diagnose GDM Screening strategya
Anjalakshi184 2007 India 23 WHO Universal OGTT
Bertini185 2005 Brazil 70 WHO Not reported
Lain186 2009 USA 99 ADA – C&C 50-g OGCT then OGTT
Langer187 2000 USA 404 C&C 50-g OGCT then OGTT
Mukhopadhyay188 2012 India 60 WHO Universal OGTT (2-hour post
load > 7.7 mmol/l only)
Ogunyemi189 2007 USA 97 Not reported Not reported
Silva190 2007 Brazil 68 WHO Universal OGTT
Tempe191 2013 India 64 C&C 50-g OGCT then OGTT
a It is assumed that, unless otherwise reported, the screening strategy advocated by the criteria used was adhered to.
Neonatal
LGA185–188,190
Macrosomia186,187,190,191
NICU admission187,191
Neonatal hypoglycaemia187–189,191
Preterm birth191
Maternal
C-section186,188,190,191
Pre-eclampsia188,192
insulin betterGlibenclamide better
0.25 0.50 4.00 8.001.00
RR
2.00
Outcome
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2
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2.44 (0.97 to 6.15)
2.66 (0.91 to 7.77)
0.95 (0.49 to 1.84)
1.60 (0.99 to 2.60)
0.50 (0.05 to 5.24)
 
0.86 (0.66 to 1.12)
1.14 (0.60 to 2.18)
RR (95% Cl)
 
59
29
0
0
0
 
25
0
I2 (%)
FIGURE 27 Glibenclamide vs. insulin: dichotomous outcomes.
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Figure 28 shows the results of the meta-analysis of trials for all continuous outcomes – gestational age at
birth, BW and Apgar score at 5 minutes – for glibenclamide vs. insulin treatment. Infants whose mothers
were given glibenclamide were generally born heavier than infants of mothers given insulin (approximately
120 g). Gestational age at birth and Apgar score at 5 minutes were both similar between the two groups.
Trials comparing glibenclamide and metformin
Two trials directly compared metformin to glibenclamide (Table 22).192,213
Figure 29 shows the risk of dichotomous outcomes for glibenclamide treatment compared with metformin
treatment, and Figure 30 shows the risk of continuous outcomes for glibenclamide treatment compared
with metformin treatment. Given the limited number of trials in this analysis with few women (349)
included, it is difficult to draw meaningful conclusions. For several outcomes, only one trial reported data,
and, even when data from two trials were combined, the results were generally non-significant, with
wide CIs.
Network meta-analysis comparing glibenclamide, insulin and metformin
For the network analysis, all trials comparing one pharmacological treatment with another have been
included: metformin, glibenclamide and insulin (Figure 31). Only dichotomous outcomes reported in at
least two glibenclamide trials were included to ensure there were sufficient trials in each network analysis
to produce meaningful results. Separate network analyses were performed for each outcome; their results
are shown in Figure 32.
The network analyses suggest that, compared with insulin, metformin reduces the risk of all reported
outcomes with the exception of C-section. However, comparisons include the null value, and the CIs are
wide and include either an increase or a decrease in risk.
TABLE 22 Trials comparing glibenclamide and metformin
Reference Year Location Population Criteria used to diagnose GDM Screening strategya
Moore192 2010 USA 149 C&C 50-g OGCT then OGTT
Silva193 2012 Brazil 200 WHO Not reported
a It is assumed that, unless otherwise reported, the screening strategy advocated by the criteria used was adhered to.
– 2.0 – 1.5 – 0.5 0.0 1.00.5– 1.0
MD
insulin betterGlibenclamide better
MD (95% Cl)
0.00 (– 0.69 to 0.68)
0.12 (– 0.25 to 0.49)
– 0.40 (– 1.24 to 0.44)
Outcome
GA at birth185–189,191
Birth weight184–191
Apgar score at 5 minutes185
Number of trials
6
8
1
I2 (%)
15
0
0
FIGURE 28 Glibenclamide vs. insulin: continuous outcomes. GA, gestational age.
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Neonatal
LGA193
Macrosomia192
NICU admission192,193
Shoulder dystocia192
Neonatal hypoglycaemia192,193
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C-section192,193
Pre-eclampsia192
 
1
1
2
1
2
 
2
1
2.29 (1.09 to 4.81)
4.05 (0.46 to 35.42)
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0.25 0.50 1.00 2.00 4.00 8.00
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RR (95% Cl)Number of trialsOutcome
0.50 (0.08 to 3.15)
1.52 (0.26 to 8.84)
FIGURE 29 Glibenclamide vs. metformin: dichotomous outcomes.
MD (95% Cl)
0.11 (– 0.65 to 0.86)
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0.06 (– 0.53 to 0.65)
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2
2
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FIGURE 30 Glibenclamide vs. metformin: continuous outcomes. GA, gestational age.
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10 trials 8 trials
Insulin
GlibenclamideMetformin
FIGURE 31 Network meta-analyses, relationship of comparisons.
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Glibenclamide compared with insulin or metformin treatment seems to increase the risk of macrosomia
and LGA. There is no evidence of a difference between glibenclamide and insulin or glibenclamide and
metformin treatment for the remaining outcomes. These results are similar to the results from the direct
meta-analyses. The loss of estimate precision (and statistical significance) for comparisons in the network
meta-analyses compared with the direct (head-to-head) meta-analyses may be a result of the increased
heterogeneity within group comparisons across trials.
Table 23 shows the estimated probability of the effectiveness of each treatment at reducing the risk of
each outcome, derived from the network meta-analysis. This analysis suggests that for all of the outcomes,
with the exception of C-section, metformin is most likely to be the most effective treatment, and for most
outcomes the probability that metformin is most effective is reasonably high.
TABLE 23 Estimated probability (%) of a treatment being the most effective in reducing the risk of a
dichotomous outcome
Outcome
Treatment
Insulin Metformin Glibenclamide
LGA 17.2 82.7 0.1
Macrosomia 3.5 96.4 0
NICU admission 1.4 50.3 48.3
Neonatal hypoglycaemia 7.9 89.5 2.7
C-section 12.6 9.4 78
Pre-eclampsia 11.5 74.6 13.9
Metformin v insulin
LGA177,178,180–182,196
Macrosomia175–179,182,183
NICU admission176,178–181,183,185,196
Neonatal hypoglycaemia176,178–180,182,183,196
C-section175–177,182,196
Pre-eclampsia176,180,182,196
Outcome Number of trials OR (95% Cl) 
OR
0.25 0.50 1.00 2.00 5.00 10.00
second betterFirst better
Glibenclamide v insulin
LGA185–188,190
Macrosomia186,187,190,191
NICU admission187,191
Neonatal hypoglycaemia187–189,191
C-section185,187,189,190
Pre-eclampsia187,191
Glibenclamide v metformin
LGA193
Macrosomia192
NICU admission192,193
Neonatal hypoglycaemia192,193
C-section192,193
Pre-eclampsia192
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0.73 (0.42 to 1.27)
0.64 (0.38 to 1.07)
0.62 (0.36 to 1.06)
0.71 (0.43 to 1.17)
1.13 (0.55 to 2.30)
0.71 (0.34 to 1.47)
 
2.37 (1.15 to 4.89)
3.43 (1.32 to 8.91)
0.62 (0.25 to 1.59)
1.38 (0.74 to 2.60)
0.70 (0.33 to 1.49)
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1.95 (0.96 to 3.96)
0.62 (0.26 to 1.51)
1.69 (0.56 to 5.11)
FIGURE 32 Network meta-analysis comparing metformin, glibenclamide and insulin. First better – treatment listed
first in the outcome column is superior; second better – treatment listed second in the outcome column is superior.
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Insulin does not ever seem to be the best treatment, with very low probabilities of being best for each
outcome. However, it should be noted that supplemental insulin was often added to treatment with
metformin in the trials that report management of blood glucose when glycaemic control was not
achieved with diet, lifestyle and metformin. This analysis therefore suggests metformin is superior (in terms
of its ability to influence the risk of associated adverse outcomes) to insulin and glibenclamide as a first-line
treatment, rather than a standalone treatment.
Other trials comparing metformin and glibenclamide
Two trials194,214 (Table 24) could not be included in any meta-analysis because there was insufficient
information reported, the trials investigated the effectiveness of metformin or glibenclamide. Both
reports194,214 were available only as conference abstracts.
The placebo controlled trial of diet with glibenclamide194 reported that glibenclamide treatment had no
additional influence on macrosomia or LGA risk over diet modification alone. Ardilouze et al.214 reported
that the infants of mothers using the metformin–glibenclamide combination of half maximum doses had
more neonatal hypoglycaemia episodes than infants of mothers using insulin; however, the number of
women included were small. Other outcome rates reported were similar between groups.
Trials comparing different insulin preparations
Five trials compared different insulin preparations:195,205,207,210,218 three compared analogue to human
insulin,195,210,218 one different numbers of doses per day,207 and one gave insulin only to women with the
most elevated glucose levels.205 Details of these trials are given in Table 25.
The differences in the composition of the insulin preparations used by the trials precluded their inclusion in
a meta-analysis. As an alternative, summary results for each trial and each outcome are presented in forest
TABLE 24 Trials comparing metformin and glibenclamide excluded because of insufficient data
Reference Year Location No. Experimental group Control group
Criteria used to
diagnose GDM
Abbassi-Ghanavanti194 2014 USA 395 Glyburidea with diet Placebo with diet NDDG
Ardilouze214 2014 Canada 63 Metformin with
glyburidea
Insulin Not reported
a Glyburide is the equivalent US adopted name for glibenclamide.
TABLE 25 Trials comparing different insulin preparations
Reference Year Location No. Experimental insulin Control insulin
Criteria used to
diagnose GDM
Balaji195 2012 India 323 Analogue insulin (Aspart
BIAsp)
Human insulin WHO
Di Cianni210 2007 Italy 96 Analogue (Aspart) or
lispro
Human insulin C&C
Jovanovic218 1999 USA 42 Lispro (humalog) Human insulin C&C
Kjos205 2001 USA 98 Insulin if fetal abdominal
circumference > 70th
centile and/or FPG > 6.7
Insulin irrespective
of fetal growth or
glucose levels
FPG
5.8–6.7 mmol/l
Nachum207 1999 Israel 392 Four times daily
administration
Twice-daily
administration
NDDG
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plots, without pooling across trials. Figure 33 shows the effects of the differing insulin preparations on
dichotomous outcomes, and Figure 34 shows the effect on continuous outcomes. For the majority of
outcomes, there are no statistically significant differences in the effectiveness of different insulin preparations.
Trials comparing different types of diet modification
Ten trials51,52,196–198,217–221 compared diet modification or advice, possibly alongside glucose monitoring and
insulin use (although this was often not reported) to routine antenatal care (usually no specific diet
modification or insulin treatment) (Table 26).
Balaji195
Balaji195
Balaji195
Di Cianni210
Jovanovic218
Kjos205
Kjos205
Kjos205
Nachum207
Nachum207
Nachum207
Nachum207
Nachum207
Trial
C-section
LGA
Preterm birth
Macrosomia
C-section
LGA
Macrosomia
Neonatal hypoglycaemia
C-section
LGA
Macrosomia
Neonatal hypoglycaemia
PIH
Outcome
1.00 (0.93 to 1.09)
0.89 (0.39 to 2.04)
0.49 (0.04 to 5.36)
0.62 (0.16 to 2.37)
1.41 (0.57 to 3.49)
1.33 (0.31 to 5.65)
1.50 (0.26 to 8.59)
1.00 (0.31 to 3.24)
1.01 (0.69 to 1.48)
0.87 (0.59 to 1.27)
0.83 (0.50 to 1.40)
0.12 (0.02 to 0.97)
0.90 (0.41 to 1.98)
RR (95% Cl)
0.1 0.2 0.5 1.0 2.0 4.0 8.0
RR
control betterExperimental better
FIGURE 33 The effect of different insulin preparation on dichotomous outcomes.
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Kjos205
Kjos205
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GA at birth
GA at birth
Apgar 5 min
BW
GA at birth
BW
GA at birth
BW
GA at birth
Outcome
0.01 (– 0.11 to 0.13)
0.67 (0.33 to 1.01)
0.00 (– 0.74 to 0.74)
0.30 (– 0.30 to 0.90)
– 0.07 (– 0.17 to 0.03)
0.00 (– 0.41 to 0.41)
0.10 (– 0.08 to 0.28)
0.10 (– 0.32 to 0.52)
0.00 (– 0.15 to 0.15)
0.30 (– 0.12 to 0.72)
MD (95% Cl)
0.0 1.0 2.01.5–1.0 – 0.5 0.5
MD
control betterExperimental better
FIGURE 34 The effect of different insulin preparation on continuous outcomes. GA, gestational age.
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In seven trials, insulin was reported as being used if required; three trials197,198,203 did not report insulin use.
Two trials220 reported secondary analyses of previously published trials;52,211 both trials220 are therefore
excluded from the analyses.
Across the included trials, the dietary interventions included specific diets, individualised advice from a
dietitian, or more general advice (the compositions of the dietary interventions were generally well
reported by trials). Two of the included reports were secondary analyses of data from the Crowther trial,51
one223 of which was a secondary analysis, examining longer-term infant (4- to 5-year-olds) obesity risk
(BMI z-scores) and so was excluded from our meta-analyses.
For the meta-analysis the varying forms of dietary modification and advice were assumed to be equivalent,
and any potential differences in insulin use were not considered. The forest plot for the meta-analysis of trials
reporting macrosomia as an outcome is presented in Figure 35 (results across trials of all other outcomes are
available from the authors on request). This analysis suggests that diet modification halves the incidence of
macrosomia compared with routine care (whatever that care may be). The three trials that did not report
insulin use report similar results to those trials reporting that supplemental insulin was used when required.
Heterogeneity was moderate (I2 = 32%), driven by the two small trials with extreme outcomes.197,202
Figure 36 shows the risk of dichotomous outcomes and diet modification compared with routine care, and
Figure 37 shows the risk of continuous outcomes and diet modification compared with routine care. Diet
modification seems to reduce the risk of LGA, macrosomia, shoulder dystocia and pre-eclampsia by around
50%, with a more modest 15% reduction in the incidence of C-section compared with routine care. Diet
modification compared with routine care also seems to reduce BW by approximately 120 g. There is no
evidence that diet modification reduces the incidence of neonatal intensive care admission, neonatal
hypoglycaemia, induced labour, preterm birth or Apgar score at 5 minutes. Heterogeneity varied across
outcomes, with I2 ranging from 0% to 67%.
TABLE 26 Trials comparing diet modification (with insulin if needed) and routine antenatal care
Reference Year Location
No.
included
Criteria used to
diagnose GDM Screening strategy
Insulin use in
diet group
Bevier202 1999 USA 103 Positive OGCT,
negative OGTT
Universal 50-g OGCT only If needed
Bonomo203 2005 Italy 300 Positive OGCT,
negative OGTT
Risk factors and 50-g
OGCT
Not reported
Crowther51 2005 UK/Australia 1000 WHO 199911 Risk factors or 50-g OGCT If needed
Deveer197 2013 Turkey 100 ACOG-positive
OGCT, negative OGTT
Universal 50-g OGCT and
OGTT
Not reported
Elnour200 2006 UAE 180 Not reporteda Not reported If needed
Garner201 1997 Canada 299 bHatem 1988221 Universal 75-g OGCT and
selective OGTT test result
If needed
Landon52 2009 USA 958 ADA 200612 Universal 50-g OGCT and
selective OGTT
If needed
Li198 1987 Hong Kong 158 NDDG 197915 Risk factors and selective
OGTT
Not reported
O’Sullivan211 1966 USA 615 O’Sullivan 196416 OGCT or risk factors Only in treated
group
Yang199 2003 China 150 WHO 1998222 Universal OGCT and
selective OGTT
If needed
a The trial was conducted in the United Arab Emirates; no details of GDM criteria reported.
b Not internationally recognised criteria.
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Subgroup analyses: diet modification trials by definition of gestation
diabetes mellitus
Unlike the trials evaluating pharmacological treatments (which tended to use recommended tests, criteria
and thresholds for diagnosing GDM) the tests, criteria and thresholds used to define a comparison group’s
‘GDM status’ varied considerably across the 10 trials included in the meta-analyses of diet modification
trials. These differences are briefly summarised in Table 27.
Three trials included women with a positive OGCT and a negative OGTT; therefore, they did not meet any
criteria for current GDM diagnoses. Some early trials, for example Li (1987) classify women as having IGT
Bevier 1999202
Bonomo 2005203
Crowther 200551
Deever 2013197
Elnour 2006200
Garner 1997201
Landon 200952
Li 1987198
O’Sullivan 1966211
0.11 (0.02 to 0.84)
0.50 (0.22 to 1.13)
0.46 (0.34 to 0.63)
0.10 (0.01 to 0.75)
0.46 (0.23 to 0.93)
0.86 (0.53 to 1.42)
0.42 (0.27 to 0.64)
0.52 (0.13 to 2.08)
0.33 (0.18 to 0.60)
0.46 (0.36 to 0.60)Pooled
RR (95% Cl)Trial
0.05 0.10 0.20 0.50 1.00 2.00
RR
routine care betterDiet and insulin better
FIGURE 35 The effect of diet modification on macrosomia incidence.
Neonatal
LGA51,52,197,198,200,203
Macrosomia51,52,197,198,200–203,211
NICU admission51,52,197,203
Shoulder dystocia51,52,197,202
Neonatal hypoglycaemia51,52,200,201,203
Preterm birth52,198,218
Apgar score of < 7 at 5 minutes52
Outcome Number
of trials
I2 (%)
0.55 (0.44 to 0.69)
0.46 (0.35 to 0.60)
0.91 (0.62 to 1.34)
0.39 (0.23 to 0.69)
1.16 (0.79 to 1.69)
0.75 (0.46 to 1.21)
0.57 (0.21 to 1.52)
0.86 (0.77 to 0.95)
0.58 (0.36 to 0.93)
1.37 (0.20 to 9.27)
1.12 (0.82 to 1.52)
RR (95% Cl)
RR
0.25 0.50 1.00 2.00 4.00
routine care betterDiet and insulin better
Maternal
C-section51,52,197–201
Pre-eclampsia51,52,197,200,202
Instrumental birth202
Induction51,52,198,202
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4
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FIGURE 36 The effect of diet modification on dichotomous outcomes.
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or mild GDM. Today, however, IGT and ‘mild’ GDM are viewed within the same spectrum of
hyperglycaemia and are therefore usually classified as GDM.
In order to investigate the impact of these potentially different populations we performed subgroup
analyses (irrespective of glucose load and glucose thresholds used), dividing the trials into four categories:
l GDM Women had GDM according to a ‘standard’ diagnostic criteria, e.g. ADA, WHO or C&C.
l Mild GDM Women described as having mild GDM.
l IGT Women described as having IGT.
l Negative OGTT Women had positive OGCT but negative OGTT.
Figure 38 shows the effect of diet modification on risk of macrosomia, with trials grouped by glucose level/
severity classification [most severe first (GDM) down to positive OGCT, negative OGTT]. Although data
within each group are limited, there is no evidence that the effect of diet modification varies substantially
according to the glucose level/severity classification. Figure 39 summarises the results for the dichotomous
– 0.5 0.0 1.00.5–1.0
MD
routine care betterDiet and insulin better
MD (95% Cl)
– 0.09 (– 0.67 to 0.48)
– 0.12 (– 0.42 to 0.19)
0.11 (– 0.51 to 0.73)
I2 (%)
45
25
77
Number of trials
7
7
2
Outcome
GA at birth51,52,197,198,201–203
Birthweight51,52,197,198,201–203
Apgar score at 5 minutes202,203
FIGURE 37 The effect of diet modification on continuous outcomes. GA, gestational age.
TABLE 27 Tests, criteria and thresholds used by included trials in diet modification trials
Reference Year
Criteria or test used
to diagnose GDM Thresholds
Bevier202 1999 Positive OGCT Positive OGCT and negative OGTT
Bonomo203 2005 Positive OGCT Positive OGCT and negative OGTT
Crowther51 2005 WHO Mild GDM fasting < 7.8 mmol/l and 2-hour post load 7.8–11.1 mmol/l
Deveer197 2013 Positive OGCT Positive OGCT and negative OGTT
Elnour200 2006 Not reported ‘GDM’ diagnosed ≤ 20 weeks’ gestation
Garner201 1997 ‘Hatem’ trial specific GDM fasting > 7.5 mmol/l 2-hour > 9.6 mmol/l
Landon52 2009 ADA Mild GDM fasting < 5.3 mmol/l and two or more of: 2-hour
> 10.0 mmol/l and 2-hour > 8.6 mmol/l, 3-hour > 7.8 mmol/l
Li198 1987 WHO IGT fasting < 7.9 mmol/l and 2-hour post load 7.8–11.1 mmol/l
O’Sullivan211 1966 O’Sullivan GDM fasting > 6.1 mmol/l 1-hour> 9.4 mmol/l, 2-hour> 6.7 mmol/l,
3-hour > 6.1 mmol/l
Yang199 2003 WHO 1998 Fasting ≥ 7.0 mmol/l and 2-hour post load 7.8–11.1 mmol/l
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GDM
Elnour 2006200
Garner 1997201
O’Sullivan 1966211
Pooled
IGT
Li 1987198
Pooled
Mild GDM
Crowther 200551
Landon 200952
Pooled
Negative OGTT
Bevier 1999202
Bonomo 2005203
Deever 2013197
Pooled
 
0.46 (0.23 to 0.93)
0.86 (0.53 to 1.42)
0.33 (0.18 to 0.60)
0.52 (0.28 to 0.96)
 
0.52 (0.13 to 2.08)
0.52 (0.13 to 2.08)
 
0.46 (0.34 to 0.63)
0.42 (0.27 to 0.64)
0.45 (0.35 to 0.58)
 
0.11 (0.02 to 0.84)
0.50 (0.22 to 1.13)
0.10 (0.01 to 0.75)
0.25 (0.08 to 0.78)
Overall pooled 0.46 (0.36 to 0.60)
Trial RR (95% Cl)
RR
0.05 0.10 0.20 0.50 1.00 2.00
routine care betterDiet and insulin better
FIGURE 38 Impact of diet modification on macrosomia, by degree of glucose intolerance [GDM, IGT, mild GDM or
(positive OGCT) negative OGTT].
RR
0.2 0.5 1.0 2.0 4.0
routine care betterDiet and insulin better
LGA200
LGA51,52
LGA198
LGA197,203
Macrosomia200,201,211
Macrosomia51,52
Macrosomia198
Macrosomia197,202,203
C-section200,201
C-section51,52
C-section198,199
C-section202,203
Pre-eclampsia200
Pre-eclampsia51,52
Pre-eclampsia197,202
Outcome
GDM
Mild GDM
IGT
OGCT only
GDM
Mild GDM
IGT
OGCT only
GDM
Mild GDM
IGT
OGCT only
GDM
Mild GDM
OGCT only
GDM definition
1
2
1
2
3
2
1
3
2
2
2
2
1
2
2
Number of trials
0.40 (0.19 to 0.86)
0.58 (0.46 to 0.72)
0.81 (0.43 to 1.51)
0.35 (0.17 to 0.72)
0.52 (0.28 to 0.96)
0.45 (0.35 to 0.58)
0.52 (0.13 to 2.08)
0.24 (0.07 to 0.80)
0.70 (0.26 to 1.88)
0.89 (0.75 to 1.05)
0.82 (0.68 to 0.98)
0.74 (0.47 to 1.17)
0.30 (0.11 to 0.84)
0.61 (0.47 to 0.81)
3.45 (0.54 to 22.09)
RR (95% Cl)
FIGURE 39 Impact of diet modification on dichotomous outcomes, by degree of glucose intolerance [GDM, IGT,
mild GDM or (positive OGCT) negative OGTT].
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outcomes LGA, macrosomia, C-section and pre-eclampsia, the outcomes where there is strongest evidence
of a benefit of diet modification. Again, there is no evidence of any treatment effect differences between
trials, although, again, data are limited.
Because women with ‘mild’ GDM and IGT may both be categorised as having GDM under current diagnostic
guidelines we combined these groups with those described as having GDM in a further subgroup analysis.
We compared this new GDM group to women without GDM (those with elevated glucose at OGCT and
with a subsequently ‘normal’ OGTT). The results of this subgroup analysis are shown in Figure 40. Diet
modification (with insulin if needed), irrespective of the severity of the hyperglycaemia identified or the test
used to identify it, seems to be effective in reducing the risk of adverse perinatal outcomes.
‘Other’ diet and exercise trials
Nine trials204,206,208,209,212,215–217,219 were too methodologically diverse to allow pooling of data. Six
trials206,209,212,215,217,219 compared two different types of diets, one trial204 compared exercise to insulin use,
one trial compared diet and insulin to diet alone, and one compared exercise with diet216 (Table 28).
As commented on above, these trials compared very different interventions (diet, exercise and insulin
preparations), therefore meta-analysis has not been undertaken; instead, summary results for each trial and
each outcome are presented in forest plots (without pooling across trials).
Figure 41 shows the effect of the differing diets, by trial, on the risk of dichotomous outcomes, and
Figure 42 shows the effect of the differing diets, by trial, on the risk of continuous outcomes. Results are
varied; however, there is no evidence that any one particular type of diet improves all outcomes reported.
See Table 28 for information on type of intervention and participant numbers.
In the three remaining trials,204,208,216 a mixture of interventions was evaluated. Bo et al.216 gave the same
diet to four groups of women; the first group also received diet recommendations, the second group
was advised to walk briskly for 20 minutes each day, the third group received behavioural dietary
recommendations and the fourth group received both of the second and third groups’ interventions. Bo
et al.216 reported that exercise reduced postprandial glucose levels and a composite measure of maternal
and neonatal complications, whereas behavioural interventions had no effect. Bung et al.204 compared
LGA51,52,198,200
LGA197,203
Macrosomia51,52,198,200,201,212
Macrosomia43,45,202
C-section51,52,198,200,201,212
C-section197,202
Pre-eclampsia51,52,200
Pre-eclampsia45,51
Outcome
GDM
OGCT only
GDM
OGCT only
GDM
OGCT only
GDM
OGCT only
GDM 
definition
4
2
6
3
6
2
3
2
Number
of trials
0.58 (0.47 to 0.71)
0.35 (0.17 to 0.72)
0.49 (0.37 to 0.63)
0.24 (0.07 to 0.80)
0.86 (0.76 to 0.98)
0.74 (0.47 to 1.17)
0.55 (0.39 to 0.79)
3.45 (0.54 to 22.09)
RR (95% Cl)
0
32
45
22
19
I2 (%)
RR
0.2 0.5 1.0 2.0 4.0
routine care betterDiet and insulin better
FIGURE 40 Impact of diet modification comparing women with GDM to those with only a positive OGCT and
negative OGTT.
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TABLE 28 ‘Other’ diet and exercise trials
Author Year Location
No.
included
Experimental
group Control group
Criteria used to diagnose
GDM
Asemi215 2014 Iran 52 ‘DASH’ diet (high
fruit, veg, wholegrain
and dairy)
Control diet ADA
Bo216 2014 Italy 200 Diet and exercise Diet only Not reported
Bung204 1991 USA 41 Exercise bike use Insulin Not reported
Cao217 2012 China 275 Individual diet
education
Standard group
diet education
Not reported
Cypryk209 2007 Poland 30 High-carbohydrate
diet
Low carbohydrate
diet
WHO
Louie219 2011 Australia 99 Low-GI diet High fibre
moderate GI diet
ADIPS
Moreno-
Castilla206
2013 Spain 152 Low-carbohydrate
diet
Control diet NDDG
Rae212 2000 Australia 124 Low-calorie diabetic
diet
Standard diabetic
diet
OGTT fasting > 5.5 mmol/l
or 2-hour > 7.9 mmol/l
(glucose load not reported)
Thompson208 1990 USA 108 Diet and insulin Diet only NDDG
DASH, Dietary Approaches to Stop Hypertension. GI, glycaemic index.
Asemi215
Asemi215
Cao217
Cao217
Cao217
Cao217
Cao217
Cao217
Cypryk209
Louie219
Louie219
Louie219
Moreno-Castilla206
Moreno-Castilla206
Moreno-Castilla206
Moreno-Castilla206
Rae212
Rae212
Rae212
Rae212
Rae212
Rae212
Rae212
Trial
C-section
Macrosomia
C-section
Induction
Macrosomia
NICU admission
Pre-eclampsia
Preterm birth
C-section
C-section
LGA
Macrosomia
C-section
LGA
Macrosomia
Neonatal hypoglycaemia
C-section
Induction
Instrumental birth
LGA
Macrosomia
Pre-eclampsia
Shoulder dystocia
Outcome
0.57 (0.36 to 0.90)
0.10 (0.01 to 0.73)
1.06 (0.92 to 1.21)
0.67 (0.20 to 2.22)
0.61 (0.31 to 1.22)
0.64 (0.43 to 0.96)
0.53 (0.19 to 1.48)
0.29 (0.08 to 1.01)
0.71 (0.29 to 1.75)
1.72 (0.63 to 4.75)
2.87 (0.61 to 13.50)
0.32 (0.03 to 2.96)
1.25 (0.76 to 2.05)
0.50 (0.13 to 1.93)
0.20 (0.02 to 1.67)
0.90 (0.39 to 2.09)
1.20 (0.75 to 1.93)
1.11 (0.73 to 1.68)
1.00 (0.39 to 2.60)
1.19 (0.66 to 2.16)
1.61 (0.64 to 4.08)
0.95 (0.49 to 1.84)
0.13 (0.01 to 2.38)
RR (95% Cl)
RR
0.05 0.20 0.50 2.00 8.00
control betterExperimental better
FIGURE 41 Effect of diet interventions on dichotomous outcomes.
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exercise and diet to insulin and diet alone in a group of women who had ‘failed’ to achieve ‘normal’
glucose levels on diet alone within a week of GDM diagnosis. Bung et al.204 reported no differences
between groups in outcomes; however, macrosomia rate was doubled in the group receiving insulin (two
vs. four), which seems contrary to results expected; numbers in the trial were small (34), however, possibly
accounting for the results. Thompson et al.208 compared diet with insulin to diet alone, reporting that the
group that was given diet advice with insulin had infants with lower BW and incidence of macrosomia
compared with the group that was given diet advice alone. Group rates of C-section, shoulder dystocia
and neonatal hypoglycaemia were similar.
Discussion
Pharmacological treatments
For women requiring pharmacological intervention to reduce hyperglycaemia (often when diet alone
had proved ineffective), metformin as first-line treatment seems to be at least as effective as insulin in
reducing the risk of adverse perinatal outcomes, and metformin and insulin seem to be more effective
than glibenclamide.
Although the treatment effects of metformin and insulin were similar, there was a trend for metformin to
perform better, or at least no worse, than insulin for most outcomes reported. For example, metformin
reduces the risk of macrosomia by 25% compared with insulin. Although not statistically significant, there
was some evidence that treatment with metformin may be associated with a greater risk of preterm birth
and an Apgar score of < 7 at 5 minutes compared with insulin treatment. Glibenclamide, performed less
well than insulin for several outcomes, for example the infants of mothers who were given glibenclamide
were, on average, 120 g heavier at birth compared with the infants of mothers who were given insulin;
the risk of LGA and macrosomia is also greater for those given glibenclamide compared with insulin, but
not significantly so. The network meta-analysis confirmed the direct trial meta-analyses findings and
suggests that there is a high probability that metformin is the most effective treatment, compared with
insulin or glibenclamide, for reducing the risk of most adverse perinatal outcomes examined within
this review.
Asemi215
Asemi215
Asemi215
Cao217
Cao217
Cypryk209
Cypryk209
Cypryk209
Louie219
Louie219
Moreno-Castilla206
Rae212
Rae212
Trial
Apgar score at 5 minutes
BW
GA at birth
BW
GA at birth
Apgar 5 min
BW
GA at birth
BW
GA at birth
GA at birth
BW
GA at birth
Outcome
0.04 (0.02 to 0.06)
– 0.60 (– 0.65 to – 0.54)
0.20 (– 0.45 to 0.85)
– 0.19 (– 0.32 to – 0.06)
– 0.13 (– 0.68 to 0.42)
– 0.50 (– 1.05 to 0.05)
– 0.02 (– 0.29 to 0.24)
– 0.10 (– 1.03 to 0.83)
0.00 (– 0.04 to 0.04)
– 0.10 (– 0.37 to 0.17)
0.10 (– 0.53 to 0.73)
0.19 (0.07 to 0.32)
0.20 (0.11 to 0.29)
MD (95% Cl)
MD
– 2.0 – 1.5 – 1.0 – 0.5 0.0 0.5 1.0
control betterExperimental better
FIGURE 42 Effect of diet interventions on continuous outcomes. GA, gestational age.
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113
Metformin, in addition to performing well, may also be preferred by women, as it is administered orally
and can be stored at room temperature as opposed to insulin, which requires subcutaneous injection and
refrigerated storage. Metformin is associated with gastrointestinal upset, however, which may affect
compliance; unfortunately, few trials report side effects or participant satisfaction, quality of life or well-
being, which should be examined by future trials.
Dietary modification
Dietary modification generally reduces the risk of most reported perinatal outcomes compared with ‘usual
or routine’ antenatal care. For example, the risk of macrosomia is halved (RR 0.46, 95% CI 0.36 to 0.60)
and the risk of C-section is reduced by 14% (RR 0.86, 95% CI 0.77 to 0.95) with dietary modification
compared with usual/routine antenatal care. If trials are adequately powered and methodologically robust
(particularly in terms of adequacy of randomisation) it is reasonable to accept that diet modification does
improve adverse outcome rates compared with routine care (without special diet modification); however,
risk of bias was generally high or unclear, suggesting poor trial quality with respect to these indicators.
There was no evidence that the effect of diet modification varied according to the types of women (or
severity of hyperglycaemia) included in the trials. For LGA, macrosomia and C-section, diet modification
seemed to be equally effective in women with a negative OGTT (usually following a positive OGCT)
compared with women with diagnosed GDM or ‘mild’ GDM. This finding suggests that modifying the diet
of women who do not have GDM (as currently defined) may be as effective in reducing risks as in women
with diagnosed GDM. This is supported by trials of diet and lifestyle modification that have been
undertaken in women who do not have GDM.224 However, compliance with diet advice may be less
(because women may be less amenable to change if they do not believe themselves at risk) and thus any
beneficial effects may be reduced. The finding that dietary modification can reduce the risk of most
adverse outcomes in women with lower glucose levels (below those currently diagnostic of GDM at the
time the trials were conducted) is important given the recommendations of the IADPSG and our analyses
findings (detailed in Chapter 2), which suggest that lower thresholds are required to identify the majority
of infants at risk of LGA and high adiposity at birth. As we have explained in Chapter 2, these outcomes
(LGA and high adiposity at birth) are associated with increased obesity and cardiometabolic risk. It is
assumed that treatment of GDM, however, will reduce the risk of these longer-term outcomes, although
that remains to be substantiated by large RCTs with longer-term follow-up.
Although our meta-analyses suggest that diet modification is effective in reducing the risk of the majority
of reported adverse perinatal outcomes compared with routine antenatal care, nine trials could not be
included because of differences between comparisons and interventions (see Table 28). These trials often
included small numbers reducing the reliability of their results, for example although Asemi et al.215
reported that their ‘Dietary Approaches to Stop Hypertension’ (DASH) diet significantly lowered BW,
reduced macrosomia, C-section rate and need for insulin compared with a control diet; only 52 women
were included, and head circumference and ponderal index were also significantly reduced in the infants
of women consuming the DASH diet compared with control diet, suggesting a detrimental effect.
The remaining trials showed varying results by outcome (see Figures 41 and 42).
Analogue and human insulin
Although the number of trials was limited, the analyses suggest that analogue and human insulin are
equally effective.
Frequency of insulin administration
One trial207 investigated frequency of insulin administration and reported a statistically significant reduction
in neonatal hypoglycaemia when insulin was administered four times daily in comparison with twice daily.
However, the number of women included were few (274) and, consequently, there were few events
(one in the four-times administration group; eight in the two-times administration group).
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We found that few trials included in this review reported negative treatment effects and it is possible that
negative outcomes such as gastrointestinal upset associated with metformin use may reduce compliance
and treatment effects.
Conclusions
Treatment of GDM with diet and lifestyle and pharmacological interventions seems to reduce the risk of
most reported perinatal adverse outcomes. Diet modification alone seems to reduce the risk of adverse
outcomes even in women with glucose levels below those currently diagnostic of GDM. Given the graded
linear association between glucose levels and adverse outcomes (reported in Chapters 2 and 3) and
findings from a systematic review of trials in non-GDM populations,224 the provision of dietary advice for all
pregnant women (irrespective of their glucose levels at OGTT) may be beneficial in terms of reducing the
risk of adverse outcomes across the whole glucose spectrum. Dietary advice, however, may be costly,
especially if specialist advice is provided above the dietary advice that could be given by obstetricians and
midwives during ‘routine’ antenatal appointments. It is also possible that women who view themselves
as ‘normal’ may be less compliant with dietary advice than women who are aware that they have GDM
and who appreciate that dietary modification may improve their and their infant’s health outcomes and
reduce their need for supplementary pharmacological intervention, especially insulin. Women requiring
pharmacological intervention in addition to diet and lifestyle, however, may also be more insulin resistant
or their insulin resistance may be more refractory than women who require only diet and lifestyle advice.
Supplemental metformin in addition to diet and lifestyle modification (if required to normalise glucose
levels) is as effective as insulin and therefore should be the first-line pharmacological treatment of choice,
as it is at least as effective as insulin and may be preferred by women because it does not require
injection, although it should be remembered that trials generally used insulin in the metformin group if
hyperglycaemia was not ‘well’ controlled. The results of this review provide reassurance, however, that a
‘step-up’ approach of first providing dietary and lifestyle advice then adding supplementary metformin or
insulin if glucose levels are not adequately controlled is a reasonable and effective approach to take.
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Chapter 7 Economic evaluation of screening and
diagnostic tests to identify and treat women with
gestational diabetes
Introduction
Existing evidence indicates that hyperglycaemia in pregnancy is associated with a range of adverse
perinatal and longer-term health outcomes. Chapters 2 and 3 of this report present evidence for a
continuum of risk between adverse perinatal outcomes and increasing blood glucose levels (at OGTT), with
no clear threshold below which there is no increased risk. A range of different glucose thresholds has been
proposed, above which women are categorised as having GDM and thus identified to receive treatment to
reduce hyperglycaemia and risk of adverse health outcomes. Diagnostic glucose thresholds for GDM have
been informed by the level of excess risk of adverse health outcomes without consideration of the impact
of diagnosis on health outcomes. In this chapter we evaluate the impact of treatment at alternative
glucose thresholds in order to determine the threshold at which it is most cost-effective to intervene. We
also consider the most cost-effective way of identifying a cohort of pregnant women with IGT for which
treatment may be beneficial. Alternative options for identifying women for treatment include maternal
characteristic/risk factor screening and blood glucose tests (OGCT).
Rates of hyperglycaemia will vary with gestational age because insulin resistance increases as pregnancy
progresses. Lowering the gestational age at which hyperglycaemia is determined allows for earlier
intervention but would be expected to detect fewer cases. Therefore, earlier detection would reduce exposure
to hyperglycaemia in some pregnancies at the expense of increased exposure in others. Repeated testing for
hyperglycaemia would minimise the number of missed cases, but at increased cost to the health service.
Consequently, the number of potential alternative strategies for identifying women with hyperglycaemia is
large and depends on the type and timing of screening, the type and timing of the diagnostic test, the
number of screening and/or diagnostic tests offered, and the threshold for initiating treatment.
Treatment to reduce the risk of the adverse health outcomes associated with hyperglycaemia during
pregnancy can be initiated on the basis of increased risk determined by screening and/or the results of a
diagnostic test. Women who screen positive can be provided with information, advice and further tests. The
benefits of screening may therefore include the impact of lifestyle advice on the risk of adverse health
outcomes, the incentivising effect of being identified as high risk in persuading women to undergo further
diagnostic testing and/or treatment, and a reduction in the number of diagnostic tests in women who are at
low risk of hyperglycaemia. Women who test positive can be provided with lifestyle advice and, as necessary,
pharmacological treatments such as metformin or insulin to reduce the risks associated with hyperglycaemia.
Methods
Overview
A decision tree model was developed to evaluate the cost-effectiveness of alternative strategies of
combined screening, diagnosis and treatment of hyperglycaemia during pregnancy in the UK for a time
horizon of 3 months in the base-case analysis. The best-performing strategy is identified by backward
induction. At the first step the best-performing diagnostic glucose thresholds are identified (defining the
best-performing diagnostic strategy). The second step is a full incremental comparison of all strategies
composed variously of screening, diagnosis and treatment, but for which the diagnostic glucose thresholds
are set at those identified at the first stage. Results are expressed in terms of costs and quality-adjusted
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life-years (QALYs). The perspective of the analysis is that of NHS and personal social services. The key
modelling assumptions in the economic analysis are listed in Appendix 6, Table 69.
Cost-effectiveness is reflected in the model using the metric of net health benefit (NHB). The NHB of each
strategy is the value of the incremental health benefits (ΔE) minus the health benefits forgone as a result
of the increased costs (ΔC). Increased costs represent health costs because within a constrained budget
any additional funds can be obtained only by reducing provision of other health-care activities. The rate at
which displaced health-care activities generate health can be used to determine a cost-effectiveness
threshold (k). A cost-effective intervention is one that generates more health per pound spent than the
activities it displaces. The cost-effectiveness threshold can be used to convert monetary costs into health
costs, or correspondingly to convert health gains to monetary gains. By this method a cost-effective
intervention is simply one that has higher net benefits than alternative activities. The model estimates net
monetary benefits (NMBs), according to equation 1:
NMB = ΔE × k−ΔC. (1)
The cost-effectiveness threshold utilised in the model to estimate net benefits was k = £20,000 per
additional QALY, which corresponds to the lower bound of the threshold range currently used by NICE.225
We also explored the impact of using alternative values of £13,000 and £30,000 per QALY. The latter
relates to the upper bound of NICE cost-effectiveness range,225 and the former is based on recent research
that was the first to use NHS routine data to provide an empirical estimate of the cost per QALY of the
current NHS activities that would be displaced to release resources for new activities.226
Screening, diagnosis and treatment of hyperglycaemia in pregnancy
Risk factor screening for hyperglycaemia in pregnancy
As described in Chapter 5, it is possible to identify pregnant women who are at increased risk of the
adverse health outcomes associated with hyperglycaemia based on their characteristics. These ‘risk factors’
can be used in isolation or in combination to form risk factor screening strategies. For example, NICE
recommends that pregnant women are assessed for risk of GDM18 and diagnostic testing is offered to all
women who have one or more of the following risk factors:
l BMI of ≥ 30 kg/m2
l previous macrosomic baby
l previous GDM
l family history of diabetes
l family minority ethnic origin with a high prevalence of diabetes.
The review presented in Chapter 5 compared alternative risk factor screening strategies composed of
several different maternal characteristics. These maternal risk factors include advanced maternal age, high
BMI, diagnosis of GDM in a previous pregnancy, previous macrosomic infant, multiparity, family history of
diabetes and ethnicity associated with higher GDM prevalence than those of white European origin
(namely SA, black or Middle Eastern origin). Two levels of risk were specified for two of the risk factors:
maternal BMI (≥ 25 or ≥ 30 kg/m2) and maternal age (≥ 25 or ≥ 30 years). The number of possible risk
factor screening strategies is large if all of the possible subsets of seven factors are considered (128), with
further variations because of two levels for two of the factors (a further 128 unique strategies) and if a
screen positive is defined by the presence of more than one factor. In order to reduce the number of risk
factor screening strategies modelled we chose to focus only on strategies for which screen positivity
required the presence of at least one characteristic (e.g. BMI ≥ 30 kg/m2 or previous GDM) rather than
those that require the presence of all characteristics (e.g. BMI ≥ 30 kg/m2 and previous GDM). We
evaluated the sensitivity and specificity of all such strategies over a range of diagnostic thresholds and
excluded those strategies that were dominated in terms of sensitivity and specificity for all diagnostic
thresholds (i.e. less sensitive and no more specific, or less specific and no more sensitive than one or more
ECONOMIC EVALUATION OF SCREENING AND DIAGNOSTIC TESTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
other strategies). This left 68 non-dominated risk factor screening strategies, to which the risk factor
screening strategy utilised by NICE18 was added, giving a total of 69 modelled risk factor screening
strategies. The list of included risk factor screening strategies can be found in Appendix 6, Table 70.
Blood-based tests for hyperglycaemia in pregnancy
There are a number of blood tests that can be administered to measure blood glucose levels. The level of
blood glucose that would be regarded as normal depends on the interval between the blood sample and
the last ingestion of glucose, and the amount of glucose ingested. The amount of glucose ingested prior
to the sample being taken can be standardised by providing a glucose load and/or by asking the woman
to fast prior to testing. FPG is typically assessed by obtaining a blood sample after an overnight fast of
approximately 12 hours. Post-load glucose response can be measured, with increasing standardisation, on
the basis of (1) a random plasma glucose (RPG) sample in which there is no control over the timing or
amount of prior glucose ingestion; (2) a plasma glucose sample obtained after the woman has ingested a
set glucose load; or (3) a plasma glucose sample obtained after the woman has fasted overnight and then
ingested a set glucose load. RPG can be assessed with no preparation or wait time. The OGCT provides a
post-load measure of plasma glucose 1 hour after ingestion of a set glucose load, typically 50 g. The OGTT
provides both a fasting glucose level and one or more post-load glucose levels taken at fixed intervals after
ingestion of a set glucose load, typically 75 g or 100 g. Traditionally in the UK, only the OGTT has been
used for diagnosis of GDM. The distinction between screening and diagnosis is in how the results of the
different tests influence the subsequent care pathway for individuals. Following a positive screening test
women are not yet regarded as having the condition (in this case GDM) and may be offered further testing
and/or preventative interventions. When such tests are administered for the purposes of screening, the
thresholds are often set towards high sensitivity. The OGCT is typically provided in this manner, in which
those who screen positive go on to receive an OGTT. Following a positive diagnostic test (OGTT), women
are regarded as having GDM and can be provided with treatment without further testing.
The review presented in Chapter 3 included one blood-based screening test: the 1-hour 50-g OGCT. This
test requires women to ingest a 50-g glucose load and a sample of blood is collected at 1 hour following
ingestion. Women whose 1-hour blood glucose values are equal to or above a predetermined screening
threshold are identified as being at a higher risk of GDM than women below the threshold, and are
offered a diagnostic test. The screening threshold value is usually set between 7.2 and 7.8 mmol/l.227
The OGCT was not administered to women in the BiB22 or Atlantic DIP59 cohorts, but was included in the
model as an alternative to risk factor screening strategies.
The commonly used diagnostic test of choice is an OGTT. In practice, two alternative glucose loads are
utilised: 75 g and 100 g. At present, there is a range of criteria for determining the presence of GDM on
the basis of exceeding thresholds for the post-load glucose levels variously in combination with thresholds
for the fasting glucose levels (see Chapters 2 and 3). Although the fasting levels should be comparable
between the 75-g and 100-g tests, the post-load measures may not be directly comparable because of the
difference in glucose load and any differences in timing of assessment. Although we do not directly
compare the 75-g and 100-g tests, the review presented in Chapter 3 indicates that the trends in outcome
incidence with graded increases in glucose level are similar for the two diagnostic test loads, but that the
associations were weaker for the 100-g OGTT than the 75-g test. In general the 75-g OGTT will be less
costly than the 100-g OGTT, as it can be administered with only two (or three) blood samples over a
2-hour interval compared with up to four samples over a 3-hour interval for the 100-g test. Ingestion of
the glucose load can be unpleasant and may induce vomiting in some women, which would preclude
completion of the test. Acceptance and completion of the test may be more favourable with the 75-g
glucose load compared with the 100-g load, as the load is less.228
The diagnostic test modelled in our economic analysis is the 2-hour 75-g OGTT administered between
26 and 28 weeks’ gestation. This matches that used in the BiB22 and Atlantic DIP59 cohorts, from which we
had access to IPD, and corresponds to current practice in the UK.18 Diagnosis based on this test relies on
dual glycaemic thresholds, with the 2-hour post-load glucose threshold identifying additional women who
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would be considered normoglycaemic on the basis of their fasting blood glucose levels alone. We varied
the glucose threshold in increments of 0.1 mmol/l between 5.0 and 7.5 mmol/l for fasting glucose and
between 5.5 and 10 mmol/l for post-load glucose, and thereafter in increments of 0.5 mmol/l up to a final
limit equal to 11.1 mmol/l (the threshold at which overt diabetes is diagnosed). By assuming that the
post-load glucose threshold should be at least 0.5 mmol/l higher than the corresponding fasting glucose
threshold, this provided 969 alternative dual glycaemic thresholds. The first step of the economic analysis
compares these 969 potential dual glycaemic thresholds to identify the fasting and post-load glucose levels
that would provide the greatest expected NHB compared with all other possible fasting and post-load
glucose levels. This best-performing diagnostic glucose threshold is then set within the full set of
alternative screening, diagnosis and treatment strategies in order (at the second step of the economic
analysis) to identify the cost-effective strategy.
Treatment of hyperglycaemia
We sought to define treatment to be reflective of current practice for women diagnosed with GDM in the
UK. This comprises provision of dietary and lifestyle advice then adding supplementary metformin or insulin
if glucose levels are not adequately controlled. The effectiveness of treatment with dietary and lifestyle
interventions, which can be provided in the absence of any blood glucose measures, was also modelled.
Intervention strategies for the identification and treatment of
hyperglycaemia in pregnancy
The sections above have described how we determined which screening strategies and which diagnostic
tests and glucose thresholds to include in the model. The full set of alternatives compared in the model are
variously composed of screening, diagnostic tests and treatment, and are outlined below. The set of
intervention strategies include:
1. No screening/testing or treatment.
2. Screen only Screening followed by dietary and lifestyle advice for those who screen positive (maternal
characteristic/risk factor screening strategies, as outlined in Chapter 5, and 1-hour 50-g OGCT).
3. Universal diagnostic test Diagnostic test followed by dietary and lifestyle advice with pharmacological
treatment as required for those who exceed either of the set fasting and post-load glucose levels
(where the best-performing glucose thresholds are identified as outlined above in Blood-based tests for
hypoglycaemia in pregnancy).
4. Screen and diagnostic test Screening followed by diagnostic test in those who screen positive, with
dietary and lifestyle advice and pharmacological treatment as required for those who exceed either of
the set fasting and post-load glucose thresholds (risk factor screening strategies combined with
diagnostic test using best-performing glucose threshold).
Additional screen, diagnosis and treatment strategies
In addition to the base-case set of combined screening, diagnostic and treatment strategies, we included
some additional scenario analyses to explore the use of an alternative diagnostic test to the OGTT and to
explore the sensitivity of the results to alternative treatment options for women diagnosed with GDM.
A further screen and diagnostic test strategy that incorporated the use of a biochemical screening test –
the 1-hour 50-g OGCT – was included but with the OGTT based on the diagnostic glucose threshold
utilised in the source trial. This diagnostic glucose threshold differs from the best-performing glucose
threshold identified in the model because we did not have sufficient information on how the sensitivity
and specificity of the OGCT would vary with alternative diagnostic glucose thresholds to those used in the
source trial. In other words, we were unable to combine screening with the OGCT with a subsequent
diagnostic test, using the best-performing diagnostic glucose threshold.
The FPG requires only one measurement of blood glucose with no wait time, and so may be more
convenient than the OGTT. We included an exploratory analysis to assess the utility of FPG as a diagnostic
test, although current clinical practice does not recommend the FPG alone. As there is a fasting blood
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glucose component of the 75-g OGTT reported in the BiB data,22 these fasting glucose values obtained
with the OGTT in the BiB study22 were used to model the FPG test performance.
We did not seek to directly compare alternative treatment options for women diagnosed with GDM.
However, in a sensitivity analysis (see Treatment costs), we considered the cost implications of replacing
supplementary insulin use (in addition to diet and lifestyle) with metformin, as the results of the review
presented in Chapter 6 indicate that metformin seems to be at least as effective and possibly superior to
insulin, and is potentially more acceptable to women who are inadequately controlled by lifestyle
modification alone. The base-case analysis incorporated treatment only to reduce the risk of immediate
perinatal outcomes associated with hyperglycaemia. In a secondary analysis we explored the impact of early
treatment and prevention of type 2 diabetes among women who experience hyperglycaemia in pregnancy.
Further sensitivity analysis was conducted to explore the potential impact of alternative assumptions in
terms of treatment effectiveness, costs and uptake of diagnostic tests.
Decision-analytic model
Screening, diagnosis and treatment
A decision-analytic model was developed to characterise the risk of adverse perinatal and longer-term
maternal health outcomes as a function of blood glucose levels. The outcomes considered were those
associated with hyperglycaemia during pregnancy, which impacted on any maternal or neonatal health-
related quality of life (HRQL), survival or health-care resource use. The choice of perinatal outcomes was
informed by analysis of IPD from the BiB22 and Atlantic DIP59 cohorts, and supplemented with additional
outcomes identified in previous reviews of screening and treatment for GDM.18 The choice of longer-term
maternal health outcomes was informed by existing evidence.
Pregnant women enter the model depicted in Figure 43, and a decision is made on whether to screen
them or not. If screening is undertaken, the cohort is divided into two groups: those who screen positive
(S+) and those who screen negative (S–). This is followed by a decision regarding whether or not to offer a
diagnostic test to women with positive screening tests. Women who screen negative will not be offered
any treatment or further testing. If a diagnostic test is provided to women who screen positive, those who
have both screened and tested positive go on to receive treatment (S+T+). Those who screen positive but
test negative are not offered any further testing or treatment (S+T–). If screening is not undertaken then all
women may still be offered a diagnostic test, with subsequent treatment for those who test positive (T+).
Women who test negative (T–) would not be offered any further testing or treatment. We assume that if
women are not screened or tested then treatment would not be provided. It is assumed that treatment in
the absence of blood glucose measurement can include dietary and lifestyle interventions, but will exclude
pharmacological interventions, such as insulin and metformin. In other words, treatment is offered to those
who screen positive (S+) and OGTT is not offered before receiving dietary and lifestyle interventions, which
differs to the treatment that can be provided in those who test positive [with an OGTT (S+T+ and T+)].
Adverse perinatal outcomes
The adverse perinatal outcomes included in the model identified from the BiB and Atlantic DIP
cohorts22,59 include:
l pre-eclampsia
l C-section
l shoulder dystocia
l instrumental delivery
l induction of labour
l admission to a neonatal care unit
l macrosomia.
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The recently updated NICE guideline for diabetes in pregnancy18 identified two further adverse health
outcomes: birth trauma and neonatal death. We follow the assumption used within those guidelines that the
rate of birth trauma and neonatal death is proportional to the rate of shoulder dystocia (see Risk models for
the prediction of adverse perinatal outcomes). For simplicity of presentation, these three outcomes are
combined in the composite outcome ‘serious perinatal complications’ within the decision tree.
The model structure allows for the fact that the probability of C-section differs between women with and
without pre-eclampsia. Similarly, the probability of admission to a neonatal care unit was affected by the
occurrence of C-section and pre-eclampsia. It was assumed that shoulder dystocia and instrumental
delivery would not occur in women who underwent C-section. This is illustrated by the subtree depicted in
Figure 43. Model assumptions are listed in Appendix 6, Table 69.
For simplicity of representation, the tree (see Figure 43) does not show induction of labour, although the
probability of this adverse outcome is incorporated into the model for all women in a similar way to that of
pre-eclampsia, that is, it is not affected by the presence of any other outcomes. The models and data
sources used to determine the risk of outcomes are presented in more detail below (see Baseline
probabilities of perinatal outcomes).
In the base-case analysis we include only immediate perinatal and maternal adverse outcomes. In a
secondary analysis the model incorporates longer-term maternal outcomes among women who are treated
for hyperglycaemia in pregnancy. Women with GDM have a sevenfold higher risk of developing type 2
diabetes later in life compared with women who were normoglycaemic during pregnancy.2,229 Diagnosing
women with GDM can therefore identify a cohort of women who are at high risk of future type 2
diabetes. Women diagnosed with GDM are routinely invited for blood glucose assessment post partum.
A proportion of women who present as hyperglycaemic during pregnancy will be found to have persistent
glucose intolerance and subsequently diagnosed with type 2 diabetes post partum. In these women,
appropriate treatment can begin immediately. Continued monitoring of women identified with
hyperglycaemia in pregnancy allows for the earlier identification, treatment and possible prevention of
type 2 diabetes. The longer-term maternal outcomes included in the model are:
l prevalence of undiagnosed overt type 2 diabetes
l incidence of type 2 diabetes associated with prior GDM.
Hypothetical cohorts of pregnant women move through the model to estimate the overall impact on
health outcomes and costs associated with each strategy. Mean levels of FPG, post-load plasma glucose
and risk factors are estimated for the possible subdivision of the cohort (all women, T+, T–, S+, S–, S+T+,
S+T–). Adverse perinatal health outcomes are reflected in the base case in terms of their risk and the
decrements in HRQL associated with them. Treatment has the effect of reducing the risk of those
outcomes. Thus, the least effective strategy will be associated with the largest overall health loss in terms
of QALYs, and the most effective strategy will be associated with the least health loss. Further to this,
any antenatal maternal health gains from treatment are characterised in terms of maternal HRQL
(see Health-related quality of life for further details).
Costs included in the model are those associated with tests (screening and diagnostic), adverse perinatal
outcomes, and the costs of treatment for GDM. Both health outcomes and costs are calculated for the
period from the beginning of the third trimester of pregnancy until the infant’s birth, that is, for the
duration of the time horizon. The benefits and costs of early treatment of type 2 diabetes and preventative
measures to reduce the probability of developing type 2 diabetes in later life were also included in the
model as one-off benefit and cost for the purposes of the secondary analysis.
Evaluating the decision tree
At each decision node, the decision between alternative branches is taken so as to maximise NHB
(screening/no screening; diagnosis/no diagnosis; treatment/no treatment) and the best-performing overall
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strategy is defined by backwards induction (i.e. working backwards through the tree) such that NMB is
maximised over the combined set of alternatives (see Intervention strategies for the identification and
treatment of hyperglycaemia in pregnancy). The method of backward induction means that we
first identify the best-performing dual glycaemic threshold to initiate treatment, that is, the fasting and
post-load glucose levels that would provide the maximum NHB among the full range of possible dual
glycaemic thresholds, given the observed results of an OGTT. The performance of alternative screening
and test strategies is then evaluated on the basis that subsequent testing and treatment is determined by
this best-performing glucose threshold.
Data used to populate the model
In the following sections, we describe how the risk models for adverse perinatal outcomes were estimated
based on IPD, and how perinatal and maternal longer-term outcomes were implemented in the model
based on previously published evidence. We also present the parameter values for treatment effects, uptake
of diagnostic tests, health benefits and costs that were applied in the base case and sensitivity analysis.
Baseline probabilities of perinatal outcomes
Risk models for the prediction of adverse perinatal outcomes
The risk models estimated in Chapter 3 show a log–linear relationship between both fasting and post-load
glucose measures and the risk of a range of perinatal outcomes. The economic model incorporates the
baseline risks of adverse outcomes that were considered to have an impact on maternal or neonatal HRQL or
associated costs, and on data collected in the BiB and Atlantic DIP22,59 data sets. We further included in the
base case the risk of macrosomia (BW of ≥ 4.5 kg), although no cost or HRQL impact was included for this
outcome. Macrosomia may be associated with longer-term outcomes, such as childhood obesity, diabetes
and metabolic disorders in later life.4,5,230 The aim was to build the economic model with the flexibility to link
to further longer-term adverse outcomes and potentially to extend the model once follow-up data on the
children from the BiB cohort22 are available. The perinatal outcomes included in the model were:
l pre-eclampsia
l C-section
l labour induction
l serious perinatal complication, including: shoulder dystocia, birth trauma and neonatal death (and/or
stillbirth)
l admission to NICU
l instrumental delivery
l macrosomia.
The risk models estimated in Chapter 3 were the basis for the risk models applied in the economic model.
The risk models were adapted in order to reflect interdependence between outcomes as depicted by the
model structure, and to combine both fasting and post-load glucose measures into a single model.
The inclusion of the fasting and post-load glucose measurements into a single risk model allows the
exploration of the impact on adverse outcomes of varying the dual diagnostic threshold. The potential
interdependence between outcomes (e.g. between pre-eclampsia and C-section) was incorporated by
including as independent covariables in the risk model for each adverse outcome any outcomes that
precede it in the decision tree structure (see Figure 43). For example, the probability of C-section was
estimated by including the occurrence of pre-eclampsia as an independent covariable in the risk model.
The risk model for admission to the NICU included the occurrences of C-section and pre-eclampsia as
independent covariables. Shoulder dystocia and instrumental delivery were assumed to be mutually
exclusive from C-section, and therefore the probabilities of shoulder dystocia and instrumental delivery
outcomes were estimated among women who did not undergo C-section.
The data set used to estimate the probabilities of adverse perinatal outcomes in untreated women
comprised women in the BiB and Atlantic DIP22,59 data sets who were not considered eligible to receive
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treatment for GDM (i.e. those with blood glucose levels of < 6.1 mmol/l at fasting, and < 7.8 mmol/l
2 hours after a 75-g OGTT test). Multiple imputation by chained equations (MICE) was used to handle
missing data in outcomes and covariables for each of the data sets, prior to combining them. This method
replaces missing values with multiple imputed values based on observed characteristics, and thus assumes
that the pattern and values of the missing data are dependent on observable characteristics alone.231
The main advantage of this method is that it is less likely to yield biased and inefficient estimates than
complete case analysis, while incorporating the uncertainty associated with the imputation method in the
estimates that replace the missing values.40
Distributions of variables from the pooling of the data sets with imputed variables were similar to those for
observed variables. Two outcomes were considered to be inadequately captured within the Atlantic DIP59
data set such that the preferred estimation sample was limited to women from BiB cohort. Induction of
labour was not recorded in Atlantic DIP;59 and the level of missingness for instrumental delivery in the
Atlantic DIP59 data set (approximately 25%) was considered too high to be adequately addressed with the
application of MICE. The output of the logistic regressions for each risk model used to predict perinatal
outcomes is reported in Appendix 6, Table 70.
In order to capture the additional adverse outcomes of neonatal death and birth trauma among women
identified with GDM it was assumed that the probability of these outcomes would be proportional to the
rate of shoulder dystocia alone. This follows the assumption used in NICE updated guideline for diabetes in
pregnancy18 and a previous cost-effectiveness study identified in the guideline,232 in which a composite
outcome of serious perinatal complications was defined to include shoulder dystocia, neonatal death and
birth trauma. The guideline reported data from two RCTs, selected by Round et al.,232 which evaluated the
impact of treatment for GDM on perinatal complications: the Australian Carbohydrate Intolerance Study in
Pregnant Women (ACHOIS) trial51 and the study by Landon et al.52 These two trials51,52 had been selected
from a meta-analysis of five trials on the effects of treatment for GDM,169 in which Round et al.232
considered that the remaining three trials did not use adequate randomisation methods. The number of
events in both treated and untreated (routine care) arms was pooled across the two trials to estimate the
total number of fatal events (neonatal and stillbirth), birth trauma and shoulder dystocia. Birth trauma was
defined as brachial plexus palsy or clavicular, humeral or skull fracture in Landon et al.,52 whereas the
ACHOIS trial51 reported only bone fracture and nerve palsy. All of these events were assumed equivalent
and aggregated as a category defined as birth trauma in the NICE guideline.18 Table 29 details the number
of events from each trial and the pooled number of events used in the NICE guideline model to estimate
the relative proportion of each outcome (death, shoulder dystocia and birth trauma) to the total composite
number of serious perinatal complications.
A multiplier of 1.37 was applied to the baseline risk of shoulder dystocia estimated in the BiB and Atlantic
DIP22,59 data to adjust it to the risk of serious perinatal complications. This follows the way in which this
outcome was modelled in the NICE updated guideline for diabetes in pregnancy.18 The multiplier is the
inverse of 0.73, that is, the inverse of the proportion of all serious perinatal complications that corresponded
to shoulder dystocia (48/66) pooled from the two RCTs.51,52 The use of pooled data from the two trials51,52
TABLE 29 Serious perinatal outcomes from ACHOIS, Landon et al.52 and the pooled estimates
Outcomes
ACHOIS 200551 (n) Landon 200952 (n)
Pooled (n)
Relative
frequencyRoutine care Treatment Routine care Treatment
Death 5 0 0 0 5 0.076
Shoulder dystocia 16 7 18 7 48 0.727
Birth trauma 4 0 6 3 13 0.197
Serious perinatal complications 25 7 24 10 66 1.00
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assumes that the two populations are equivalent despite the differences in diagnostic test glucose load
between the trials (100 g in Landon et al.,52 75 g in Crowther et al.51), and the relative frequency of each
individual component of the serious perinatal complications outcome is similar in both trials.
Prevalence of undiagnosed overt maternal type 2 diabetes
The prevalence of undiagnosed overt type 2 diabetes among women who were diagnosed with
hyperglycaemia in pregnancy was assumed to be 11%, based on a study233 that measured the rate of
type 2 diabetes among women who would be diagnosed with GDM based on the 1999 WHO criteria.11
We have sourced the prevalence parameter from this study233 because the data were collected from an
obstetric population attending the same NHS Trust as those in the BiB cohort (the Bradford Teaching
Hospitals Trust) and, therefore, it is likely to reflect the characteristics of the BiB study22 population.
This estimate is in line with estimates of between 7% and 11.6% reported in other studies that have
been identified to inform rates of uptake of post-partum follow-up (see Uptake of screening, diagnosis
and treatment).127,234 A further study235 was identified, which reported a much lower estimate of
prevalence of type 2 diabetes detected post partum (2.4%). However, this study235 was conducted in a
population where 86% of women were Caucasian and was, therefore potentially less reflective of the
BiB cohort.235
Incidence of type 2 diabetes among women with a history of gestational
diabetes mellitus
Women with GDM have a sevenfold increase in the risk of developing type 2 diabetes later in life
compared with women who were normoglycaemic during pregnancy.2,229 The estimated incidence of
type 2 diabetes among women with a history of GDM was taken from women who were randomised to
receive placebo in the Diabetes Prevention Program Outcome Study (DPPOS).236,237 Women recruited to
the DPPOS236,237 were on average 12 years post pregnancy. A history of GDM was associated with an
additional 10-year incidence of 14.8% (64.7% cumulative incidence in women with a self-reported history
of GDM compared with 49.9% in women without a history of GDM). The benefit of this approach to
estimating the risk of type 2 diabetes is that it allows us to isolate the proportion of type 2 diabetes that
could be predicted only on the basis of diagnosing GDM (by controlling for the correlated risk factors of
IGT and obesity). The DPPOS236,237 was conducted in a US setting in obese women with IGT (defined as
fasting glucose between 5.2 and 7.0 mmol/l).236,237 Consequently, we assumed that this increased risk of
type 2 diabetes applied to only the proportion of women who test positive for GDM and have a BMI
of ≥ 30 kg/m2.
Treatment effects
The impact of treatment on perinatal outcomes was incorporated by means of a RR reduction, as reported
in the systematic review and meta-analysis in Chapter 6. The impact of treatments on the risks of
longer-term adverse maternal health outcomes were informed by literature and included in exploratory
analysis. Where the available evidence related outcome risks to diagnosis of GDM and not blood glucose
level, additional assumptions were required as to the impact of altering the diagnostic glucose threshold.
These assumptions are reported in detail in Appendix 6, Table 69.
In the model, the diagnostic glucose threshold for treatment determines the proportion of women who are
treated for GDM in each strategy, and therefore the proportion of women whose baseline risk of adverse
outcomes will be modified by applying a RR to estimate the ‘treated’ probability of each perinatal
outcome. The estimates of RR applied in the model for the adverse outcomes were sourced from the
treatment review (see Chapter 6). The base-case analysis used the meta-analysis that compares diet
modification or advice – accompanied by glucose monitoring and insulin use in some women – to routine
antenatal care. This treatment ‘bundle’ was selected as it more closely reflects the current practice for the
treatment of GDM in the UK, that is, diet and exercise modification as first-line treatment followed by
pharmacological therapy (metformin and/or insulin) if first-line therapy is unsuccessful.18 Although the
meta-analysis of trials of diet modification did not include metformin, it was assumed, nevertheless, that
the effectiveness of the treatment ‘bundle’ would not change by replacing insulin with metformin in a
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proportion of the women treated for GDM. This assumption was based on the review presented in
Chapter 6, which suggests that the effects of metformin and insulin were generally comparable and that
there was a trend for metformin to perform better, or at least no worse, than insulin for all adverse
outcomes reported, with the exception of assisted/instrumental delivery.
The base-case analysis assumes that all of those who test positive (S+T+ or T+) will undergo treatment.
As treatment effects are derived from an intention-to-treat analysis, it is assumed that compliance and
adherence will be reflected within the RR estimates. As the fasting and post-load glucose levels above
which treatment is offered are varied in the model, an assumption is required as to whether or not the
magnitude of the relative treatment effect will remain constant regardless of the mean glucose levels in the
treated groups. Subgroup analysis by definition of GDM (see Chapter 6) did not find evidence that the
effect of diet modification varied according to the population included in the trials in terms of levels of
glucose (GDM, mild GDM, IGT or women who screened positive with OGCT, but tested negative with
OGTT). In the base case, the relative treatment effect on adverse perinatal outcomes is assumed constant,
regardless of the fasting and post-load glucose thresholds above which treatment is initiated (although it
should be noted that the baseline risk of those outcomes, and thus the absolute risk reduction offered by
treatment, is adjusted with those thresholds). Although data collected on BiB and Atlantic DIP22,59 refer to
admissions to neonatal care (in which intensive care is also included), data that were specific to admissions
to NICU were not available. As NICU is the outcome for which the treatment affect is reported in Chapter 6,
we assumed that the treatment effect on neonatal admissions would be equivalent to that for NICU.
Table 30 shows the base-case estimates of the RR for each adverse outcome in the model with treatment.
As the trials included in the meta-analyses had some variation in terms of treatment delivered, and
uncertainty over the length of time insulin was used, a scenario analysis was also conducted with alternative
RR estimates as used in a previous study232 and applied in the NICE updated guideline for diabetes in
pregnancy.18 Round et al.232 pooled the results of two high-quality trials51,52 that allowed treatment with
insulin in addition to diet modification to estimate treatment effects for each outcome. These trials51,52 are a
subset of the trials included in the treatment review (see Chapter 6, Trials comparing different types of diet
modification). The estimated RRs used in the scenario analysis are reported in Table 31.
The only adverse effect of treatment which is considered sufficiently important to impact significantly on
costs or outcomes was hypoglycaemia. We incorporated this adverse effect following the same approach
utilised in the NICE updated guidelines to estimate a probability of severe hypoglycaemia. The probability
of hypoglycaemia for women treated with insulin was sourced from a trial that compared the effectiveness
of insulin and glibenclamide in GDM, and corresponded to 0.202.187 In the NICE updated guideline it was
assumed that there was a 0.05 probability of severe hypoglycaemia in those women treated for GDM who
developed hypoglycaemia as an adverse effect.18 In our analysis we applied the same probability of severe
TABLE 30 Relative risks of adverse health outcomes with treatment for hyperglycaemia: base case
Adverse perinatal outcome RR SE log RR
NICU 0.91 0.197
Shoulder dystocia 0.39 0.280
C-section 0.86 0.054
Pre-eclampsia 0.58 0.242
Labour induction 1.12 0.157
Instrumental delivery 1.37 0.979
Macrosomia 0.46 0.130
NICU, admission to NICU.
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hypoglycaemia (0.05 × 0.202 = 0.010) to women who received treatment with insulin, but assumed that
metformin would not be associated with severe hypoglycaemia.
It was assumed that treatment in the absence of blood glucose testing would not include pharmacological
interventions. The treatment effects on adverse perinatal outcomes applied to women who are treated
without undergoing a blood glucose test (i.e. S+ in the screen-only strategies) are sourced from a review on
the effects of dietary and lifestyle interventions on obstetric outcomes.224
The Thangaratinam review224 (Table 32) does not report estimates for instrumental delivery or macrosomia.
For the latter, this is not an issue, as macrosomia does not impact on costs or health benefits in the current
model set up (see Baseline probabilites of perinatal outcomes). For instrumental delivery we assume that it
had the same treatment effect as the base-case treatment (i.e. RR = 1.37).
Treatment for longer-term maternal outcomes
Women who are diagnosed with GDM are routinely invited for blood glucose assessment post partum.
A proportion of women who present with hyperglycaemia during pregnancy will be found to have
persistent glucose intolerance post partum, and may be diagnosed with type 2 diabetes. In these women,
appropriate treatment can begin immediately. The benefits of early treatment of type 2 diabetes will
depend on whether or not those women would have been identified with type 2 diabetes in the absence
TABLE 31 Relative risks of adverse health outcomes with GDM treatment: scenario analysis
Adverse perinatal outcome RR SE log RR Source
NICUa 0.77 0.194 Landon52
Shoulder dystocia 0.41 0.314 Crowther,51 Landon52
C-section 0.88 0.068 Crowther,51 Landon52
Pre-eclampsiab 0.46 0.345 Landon52
Labour induction 1.17 0.069 Landon52
Instrumental deliveryc 1.37 0.979 Diet modification meta-analysis (see Chapter 6)
Macrosomiad 0.47 0.161 Crowther51
NICU, admission to NICU.
a Outcome not collected in the Crowther et al. study.51
b Estimate considered to be too high, by the guideline development group, in the Crowther et al. study.51
c Outcome not collected in the studies by Crowther et al.51 and Landon et al.52
d Outcome not collected in the Landon et al. study.52
TABLE 32 Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of
randomised evidence224
Perinatal outcome RR SE log RR
NICU 1.00 0.146
Shoulder dystocia 0.39 0.295
C-section 0.93 0.044
Pre-eclampsia 0.74 0.109
Labour induction 1.12 0.059
Instrumental delivery – –
Macrosomia – –
NICU, admission to NICU.
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of pregnancy screening and, if they would have been identified, at what point in time. We were unable to
directly model the benefit of early detection of type 2 diabetes among pregnant women. Instead, the
potential benefits of the early detection of undiagnosed type 2 diabetes were informed by a study238 that
evaluated the cost-effectiveness of screening for type 2 diabetes. We used estimates of the QALY gain and
incremental costs associated with a one-off screening strategy for type 2 diabetes in order to estimate a
NHB for those women diagnosed with GDM who are found to have type 2 diabetes at 6 weeks’ post-
partum follow-up. It is important to emphasise that the population in the Gillies study238 is different from
the group for which they are being applied here (model cohort included both men and women, and the
base-case estimated cost and QALYs for screening at 45 years old). This estimate is intended to explore
the potential impact of early detection and is incorporated in only a secondary analysis.
Diagnosing women with hyperglycaemia in pregnancy identifies a cohort of women at high risk of future
type 2 diabetes. Continued monitoring of these women post partum allows for the early identification,
treatment and possible prevention of type 2 diabetes. The rate of type 2 diabetes that could be potentially
avoided among women diagnosed with hyperglycaemia in pregnancy was determined by combining the
additional risk of developing type 2 diabetes that is associated with previous GDM with evidence for the
reduction in risk from a preventative treatment package that could be offered to the proportion of women
that are followed up post partum. This preventative treatment package was defined in terms of the
intensive lifestyle intervention (ILS) utilised in the Diabetes Prevention Program (DPP) study236,237 and
DPPOS,239 which was associated with a RR of 0.352 for incidence of type 2 diabetes. The increased
incidence of type 2 diabetes attributable to testing positive for hyperglycaemia in pregnancy would be
expected to vary with the diagnostic threshold. However, the estimates for this RR were available based on
diagnosis of GDM determined at a fixed threshold. These longer-term maternal benefits of prevention are
applicable only to the proportion of women who test positive and have a BMI of ≥ 30 kg/m2. As the rate
of obesity among women who test positive does vary with the diagnostic threshold, this allows the
longer-terms benefits to be a function of the alternative diagnostic thresholds.
Uptake of screening, diagnosis and treatment
The effects of screening and treatment were further reduced in the model by assumptions about rates of
uptake. Uptake of screening and diagnostic tests has been found to be an important area of uncertainty in
previous NICE guidance,240 although it was not incorporated in the economic model in the updated
guideline.18 In our model, we evaluate uptake at four points relating to the offering of screening and
diagnostic tests and treatment.
Uptake of:
l screening
l diagnostic test
l post-partum blood glucose tests
l preventative interventions post partum.
In all cases we assume that uptake is not a function of the population characteristics. There is evidence to
suggest that uptake of screening varies with the type of test.228 In the economic analysis we focus on risk
factor screening strategies and consider scenarios for screening with OGCT. We assume that uptake of risk
factor screening (assessment of maternal characteristics) can be 100%, as it can easily be integrated in
current routine antenatal care. The performance of risk factor screening strategies may be affected if some
factors are difficult to determine in practice (e.g. family history of diabetes).
Available evidence also suggests that uptake of diagnostic tests is higher in a population identified by
screening as high risk of GDM than in an unscreened population (and therefore universally tested).124,228
We assume that uptake of OGTT is 63% in an unscreened population and 89% in a risk factor-screened
population. That is, risk factor screening increases uptake of the diagnostic test by > 30%. The estimate
for the uptake of universal OGTT is sourced from a study124 based on routine hospital data from Bradford
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in the period between 2008 and 2010. The same study124 also provides an estimate of 99% for the uptake
of OGTT on a risk factor-screened group corresponding to an earlier period (2004–6). Based on the advice
of the study authors, we considered that this latter estimate could be artificially high, as uptake may
have been increased by more intensive pursuit of participants with telephone reminders that may not
reflect current practice across the UK. Thus, in the base case we averaged the uptake estimates in risk
factor-screened populations from two UK studies,124,235 resulting in an estimated uptake of approximately
90%. We explore the impact of these assumptions on diagnostic uptake in a sensitivity analysis, in which
we simultaneously apply a higher uptake of diagnostic estimate for an unscreened population and a lower
estimate for a risk factor-screened population. The alternative diagnostic uptake estimates are sourced from
an unscreened population (73%),150 and from a risk factor-screened population (80%),235 and correspond
to more extreme estimates of the parameters found in the literature. This scenario analysis aims to test if
the model is sensitive to smaller improvements in uptake of diagnostic tests in a screened population in
comparison with an unscreened one.
Post-partum follow-up may also be influenced by the type of screening. This assumes that, conditional on
diagnosis of GDM, the experience of having been risk factor screened prior to diagnosis influences uptake
of further screening. Gregory et al.127 reported an uptake of follow-up for women with GDM who were
identified with universal OGTT of 52%. For women who were previously screened by risk factors, a higher
estimate of follow-up uptake was identified (83%) from a retrospective study233 based on routine hospital
data collected in Bradford. We assumed that 52% of women who were never screened attend for glucose
testing at 6-week postnatal follow-up. We assumed that 83% of women who were screened for being at
high risk of having GDM would attend for glucose testing at 6-week postnatal follow-up. Alternative
scenarios were undertaken with estimates from a retrospective US study241 of women with GDM, which
indicated that 38% would have any type of glucose testing post partum and 23% would be screened with
an appropriate test (FPG or OGCT). As it is not clear whether or not women in the study241 were screened
or not for GDM, the estimates were applied to a set of strategies with and without selective screening.
Test characteristics of screening
The presence of maternal risk factors in the hypothetical cohort and the mean fasting and post-load
glucose measures for each cohort (all, T–, T+, S–, S+T+, S+T–) are estimated over the range of alternative dual
glycaemic thresholds using the BiB study22 IPD. In other words, the sensitivity and specificity of the
alternative risk factor screening strategies was estimated directly using the BiB cohort22 data.
A screening strategy based on providing all women with a 1-hour 50-g OGCT was explored by applying
estimates of test performance (sensitivity and specificity compared to the 2-hour 75-g OGTT) sourced
from the literature.242 The study242 used to inform test performance in the model was identified in the NICE
guidance and applied in their economic model.18 The reported sensitivity (80%) and specificity (43%) of
the OGCT correspond to the diagnostic threshold used in the study,242 which was a fasting glucose level of
≥ 7.0 mmol/l or a post-load glucose level of ≥ 7.8 mmol/l. These estimates of sensitivity and specificity were
combined with the proportion of women that would be identified as having GDM (T+) based on BiB data22
at this same diagnostic threshold. We assumed that true positives (S+T+) would have the same mean blood
glucose levels as women who tested positive (T+) and that false positives (S+T–) would have the same mean
blood glucose levels as those who test negative (T–). Similarly, the mean blood glucose levels for those who
screen negative was estimated by assuming that true negatives would have the same mean blood glucose
levels as those who test negative, and false negatives would have the same mean blood glucose level as
those who test positive. Table 33 summarises the data from South Asian et al.,242 alongside the proportion
of women in the model (S+, S–, S+T+ and S+T–) that was estimated based on that study.
Health-related quality of life
The health benefits of the alternative strategies are summarised in terms of mean QALY by adjusting the
period of time spent in alternative health states by the HRQL (also referred to as utility value) that is
associated with that health state. In the model, we estimated the QALY loss associated with the
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occurrence of adverse outcomes, the QALY gains from treatment of GDM and from ILS to reduce the risk
of future maternal type 2 diabetes.
Health-related quality of life loss from adverse perinatal outcomes
The NICE updated guideline18 for diabetes in pregnancy included QALY loss only from serious perinatal
complications in the economic model. As we considered that other perinatal outcomes would also imply
HRQL loss, we sourced QALY loss estimates for those outcomes from NICE clinical guidelines, as described
throughout this subsection.
The perinatal outcomes for which a QALY loss was applied in the model were:
1. pre-eclampsia
2. C-section
3. serious perinatal complications
4. instrumental delivery.
Pre-eclampsia
The NICE hypertension in pregnancy guideline243 assumed that the QALY loss from pre-eclampsia could be
attributed to severe complications of pre-eclampsia alone, and calculated that the weekly QALY loss from
these would correspond to 0.019. The time spent in this health state was assumed to be 2 weeks, the
maximum number of weeks that women would spend in treatment for the severe complications.243 This
2-week QALY loss from severe complications of pre-eclampsia is multiplied by the probability of developing
severe complications conditional on having pre-eclampsia as sourced from the hypertension in pregnancy
guideline.243 The resultant QALY loss associated with pre-eclampsia applied in the model was calculated as
a total loss of 0.00456 QALYs.
Caesarean section
The estimate of QALY loss from C-section was adapted from the NICE clinical guideline on C-section,33 and
consisted of the difference between the expected HRQL in women with adverse outcomes from C-section
compared with that for a vaginal delivery. This weighted average of HRQL for each mode of delivery is
calculated by multiplying the utility loss of individual adverse outcomes, namely maternal death,
hysterectomy, hypoxic–ischaemic encephalopathy and urinary incontinence, by the risk of those outcomes
depending on the mode of delivery. In the C-section guideline, the weighted average also included
neonatal death, which in our model is accounted for through the QALY loss associated with serious
perinatal complications, and thus was excluded from these calculations. This yields a QALY loss of
approximately 0.0017 for C-section. If neonatal death had been included in the calculation the QALY loss
associated with C-section would have been approximately 0.030. Table 34 summarises the calculation of
QALY loss from C-section.
TABLE 33 Oral glucose challenge test performance reported by Seshiah et al.242 and proportion of women in each
branch of the decision tree
Economic model
Reported (n) Calculated proportion
Parameter
T+ T– T+ S+T+ S+T– S+ S– T–
S+ 134 414 0.08 0.06 0.26 0.32 0.68 0.92
S– 34 309 – – – – – –
Mean fasting glucose 5.24 5.24 4.46 4.65 4.54 4.47
Mean post-load glucose 9.12 9.12 5.39 6.30 5.71 5.39
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Adverse perinatal complications
As reported above (see Adverse perinatal outcomes), the composite outcome of serious perinatal
complications includes shoulder dystocia, birth trauma and neonatal death (including stillbirths). In the
model, we applied the estimate of QALY loss from the NICE updated guideline for serious perinatal
complications.18 This estimate is a weighted average of the QALY loss from shoulder dystocia, birth trauma
and neonatal death, for which the weights correspond to the relative frequency of each individual
outcome from the Crowther and Landon trials.51,52 The QALY loss for shoulder dystocia in the NICE
guidelines18 includes the utility decrement from brachial plexus injury, adjusted for the proportion of
neonates that suffer the complication of shoulder dystocia, and the average time until the complication is
resolved. As in the NICE guideline,18 the QALY loss associated with birth trauma was assumed to be the
same as for shoulder dystocia. The QALY loss from neonatal death was approximated as the discounted
QALY (at a rate of 3.5%) from a life expectancy of 80 years lived in perfect health. Table 35 shows the
QALY loss, and relative frequency by adverse outcome, from serious perinatal complications.
Instrumental delivery
The estimate of QALY loss from instrumental delivery was adapted from the NICE clinical guideline on
C-section,33 and calculated similarly to the QALY loss from C-section. Thus it is the difference in QALY loss
between instrumental delivery and vaginal delivery, for which the QALY loss for each mode of delivery is a
weighted average of the QALY loss from urinary incontinence (permanent) multiplied by the risk of this
outcome for each mode of delivery. It was assumed that the only outcome with impact on HRQL, and
which occurs at a different rate depending on whether the delivery is assisted or not, is maternal urinary
incontinence . The calculation yields a QALY loss of approximately 0.053 for instrumental delivery.
Table 36 summarises the calculation of QALY loss from instrumental delivery.
TABLE 34 Calculation of QALY loss from C-section
Outcome QALY loss
Vaginal delivery C-section
Risk Weighted QALY loss Risk Weighted QALY loss
Maternal deatha 24.8 0.00002 0.000496 0 0
Hysterectomy 9.79 0.00016 0.0015664 0.00058 0.0056782
Hypoxic–ischaemic
encephalopathy
4.43 0.00234 0.0103662 0.00191 0.0084613
Total – – 0.0124286 – 0.0141395
Difference – – – – 0.0017109
a Based on the 50 years’ remaining life expectancy of a mother giving birth at an age of 29.4 years, and assuming that
remaining years are lived in full health.
TABLE 35 Quality-adjusted life-year loss from serious perinatal complications
Outcome QALY loss Relative frequency51,52
Shoulder dystocia 0.179 0.727
Birth trauma 0.179 0.197
Neonatal death 25a 0.076
Weighted QALY loss 2.05
a This value is an approximation of the QALYs accrued over a life expectancy of 80 years in perfect health discounted at
3.5% annually (27.6 QALYs), and corresponds with the estimate applied in the current NICE guidance on diabetes
in pregnancy.18
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Health-related quality of life gains from treatment of maternal hyperglycaemia
The ACHOIS trial51 collected HRQL data for women during pregnancy and in the post-partum period,
according to whether they were treated or untreated for GDM. This suggests that women who are treated
for hyperglycaemia experience direct improvements in HRQL prior to giving birth. The estimates from the
trial are shown in Table 37.
We assumed that these differences in HRQL would be applied for the duration of treatment during
pregnancy (i.e. last 3 months of pregnancy) and so we time adjusted the estimates (by multiplying each by
0.25). The QALY gain from GDM treatment was estimated by subtracting the time-adjusted HRQL when
untreated from the time-adjusted HRQL when treated, which resulted in a QALY gain of 0.0050. This
assumes that maternal HRQL is not related to glucose levels – only to whether or not the women
are treated.
Health-related quality of life gains from the prevention of maternal type 2 diabetes
We assumed that women who go on to develop type 2 diabetes that is related to their GDM would do so
on average 15 years after pregnancy, and would, on average, experience 10.5 years of asymptomatic
diabetes before progressing to symptomatic diabetes.244 The life expectancy of women who developed
diabetes was assumed to be 69 years if untreated, whereas non-diabetic women were assumed to have
80 years of life expectancy.244 Age- and gender-adjusted lifetime QALYs after pregnancy245 were estimated,
applying a 3.5% annual discount rate in accordance to current NICE guidance.225 The utility loss of having
asymptomatic and symptomatic diabetes was sourced from a UK catalogue of EQ-5D (European Quality of
Life-5 Dimensions) estimated disutilities,246 and applied in the calculation of lifetime QALYs for diabetic
women. The QALY gain from intervening to prevent diabetes was applied as the difference between the
lifetime post-pregnancy QALYs of a healthy woman (21.17) and a diabetic woman (19.08), multiplied by
the reduction in RR of developing diabetes given treatment with the ILS, and corresponded to QALY loss of
approximately 0.20. The probability of developing diabetes or intolerance to glucose being attributable to
having experienced a GDM pregnancy (0.148), and the RR reduction from delivering the ILS (0.352) were
sourced from Aroda et al.239 The utility gain was applied in the model to the proportion of women with
GDM who were treated with the ILS, which consisted of those with a BMI > 30 kg/m2 who were treated
for hyperglycaemia in pregnancy, and who subsequently attended the 6-week follow-up and accepted
treatment with the ILS.
Health-related quality of life loss from severe hypoglycaemia
The average utility loss associated with severe hypoglycaemia (an adverse event of treatment with insulin)
is small, and, therefore, was assumed to be negligible given the short duration of this event.
TABLE 36 Calculation of QALY loss from instrumental delivery
Outcome QALY loss
Vaginal delivery Instrumental delivery
Risk Weighted QALY loss Risk Weighted QALY loss
Urinary incontinence 2.77 0.199 0.55123 0.218 0.60386
Difference – – – – 0.05263
TABLE 37 Maternal utility in ACHOIS trial
Pregnancy QALYs SE
Treated 0.72 0.03
Untreated 0.70 0.02
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Resource use and costs
Resource use and costs applied in the model include treatment and test-related costs, as well those
associated with the consumption of health resources resulting from adverse perinatal outcomes. The
majority of costs are based on the 2013 price year, the exceptions being drugs, insulin, needles, lancets,
test strips, glucose solution and laboratory costs (all 2014 prices). No discount rate was applied to costs
that were assumed to occur within 12 months of testing (screening and/or diagnosis), that is, all costs
except those related to the ILS. Future costs that were assumed to occur beyond 12 months of testing
were discounted at a 3.5% annual rate, in accordance with current NICE guidance.225
Screening and diagnostic testing costs
The cost of diagnosing with a 75-g OGTT 2-hour test was based on the NICE updated guideline.18 This
cost included the costs associated with time spent by a specialised nurse (band 6) to explain the test and
inform the participant of the test result (5 minutes) and the time needed by a health assistant to obtain
participant consent, prepare the glucose solution and collect blood samples (20 minutes), as well as the
costs associated with laboratory work and the glucose solution.18 The costs of the screening test were also
included in the economic model, namely for the 50-g OGCT 1-hour test and FPG test. As the NICE
updated guideline for diabetes in pregnancy18 did not include these tests in their main analysis, it was
assumed that both tests would imply the same laboratory costs and nurse time as the 2-hour 75-g OGTT.
Furthermore, it was assumed that the 1-hour 50-g OGCT would also imply the same health assistant time
and same preparation of glucose solution as the 2-hour 75-g OGTT. The FPG does not require the
ingestion of a glucose solution, and therefore this cost was not included, and the time spent by the health
assistant was assumed to be 10 minutes. Table 38 shows the resource use and unit costs applied in the
model for the costs associated with blood-based glucose tests.
The cost of testing with 2-hour 75-g OGTT and 1-hour 50-g OGCT was £22.06 per test, and the cost of
testing with FPG was £20.42 per test. Our clinical advisors considered that the underlying assumptions to
the cost calculation for the three tests, as well as the resulting cost estimates, were plausible.
No additional cost of screening activities based on risk factors was included in the model. This was because
it was assumed that this type of screening would occur within one of the routine antenatal visits, and
therefore was not associated with any additional costs.
Adverse perinatal outcomes costs
The costs associated with adverse perinatal outcomes were estimated based on the frequency of these
outcomes as predicted by the model, and applying the costs used in the NICE updated guideline.18
We reviewed the sources of unit costs applied in the NICE updated guideline, and considered them to be
consistent and in accordance with recommended costing approaches.225 All costs related with the birth
were calculated as an incremental cost above the cost of a vaginal delivery according to the NHS reference
costs schedule.225 Although the economic model in the NICE updated guideline18 did not include a cost
for instrumental delivery, we considered that it should be included, and a unit cost was calculated for
instrumental delivery based on costs in excess of those for a vaginal delivery. As described above (see
Baseline probabilities of perinatal outcomes), although the outcomes ‘birth trauma’ and ‘neonatal death’
were not collected in the available data (BiB and Atlantic DIP22,59 data sets), they were included in the
model via the estimated relationship between their relative frequency compared with shoulder dystocia,
obtained by pooling the event rates in two.51,52 The pooling of these event rates also allowed estimation of
the relative weights for these three outcomes in the cost composition of serious perinatal complications
(see Health-related quality of life). The unit cost for serious perinatal complications was thus calculated in
the NICE updated guideline18 as a weighted average of the unit costs of shoulder dystocia, birth trauma
and neonatal death.18 As mentioned above (see Treatment effects). Admission to neonatal care unit was
the adverse perinatal outcome reported in the BiB22 and Atlantic DIP59 studies, and therefore that which
was included in the model. The unit cost estimate applied in the model to this adverse outcome
corresponds with cost of admission to NICU, which is likely to be an overestimation of the cost. Table 39
summarises the costs associated with adverse perinatal outcomes that are included in the model.
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Treatment costs
The majority of treatment costs applied in the model are based on the NICE ‘Diabetes in pregnancy’
guideline,18 and include the costs of self-monitoring glucose levels, hypoglycaemic therapy, insulin therapy
instruction, dietary instruction and assessment, and additional antenatal care.
Treatment was assumed to have a duration of 90 days, and to consist of diet as first line, as in the NICE
guideline.18 The NICE guideline18 did not include the cost of metformin in the treatment costs, for those
women whose glycaemia is not controlled with the first-line of treatment. We assumed in the base case
that 27% of women would continue solely on diet throughout the treatment duration, whereas the
remaining women would transition to metformin (35%) or insulin therapy (28%) after the first 10 days of
diet. The proportion of women for which treatment consisted of diet alone was based on the proportion
of women with GDM on each treatment component until the end of pregnancy, averaged across four NHS
Hospital trusts, as reported in the NICE updated guideline.18 Our clinical advisors considered that the
averaged proportion of women in each type of treatment was reflective of current UK practice.
Two alternative assumptions regarding the relative proportion of each treatment type was applied in a
sensitivity analysis. First, we sourced the proportion estimates for the treatment types from the NHS
hospital trust (of the four reported in the guideline) that reported less frequent use of insulin (scenario 3:
TABLE 38 Unit costs for resource use associated with screening and diagnostic tests
Resource Unit cost
Source of unit
costs Comments
2-hour 75-g OGTT: £22.06 per test
Nurse, band 6: 5 minutes £49.00 per hour PSSRU 2013247 Duration based on assumption of GDG;18 time to
explain the test, and inform the participant of result
Health-care assistant,
band 3: 20 minutes
£25.00 per hour aPSSRU 2013247 Duration based on assumption of GDG;18 time
needed to obtain participant consent, prepare the
glucose solution and collect blood samples
Laboratory £8.00 NICE guideline18 From a NHS hospital trust personal
communication18
Glucose solution, 200ml £1.64 BNF248 aPolycal®
1-hour 50-g OGCT: £22.06 per test
Nurse, band 6: 5 minutes £49.00 per hour PSSRU 2013247 Assumed to be the same as for 2-hour 75-g OGTT
Health-care assistant,
band 3: 20 minutes
£25.00 per hour bPSSRU 2013247 Assumed to be the same as for 2-hour 75-g OGTT
Laboratory £8.00 NICE guideline18 Assumed to be the same as for 2-hour 75-g OGTT
Glucose solution, one
bottle 200 ml
£1.64 BNF248 Assumed to be the same as for 2-hour 75-g OGTT
FPG: £20.42 per test
Nurse, band 6: 5 minutes £49.00 per hour PSSRU 2013247 Assumed to be the same as for 75-g OGTT, two
hours
Health-care assistant,
band 3: 10 minutes
£25.00 per hour aPSSRU 2013247 Assumed to be the same as the for the 2-hour
75-g OGTT
BNF, British National Formulary; GDG, Guideline Development Group; PSSRU, Personal Social Services Research Unit.
a Polycal is a food for special medical purposes for use under medical supervision (Nutricia Medical Ireland, Deansgrange
Business Park, Dublin, Ireland).
b The unit cost is not directly reported in the PSSRU, but was calculated based on the mean annual pay of a band 3
(£16,522) health-care assistant, and assuming that the cost per hour will correspond to 52% of a band 6 nurse cost per
hour. The basis of this assumption is that mean annual pay of a band 3 health-care assistant corresponds with 52% of a
band 6 nurse mean annual pay.
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11% insulin, 100% metformin, 47% diet and activity advice). Second, we assumed that women would
not receive insulin therapy (scenario 4: 64% metformin, 100% diet and activity advice), which was part of
an extreme low-cost scenario.
The cost of providing dietary advice was applied to all treated women, and consisted of the cost of
15 minutes of a nurse (band 6) and 30 minutes of a dietitian (band 5). The NICE guideline18 assumed that
a nurse band 7 would deliver the service alongside a dietitian. However, according to our clinical advisors,
diet advice was more likely to be delivered by a band 6 health professional, more specifically a band 6
midwife. We assumed that the cost would be similar as to the service being provided a nurse (band 6).
The unit cost of a dietitian (band 5) was adjusted so as to reflect cost per hour of patient contact rather
than cost per hour. This was done by multiplying the unit cost per hour estimate for dietitian (band 5) by
the ratio between the cost per hour of patient contact and cost per hour of a nurse (grade 6) (£119/£49).
The resulting cost per patient hour for a dietitian (band 5) was £85.247 This adjustment was required as the
Personal Social Services Research Unit (PSSRU) cost schedule247 reports only the cost per hour for dietitians.
In scenario 4, it was assumed that dietary and exercise advice was delivered to a group of 12 women.
The cost of insulin treatment included the cost of insulin use instruction and treating severe
hyperglycaemia caused by insulin. Insulin instruction was assumed to be delivered by a midwife band 6
TABLE 39 Unit costs of perinatal outcomes
Outcome Cost (£) Source Comments
Admission to NNU 1118 NHS reference
costs 2012–13225
Currency code XA01Z (Neonatal Critical Care, Intensive Care,
Total HRGs)
Induction of labour 329 NHS reference
costs 2012–13225
Costs over and above those incurred in a normal vaginal
delivery, in woman with a non-elective long stay admission and
with CC score 0 (currency code NZ30C, Obstetrics)
Currency code NZ31C (Epidural or Induction)
C-section 884 NHS reference
costs 2012–13225
Costs over above those incurred in a normal vaginal delivery,
in woman with a non-elective long stay admission and with CC
score 0 (currency code NZ30C, Obstetrics)
Currency code NZ50C (Planned C-Section, Obstetrics)
Shoulder dystocia 1256 NHS reference
costs 2012–13225
Currency code PB02Z (Minor neonatal diagnoses, Neonatology,
non-elective long stay admission and with CC score 0)
Neonatal death 767 NHS reference
costs 2005–6249
Currency code PB02Z (Neonatal death)
Uprated to 2012–13 prices using the HCHS index247
Birth trauma 1256 NHS reference
costs 2012–13225
Currency code PB02Z (Minor neonatal diagnoses, Neonatology,
non-elective long stay admission and with CC score 0)
Serious perinatal
complications
1219 Calculated Weighted average of the unit costs of shoulder dystocia,
neonatal death and birth trauma
Pre-eclampsia 4656 NICE hypertension
in pregnancy
guideline243
Uprated to 2012–13 prices using the HCHS index247
Instrumental birth 1086 NHS reference
costs 2012–13225
Costs over and above those incurred in a normal vaginal
delivery, in woman with a non-elective long stay admission and
with CC score 0 (currency code NZ30C, Obstetrics)
Currency code NZ40C (Assisted Delivery with CC score 0,
Obstetrics)
CC, complications and comorbidities; HCHS, Hospital and Community Health Services; HRG, Healthcare Resource Group;
NNU, neonatal unit.
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and have a duration of 45 minutes. The NICE updated guideline18 assumed that the instruction would be
delivered by a nurse band 7, but for the same reason as described above for dietary advice, we applied the
unit cost for a nurse band 6.247 In scenario 4, it was assumed that insulin use instruction was delivered to a
group of 12 women. The cost of the use of insulin included the cost of 20 units per day of rapid-acting
insulin and 10 units per day of intermediate insulin and needles required for four injections of insulin per
day, over 80 days of treatment. The unit cost of treating severe hyperglycaemia corresponded with the
cost of an ambulance service and a weighted average of the unit costs for the health-care resource groups
related to the treatment of diabetes with hypoglycaemic disorders from the NHS reference.225
The instruction on blood glucose self-monitoring (BGSM) was assumed to be delivered by a midwife
(band 6) – and not by a band 7 nurse as in the guideline (for the same reasons described above for the
delivery of dietary advice) –and have a duration of 30 minutes. All women who were treated for GDM
were assumed to receive BGSM instruction and to test themselves four times a day during the 90 days of
treatment. Women who were treated with insulin did three additional tests per day for 80 days. The cost
of the BGSM test included the test strips and lancets. In scenario 4, it was assumed that BGSM instruction
was delivered to a group of 12 women.
The costs of metformin corresponded to the cost of taking a dosage of 850 mg three times a day, which is
the recommended dosage according to the British National Formulary (BNF) for 80 days.248
We also included the cost of additional antenatal care for women with GDM, including three standard
antenatal ultrasound scans and three antenatal appointments. These were costed by applying unit costs
from the NHS reference costs schedule.225 All durations of contacts with NHS staff were sourced from the
NICE ‘Diabetes in pregnancy’ updated guideline,18 and were considered to be reflective of NHS practice
according to our clinical advisors. Our clinical advisors also considered that resource-use assumptions in
terms of drug dosages, treatment of severe hyperglycaemia, test consumables, staff required to deliver
services and composition of additional antenatal care were reflective of current NHS practice. The costs
reported here differ to those reported in the NICE guideline18 after we corrected values that did not match
the cited source.
Resource use, unit costs and respective sources are summarised in Table 40 for each cost category, and the
updated costs for base-case treatment bundle (35% metformin, 28% insulin) are displayed. The total cost
of treatment accrues to £935 per woman with GDM in the base case.
The cost composition for the base-case treatment ‘bundle’ (28% insulin, 35% metformin, 100% diet and
advice) and two alternative costing scenarios described above in this section (1) 11% insulin, 42%
metformin, 100% diet and advice; and (2) 64% metformin, 100% diet and advice) is detailed in Table 41.
Costs of intensive lifestyle intervention for prevention of type 2 diabetes
A cost estimate was also included for the delivery of the ILS to 36% of the GDM treated women in the
base case, that is, the proportion of those who had a BMI of ≥ 30 kg/m2 in the BiB study22 (see Scenario
analysis: maternal longer-term outcomes). The ILS consisted of 16 individual sessions of dietary and
exercise advice, lasting 1 hour, and delivered over 1 year. This initial delivery of the intervention followed
by a maintenance phase started approximately 3 years after the initial advice session, which consisted of
up to 12 quarterly 1-hour group sessions.251 It was assumed that the sessions were delivered by a dietitian
(band 5) and that the groups in the maintenance phase were composed of 10 individuals. It was further
assumed that the group sessions would continue to be delivered until the end of life in the model.
Although an estimate of direct medical costs (hospital stays, emergency room, urgent care, outpatient
services and telephone calls to health-care providers) of ILS was available in the literature, this was not
included, as the study251 was set in the USA, and was therefore unlikely to be reflective of UK practice.
Excluding these costs is likely to be conservative, as, in the follow-up study of DPP, the ILS was found to
accrue less direct medical costs than placebo (US$26,810 vs. US$29,007).251
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TABLE 40 Unit costs for resource use associated with treatment of GDM
Resource use Unit cost (£)
Source of
unit costs Comments
Dietary instruction and assessment: for all women treated for GDM
Midwife, band 6: 15 minutes 119.00 per
patient hour
PSSRU, 2013247 Assessment duration based on assumption of GDG
Nurse team leader
Dietitian, band 5: 30 minutes 85.00 per
patient hour
PSSRU, 2013247 Instruction duration based on assumption of GDG
Hour of patient contact was calculated assuming
the same mathematical relationship as between the
cost per hour and cost per patient hour for a nurse
team leader (band 6)
Insulin instruction and use: for 28% of all women treated for GDM and for 80 days of treatment
Midwife, band 6: 45 minutes 119.00 per
patient hour
PSSRU247 Instruction duration based on assumption of GDG
Rapid-acting insulin (aspart):
20 units per day
0.02 BNF248 Novo Rapid® (insulin aspart; Novo Nordisk A/S,
Bagsværd, Denmark)
Intermediate insulin
(isophane): 10 units per day
0.01 BNF248 Insuman® (regular insulin; Sanofi UK, Guildford, UK)
Needles: four per day 0.10 NHS Drug
Tariff250
BD Micro-Fine™ Ultra 4-mm/32-gauge (syringe; BD
Medical, Oxford, UK)
Treatment of severe
hypoglycaemia
629.00 NHS reference
costs225
Cost of an ambulance (Currency code ASS02) and
a weighted average of A&E costs for diabetes with
hypoglycaemic disorders (Currency code KB01C,
KB01D, KB01E and KB01F)
Metformin use: for 35% of all women treated for GDM and for 80 days of treatment
Metformin 500 mg 0.01 per tablet BNF248 Non-proprietary, 84 tablets presentation
BGSM instruction and testing: for all women treated for GDM
Nurse band 6: 30 minutes 119.00 per
patient hour
PSSRU247 Assessment duration based on assumption of GDG
Lancets:
Four per day if on diet only
Seven per day if on insulin
therapy
0.03 NHS Drug
Tariff250
BD Micro-Fine+ 0.20-mm/33-gauge (syringe; BD
Medical, Oxford, UK)
Test strips:
4 per day if on diet only
7 per day if on insulin
therapy
0.20 BNF248 Accu-Check™ Active (blood glucose monitor;
Roche Diagnostics Ltd, Burgess Hill, UK)
Additional antenatal care: for all women treated for GDM
Three antenatal standard
ultrasounds
130.00 NHS reference
costs225
Code NZ21Z – Procedures in Outpatients,
Obstetrics, Antenatal Standard ultrasound
Three antenatal appointments 89.00 NHS reference
costs225
Code WF01A- Obstetrics, non-consultant led,
non-admittance, follow-up appointment
A&E, Accident and Emergency. GDG, Guideline Development Group.
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All ILS costs were discounted at a 3.5% annual rate. The total discounted cost of the ILS intervention
accrued to £3585 per woman treated for GDM. Unit costs and resource use for the ILS intervention are
displayed in Table 42.
Net benefit of early detection of diabetes
We identified a study238 that assessed the cost-effectiveness of screening for type 2 diabetes. We used
estimates of the QALY gain and incremental costs associated with screening and treating for type 2
diabetes at age 45 years in a population at risk as a proxy for the potential NHB for those women
diagnosed with GDM who are found to have type 2 diabetes at 6-week post-partum follow-up. Although
we recognise that the population in the Gillies et al. study238 is different from the group considered here,
this scenario allows the exploration of the inclusion of a potential longer-term benefit, but we were
unable to model this directly for a population of pregnant women. The study238 estimates a discounted
incremental cost of £587, a discounted incremental QALY gain of 0.03, and a corresponding incremental
cost-effectiveness ratio (ICER) of £14,150 for a one-off screening strategy in a white population with an
underlying prevalence of 5% type 2 diabetes. The reported mean costs and QALYs did not match the
ICER, and so we utilised an incremental costs of £425. The study238 reports undiscounted scenario
analyses, which suggest that the ICER for the screening strategy is similar between populations, with
underlying prevalence of type 2 diabetes of 5% and 10%, the latter value being similar to the estimated
underlying prevalence of 11% type 2 diabetes at 6 weeks post partum among women diagnosed with
GDM. The study238 estimates that the incremental costs of screening a SA population are approximately
52% higher than those for a white population, and that incremental QALYs are 83% higher for a SA
TABLE 41 Cost composition of treatment for base-case and scenario analysis
Cost category
Base case Scenario three Scenario four
Treated
women (%)
Cost per
woman (£)
Treated
women (%)
Cost per
woman (£)
Treated
women (%)
Cost per
woman (£)
Dietary instruction and
assessment
100 72 100 72 100 6
SMBG instruction and testing 100 142 100 142 100 88
More intensive antenatal
care
100 657 100 657 100 657
Insulin instruction and use 28 160 11 160 0 –
Additional SMBG for women
on insulin
28 55 11 55 0 –
Metformin use 35 3 42 3 64 3
Total cost of treatment 935 897 753
SMBG, self-monitored blood glucose.
TABLE 42 Unit costs for resource use associated with the delivery of ILS intervention
Resource use Unit cost (£) Source of unit costs Comments
ILS initial phase
Dietitian, band 5: 60 minutes 35.00 per hour PSSRU254 Individual sessions
ILS maintenance phase
Dietitian, band 5: 60 minutes 35.00 per hour PSSRU254 Group session for 10 individuals
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population than a white population. We therefore adjusted the incremental costs and QALY gain of early
detection according to the proportion of women of SA ethnicity in the BiB cohort.22 The model parameters
are summarised in Table 43.
Sensitivity and scenario analysis
Sensitivity analysis was conducted so as to characterise uncertainty at different levels in the economic
analysis. The methods used to conduct sensitivity analysis in the model are described in this section.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis was performed to quantify and incorporate into results the joint uncertainty
of the model input parameters. Probability distributions were specified for the model parameters so as to
reflect uncertainty in the mean estimates.252,253 The selection of probability distributions for each parameter
was based on well-established literature recommendations254 and is reported alongside the parameter
point estimates for the base-case in the model (see Appendix 6, Table 73). Monte Carlo simulation was
used to propagate uncertainty in input parameters through the model, by sampling from each parameter’s
distribution and estimating the corresponding expected costs and QALYs for each alternative strategy. The
Monte Carlo simulation was performed for 5000 iterations, and mean values for the model outputs were
estimated as the average across the iterations. The results reported are based on the mean values of
expected costs and QALYs across simulations, and are therefore probabilistic, in accordance with current
NICE guidance.225 The probability that each strategy would represent the most cost-effective strategy was
estimated by the proportion of the 5000 simulations in which it would be regarded as having the
maximum NHB.
We calculated the gain in net benefits that could be achieved if all of the parameter uncertainty were
eliminated from the model. This is the expected value of perfect information (EVPI), which forms an upper
bound for the value of further research. It was estimated by evaluating the model using 5000 random
possible input sets, determined by the probability distributions assigned to each of the inputs in order to
generate a distribution of 5000 possible total costs and QALYs for each strategy. The EVPI is the difference
between the average of the maximum net benefit that could be achieved within each of the 5000
simulations and the expected net benefits of the best-performing strategy (i.e. the net benefits expected to
be achieved if the cost-effective strategy is determined and implemented based on current information).
The structure of the decision model is such that the best-performing diagnostic glucose threshold is estimated
first, and then the best-performing strategy with respect to do nothing, test and treat, screen and treat,
or screen test and treat, is calculated at the predetermined best-performing diagnostic glucose threshold.
This poses a challenge for calculating the EVPI, as the uncertainty in the best preforming diagnostic glucose
threshold is not propagated through to the decision uncertainty between alternative strategies.
The value of further research around individual input parameters was estimated using the Sheffield
Accelerated Value of Information (SAVI) software, release version 2.0.10: 2015-09-24 (University of
Sheffield, Sheffield, UK).123 This provides an estimate of the gain in NHBs that could be achieved if the
TABLE 43 Detection of type 2 diabetes at 6 weeks’ follow-up: model parameters
Parameter
Estimate (95%
credible interval) Source Comments
Additional cost associated with detecting
and treating diabetes post partum
558 (61 to 1525) Gillies 2008238 Time horizon 50 years
Discounted at 3.5%
Uprated to 2013 price year
QALYs gain associated with detecting
and treating diabetes post partum
0.05 (–0.03 to 0.14) Gillies 2008238 Time horizon 50 years
Discounted at 3.5%
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uncertainty were eliminated from each individual parameter in the model, and can indicate where
additional research would be most valuable.
For the main analysis the best-performing diagnostic glucose threshold was calculated by evaluating
the model with each input set to its mean value (i.e. deterministically). A probabilistic evaluation of the
best-performing diagnostic glucose threshold would have required more computing time, which would have
restricted the number of scenario and subgroup analyses feasible. However, for these EVPI calculations we
evaluated the best-performing diagnostic glucose threshold using 5000 random possible input parameter
sets for the base-case analysis and for a single cost-effectiveness threshold in the scenario incorporating
maternal longer-term outcomes. We evaluated the value of further research for cost-effectiveness thresholds
of £13,000, £20,000 and £30,000 per QALY for the base-case results, and for a cost-effectiveness threshold
of £20,000 per QALY for the scenario analysis with maternal longer-term outcomes included. Consequently,
the net benefits associated with the best-performing diagnostic strategy may differ between the EVPI
calculations and the base-case results.
Scenario analysis
Scenario analysis was conducted when assumptions underlying the base-case analysis were varied. The aim
of this sensitivity analyses was to assess the robustness of base-case results to alternative assumptions in
terms of costs, treatment effectiveness, uptake of screening and diagnostic tests, and inclusion of potential
longer-term maternal outcomes. The scenario analysis has been described throughout this report. Table 44
illustrates which elements were varied in each scenario analysis.
TABLE 44 Key elements of the base-case analysis and the variation used in scenario analysis
Scenario Element Base case Variation for the sensitivity analysis
1 Longer-term
outcomes
No longer-term outcomes are included in the
analysis
Includes costs and QALY gains from early
detection of maternal type 2 diabetes at
post-partum follow-up, and of prevention of
type 2 diabetes later in maternal life by
delivering an intensive lifestyle intervention to
women who were treated for GDM
2 Treatment
effectiveness
RR of GDM treated was sourced from the diet
modification meta-analysis (see Chapter 6)
RR of GDM treated was sourced from NICE
previous guidance18
3 Cost of
treatment
for GDM
Cost of treatment reflects the treatment
‘bundle’ in which the proportion on each
treatment is:
l 28% insulin (in addition to diet)
l 35% metformin (in addition to diet)
l 100% diet advice
Cost of treatment reflects the treatment
‘bundle’ in which the proportion on each
treatment is:
l 11% insulin (in addition to diet)
l 42% metformin (in addition to diet)
l 100% diet advice
4 Cost of
treatment
for GDM
Cost of treatment reflects the treatment
‘bundle’ in which the proportion on each
treatment is:
l 28% insulin (in addition to diet)
l 35% metformin (in addition to diet)
l 100% diet advice
Dietary and exercise advice, and insulin use
and BGSM instruction is delivered individually
to women
Cost of treatment reflects the treatment
‘bundle’ in which the proportion on each
treatment is:
l 64% metformin (in addition to diet)
l 100% diet advice
Dietary and exercise advice, and insulin use
and BGSM instruction is delivered to groups
of 12 women
5 Uptake of
diagnostic
test
Uptake of diagnostic test is:
l 89.66% for women previously screened
for higher risk of GDM
l 62.83% for women who are not
screened for higher risk of GDM
Uptake of diagnostic test is:
l 80.26% for women previously screened
for higher risk of GDM
l 73.53% for women who are not
screened for higher risk of GDM
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Subgroup analysis
In Chapter 2, it was highlighted that GDM prevalence is higher in SA women than WB women across the
different diagnostic criteria (see Table 6) and this is due to differing population characteristics. To explore
whether or not this differing characteristics would impact on the cost-effective strategy identified in the
model, the BiB study data22 were divided in two subgroups, and the costs and QALYs of the alternative
intervention strategies were evaluated in each population separately. The first subgroup included all SA
women, as well as of all other ethnicities excluding WB. The rationale for including the category ‘Other’
in the subgroup was that higher prevalence of GDM can also be found in ethnicities such as black
Caribbean and Middle Eastern, which are likely to be captured under this category. The second subgroup
corresponded to WB women. The analysis was conducted by repeating the base-case analysis and scenario
1 (inclusion of longer-term outcomes) using only the individual patient data for each subgroup. The
average baseline characteristics by subgroup are shown in Appendix 6, Table 74.
Results
The alternative screening and diagnostic intervention strategies are evaluated on the 10,353 women in
the BiB data set22 in order to determine the cohort characteristics for the decision model. This includes the
proportion that would screen positive, the proportion that would test positive, the mean fasting and
post-load glucose levels and the risk factors for each subdivision of the cohort. For example, Table 45
shows the cohort characteristics for each subdivision of the cohort if the NICE risk factor screening strategy
is applied and a diagnostic threshold of 6.1 mmol/l for fasting blood glucose and 7.8 mmol/l for post-load
blood glucose is used.
In the BiB data set,22 81 individuals (0.78%) had fasting or post-load blood glucose measures of ≥ 11.1mmol/l.
In the remainder, the fasting glucose measure varied between 3.0 and 9.4 mmol/l, and the post-load glucose
measure varied between 1.6 and 11.0mmol/l. Women who had fasting glucose measures of > 9.5mmol/l all
had a post-load glucose measurement of ≥ 11.1mmol/l, and hence 9.5mmol/l forms an effective upper
bound for the fasting glucose threshold in this cohort.
TABLE 45 Cohort characteristics for NICE risk factor screening and diagnostic threshold of 6.1 and 7.8 mmol/l
Characteristics All S+T+ S+T– S+ S– T+ T–
Proportion of cohort (%) 100 7.5 70.0 77.6 22.4 8.2 91.8
Mean fasting blood glucose (mmol/l) 4.52 5.36 4.50 4.58 4.34 5.28 4.46
Mean post-load blood glucose (mmol/l) 5.68 9.05 5.47 5.82 5.27 9.00 5.39
Mother’s age 27.6 30.8 27.7 28.0 26.1 30.6 27.3
BMI 26 29 27 27 24 28 26
Previous GDM 0.01 0.06 0.01 0.01 0 0.06 0.01
Previous macrosomia 0.05 0.10 0.06 0.07 0 0.09 0.04
SA 0.52 0.78 0.69 0.70 0 0.70 0.51
White 0.39 0.15 0.20 0.19 1 0.24 0.41
Other ethnicity 0.08 0.08 0.11 0.11 0 0.07 0.08
Nulliparous 0.41 0.28 0.35 0.35 0.58 0.31 0.40
One child 0.29 0.22 0.28 0.28 0.26 0.23 0.28
Two children 0.17 0.20 0.18 0.18 0.09 0.19 0.16
Three or more children 0.13 0.26 0.15 0.16 0.04 0.24 0.12
Family history of diabetes 0.26 0.43 0.33 0.34 0 0.38 0.24
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Without treatment, the model predicts a cost per pregnant woman of £466 and an expected QALY loss of
–0.036 as a result of adverse perinatal outcomes. These are the cost and QALYs estimated for the ‘no
screening/testing or treatment’ strategy. Among the whole cohort of pregnant women, and without any
intervention for hyperglycaemia, the model would predict 2% to have pre-eclampsia, 16.6% would have
induction of labour, 20.2% would be expected to have C-section and 7.1% would require instrumental
delivery. Immediate birth outcomes would include 4.1% with admission to a neonatal unit and 1.5%
serious perinatal complications.
In the following sections we build up the results, first considering the best-performing strategy of each
type. We start with the best-performing diagnostic glucose threshold (see Best-performing diagnostic
threshold). We then consider the best-performing screen-only strategy (see Screen-only strategies),
through which no one is provided with a diagnostic test and diet, and lifestyle modification advice is
provided to women on the basis of screening positive. Next (see Screen and test strategies) we consider
the best-performing screen and test strategy in which women are first subject to screening, with those
who screen positive offered a diagnostic test using cut-offs determined by the best-performing fasting and
post-load glucose levels. Women who have screened positive, and in whom blood glucose levels exceed
either of the best-performing cut-off values, are offered diet and lifestyle modification advice, followed by
pharmacological therapy as required. Finally, we report the results of the full incremental analysis (see Full
incremental analysis) in order to determine which is the most cost-effective intervention strategy for the
screening, diagnosis and treatment of GDM.
Best-performing diagnostic threshold
Base-case results
The best-performing diagnostic glucose threshold was estimated by evaluating the costs and QALYs
associated with a universal diagnostic test strategy for all of the 969 potential dual glucose thresholds, and
identifying the fasting and post-load blood glucose levels at which the NHB (and equivalently NMB) would be
maximised. The best-performing diagnostic glucose threshold will differ according to the cost-effectiveness
threshold, because NHBs are calculated by dividing through the costs by the cost-effectiveness threshold and
subtracting them from the QALYs. That is to say, the fasting and blood-glucose diagnostic thresholds at
which NHBs are maximised depend on the cost-effectiveness threshold. The model predicts that the cost per
pregnant woman is increased and QALY losses are decreased as the fasting and post-load glucose thresholds
are decreased from their maximum values. In other words, as fasting and post-load glucose cut-offs for
diagnosis are lowered, and a larger proportion of women are diagnosed with GDM, the cost per pregnant
woman increases, but the QALY losses are reduced, that is, lower diagnostic glucose threshold values are
more costly and more effective than higher threshold values. The incremental difference in expected costs
and QALYs is very small for every 1-mmol/l increment in diagnostic thresholds. In the base-case analysis that
includes only short-term health outcomes, the QALYs vary between a maximum of –0.0274 (lowest
threshold: fasting 5.0 mmol/l, post-load 5.5 mmol/l) and a minimum –0.036 (highest threshold: fasting
9.5 mmol/l and post-load 11.1 mmol/l). Costs vary between £784 and £491 per pregnant woman. The costs
and QALYs for the £20,000 per QALY cost-effectiveness thresholds for the base case are shown via heat
maps in Appendix 6, Figures 66 and 67.
Using a cost-effectiveness threshold of £20,000 per QALY, the best-performing diagnostic glucose
threshold is to treat women identified with a post-load glucose level that exceeds 10.0 mmol/l. NHBs
cannot be improved further by treating any additional women on the basis of fasting glucose levels. If the
cost-effectiveness threshold is increased to £30,000 per QALY, the best-performing diagnostic glucose
threshold is 5.2 mmol/l for fasting glucose and 8.8. mmol/l for post-load glucose. Table 46 and Figure 44
show the relationship between the cost-effectiveness threshold and the best-performing fasting glucose
and post-load glucose levels at which to treat.
Below a cost-effectiveness threshold of £18,000 per QALY it is not cost-effective to diagnose women as
having GDM. As the cost-effectiveness threshold increases from £18,000 to £26,000, the best-performing
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fasting and post-load glucose thresholds at which treatment would commence fall. Once the
cost-effectiveness threshold reaches £27,000 there is a switch, and the best-performing fasting glucose
level drops to 5.4 mmol/l while the post-load glucose level returns to the maximum of 11.1 mmol/l.
The best-performing fasting and post-load diagnostic thresholds then both reduce as the cost-effectiveness
threshold increases, until they reach the minimum bounds tested of 5.0 mmol/l for fasting glucose and
5.5 mmol/l for post-load glucose levels.
Although Figure 44 identifies a particular best-performing threshold, the results indicate that there are
ranges of diagnostic thresholds that would be associated with very similar costs and health outcomes.
Compared with the base-case best-performing threshold, the diagnosis and treatment of women – based
on the criteria utilised in the BiB study,22 that is, 6.1 mmol/l for fasting glucose and 7.8 mmol/l for post load
glucose – would increase costs by £36 per pregnant woman and increase QALYs by 0.001. Differences
between this threshold and the best-performing diagnostic glucose threshold are small, but the criteria
TABLE 46 Best-performing diagnostic glucose thresholds for base-case analysis
Cost-effectiveness
threshold (£)
Fasting glucose,
mmol/l
Post-load glucose,
mmol/l Proportion T+ Costs (£) QALYs
18,000 9.5 11.1 0.008 491 –0.036
19,000 9.5 10 0.015 495 –0.036
20,000 9.5 10 0.015 495 –0.036
21,000 9 9.5 0.020 498 –0.036
22,000 8.5 9.2 0.025 501 –0.035
23,000 8.5 9.1 0.028 502 –0.035
24,000 8 8.8 0.033 505 –0.035
25,000 8 8.5 0.043 510 –0.035
26,000 8 8.5 0.043 510 –0.035
27,000 5.4 11.1 0.058 518 –0.035
28,000 5.3 9.8 0.072 526 –0.034
29,000 5.3 8.8 0.082 532 –0.034
30,000 5.2 8.8 0.102 543 –0.034
31,000 5.2 8.1 0.122 554 –0.034
32,000 5.1 8.2 0.138 562 –0.033
33,000 5.2 7.2 0.177 584 –0.033
34,000 5 7.2 0.222 609 –0.032
35,000 5 7.2 0.222 609 –0.032
36,000 5 6.6 0.287 645 –0.031
37,000 5 6.6 0.287 645 –0.031
38,000 5 6.2 0.356 683 –0.030
39,000 5 6.1 0.377 695 –0.030
40,000 5 6 0.401 708 –0.029
41,000 5 5.7 0.479 752 –0.028
42,000 5 5.6 0.508 768 –0.028
43,000 5 5.5 0.536 784 –0.027
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used in the BiB study22 are predicted to provide lower NHBs than ‘no screening/testing or treatment’ and
lower NHBs than the best-performing diagnostic glucose threshold.
At a cost-effectiveness threshold of £20,000 per QALY, the model predicts that for a universal diagnostic
test strategy using the best-performing diagnostic glucose threshold, the cost per pregnant woman is £495
and the expected QALY loss is –0.036 as a result of adverse perinatal outcomes. At the diagnostic
thresholds of fasting glucose 9.5 mmol/l and post-load glucose 10.0 mmol/l, 1.5% of women would be
diagnosed with GDM and offered treatment. Treatment reduces pre-eclampsia, C-section, admission to
neonatal unit and serious perinatal complications, but increases instrumental delivery and induction. With
only 1.5% of women offered treatment, and uptake at 63%, the differences in perinatal outcomes are
indistinguishable when figures are rounded to one decimal place. The QALY difference between a
universal diagnostic test strategy using the best-performing diagnostic glucose threshold compared with
‘no screening/testing or treatment’ is 0.00 per pregnant woman, and the incremental cost is £28, resulting
in a large ICER. Among the 1.5% of women who were diagnosed with GDM at this best-performing
threshold, the QALY gain is estimated to be 0.006 (0.00009/0.015), and this would need to be increased
to 0.09 in order for NHBs to exceed those of ‘no screening/testing or treatment’.
At a cost-effectiveness threshold of £30,000 per QALY, the best-performing diagnostic thresholds are
5.2 mmol/l for fasting blood glucose and 8.8 mmol/l for post-load glucose. Using these values, 10.2%
of women would be diagnosed with GDM. The model predicts a cost per pregnant woman of £543
and QALYs of –0.034. The rate of perinatal outcomes is 1.9% pre-eclampsia, 20.2% C-section (small
reduction), 4.1% admission to the neonatal unit (NNU), 7.7% instrumental delivery, 1.4% serious perinatal
complications and 17.0% induction of labour. The cost per QALY gained with universal diagnostic test
compared with ‘no screening/testing or treatment’ is £80 per 0.002 QALYs, giving an ICER of £45,000.
Even with the best-performing diagnostic threshold, the NHBs of a universal diagnostic test strategy do not
exceed those of ‘no screening/testing or treatment’.
Scenario analysis: maternal longer-term outcomes
If longer-term health outcomes are included in the model, the expected costs and QALYs, given fasting
and post-load glucose levels, are increased compared with the base-case analysis. When the QALY gains
and additional costs associated with the treatment and prevention of type 2 diabetes are incorporated, the
model predicts expected QALY per pregnant woman of between a maximum of –0.015 (lowest threshold:
fasting 5.0 mmol/l, post-load 5.5 mmol/l) and a minimum of –0.036 (highest threshold: fasting 9.5 mmol/l
and post-load 11.1 mmol/l). The corresponding expected cost per pregnant woman varies between £971
4.0
4.5
5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
9.0
9.5
10.0
10.5
11.0
11.5
12.0
12.5
13.0
13.5
14.0
18 23 28 33 38 43
B
lo
o
d
 g
lu
co
se
 (
m
m
o
l/l
)
Cost-effectiveness threshold (£000)
Fasting threshold
Post-load threshold
Mean fasting T+
Mean post-load T+
FIGURE 44 Best-performing diagnostic glucose threshold and mean blood glucose levels among those diagnosed.
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
145
and £495 per pregnant woman. Table 47 shows the relationship between the best-performing diagnostic
glucose thresholds and the cost-effectiveness threshold. With the inclusion of longer-term outcomes, the
best-performing diagnostic glucose threshold is lower than the base-case analysis for cost-effectiveness
thresholds in the range of £18,000–43,000.
At a cost-effectiveness threshold of £20,000 per QALY, the model predicts that for a universal diagnostic
test strategy using the best-performing diagnostic glucose threshold, the cost per pregnant woman is £545
and the expected QALY loss is –0.033 resulting from adverse perinatal outcomes. Compared with ‘no
screening/testing or treatment’, the cost per QALY gained is £81 per 0.003 QALYs, giving an ICER of
£29,752. Among the 5.8% of women diagnosed with GDM the QALY gain is estimated to be 0.05. This
QALY gain would have to be increased to 0.07 in order for the NHBs to exceed those associated with ‘no
screening/testing or treatment’. For the scenario incorporating longer-term maternal outcomes, the NHB of
a universal diagnostic test strategy using the best-performing diagnostic glucose threshold would exceed
the NHB of ‘no screening/testing or treatment’ at cost-effectiveness thresholds of > £24,000. However, in
order to determine whether or not a universal diagnostic test strategy is cost-effective it is necessary to
compare with the full range of alternative strategies. The results of this full incremental analysis are shown
below (see Full incremental analysis).
Scenario analysis: fasting plasma glucose test
At a cost-effectiveness threshold of £20,000 per QALY, the best-performing fasting glucose level is
11.1 mmol/l, suggesting that it is not cost-effective to diagnose women with GDM. If the cost-effectiveness
threshold is increased to £30,000 per QALY, the best-performing fasting blood glucose level at which to
commence treatment is 5.2 mmol/l. At this fasting blood glucose threshold, 8.8% of women would be
diagnosed with GDM and the expected cost per pregnant woman is £532, with associated QALY loss of
0.034. The mean fasting blood and post-load glucose measures among women in the BiB study,22 who
would be diagnosed with GDM on the basis of a FPG test with a threshold of 5.2 mmol/l, are 5.73 mmol/l
and 7.48 mmol/l. If the post-load measure is taken into account with a threshold set at 8.8 mmol/l, as
indicated in Table 46, a further 1.4% of women would be diagnosed with GDM. and the mean fasting
blood glucose levels would reduce to 5.59 mmol/l, whereas the mean post-load glucose level would
increase to 7.76 mmol/l. Compared with the OGTT, the use of FPG as a diagnostic test appears to offer
similar health outcomes, but at a lower cost. The expected difference in expected QALYs is very small but
negative, indicating that the FPG is not dominant (i.e. not less costly and more effective) compared with
the OGTT.
TABLE 47 Best-performing diagnostic glucose thresholds for longer-term outcomes
Cost-effectiveness
threshold (£)
Fasting glucose
(mmol/l)
Post-load glucose
(mmol/l) Proportion T+ Costs QALYs
Proportion
obese T+
17,000 9.5 11.1 0.008 495 –0.036 0.45
18,000 9 9.5 0.020 507 –0.035 0.45
19,000 8.5 9.1 0.028 514 –0.035 0.43
20,000 5.4 11.1 0.058 545 –0.033 0.46
21,000 5.2 9.9 0.092 578 –0.031 0.42
22,000 5 8.3 0.167 647 –0.028 0.37
23,000 5 7.2 0.222 695 –0.026 0.33
24,000 5 6.2 0.356 816 –0.021 0.30
25,000 5 5.6 0.508 947 –0.016 0.27
26,000 5 5.5 0.536 971 –0.015 0.26
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Screen-only strategies
At a cost-effectiveness threshold of £20,000 per QALY, the screen-only strategy associated with the highest
NHB compared with all screen-only strategies is to offer treatment to women who have experienced GDM
in a previous pregnancy. In the BiB data set22 only 1% of women would screen positive on this basis.
The expected cost per pregnant woman of providing diet and lifestyle modification to women with prior
GDM is £484 and the expected QALY loss is 0.036. The QALYs are higher than those expected with ‘no
screening/testing or treatment’ or a universal ‘test and treat’ strategy, but the differences are very small. The
cost per pregnant woman is estimated to be £484, and hence a screen-only strategy would provide similar
QALY outcomes, but at a lower cost than a universal diagnostic test strategy (–£12) and at a higher cost
than a ‘no screening/testing or treatment’ strategy (£18). The ICER for a screen-only strategy compared with
a ‘no screening/testing or treatment’ strategy is £77,574, and the QALY gain per woman with previous
GDM is estimated to be 0.02. The estimated QALY gain per woman with previous GDM would have to be
increased to 0.08 in order for the NHBs of this screen-only strategy to exceed those of a ‘no screening/
testing or treatment’ strategy.
Scenario analysis: maternal longer-term outcomes
If maternal longer-term outcomes are incorporated in the model, the best-performing screen-only strategy
remains to screen women on the basis of prior GDM. The expected cost per pregnant woman is increased
to £495 and the QALY loss is reduced to 0.035. Screen-only remains cheaper than universal diagnostic
test, but is no longer more effective. When the cost-effectiveness threshold is increased to £30,000 per
QALY, the best-performing screen-only strategy is to offer treatment to any woman based on maternal
age ≥ 25, BMI ≥ 25kg/m2 and non-white ethnicity. Using these criteria 92% of women would be expected
to screen positive and the expected cost per pregnant woman would be £1,920 with a QALY gain of
0.029. In this scenario the maternal longer-term QALY gains from the early treatment and prevention of
type 2 diabetes exceed the QALY losses from perinatal outcomes. For full incremental results (see Full
Incremental analysis).
Scenario analysis: screen only with oral glucose challenge test
With a 1-hour 50-g OGCT and threshold of 7.2 mmol/l for post-load glucose the model estimates that
32% of women would screen positive. The expected cost per pregnant woman would be £769 and the
QALY losses would be –0.034. This represents an additional cost of £285 and a QALY gain of 0.002
compared with the best-performing risk factor screening strategy, giving an ICER of £161,271.
Screen and test strategies
At a cost-effectiveness threshold of £20,000 per QALY, the best-performing screen and diagnostic test
strategy among all possible screen and diagnostic test strategies is to offer OGTT only to women with prior
GDM. The model predicts an expected cost per pregnant woman of £478 and a QALY loss of 0.036.
Hence ‘screen and diagnostic test’ offers similar QALY gains to the other intervention strategies, but at a
lower cost than ‘screen only’ or ‘universal diagnostic test’ and an incremental cost of £11 per pregnant
woman compared with ‘no screening/testing or treatment’. In general, screen and diagnostic test
strategies incur lower costs and QALYs than the commensurate ‘screen-only’ strategy as fewer women are
offered treatment, the cost of which exceeds the cost of the test.
Scenario analysis: longer-term outcomes
When maternal longer-term outcomes are incorporated in the model, the best-performing screen and
diagnostic test strategy is unchanged; however, the expected cost per pregnant woman is increased to
£482. When maternal longer-term outcomes are incorporated and the cost-effectiveness threshold is
increased to £30,000 per QALY, the best-performing screen and diagnostic test strategy is to offer OGTT
to women based on maternal age of ≥ 25 years, BMI of ≥ 25 kg/m2 and non-white ethnicity. For complete
incremental results, see the following section.
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Full incremental analysis
A full incremental analysis is used to compare all of the intervention strategies. The universal diagnostic
test strategy is defined using the best-performing diagnostic threshold identified above (see Screening,
diagnosis and treatment). The set of risk factor screening strategies was explained above (see Screening,
diagnosis and treatment of hyperglycaemia in pregnancy). Combining the best-performing diagnostic
threshold (identified in Best-performing diagnostic threshold) with the alternative screening strategies
provides the full set of screen and diagnostic test interventions. This results in 140 possible alternative
strategies (‘no screening/testing or treatment’, ‘universal diagnostic test’, 69 ‘risk factor screening’
strategies and 69 ‘screen and diagnostic test’ strategies). For brevity, the results tables show only the
best-performing strategy from each type of intervention. Cost-effectiveness results for the base case are
summarised in Table 48, and reported for all remaining non-dominated strategies in Appendix 6,
Tables 75–79.
At a cost-effectiveness threshold of £20,000 it is not cost-effective to identify women for treatment for
hyperglycaemia. This remained the case when the cost-effectiveness threshold was increased to £30,000.
Scenario analysis: full incremental
For all scenario analysis, the cost-effective strategy at a £20,000 cost-effectiveness threshold is ’no
screening/testing or treatment’, despite the variations in results that we highlight in the following
paragraphs. The results of the four scenario analyses performed at a cost-effectiveness threshold of
£20,000 per QALY are presented in Table 49 (alongside the base-case analysis results to facilitate
the comparison).
For scenarios 2 and 5, the best-performing diagnostic glucose threshold remained that of the base case,
that is, fasting glucose level of ≥ 9.5 mmol/l and post-load glucose level ≥ 10.0 mmol/l. However, in scenario
1, which included maternal longer-term outcomes, the best-performing diagnostic glucose threshold was
lowered for fasting glucose (5.4 mmol/l), but increased for post-load glucose (11.1 mmol/l) comparison.
The inclusion of maternal longer-term outcomes will increase the costs (545 vs. £495) and the effectiveness
(–0.0350 vs. –0.0357) of the universal diagnostic test strategy compared with the base case, with more
women being treated in the scenario.
In scenario 3, for which an alternative treatment ‘bundle’ with a smaller proportion of women on insulin
than the base case (11% vs. 28%), the best-performing diagnostic glucose threshold was reduced to
fasting glucose ≥ 9.0 mmol/l and post-load glucose ≥ 9.5 mmol/l. The reduction of the cost of treatment
for pregnant woman from £935 (base case) to £897 translates into more women (2.0% vs. 1.5%) being
treated in scenario 3 for the universal diagnostic strategy for a small increase in cost compared with the
base-case equivalent strategy (£3). When the cost of treatment is further reduced in scenario 4 with
insulin not being offered, and all advice and instruction activities being delivered as group sessions for
12 women, the best-performing diagnostic glucose threshold was further reduced to fasting glucose level
of ≥ 8.0 mmol/l and post-load glucose level of ≥ 8.5 mmol/l. Similarly to scenario 3, the reduction in
treatment cost (from £935 to £753) will translate into more women being treated in scenario 4 (4.3% vs.
1.5%) for the universal diagnostic strategy for a small increase in cost compared with the base-case
equivalent strategy (£12).
To explore the individual impact of removing the cost of insulin and delivering advice and instruction to
groups of 12 (reducing the cost of treatment to £874 and £791, respectively) scenario 4 was initially run
separately for each element of cost reductions. The results were broadly consistent with the base-case at
£13,000 and £20,000 per QALY for these sub-scenarios. In scenario 4, and at a cost-effectiveness threshold
of £30,000 per QALY, the best-performing strategy is to screen, based on a maternal age of ≥ 25 years,
BMI of ≥ 25kg/m2 and non-white ethnicity, and offer treatment to women who test positive on the 2-hour
75-g OGTT (fasting glucose level of ≥ 5.0 mmol/l and/or post-load glucose level of ≥ 6.4 mmol/l), which
corresponds to treating 24% of the population at an expected cost of £647 per woman and minus 0.295
expected QALYs. When only the cost reduction of delivering instruction and advice in groups of 12 women is
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included in the scenario analysis, the same strategy emerges as ‘best performing’ at a cost-effectiveness
threshold of £30,000 per QALY, although at a slightly higher diagnostic threshold for post-load glucose level
(6.9 mmol/l). When only the cost of insulin therapy is removed from the cost of treatment, ‘no screening/
testing or treatment’ remains the best-performing strategy at cost-effectiveness thresholds of £13,000,
£20,000 and £30,000 per QALY. This implies that cost reductions by restructuring the delivery of advice
and instruction regarding treatment may improve cost-effectiveness of this type of intervention strategy
compared with ‘no screening/testing or treatment’.
The best-performing screening criterion at a cost-effectiveness threshold of £20,000 per QALY in the
‘screen-only’ and ‘screen and test’ strategies is previous GDM for all scenarios and the same as for
the base case.
In scenario 2, changes in the uptake of diagnostic test following or selective risk factor screening (–10%)
and the uptake of a universal diagnostic test (+11%) did not result in considerable changes to results
compared with the base case. Costs were slightly reduced for the ‘screen and test’ strategy (£1) and
increased for the universal diagnostic strategy (£5), with no visible changes in outcomes. These changes in
uptake of diagnostic test reduce the difference in terms of proportion of women treated when comparing
‘screen and test’ with the universal diagnostic test. In the base case, ‘screen and test’ increased the rate of
treatment compared with the universal diagnostic test by 15%, whereas in scenario 2 the corresponding
increase is only 11%. A further extreme case scenario in which all types of uptake were set to 100% did
not alter the best-performing intervention strategy (results available from the corresponding author
on request).
It is only with the inclusion of maternal longer-term health outcomes (scenario 1) and at cost-effectiveness
thresholds of > £24,000 per QALY that NHBs are improved by intervening. At a cost-effectiveness
threshold of £30,000 per QALY, the best-performing intervention strategy is to offer treatment to women
based on maternal age ≥ 25 years, BMI of ≥ 25 kg/m2 and non-white ethnicity. This would entail treating
92% of pregnant women at an expected cost of £1921 per woman and a QALY gain of 0.0295, largely
attributable to the benefits of early treatment and prevention of type 2 diabetes. Adding a diagnostic test
to those that screened positive would reduce the proportion offered treatment to 34%, and result in
an expected cost per pregnant woman of £1035 and an associated QALY loss of –0.009. ‘Screen and
diagnostic test’ would be associated with higher NHBs than ‘no screening/testing or treatment’ or universal
diagnostic test, but lower NHBs compared with ‘screen only’ testing.
The base-case results were robust to the remaining scenarios at all evaluated cost-effectiveness thresholds
(£13,000, £20,000 and £30,000 per QALY).
Subgroup analysis
We evaluated the results separately in a population of WB ethnicity and in a population of SA and ‘Other’
ethnicity (see Appendix 6, Tables 79–81). Among the SA and ‘Other’ subgroup, the mean fasting blood
glucose level was 4.60 mmol/l and the mean post-load glucose level was measured at 5.83 mmol/l. We
had observations of 6265 participants with SA or ‘Other’ ethnicity in the BiB study,22 of which 75 (1.2%)
had fasting or post-load glucose measures of > 11.1 mmol/l. The remainder had fasting blood glucose
levels in the range 3–9.4 mmol/l and post-load blood glucose measurements in the range of 2.2–11 mmol/l.
The model predicts that 2% would experience pre-eclampsia, 19.5% would undergo C-section and
15.5% would receive induction of labour. Immediate birth outcomes would be predicted to include 4.2%
admission to neonatal unit, 6.4% instrumental delivery and 1.6% serious perinatal complications. In the
subgroup of WB ethnicity, the mean fasting glucose level was 4.41 mmol/l and the mean post-load glucose
level was 5.44 mmol/l. There were 4088 women of WB ethnicity in the BiB data set22 that was used for
the analysis, of whom only six (0.2%) had fasting or post-load glucose measures of > 11.1 mmol/l. The
remainder had blood glucose levels in the range of 3–7.6 mmol/l for fasting glucose and 1.6–10.9 mmol/l
for post-load glucose. In this group, the upper bound for the fasting threshold is 7.6 mmol/l, and values of
> 7.6 mmol/l suggest that no-one be diagnosed with GDM on the basis of fasting glucose. The model
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would predict that 1.8% of white women would experience pre-eclampsia, 21.4% would undergo
C-section and 18.3% would receive induction of labour. In this subgroup, immediate birth outcomes
would include 4.1% admission to neonatal unit, 8.3% instrumental delivery and 1.5% serious
perinatal complications.
The results indicate that the best-performing diagnostic glucose threshold would be similar in a SA cohort
compared with the overall cohort, but that cost per pregnant woman would be increased and QALY losses
reduced for every intervention strategy. At a cost-effectiveness threshold of £20,000 per QALY, the
best-performing diagnostic glucose threshold is the same as that found in the base case, that is, 9.5 mmol/l
for fasting blood glucose level and 10.0 mmol/l for post-load glucose level. Using this threshold, 2.3% of
SA woman would be diagnosed as having GDM. The expected cost per pregnant woman of a universal
diagnostic test strategy is increased to £499 and the QALY loss reduced to –0.035. This is compared with
an expected cost of £454 associated with ‘no screening/testing or treatment’ and a QALY loss of –0.036.
In a population of white ethnicity, the best-performing diagnostic glucose threshold is altered, compared
with the base case, from 9.5 mmol/l to 8.0 mmol/l for fasting glucose level, and from 10.0 to 11.1 mmol/l
for post-load glucose level. However, this effectively forms the upper bound for the observed glucose
levels, indicating that very few women (0.2%) would be diagnosed with GDM. At these fasting and
post-load glucose levels, the cost per woman of a universal diagnostic test strategy is predicted at £508,
with an associated QALY loss of 0.036. In the base-case analysis, the best-performing diagnostic glucose
thresholds remain at these upper bounds, even if the cost-effectiveness threshold is raised to £30,000
per QALY.
Scenario analysis: maternal longer-term outcomes
When longer-term outcomes are included it does become cost-effective to intervene at a threshold of
£20,000 for a cohort of SA women. The best-performing intervention strategy is to screen women on the
basis of BMI of > 25 kg/m2 and to treat all women who screen positive. In the BiB cohort,22 48% of
women of SA or ‘Other’ ethnicity had BMI of ≥ 25 kg/m2, and the mean glucose measures in those that
would screen positive would be a fasting glucose level of 4.79 mmol/l and post-load glucose level of 6.74.
The expected cost per woman would be £1306, but QALY losses from perinatal outcomes would be
outweighed by large gains from the early treatment and prevention of type 2 diabetes, resulting in an
expected QALY gain per pregnant woman of 0.007. The benefits of the early detection of type 2 diabetes
were modelled as higher in a SA population. The benefits of the ILS to prevent the development of type 2
diabetes were adjusted for the proportion of women that had a BMI of ≥ 30 kg/m2, which was higher
among the SA and ‘Other’ subgroup than the overall cohort. Although the best-performing diagnostic
glucose threshold would be 5.2 mmol/l for fasting glucose and 11.1 mmol/l for post-load glucose, the
NHBs of a universal diagnostic test strategy (12% diagnosed; expected cost £595 and QALYs –0.031) and
the best-performing screen and test strategy (3% diagnosed; expected cost £521 and expected QALYs
–0.033) are still lower than the best-performing ‘screen only’ strategy, but ‘screen and test’ would improve
NHBs compared with ‘no screening/testing or treatment’. When the cost-effectiveness threshold increases
to £30,000 per QALY it is optimal to intervene with a screen-only strategy on the basis of maternal age of
≥ 25 years, BMI of ≥ 25 kg/m2 and family history of diabetes. This would increase the proportion of
women who screen positive and are treated to 87% of the cohort, with an expected cost per pregnant
woman of £1833 and a QALY gain of 0.03.
Value of information analysis
In the base-case analysis for a cost-effectiveness threshold of £20,000 per QALY, there does not appear to
be value in further research. There is uncertainty as to the best-performing diagnostic glucose threshold,
but the expected net benefit that could be achieved in the absence of this uncertainty (–£1205) is still less
than that expected with ‘no screening/testing or treatment’ based on current information. This would
seem to indicate that there is no value in research to reduce uncertainty in the best-performing diagnostic
glucose threshold.
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At a cost-effectiveness threshold of £20,000 per QALY, the expected net benefit that could be achieved in
the absence of uncertainty regarding the best-performing diagnostic glucose threshold (–£1205) is, again,
less than that expected with ‘no screening/testing or treatment’ based on current information. In the full
incremental analysis and using the best-performing diagnostic glucose threshold, the likelihood that a ‘no
screening/testing or treatment’ strategy is cost-effective is 0.98 (EVPI £1 per decision), and the probability
that a universal diagnostic test strategy is cost-effective is 0.02. The parameters predominantly associated
with decision uncertainty are the fasting and post-load glucose levels among women who would test
negative at the best-performing threshold (expected value of partial perfect information for each £0.01
per person).
At a cost-effectiveness threshold of £30,000 per QALY, the expected net benefit that could be achieved in
the absence of uncertainty regarding the best-performing diagnostic glucose threshold does exceed that
associated with a ‘no screening/testing or treatment’ strategy. This suggests that the probability that ‘no
screening/testing or treatment’ is cost-effective could be lower than that evaluated at a fixed diagnostic
threshold (0.51), and that the value of further research could potentially be even higher than the estimated
£55 EVPI per decision. If this £55 is multiplied by 700,000255 to represent the number of pregnancies in
England in a 1-year period, this would suggest a very high upper bound for the population value of
research (£38.5M). The other strategies associated with a probability of > 1% that could be the most
cost-effective are ‘screen and treat’ based on BMI of ≥ 25 kg/m2 (0.08); ‘screen and treat’ based on BMI of
≥ 30 kg/m2 and previous GDM (0.06); ‘screen, test and treat’ based on maternal age of ≥ 30 years and
BMI of ≥ 25 kg/m2 (0.02); ‘screen and treat’ based on maternal age of ≥ 25 years, BMI of ≥ 25 kg/m2 and
non-white ethnicity (0.21); and to ‘screen and treat’ based on BMI of ≥ 25 kg/m2 and previous GDM
(0.02). The inputs that contribute most to the decision uncertainty (EVPI > £1 per decision) include the
maternal utility gain from GDM treatment (£16), the effect of treatment (applied only to women who test
positive on OGTT) on risk of instrumental delivery (£9), and the effect of diet and exercise (applied to
women who are identified and treated based on screening alone applied to the screen and treat
strategies) on the risk of shoulder dystocia (£2).
In the scenario analysis with maternal longer-term outcomes included and at a cost-effectiveness threshold
of £20,000 per QALY, there is again a high value to further research. Using the best-performing diagnostic
glucose threshold, the likelihood that a ‘no screen/test or treat’ strategy is cost-effective is 0.87 and the
EVPI is £252 per decision. If this is multiplied by 700,000 to represent the number of pregnancies in
England in a 1-year period, this would suggest a very high population value of research. The value of
further research is estimated to be high because there is uncertainty surrounding the benefits attributed to
longer-term outcomes, and in some scenarios these convey large additional net benefits to all women who
exceed the given diagnostic threshold. Two other strategies associated with a probability of > 1%, which
may be the most cost-effective, are ‘screen and treat’ based on a BMI of ≥ 25 kg/m2 (0.0124) and ‘screen
and treat’ based on maternal age of ≥ 25 years, a BMI of ≥ 25 kg/m2 and non-white ethnicity (0.0956).
The parameter that contributes most to the decision uncertainty is the QALY gain associated with early
detection of maternal type 2 diabetes at post-partum follow-up (EVPI £196). The other parameters that are
associated with EVPI of > £1 per decision include the costs associated with the early detection of maternal
type 2 diabetes at post-partum follow-up (£58), the maternal utility gain from GDM treatment (£17), the
effect of treatment (applied only to women who test positive on OGTT) on risk of instrumental delivery
(£20) and the effect of diet and exercise (applied to women who are identified and treated based on
screening alone applied to the screen and treat strategies) on the risk of shoulder dystocia (£4).
Discussion
We had access to large IPD sets that allowed us to specify risk models for immediate perinatal outcomes
based on the glucose measurements obtained from a 2-hour 75-g OGTT given at between 26 and
28 weeks’ gestation. The effects of treatment on perinatal outcomes were estimated in meta-analyses.
We combined these risk models in a decision-analytic model with evidence from the wider literature in
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order to model the cost-effectiveness of alternative screen, diagnostic and treatment strategies. The costs
and QALYs were sourced from the wider literature, with key reference to sources used in the recent
NICE guideline.18
The base-case analysis indicates that it is not cost-effective to identify women for treatment for
hyperglycaemia at a cost-effectiveness threshold of £20,000 per QALY. Although treatment reduces the
risk of some adverse outcomes, it increases the risk of others and the overall QALY gains from treatment
compared with ‘no screening/testing or treatment’ are not sufficient to justify the increased costs. The
treatment costs are driven largely by more intensive antenatal care, and drug costs are low such that
switching from insulin to metformin use has little impact on the conclusions, because antenatal
surveillance remains the same for both drugs. However, if pharmacological intervention, additional to
routine antenatal care is provided with no, or limited, additional surveillance, costs may be similar to those
for women without GDM who receive only routine care, but the risk of adverse perinatal outcomes may be
reduced. The costs of diagnostic testing could also be reduced by utilising a FPG in place of the full OGTT.
Our analysis suggests that the FPG could result in similar benefits to the OGTT, but at a reduced cost.
However, the cost savings are not sufficient to make intervention cost-effective, even at a cost-effectiveness
threshold of £30,000 per QALY.
Our results are broadly in line with those of the recent NICE update,18 which estimated ICERs in excess of
£20,000 for diagnosis at commonly used glucose thresholds. The NICE guideline18 provided estimates of
cost-effectiveness in two data sets: HAPO (four centres: Belfast and Manchester in the UK and Brisbane
and Newcastle in Australia) and Norwich. In the Norwich data set they estimated that ‘no treatment’
(equivalent to ‘no screening/testing or treatment’ in our model) was cost-effective, with the next-best
alternative of diagnosis based on WHO 1999 criteria providing an ICER of £35,000 per QALY. In the HAPO
(four centres) data set the next best alternative to ‘no treatment’ was a fasting glucose level of 5.5 mmol/l
and a post-load glucose level of 8.5 mmol/l, associated with an ICER of £28,103 per QALY. The NICE
guideline18 did not perform a full incremental analysis of alternative screen and test strategies and
screen-only approaches. However, NICE did compare diagnosis at commonly used thresholds following NICE
risk factor screening in the HAPO (four centres) data set, and found that treating above a fasting glucose
level of 5.6 mmol/l or a post-load glucose level of 8.5 mmol/l was associated with an ICER of £23,902
compared with ‘no treatment’. The reported ICERs in the NICE guideline were based on deterministic analysis
and, as such, may be subject to bias if the cost-effectiveness model is non-linear. However, a probabilistic
analysis was conducted that estimated the probability that each strategy was cost-effective. When risk factor
screening was not considered, ‘no treatment’ had 99.8% (at a cost-effectiveness threshold £20,000 per
QALY) and 82.7% (at a cost-effectiveness threshold of £30,000 per QALY) probability of being the most
cost-effective. Applying NICE risk factor screening, then at a cost-effectiveness threshold of £20,000 per
QALY, ‘no treatment’ had 82.5% probability of being the most cost-effective compared with 9.4% for
diagnosis at a fasting glucose level of > 5.6 mmol/l or post-load glucose level of > 8.5 mmol/l. These
respective probabilities for a cost-effectiveness threshold of £30,000 were 40.1% and 6.2% (the strategy
with the highest probability of being cost-effective of 41.0% was, in fact, diagnosis using the WHO criteria
following NICE risk factor screening).
Intervention is likely to appear comparatively less cost-effective in our analysis because, in contrast with the
economic evaluation for the NICE guideline, we include a cost for instrumental delivery, the risk of which
is increased by treatment. Intervention strategies may also appear more cost-effective in the HAPO (four
centres) based on higher baseline risk of GDM and of adverse perinatal outcomes given the reported mean
BMI of 29 kg/m2 compared with 26 kg/m2 in the BiB study.22 However, the proportion of women of white
ethnicity was higher in HAPO (four centres), which would be associated with lower baseline risk of GDM.
The updated NICE guideline18 recommendations do not draw on the reported cost-effectiveness analysis,
instead suggesting a fasting glucose level of 5.6 mmol/l and a post-load glucose level of 7.8 mmol/l, which
were not found to be cost-effective at a threshold of £30,000 per QALY in both our and their analyses.
The guideline group considered that the fasting threshold of 7.0 mmol/l in the WHO 1999 criteria was too
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high, based on the fact that they had observed that the treatment trials utilised lower fasting glucose
thresholds for inclusion. Furthermore, they expressed concern that the regression models underpinning the
economic analysis in the NICE guideline did not incorporate fasting blood glucose levels, as this covariate
had been dropped in the stepwise selection process. We did not use a stepwise selection process, and our
risk models for adverse perinatal outcomes all include both fasting and post-load glucose levels. This
further supports the view that although intervention at lower glucose thresholds does improve health
outcomes, the resources required result in the displacement of greater health outcomes elsewhere in the
NHS. We identified the best-performing diagnostic glucose threshold, but differences between similar
thresholds were small. However, if clinicians use a lower diagnostic glucose threshold than that suggested
by the model then the result will be a greater volume of women being treated, and hence an increase in
the absolute volume of resources required and, correspondingly, an increase in the absolute amount of
health displaced elsewhere in the NHS.
In a scenario analysis, we also included the longer-term impact of diagnosing women with GDM in terms
of the early treatment of type 2 diabetes and the provision of further interventions to prevent the onset of
type 2 diabetes post partum. Although it is not cost-effective to treat GDM on its own, in combination with
early detection post partum and/or prevention of type 2 diabetes it could be cost-effective, particularly in a
population with a higher risk of type 2 diabetes in later life, for example a SA population. The generalisability
and sustainability of diabetes prevention programme effects, however, have been questioned recently.256
At a cost-effectiveness threshold of £20,000 per QALY and with maternal longer-term outcomes included,
the best-performing strategy for a SA cohort is to screen on the basis of BMI of ≥ 25 kg/m2 and then to treat
all women. Because evidence related to longer-term infant outcomes is limited, and the generalisability
and sustainability of diabetes prevention programmes are not clear, the results of the scenario analyses
incorporating longer-term outcomes should be interpreted with caution. The benefits of early treatment
of type 2 diabetes were based on a trial that considered a mixed-gender population, with underlying
prevalence rates of 5% and 10%, and we did not adjust the estimated benefits as we altered the diagnostic
threshold used in the model. The benefits of the ILS intervention was adjusted with the diagnostic threshold
in terms of the proportion of women with BMI of ≥ 30 kg/m2 among those who would test positive. We
assumed that treatment in the absence of a blood glucose test could not include metformin and insulin,
and we applied no lower bound for the glucose level at which treatment benefits would cease to apply. In
this strategy, the benefits of the diet and lifestyle intervention are assumed to extend to the 48% of women
who would screen positive. If this intervention strategy is considered to be unrealistic, the next-best strategy
would be ‘no screening/testing or treatment’.
Strengths and limitations
This study is, to the best of our knowledge, the first cost-effectiveness analysis that selects diagnostic
glucose thresholds on the basis of cost-effectiveness and NHBs within the NHS (rather than excess risk of
adverse outcomes), and the first to provide a direct simultaneous comparison of alternative intervention
strategies that are composed of all of the combinations of screening, diagnostics and treatment for
GDM. Furthermore, data from a large UK obstetric cohort (n = 10,353) were used to model women’s
characteristics and glucose levels, while two data sets combining data from the BiB and Atlantic DIP22,59
untreated population (n = 14,368) informed the majority of adverse perinatal outcomes. Both of these
sources of data contributed to the high quality of the analysis. Importantly, this study explored the
potential impact of longer-term maternal outcomes on the cost-effectiveness of the competing strategies,
and allowed us to identify effects on longer-term outcomes as an important topic for future research.
Nevertheless, there are limitations to our study, which mostly relate to areas of uncertainty and/or evidence
gaps. One of the key findings of our study is that unless the costs of treatment are reduced considerably or
there is evidence that the net benefit from longer-term outcomes would offset the costs of testing and
treating then ‘no screening/testing or treatment’ is the cost-effective intervention at the considered range
of cost-effectiveness thresholds. Although we found evidence suggesting that women with previous GDM
are at a higher risk of developing glucose intolerance, and, ultimately, type 2 diabetes later in life
ECONOMIC EVALUATION OF SCREENING AND DIAGNOSTIC TESTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
156
compared with women without GDM in their pregnancy, we did not find evidence that the decrease in
risk was mediated via treatment for GDM. Thus in the model, treatment for GDM does not modify the risk
of type 2 diabetes. Instead, it is assumed that women who have had GDM will be identified as being at a
higher risk of type 2 diabetes and that a preventative intervention will be delivered to those with IGT
(proxied by having a BMI of ≥ 30kg/m2) to decrease this risk. The first issue here is whether or not the
proxy for IGT is appropriate, but a more important issue is the inclusion of the ILS intervention in the
model; we should also consider other interventions that could be offered to prevent type 2 diabetes and
which do not require identification of GDM. In this sense, we can consider that the comparison
is incomplete.
The other component of maternal longer-term outcomes included in scenario analysis was early detection
of type 2 diabetes during the post-partum follow-up. The net benefit attributed to this outcome was
sourced from a study238 in a previously undiagnosed older population (45 years old) that included males
and females, and was exclusively of white ethnicity. The characteristics of the population in this study are
considerably different from those of the obstetric population in the model, and, therefore, it is likely that
the size of the benefit of screening for type 2 diabetes is different from what it would be for the cohort in
the model. In the absence of evidence in an obstetric population, this was the best estimate that we could
apply within the time constraints, but identifying the size of this benefit for women with GDM would be
important to resolve the uncertainty around the size of the benefits of improving longer-term maternal
outcomes. Furthermore, the benefits obtained by screening women identified with GDM were not
compared with alternative policies to screen for the detection of type 2 diabetes.
It is important to notice that the longer-term maternal outcomes included in scenario analysis were not
linked to varying diagnostic thresholds and mediated only through obesity levels. As the diagnostic
threshold for GDM is lowered, it would be expected that the risk of type 2 diabetes in the post-partum
period and later in maternal life will change in women identified with GDM.
This study did not include longer-term outcomes for the offspring of pregnant women diagnosed with
GDM because of the paucity of evidence that would link GDM and treatment of GDM to changes in
longer-term outcomes such as obesity and metabolic syndrome in the offspring. Nevertheless, the infants
in the BiB cohort22 will continue to be followed up, so it is possible that as more data become available in
the future it may be used to overcome this limitation.
Although IPD from a large cohort (n = 10,353) were used to inform population characteristics and glucose
level, this constrains the model to the range of observed characteristics and glucose measurements in
the BiB cohort.22 We attempted to model glucose levels as a function of maternal characteristics, but we
did not identify a statistical model that adequately fitted the data, especially at the tails of the glucose
distribution. The use of more complex statistical models may overcome this limitation, making the
decision-analysis model more flexible and more generalisable. Given that the model is currently constrained
to the characteristics of the BiB cohort,22 it was not possible to present separate subgroup analyses for
other ethnicities also at higher risk of GDM, such as Afro-Caribbean and Middle Eastern women.
Finally, the treatment effect estimates applied in the model were sourced from pooled RCT data, and may
not be directly generalisable to (1) the GDM obstetric population in the model, as study entry criteria are in
general more restrictive than for observational studies and (2) treatment at more extreme GDM diagnostic
thresholds outside of the range that was used for diagnosis in the RCTs. Nevertheless, these were best
treatment effectiveness estimates that were available to inform the model, despite this caveat.
Implications for future research
Value of information analysis may identify areas for which an investment in further research could provide
better value. At cost-effectiveness thresholds ranging from £13,000 to £20,000 per QALY there is
uncertainty surrounding the best-performing diagnostic glucose threshold. However, the expected net
benefit that could be achieved in the absence of uncertainty regarding the best-performing diagnostic
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
157
glucose threshold is less than that expected with ‘no screening/testing or treatment’ based on current
information, suggesting that it would not be worth conducting further research. At a cost-effectiveness
threshold of £30,000 per QALY, three parameters were identified as contributing the most for decision
uncertainty: (1) maternal utility gain from GDM treatment (population EVPI £11M); (2) the effect of
treatment on risk of instrumental delivery (population EVPI £6M); and (3) the effect of diet and exercise on
the risk of shoulder dystocia (population EVPI £1M).
Once maternal longer-term outcomes are included in the value of information analysis, there is a high
value to further research at a cost-effectiveness threshold of £20,000 per QALY. The EVPI (accounting for
the 700,000 pregnancies per year in England and Wales) at this cost-effectiveness threshold suggests
that it would be worth investing up to £38.5M to resolve uncertainty at this level, as this represents the
potential opportunity cost of taking the wrong decision. Thus, the upper bound for investing in research
that would provide more accurate and reliable data on the cost-effectiveness of identifying and treating
GDM (including longer-term outcomes) is £38.5M. The EVPI estimates allow prioritisation of the research
by focusing on areas for which resolving uncertainty would be of greater value. The parameter that
contributes most to the decision uncertainty is the QALY gain associated with early detection of maternal
type 2 diabetes at post-partum follow-up, with an EVPI of £196 per pregnancy and £134M for the
population. The parameter with the second highest EVPI was the costs associated with early detection of
maternal type 2 diabetes at post-partum follow-up (population EVPI £41M). However, as described above
(see Strengths and limitations), these uncertain benefits pertain to the screening for type 2 diabetes in a
high-risk population that is identified on the basis of GDM. The cost-effectiveness analysis here does not
compare alternative screening programmes for type 2 diabetes.
Although this aspect could not be captured by the value of information analysis, as this is not an area of
uncertainty but rather a question of how service delivery can be more efficiently organised, research into
less expensive ways of delivering treatment for GDM is another potential area of interest. The results suggest
that the cost-effectiveness of screening, testing and treating strategies can be improved considerably by
delivering dietary advice and insulin instruction in large groups, rather than individually. It is, however,
worth emphasising that, even with this reduction in cost, these strategies would not be cost-effective at a
£20,000 per QALY, but only at £30,000 per QALY and when including longer-term maternal outcomes.
The use of the higher £30,000 cost-effectiveness threshold (NICE) can be applied in circumstances in which
there is little uncertainty and when there are significant health benefits that have not been captured within
the economic analysis. We did seek to capture longer-term health benefits within the model, but they are
estimated with considerable uncertainty, suggesting that a cost-effectiveness threshold of £30,000 may not
be applicable.
Conclusion
The evidence of the effects of identifying and treating women with GDM in terms of the reduction in
adverse perinatal outcomes is not sufficient to justify the cost of treatment at a cost-effectiveness threshold
of £20,000 per QALY. However, if longer-term outcomes are included in the model (although evidence is
limited) and costs of providing GDM treatment are reduced by more efficiently deploying existing resources
then it may be cost-effective to intervene in populations with a high prevalence of glucose intolerance.
The considerable uncertainty surrounding the potential size of longer-term benefits suggests that at a
cost-effectiveness threshold of £20,000 per QALY it would be worth conducting additional research on the
HRQL gains and costs of early detection of maternal type 2 diabetes. Furthermore, there are important
evidence gaps regarding offspring longer-term outcomes and data that allow linking longer-term
outcomes to varying diagnostic thresholds.
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Chapter 8 Conclusions
Conclusions, implications and recommendations for future research
Previously the aim of diagnosing GDM has been to reduce the risk of perinatal complications through the
treatment of hyperglycaemia and to identify women at risk of developing future type 2 diabetes.166,257
Newly proposed criteria, however, seek to identify infants at risk of future obesity through its association
with LGA, high infant adiposity and high cord blood C-peptide levels.8 The shift in the aim of diagnosing
GDM is particularly important for SAs, as their infants, in comparison with white Europeans, have
markedly lower BW and reduced risk of LGA, but this lower BW masks a propensity to greater adiposity
and associated cardiometabolic risk. Our analysis using the BiB study IPD123 detailed in Chapter 2 suggests
that to capture the majority of those infants at risk of LGA and/or high adiposity at birth (by the methods
used by the IADPSG), glucose thresholds at OGTT used to diagnose GDM would need to be lowered
(compared with previous threshold criteria,11 and more in line with the new IADPSG criteria8). Lowering
glucose thresholds in this way will increase the proportion of women at risk of important adverse perinatal
outcomes: one in 12 WB women and one in four SA women will be diagnosed based on estimates using
the BiB study IPD123 (see Chapters 2 and 4). As there are effective, safe and relatively cheap treatments for
GDM (lifestyle advice, metformin and insulin), which reduce glucose levels across its distribution and
help prevent adverse perinatal outcomes (see Chapter 6), applying lower threshold criteria may importantly
improve perinatal outcomes. However, there is limited evidence from observation studies regarding the
strength of the association between maternal glucose levels and longer-term outcomes (maternal and
infant obesity and diabetes) (see Chapter 3) and there are no treatment trials examining treatment effects
and the risk of future adverse outcomes, including infant obesity (see Chapter 6). Therefore, the degree
to which new criteria will influence perinatal and longer-term outcomes is unclear. This has resulted in
concern that lowering glucose thresholds will increase GDM prevalence and associated costs without
evidence of benefit.258
The increased identification of women resulting from lowering glucose thresholds has resource implications
for the NHS in terms of antenatal services (OGTTs, treatments, induction of labour), intrapartum care
(C-section) and postnatal services (infant care needs, 6-week screening for type 2 diabetes). There are also
resource implications for primary care, in terms of the increased numbers of women requiring yearly
screening for type 2 diabetes. Our economic analysis suggests that the benefits of identifying and treating
women with GDM in terms of the reduction in risk of perinatal outcomes are not sufficient to justify the
cost of treatment at a cost-effectiveness threshold of £20,000 per QALY. This finding may seem surprising,
given that our analyses suggest that lower glucose levels are required to identify the majority of infants
(using the methods of the IADPSG) at increased risk of future obesity (see Chapter 2) and that our
treatments for GDM review (see Chapter 6) show statistically significant reduction in risks of most adverse
perinatal outcomes if treatment to reduce maternal glucose is provided (compared with routine care).
There are, however, several factors that are contributing to the findings of the economic evaluation.
The higher cost perinatal outcomes associated with GDM, such as shoulder dystocia and neonatal unit
admission, occur relatively infrequently and the reduction in these costs from treatment is therefore small
(even although costs associated with one shoulder dystocia or one neonatal unit admission may be
substantial). The more frequent adverse outcomes, such as C-section, are less costly. Moreover, some
adverse outcomes are increased in treated women, including induction of labour, and, as discussed above,
there is uncertainty about the effects of treating hyperglycaemia (at any glucose level) on longer-term
maternal and infant outcomes; therefore, the use of a higher QALY threshold may not be appropriate.
Because there is uncertainty about GDM treatment effects on longer-term maternal and infant health, it is
unclear if interventions outside pregnancy (e.g. obesity and diabetes prevention programmes) would
convey greater gains compared with interventions delivered during pregnancy. However, there is little
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
159
evidence on best timing of interventions outside pregnancy or what would constitute an effective obesity
or diabetes prevention intervention.
We attempted to characterise longer-term effects in our economic model; however, we were unable to
link them directly to alternative diagnostic thresholds. The magnitude of effects (both positive and
negative) for the longer-term outcomes related to different diagnostic thresholds and approaches to the
identification of women at risk (e.g. timing or diagnostic test) for treatment would seem key in
determining whether or not it is cost-effective to intervene in pregnancy and therefore this should be
examined. Also research examining the effectiveness of diabetes prevention programmes for women who
have had GDM would help quantify the potential effects of identifying women with GDM, especially in
light of recent concerns questioning the effectiveness of diabetes prevention programmes for the general
at-risk population.256
The cost-effectiveness analysis presented here suggests that the health gained by addressing GDM is
comparatively lower than that generated by other NHS activities. As NHS funding is unlikely to be
increased to address rising GDM prevalence, cheaper and/or more efficient ways of identifying GDM,
and new and innovative methods of providing care, are required. Although our systematic review (see
Chapter 6) found that the ‘step-up approach’ to treating GDM with diet first and glucose monitoring,
with supplemental metformin or insulin if needed, is effective in reducing risks, trials investigating different
packages of care or approaches to care are needed.
Treatment trials have not generally reported negative effects such as medicalisation, anxiety or drug side
effects; this information would help to fully understand the effectiveness of treatments and the influence
of non-compliance.
Our analysis detailed in Chapter 5 suggests that the assessment of maternal characteristics (e.g. ethnicity
with a high prevalence of diabetes or previous macrosomic infant), currently recommended by NICE18
to identify high-risk women for diagnostic testing, in whatever form, performs poorly, because a large
proportion of women need to be offered an OGTT, and it is likely that some women with hyperglycaemia
would not be identified (low specificity) and therefore would not benefit from treatment. The identification
of women who are at low risk of developing GDM and do not require an OGTT may be advantageous in
some populations, however, and may prevent testing in at least 30%.
There is a balance between costs and improved perinatal and longer-term health impacts from the
application of different diagnostic criteria and treatments. We found that at a cost-effectiveness threshold
of £20,000 per QALY it is not cost-effective to identify women for treatment for hyperglycaemia, even in
the scenario in which longer-term outcomes are incorporated into the model. It is only with the inclusion
of longer-term health outcomes and at cost-effectiveness thresholds of > £24,000 per QALY (which is
above the £20,000-per-QALY threshold recommended when there are uncertainties regarding treatment
effectiveness) that NHBs are improved by intervening. Given the uncertainty surrounding the estimation of
longer-term outcomes, and that only when these are incorporated into our economic model are health
benefits improved, further research in this area (longer-term health effects) would be useful. Research
examining the performance (sensitivity, specificity) and influence on outcomes of different methods
to identify women at risk (screening tests) and those with GDM (diagnostic tests) are needed. The
influence of alternative diagnostic thresholds and different treatment approaches on outcomes also
require investigation.
CONCLUSIONS
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Appendix 1 Tables and figures for Chapter 2
TABLE 50 Distributions of variables with missing data comparing observed complete case data to results from
pooling the data sets with imputed variables from multiple imputation
Variables Level/unit
No. (%) with
missing data Complete case
Multiple
imputationa
BW Mean (SE) SD score 1 (–0.37 0.01) (–0.37 0.01)
Sum of skinfolds Mean (SE) 3051 (32.1) 9.82 (0.03) 9.75 (0.02)
Pre-eclampsia % 389 (4.1) 2.5 2.5
Instrumental vaginal deliverya % 7 (0.1) 12.4 12.4
Maternal BMI Mean (SE) 436 (4.6) 25.8 (0.06) 25.9 (0.06)
Maternal education % 5+GCSE equivalent 126 (1.3) 31.5 31.5
% higher than A-level equivalent 25.6 25.6
Smoking % 15 (0.2) 17.0 17.0
Alcohol % 36 (0.4) 20.6 20.6
Parity % primiparious 358 (3.8) 41.7 41.4
Family history of diabetes % 297 (3.1) 25.1 25.1
Family history of hypertension % 306 (3.2) 27.4 27.4
Previous macrosomia % 874 (16.4) 4.5 4.8
a These analyses exclude women who had a C-section, therefore N = 7526.
TABLE 51 Comparison of included and excluded women, n (%) or mean (SD)
Variable Category/statistic
n with
observed
data from
included
Included in
study
maximum
(N= 9509)
n with observed
data from the
potentially
eligible
Potentially
eligiblea
maximum
(N= 12,044)
Ethnicity WB 9509 3888 (40.9%) 9929 4067 (41.0%)
SA 4821 (50.7%) 5015 (50.5%)
Other 800 (8.4%) 847 (8.5%)
Maternal age Mean (SD) 9509 27.3 (5.5) 12,044 27.2 (5.5)
Maternal booking BMI Mean (SD) 9073 25.8 (5.6) 9469 25.8 (5.6)
BW Mean (SD) 9505 3253 (548) 12,044 3238 (552)
Sum of skinfolds Mean (SD) 6458 9.82 (2.02) 8238 9.82 (2.04)
C-section No 9509 7526 (79.1%) 12,044 9458 (78.5%)
Yes 1983 (20.9%) 2586 (21.5%)
a Potentially eligible includes 13,061 women (shown in flow chart) minus 1017 women with GDM so that in both groups
(included and potentially eligible) women who delivered a live singleton child in the Bradford Royal Infirmary and who
did not have existing diabetes or reach the criteria applied in the hospital during study recruitment for GDM
are compared.
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TABLE 52 Unadjusted associations of maternal fasting and post-load glucose levels with primary outcomes
Outcomes by fasting glucose
categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
OR 95% CI OR 95% CI OR 95% CI
Primary outcomes
BW of > 90th centile
1 reference 1.00 – 1.00 – 1.00 –
2 1.23 0.95 to 1.58 1.31 0.95 to 1.79 1.15 0.66 to 2.02
3 1.48 1.16 to 1.88 1.84 1.36 to 2.48 1.34 0.81 to 2.21
4 1.62 1.19 to 2.20 2.22 1.50 to 3.29 1.60 0.88 to 2.90
5 2.16 1.59 to 2.94 2.47 1.57 to 3.86 3.26 1.91 to 5.54
6 3.48 2.36 to 5.13 3.92 1.98 to 7.75 5.71 3.15 to 10.34
7 3.37 1.83 to 6.24 3.77 1.50 to 9.50 5.99 2.49 to 14.44
Per 1 SD 1.37 1.27 to 1.49 1.44 1.29 to 1.60 1.67 1.45 to 1.92
Sum of skinfolds of > 90th centile
1 reference 1.00 – 1.00 – 1.00 –
2 1.16 0.93 to 1.46 1.11 0.79 to 1.56 1.34 0.96 to 1.88
3 1.57 1.28 to 1.93 1.55 1.12 to 2.14 1.72 1.27 to 2.32
4 1.97 1.53 to 2.53 2.04 1.34 to 3.10 2.04 1.43 to 2.90
5 2.55 1.97 to 3.30 2.62 1.63 to 4.20 2.67 1.88 to 3.80
6 4.20 3.01 to 5.87 4.20 2.10 to 8.38 4.15 2.67 to 6.45
7 3.82 2.19 to 6.67 3.57 1.34 to 9.48 4.41 2.16 to 8.98
Per 1 SD 1.47 1.37 to 1.57 1.46 1.29 to 1.65 1.47 1.34 to 1.62
Caesarean delivery
1 reference 1.00 – 1.00 – 1.00 –
2 1.03 0.90 to 1.19 1.12 0.91 to 1.37 1.04 0.83 to 1.30
3 1.25 1.09 to 1.43 1.34 1.09 to 1.64 1.32 1.08 to 1.62
4 1.41 1.18 to 1.69 1.60 1.20 to 2.13 1.56 1.21 to 1.99
5 1.49 1.22 to 1.81 1.77 1.26 to 2.47 1.41 1.07 to 1.85
6 1.51 1.14 to 2.01 2.54 1.50 to 4.29 1.27 0.86 to 1.87
7 2.63 1.68 to 4.10 1.88 0.85 to 4.19 3.43 1.95 to 6.03
Per 1 SD 1.18 1.12 to 1.24 1.24 1.15 to 1.35 1.18 1.10 to 1.26
Outcome by 2-hour post-load glucose categorya and per 1 SD
BW of > 90th percentile
1 reference 1.00 – 1.00 – 1.00 –
2 0.99 0.78 to 1.27 1.13 0.84 to 1.53 1.09 0.64 to 1.86
3 1.22 0.96 to 1.56 1.25 0.92 to 1.70 1.40 0.83 to 2.34
4 1.54 1.13 to 2.11 1.60 1.07 to 2.41 2.06 1.12 to 3.78
5 1.95 1.45 to 2.64 1.77 1.18 to 2.66 2.98 1.68 to 5.28
6 2.12 1.37 to 3.29 2.72 1.54 to 4.82 2.30 1.01 to 5.26
7 1.50 0.79 to 2.85 1.66 0.69 to 4.01 2.54 0.94 to 6.89
Per 1 SD 1.26 1.15 to 1.38 1.25 1.12 to 1.40 1.46 1.23 to 1.72
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TABLE 52 Unadjusted associations of maternal fasting and post-load glucose levels with primary outcomes
(continued )
Outcomes by fasting glucose
categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
OR 95% CI OR 95% CI OR 95% CI
Sum of skinfolds > 90th percentile
1 reference 1.00 – 1.00 – 1.00 –
2 1.09 0.87 to 1.38 1.31 0.94 to 1.83 1.01 0.72 to 1.41
3 1.49 1.19 to 1.86 1.27 0.89 to 1.82 1.68 1.23 to 2.29
4 2.16 1.66 to 2.81 2.03 1.31 to 3.16 2.30 1.60 to 3.31
5 2.32 1.77 to 3.03 2.21 1.41 to 3.46 2.56 1.78 to 3.68
6 2.79 1.91 to 4.08 3.21 1.74 to 5.89 2.50 1.48 to 4.23
7 3.06 1.88 to 4.98 1.99 0.76 to 5.21 3.83 2.13 to 6.88
Per 1 SD 1.40 1.29 to 1.51 1.34 1.18 to 1.51 1.47 1.32 to 1.63
Caesarean delivery
1 reference 1.00 – 1.00 – 1.00 –
2 1.02 0.89 to 1.17 0.99 0.80 to 1.22 1.14 0.92 to 1.41
3 1.23 1.07 to 1.42 1.32 1.07 to 1.63 1.15 0.92 to 1.43
4 1.35 1.12 to 1.64 1.23 0.91 to 1.66 1.45 1.10 to 1.92
5 1.29 1.06 to 1.57 1.53 1.14 to 2.06 1.17 0.87 to 1.57
6 1.79 1.34 to 2.39 2.00 1.26 to 3.15 1.66 1.11 to 2.49
7 1.48 1.00 to 2.20 1.26 0.65 to 2.45 1.60 0.94 to 2.73
Per 1 SD 1.14 1.09 to 1.20 1.15 1.07 to 1.25 1.12 1.04 to 1.21
a Glucose categories are defined as follows: FPG level – category 1, < 4.3 mmol/l; category 2, 4.3–4.4 mmol/l; category 3,
4.5–4.7 mmol/l; category 4, 4.8–4.9 mmol/l; category 5, 5.0–5.2 mmol/l; category 6, 5.3–5.6 mmol/l; category 7,
5.7–6.0 mmol/l. Post-load plasma glucose level–category 1, < 4.7 mmol/l; category 2, 4.7–5.4 mmol/l; category 3,
5.5–6.2 mmol/l; category 4, 6.3–6.6 mmol/l; category 5, 6.7–7.2 mmol/l; category 6, 7.3–7.5 mmol/l; category 7,
7.6–7.7 mmol/l.
TABLE 53 Unadjusted associations of maternal fasting and post-load glucose levels with secondary outcomes
Outcome by fasting glucose
categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
OR 95% CI OR 95% CI OR 95% CI
Pre-eclampsia
1 reference 1.00 – 1.00 – 1.00 –
2 1.45 0.98 to 2.14 1.39 0.79 to 2.44 1.46 0.83 to 2.56
3 1.33 0.90 to 1.95 1.22 0.67 to 2.20 1.24 0.72 to 2.15
4 2.00 1.28 to 3.15 2.66 1.37 to 5.15 1.54 0.81 to 2.92
5 2.29 1.41 to 3.71 3.52 1.69 to 7.36 1.35 0.65 to 2.79
6 2.69 1.42 to 5.09 1.86 0.43 to 8.03 2.14 0.91 to 5.03
7 3.23 1.27 to 8.23 2.03 0.27 to 15.46 3.71 1.26 to 10.97
Per 1 SD 1.31 1.15 to 1.48 1.38 1.13 to 1.69 1.19 1.00 to 1.43
continued
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TABLE 53 Unadjusted associations of maternal fasting and post-load glucose levels with secondary outcomes
(continued )
Outcome by fasting glucose
categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
OR 95% CI OR 95% CI OR 95% CI
Preterm delivery
1 reference 1.00 – 1.00 – 1.00 –
2 0.84 0.65 to 1.08 0.74 0.50 to 1.09 0.96 0.66 to 1.41
3 0.94 0.74 to 1.20 0.91 0.63 to 1.32 0.97 0.68 to 1.40
4 0.78 0.55 to 1.12 0.96 0.56 to 1.64 0.70 0.42 to 1.18
5 1.01 0.70 to 1.45 1.06 0.57 to 1.97 1.02 0.63 to 1.67
6 0.74 0.40 to 1.38 0.85 0.26 to 2.78 0.62 0.27 to 1.46
7 1.65 0.79 to 3.48 0.59 0.08 to 4.37 2.10 0.87 to 5.08
Per 1 SD 0.93 0.84 to 1.03 0.91 0.77 to 1.08 0.93 0.80 to 1.08
Shoulder dystociab
1 reference 1.00 – 1.00 – 1.00 –
2 0.89 0.51 to 1.56 0.48 0.17 to 1.30 1.15 0.50 to 2.61
3 0.87 0.50 to 1.53 1.06 0.48 to 2.33 0.90 0.39 to 2.08
4 1.80 0.98 to 3.30 1.59 0.58 to 4.37 1.43 0.56 to 3.66
5 1.33 0.63 to 2.81 1.52 0.44 to 5.26 1.50 0.56 to 4.02
6 2.32 0.96 to 5.63 3.86 0.86 to 17.34 1.16 0.26 to 5.25
7 2.70 0.63 to 11.57 – – 5.05 1.09 to 23.46
Per 1 SD 1.26 1.04 to 1.52 1.26 0.90 to 1.74 1.21 0.91 to 1.59
Instrumental vaginal deliveryb
1 reference 1.00 – 1.00 – 1.00 –
2 1.09 0.90 to 1.31 1.03 0.79 to 1.34 0.99 0.74 to 1.33
3 1.03 0.85 to 1.24 0.97 0.73 to 1.28 1.06 0.80 to 1.40
4 1.01 0.78 to 1.30 0.95 0.62 to 1.45 1.05 0.73 to 1.51
5 1.18 0.90 to 1.56 1.47 0.93 to 2.32 1.22 0.84 to 1.77
6 0.98 0.63 to 1.52 0.96 0.37 to 2.50 1.09 0.63 to 1.86
7 1.33 0.64 to 2.73 1.59 0.52 to 4.80 1.37 0.52 to 3.59
Per 1 SD 1.02 0.95 to 1.09 1.05 0.94 to 1.18 1.04 0.93 to 1.15
Admission to neonatal unit
1 reference 1.00 – 1.00 – 1.00 –
2 0.88 0.67 to 1.17 0.85 0.57 to 1.28 0.91 0.60 to 1.39
3 0.94 0.72 to 1.22 0.75 0.49 to 1.16 1.09 0.74 to 1.59
4 1.15 0.81 to 1.61 1.12 0.64 to 1.96 1.20 0.75 to 1.91
5 1.14 0.78 to 1.66 0.64 0.27 to 1.49 1.45 0.90 to 2.34
6 1.26 0.73 to 2.18 2.66 1.16 to 6.07 0.88 0.39 to 1.96
7 0.97 0.35 to 2.69 – – 1.19 0.36 to 3.94
Per 1 SD 1.00 0.90 to 1.11 0.94 0.78 to 1.14 1.03 0.89 to 1.18
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TABLE 53 Unadjusted associations of maternal fasting and post-load glucose levels with secondary outcomes
(continued )
Outcome by 2-hour post-load
glucose categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
OR 95% CI OR 95% CI OR 95% CI
Pre-eclampsia
1 reference 1.00 – 1.00 – 1.00 –
2 1.16 0.78 to 1.74 1.79 0.95 to 3.39 0.80 0.47 to 1.37
3 1.58 1.07 to 2.33 2.28 1.22 to 4.29 0.97 0.57 to 1.64
4 1.65 1.00 to 2.71 2.85 1.32 to 6.13 0.99 0.49 to 1.99
5 1.86 1.13 to 3.05 3.03 1.40 to 6.53 0.95 0.46 to 1.99
6 1.51 0.67 to 3.40 2.37 0.67 to 8.32 1.05 0.36 to 3.07
7 2.78 1.22 to 6.31 1.65 0.21 to 12.77 2.30 0.86 to 6.15
Per 1 SD 1.26 1.11 to 1.43 1.36 1.14 to 1.64 1.10 0.91 to 1.34
Preterm delivery
1 reference 1.00 – 1.00 – 1.00 –
2 0.99 0.77 to 1.28 1.00 0.69 to 1.44 1.06 0.72 to 1.56
3 0.95 0.72 to 1.24 0.93 0.62 to 1.38 0.97 0.65 to 1.45
4 1.14 0.80 to 1.62 1.14 0.67 to 1.93 1.26 0.76 to 2.09
5 0.99 0.68 to 1.44 0.81 0.44 to 1.50 1.08 0.63 to 1.84
6 1.43 0.86 to 2.40 1.02 0.40 to 2.60 1.81 0.93 to 3.51
7 0.83 0.36 to 1.93 1.99 0.76 to 5.19 0.25 0.03 to 1.82
Per 1 SD 1.04 0.94 to 1.14 1.02 0.89 to 1.17 1.05 0.91 to 1.20
Shoulder dystociab
1 reference 1.00 – 1.00 – 1.00 –
2 1.00 0.55 to 1.83 1.14 0.50 to 2.60 1.19 0.39 to 3.65
3 1.68 0.96 to 2.95 1.20 0.51 to 2.85 3.19 1.19 to 8.59
4 1.86 0.90 to 3.82 1.71 0.59 to 4.97 2.49 0.72 to 8.66
5 1.74 0.83 to 3.65 0.76 0.17 to 3.46 3.94 1.28 to 12.13
6 1.58 0.47 to 5.37 1.33 0.17 to 10.51 3.01 0.58 to 15.68
7 3.67 1.23 to 10.93 2.20 0.28 to 17.49 8.09 1.89 to 34.62
Per 1 SD 1.36 1.12 to 1.66 1.16 0.86 to 1.55 1.72 1.27 to 2.31
Instrumental vaginal deliveryb
1 reference 1.00 – 1.00 – 1.00 –
2 0.86 0.71 to 1.04 0.95 0.72 to 1.25 0.84 0.63 to 1.12
3 0.98 0.81 to 1.19 1.06 0.80 to 1.42 0.96 0.72 to 1.29
4 1.15 0.89 to 1.50 1.18 0.80 to 1.76 1.25 0.86 to 1.83
5 1.05 0.81 to 1.38 1.26 0.84 to 1.90 0.99 0.66 to 1.47
6 1.35 0.90 to 2.05 2.09 1.13 to 3.85 1.23 0.68 to 2.20
7 1.12 0.64 to 1.97 0.77 0.27 to 2.20 1.46 0.72 to 2.96
Per 1 SD 1.07 0.99 to 1.14 1.11 1.00 to 1.23 1.06 0.95 to 1.18
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TABLE 53 Unadjusted associations of maternal fasting and post-load glucose levels with secondary outcomes
(continued )
Outcome by 2-hour post-load
glucose categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
OR 95% CI OR 95% CI OR 95% CI
Admission to neonatal unit
1 reference 1.00 – 1.00 – 1.00 –
2 0.89 0.68 to 1.16 1.12 0.75 to 1.66 0.70 0.47 to 1.04
3 0.85 0.64 to 1.13 0.81 0.52 to 1.27 0.79 0.53 to 1.16
4 0.94 0.64 to 1.38 0.85 0.45 to 1.62 0.87 0.52 to 1.46
5 0.84 0.56 to 1.25 0.83 0.42 to 1.61 0.85 0.50 to 1.44
6 0.55 0.25 to 1.20 0.97 0.34 to 2.76 0.35 0.11 to 1.14
7 1.48 0.76 to 2.90 1.38 0.42 to 4.60 1.31 0.54 to 3.13
Per 1 SD 0.98 0.88 to 1.08 0.97 0.83 to 1.12 0.98 0.85 to 1.13
a Glucose categories are defined as follows: FPG level – category 1, < 4.3 mmol/l; category 2, 4.3–4.4 mmol/l; category 3,
4.5–4.7 mmol/l; category 4, 4.8–4.9 mmol/l; category 5, 5.0–5.2 mmol/l; category 6, 5.3–5.6 mmol/l; category 7,
5.7–6.0 mmol/l. Post-load plasma glucose level – category 1, < 4.7 mmol/l; category 2, 4.7–5.4 mmol/l; category 3,
5.5–6.2 mmol/l; category 4, 6.3–6.6 mmol/l; category 5, 6.7–7.2 mmol/l; category 6, 7.3–7.5 mmol/l; category 7,
7.6–7.7 mmol/l.
b These analyses exclude women who had a C-section, therefore n= 7526.
TABLE 54 Confounder adjusted associations of maternal fasting and 2-hour post-load glucose with secondary outcomes
Outcome by fasting glucose
categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
p-interactionbOR 95% CI OR 95% CI OR 95% CI
Pre-eclampsia
1 reference 1.00 – 1.00 – 1.00 – 0.62
2 1.37 0.92 to 2.04 1.28 0.72 to 2.27 1.38 0.78 to 2.46
3 1.17 0.78 to 1.75 1.08 0.58 to 1.99 1.07 0.60 to 1.91
4 1.57 0.97 to 2.53 1.88 0.94 to 3.75 1.28 0.65 to 2.50
5 1.88 1.11 to 3.19 2.65 1.18 to 5.93 1.16 0.53 to 2.52
6 1.99 1.02 to 3.87 1.16 0.31 to 4.39 1.55 0.63 to 3.82
7 2.60 0.97 to 6.97 1.65 0.19 to 14.58 2.76 0.86 to 8.91
Per 1 SD 1.20 1.04 to 1.38 1.24 0.98 to 1.55 1.10 0.90 to 1.33
Preterm delivery
1 reference 1.00 – 1.00 – 1.00 – 0.72
2 0.86 0.66 to 1.12 0.76 0.52 to 1.12 0.97 0.66 to 1.42
3 1.02 0.79 to 1.31 1.04 0.71 to 1.51 1.02 0.71 to 1.47
4 0.86 0.60 to 1.25 1.15 0.67 to 1.99 0.74 0.44 to 1.24
5 1.15 0.79 to 1.67 1.30 0.69 to 2.45 1.09 0.66 to 1.81
6 0.83 0.43 to 1.58 1.05 0.31 to 3.51 0.68 0.28 to 1.66
7 2.12 0.98 to 4.57 0.82 0.10 to 6.33 2.30 0.91 to 5.82
Per 1 SD 0.96 0.86 to 1.08 0.98 0.82 to 1.17 0.95 0.81 to 1.10
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TABLE 54 Confounder adjusted associations of maternal fasting and 2-hour post-load glucose with secondary outcomes
(continued )
Outcome by fasting glucose
categorya and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
p-interactionbOR 95% CI OR 95% CI OR 95% CI
Shoulder dystociac
1 reference 1.00 – 1.00 – 1.00 – 0.52
2 0.88 0.50 to 1.54 0.43 0.15 to 1.17 1.18 0.52 to 2.72
3 0.87 0.49 to 1.53 0.90 0.41 to 1.96 0.92 0.39 to 2.21
4 1.69 0.90 to 3.16 1.26 0.47 to 3.35 1.40 0.53 to 3.65
5 1.19 0.55 to 2.58 1.13 0.33 to 3.87 1.38 0.49 to 3.86
6 2.01 0.79 to 5.12 2.85 0.69 to 11.72 0.98 0.21 to 4.64
7 2.56 0.59 to 11.10 – – 4.49 0.92 to 21.87
Per 1 SD 1.22 1.00 to 1.49 1.13 0.82 to 1.56 1.17 0.88 to 1.55
Instrumental vaginal deliveryc
1 reference 1.00 – 1.00 – 1.00 – 0.87
2 1.16 0.96 to 1.42 1.08 0.81 to 1.43 1.06 0.77 to 1.45
3 1.15 0.94 to 1.40 1.01 0.75 to 1.36 1.18 0.87 to 1.60
4 1.18 0.89 to 1.57 0.93 0.59 to 1.47 1.30 0.87 to 1.93
5 1.53 1.12 to 2.08 1.61 0.97 to 2.68 1.54 1.02 to 2.33
6 1.27 0.78 to 2.06 0.94 0.33 to 2.69 1.43 0.78 to 2.62
7 2.21 0.92 to 5.29 2.11 0.51 to 8.77 2.44 0.78 to 7.68
Per 1 SD 1.11 1.02 to 1.20 1.07 0.94 to 1.22 1.13 1.00 to 1.27
Intensive neonatal care
1 reference 1.00 – 1.00 – 1.00 – 0.13
2 0.90 0.68 to 1.19 0.87 0.58 to 1.30 0.93 0.61 to 1.43
3 0.96 0.73 to 1.25 0.78 0.50 to 1.20 1.15 0.79 to 1.68
4 1.17 0.82 to 1.66 1.17 0.67 to 2.03 1.29 0.80 to 2.08
5 1.6 0.79 to 1.70 0.64 0.27 to 1.50 1.58 0.97 to 2.56
6 1.23 0.70 to 2.17 2.47 1.06 to 5.75 0.96 0.42 to 2.21
7 1.04 0.37 to 2.91 – – 1.33 0.40 to 4.45
Per 1 SD 1.00 0.89 to 1.12 0.93 0.77 to 1.13 1.05 0.91 to 1.22
Outcome by 2-hour
post-load glucose categorya
and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
p-interactionbOR 95% CI OR 95% CI OR 95% CI
Pre-eclampsia
1 reference 1.00 – 1.00 – 1.00 – 0.33
2 0.99 0.65 to 1.49 1.56 0.82 to 2.98 0.64 0.37 to 1.12
3 1.27 0.84 to 1.90 1.77 0.92 to 3.37 0.78 0.45 to 1.36
4 1.21 0.72 to 2.06 2.29 1.03 to 5.08 0.66 0.32 to 1.36
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TABLE 54 Confounder adjusted associations of maternal fasting and 2-hour post-load glucose with secondary outcomes
(continued )
Outcome by 2-hour
post-load glucose categorya
and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
p-interactionbOR 95% CI OR 95% CI OR 95% CI
5 1.34 0.80 to 2.25 2.02 0.92 to 4.43 0.66 0.31 to 1.43
6 1.03 0.44 to 2.41 1.43 0.38 to 5.32 0.70 0.23 to 2.12
7 2.13 0.91 to 4.97 1.09 0.14 to 8.74 1.77 0.65 to 4.83
Per 1 SD 1.13 0.99 to 1.30 1.19 0.99 to 1.45 0.98 0.80 to 1.21
Preterm delivery
1 reference 1.00 – 1.00 – 1.00 – 0.61
2 1.02 0.78 to 1.32 1.07 0.73 to 1.56 1.02 0.69 to 1.51
3 1.00 0.76 to 1.31 1.02 0.68 to 1.54 0.96 0.64 to 1.44
4 1.21 0.84 to 1.73 1.25 0.73 to 2.14 1.26 0.75 to 2.11
5 1.09 0.75 to 1.58 0.96 0.52 to 1.78 1.14 0.67 to 1.94
6 1.58 0.93 to 2.68 1.25 0.48 to 3.25 1.87 0.95 to 3.68
7 0.90 0.39 to 2.09 2.13 0.81 to 5.60 0.28 0.04 to 2.09
Per 1 SD 1.07 0.97 to 1.18 1.08 0.93 to 1.24 1.07 0.93 to 1.24
Shoulder dystociac
1 reference 1.00 – 1.00 – 1.00 – 0.33
2 0.98 0.53 to 1.79 1.13 0.49 to 2.57 1.10 0.36 to 3.39
3 1.61 0.90 to 2.88 1.07 0.44 to 2.61 3.02 1.09 to 8.35
4 1.74 0.82 to 3.69 1.39 0.45 to 4.27 2.36 0.64 to 8.65
5 1.57 0.74 to 3.35 0.53 0.12 to 2.34 3.80 1.21 to 11.97
6 1.37 0.39 to 4.83 0.82 0.09 to 7.55 2.73 0.53 to 14.03
7 3.47 1.15 to 10.50 1.81 0.26 to 12.67 9.05 2.00 to 40.91
Per 1 SD 1.33 1.08 to 1.64 1.05 0.79 to 1.40 1.75 1.27 to 2.41
Instrumental vaginal deliveryc
1 reference 1.00 – 1.00 – 1.00 – 0.53
2 0.81 0.67 to 1.00 0.90 0.67 to 1.21 0.75 0.55 to 1.03
3 0.96 0.78 to 1.18 0.98 0.72 to 1.33 0.94 0.69 to 1.30
4 1.15 0.86 to 1.53 1.09 0.71 to 1.68 1.35 0.88 to 2.06
5 1.01 0.74 to 1.36 1.14 0.71 to 1.84 0.97 0.62 to 1.50
6 1.46 0.94 to 2.25 1.66 0.86 to 3.18 1.49 0.81 to 2.73
7 1.00 0.54 to 1.85 0,49 0.16 to 1.50 1.54 0.71 to 3.34
Per 1 SD 1.07 0.99 to 1.15 1.05 0.94 to 1.18 1.10 0.98 to 1.24
Intensive neonatal care
1 reference 1.00 – 1.00 – 1.00 – 0.43
2 0.88 0.67 to 1.15 1.16 0.78 to 1.72 0.68 0.46 to 1.01
3 0.84 0.63 to 1.10 0.83 0.53 to 1.30 0.78 0.53 to 1.15
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TABLE 55 Adjusted ORs (95% CI) for models including a squared term of the standardised glucose values to
examine evidence of a quadratic effect indicative of a curvilinear association for pregnancy outcomes
Outcomes
Fasting Post load
OR (95% CI) for
1 SD increase
OR (95% CI) for
glucose squared
OR (95% CI) for
1 SD increase
OR (95% CI) for
glucose squared
Primary
BW of > 90th centile 1.22 (1.08 to 1.38) 1.04 (0.96 to 1.13) 1.10 (0.98 to 1.23) 1.04 (0.96 to 1.13)
Sum of skinfolds of > 90th
centile
1.35 (1.18 to 1.54) 1.04 (0.95 to 1.14) 1.25 (1.11 to 1.41) 1.04 (0.95 to 1.15)
Caesarean delivery 1.06 (0.97 to 1.16) 1.00 (0.95 to 1.06) 1.02 (0.94 to 1.10) 1.00 (0.95 to 1.07)
Secondary
Pre-eclampsia 1.24 (0.98 to 1.57) 0.88 (0.75 to 1.04) 1.26 (0.99 to 1.60) 0.86 (0.72 to 1.02)
Preterm delivery 0.98 (0.82 to 1.17) 0.99 (0.90 to 1.09) 1.08 (0.93 to 1.24) 1.00 (0.90 to 1.11)
Shoulder dystociaa 1.14 (0.82 to 1.59) 0.92 (0.73 to 1.17) 1.05 (0.76 to 1.44) 0.93 (0.73 to 1.18)
Instrumental deliverya 1.07 (0.94 to 1.22) 0.99 (0.91 to 1.07) 1.05 (0.94 to 1.18) 0.99 (0.91 to 1.08)
Intensive neonatal care 0.94 (0.77 to 1.13) 0.99 (0.87 to 1.12) 0.97 (0.83 to 1.13) 0.98 (0.86 to 1.12)
a These analyses exclude women who had a C-section, therefore n= 7526.
Models adjusted for gestational age at OGTT, presence or absence of family history of diabetes, family history of
hypertension, previous GDM, previous macrosomia, smoking status, alcohol during pregnancy, mother’s age and mother’s
BMI, mothers education, ethnicity, baby gender, parity. BW of > 90th percentile, sum of skinfolds of > 90th percentile and
preterm delivery additionally adjusted for squared BMI. Shoulder dystocia models not adjusted for previous GDM due to
small numbers.
TABLE 54 Confounder adjusted associations of maternal fasting and 2-hour post-load glucose with secondary outcomes
(continued )
Outcome by 2-hour
post-load glucose categorya
and per 1 SD
All women (N= 9509) WB (n= 3888) SA (n= 4821)
p-interactionbOR 95% CI OR 95% CI OR 95% CI
4 0.90 0.62 to 1.33 0.83 0.44 to 1.59 0.87 0.51 to 1.46
5 0.83 0.55 to 1.24 0.85 0.44 to 1.66 0.87 0.51 to 1.49
6 0.52 0.24 to 1.15 1.03 0.36 to 2.93 0.35 0.11 to 1.17
7 1.44 0.73 to 2.86 1.27 0.37 to 4.40 1.42 0.58 to 3.48
Per 1 SD 0.97 0.88 to 1.08 0.97 0.84 to 1.13 0.99 0.86 to 1.15
a Glucose categories are defined as follows: FPG level – category 1, < 4.3 mmol/l; category 2, 4.3–4.4 mmol/l; category 3,
4.5–4.7 mmol/l; category 4, 4.8–4.9 mmol/l; category 5, 5.0–5.2 mmol/l; category 6, 5.3–5.6 mmol/l; category 7,
5.7–6.0 mmol/l. Post-load plasma glucose level–category 1, < 4.7 mmol/l; category 2, 4.7–5.4 mmol/l; category 3,
5.5–6.2 mmol/l; category 4, 6.3–6.6 mmol/l; category 5, 6.7–7.2 mmol/l; category 6, 7.3–7.5 mmol/l; category 7,
7.6–7.7 mmol/l.
b Testing the null hypothesis that the associations of glucose categories with outcome do not differ between WB and
SA women.
c Vaginal births only (n= 7541).
Models adjusted for gestational age at OGTT, presence or absence of family history of diabetes, family history of
hypertension, previous GDM, previous macrosomia, smoking status, alcohol during pregnancy, mother’s age and mother’s
BMI, mother’s education, baby gender and parity. Models for all women additionally adjusted for ethnicity. Models for SA
women not adjusted for alcohol during pregnancy. BW of > 90th percentile, sum of skinfolds > 90th percentile and
preterm delivery additionally adjusted for squared BMI. Shoulder dystocia models not adjusted for previous GDM due to
small numbers.
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TABLE 58 Unadjusted and confounder adjusted ORs (95% CI) for associations between maternal fasting and
post-load glucose levels and primary outcomes for Pakistani women only (N = 4201)
Outcome by fasting glucose
categorya and per 1 SD
Unadjusted Confounder adjusted
OR 95% CI OR 95% CI
Primary outcomes
BW of > 90th centile
1 reference 1.00 – 1.00 –
2 1.35 0.75 to 2.41 1.31 0.71 to 2.41
3 1.45 0.85 to 2.46 1.22 0.69 to 2.14
4 1.86 1.01 to 3.45 1.26 0.65 to 2.43
5 3.71 2.12 to 6.49 2.45 1.34 to 4.46
6 6.59 3.53 to 12.31 3.82 1.89 to 7.70
7 6.68 2.72 to 16.42 3.77 1.47 to 9.66
Per 1 SD fasting glucose 1.70 1.48 to 1.96 1.45 1.24 to 1.70
Sum of skinfolds of > 90th centile
1 reference 1.00 – 1.00 –
2 1.36 0.96 to 1.93 1.31 0.92 to 1.88
3 1.78 1.30 to 2.45 1.60 1.15 to 2.22
4 2.09 1.43 to 3.04 1.76 1.19 to 2.59
5 2.60 1.78 to 3.80 2.05 1.38 to 3.05
6 4.07 2.54 to 6.53 3.02 1.85 to 4.92
7 4.21 1.97 to 8.99 2.90 1.29 to 6.51
Per 1 SD fasting glucose 1.45 1.31 to 1.60 1.33 1.19 to 1.48
Caesarean delivery
1 reference 1.00 – 1.00 –
2 1.05 0.83 to 1.34 0.99 0.78 to 1.27
3 1.30 1.04 to 1.63 1.17 0.93 to 1.47
4 1.59 1.22 to 2.07 1.37 1.04 to 1.81
5 1.46 1.09 to 1.95 1.22 0.90 to 1.65
6 1.28 0.83 to 1.95 1.01 0.64 to 1.60
7 3.23 1.77 to 5.90 2.64 1.39 to 5.04
Per 1 SD fasting glucose 1.18 1.10 to 1.28 1.11 1.02 to 1.21
Outcome by 2-hour post-load glucose categorya and per 1 SD
BW of > 90th centile
1 reference 1.00 – 1.00 –
2 1.25 0.71 to 2.20 1.11 0.62 to 1.96
3 1.59 0.92 to 2.74 1.21 0.70 to 2.12
4 2.44 1.30 to 4.58 1.64 0.83 to 3.22
5 3.22 1.76 to 5.91 2.25 1.18 to 4.30
6 2.40 0.99 to 5.83 1.77 0.69 to 4.54
7 2.93 1.06 to 8.08 1.97 0.63 to 6.11
Per 1 SD fasting glucose 1.48 1.25 to 1.75 1.30 1.08 to 1.58
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TABLE 58 Unadjusted and confounder adjusted ORs (95% CI) for associations between maternal fasting and
post-load glucose levels and primary outcomes for Pakistani women only (N= 4201) (continued )
Outcome by fasting glucose
categorya and per 1 SD
Unadjusted Confounder adjusted
OR 95% CI OR 95% CI
Sum of skinfolds > 90th centile
1 reference 1.00 – 1.00 –
2 0.99 0.69 to 1.41 0.94 0.65 to 1.34
3 1.60 1.16 to 2.23 1.45 1.04 to 2.01
4 2.34 1.60 to 3.43 1.96 1.32 to 2.90
5 2.58 1.77 to 3.76 2.21 1.50 to 3.27
6 2.40 1.37 to 4.22 2.03 1.14 to 3.61
7 3.24 1.70 to 6.16 2.64 1.35 to 5.14
Per 1 SD fasting glucose 1.45 1.30 to 1.62 1.36 1.21 to 1.53
Caesarean delivery
1 reference 1.00 – 1.00 –
2 1.22 0.96 to 1.54 1.16 0.91 to 1.48
3 1.19 0.94 to 1.51 1.07 0.84 to 1.37
4 1.55 1.15 to 2.09 1.31 0.95 to 1.79
5 1.26 0.92 to 1.72 1.04 0.75 to 1.45
6 1.66 1.07 to 2.59 1.41 0.88 to 2.26
7 1.50 0.85 to 2.65 1.15 0.63 to 2.10
Per 1 SD fasting glucose 1.13 1.04 to 1.23 1.06 0.97 to 1.15
a Glucose categories are defined as follows: FPG level – category 1, < 4.3 mmol/l; category 2, 4.3–4.4 mmol/l; category 3,
4.5–4.7mmol/l; category 4, 4.8–4.9mmol/l; category 5, 5.0–5.2mmol/l; category 6, 5.3–5.6mmol/l; category 7, 5.7–6.0mmol/l.
Post-load plasma glucose level – category 1, < 4.7 mmol/l; category 2, 4.7–5.4 mmol/l; category 3, 5.5–6.2 mmol/l;
category 4, 6.3–6.6 mmol/l; category 5, 6.7–7.2 mmol/l; category 6, 7.3–7.5 mmol/l; category 7, 7.6–7.7 mmol/l.
Models adjusted for gestational age at OGTT, presence or absence of family history of diabetes, previous GDM, previous
macrosomia, smoking status, mother’s age and mother’s BMI, mother’s education, baby gender and parity. BW of > 90th
percentile, sum of skinfolds of > 90th percentile and preterm delivery additionally adjusted for squared BMI. Shoulder
dystocia models not adjusted for previous GDM due to small numbers.
TABLE 59 Unadjusted and confounder adjusted ORs (95% CI) for associations between maternal fasting and
post-load glucose levels and secondary outcomes for Pakistani women only (N = 4201)
Outcome by fasting glucose
categorya and per 1 SD
Unadjusted Confounder adjusted
OR 95% CI OR 95% CI
Primary outcomes
Pre-eclampsia
1 reference 1.00 – 1.00 –
2 1.41 0.78 to 2.55 1.31 0.72 to 2.41
3 1.24 0.70 to 2.19 1.06 0.58 to 1.92
4 1.57 0.81 to 3.04 1.25 0.62 to 2.52
5 1.48 0.71 to 3.11 1.18 0.53 to 2.63
6 1.40 0.48 to 4.08 0.99 0.34 to 2.89
7 3.86 1.30 to 11.51 2.70 0.78 to 9.38
Per 1 SD fasting glucose 1.16 0.96 to 1.41 1.06 0.86 to 1.29
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TABLE 59 Unadjusted and confounder adjusted ORs (95% CI) for associations between maternal fasting and
post-load glucose levels and secondary outcomes for Pakistani women only (N = 4201) (continued )
Outcome by fasting glucose
categorya and per 1 SD
Unadjusted Confounder adjusted
OR 95% CI OR 95% CI
Premature delivery
1 reference 1.00 – 1.00 –
2 1.01 0.66 to 1.53 1.01 0.66 to 1.54
3 1.04 0.70 to 1.54 1.09 0.73 to 1.62
4 0.70 0.39 to 1.24 0.72 0.40 to 1.29
5 1.18 0.70 to 1.99 1.25 0.73 to 2.14
6 0.67 0.26 to 1.70 0.72 0.27 to 1.93
7 2.52 1.03 to 6.18 2.74 1.08 to 6.97
Per 1 SD fasting glucose 0.98 0.84 to 1.15 1.00 0.85 to 1.18
Shoulder dystociab
1 reference 1.00 – 1.00 –
2 1.13 0.48 to 2.67 1.16 0.49 to 2.78
3 0.66 0.26 to 1.72 0.69 0.26 to 1.85
4 1.33 0.49 to 3.60 1.31 0.47 to 3.61
5 1.08 0.34 to 3.43 1.04 0.33 to 3.27
6 1.29 0.28 to 5.89 1.06 0.22 to 5.21
7 5.05 1.07 to 23.74 4.44 0.86 to 22.82
Per 1 SD fasting glucose 1.17 0.85 to 1.62 1.14 0.82 to 1.58
Instrumental vaginal deliveryb
1 reference 1.00 – 1.00 –
2 0.95 0.68 to 1.31 0.99 0.70 to 1.40
3 1.03 0.75 to 1.40 1.11 0.79 to 1.55
4 1.15 0.78 to 1.69 1.33 0.87 to 2.03
5 1.03 0.67 to 1.58 1.25 0.78 to 2.01
6 1.29 0.73 to 2.28 1.77 0.93 to 3.37
7 1.55 0.58 to 4.11 2.45 0.78 to 7.74
Per 1 SD fasting glucose 1.05 0.94 to 1.18 1.14 1.00 to 1.30
Intensive neonatal care
1 reference 1.00 – 1.00 –
2 0.87 0.55 to 1.38 0.87 0.55 to 1.39
3 1.09 0.73 to 1.64 1.13 0.76 to 1.69
4 1.24 0.75 to 2.05 1.29 0.77 to 2.15
5 1.45 0.86 to 2.43 1.52 0.90 to 2.57
6 1.06 0.47 to 2.39 1.11 0.47 to 2.59
7 1.33 0.40 to 4.42 1.38 0.41 to 4.63
Per 1 SD fasting glucose 1.06 0.91 to 1.24 1.07 0.92 to 1.26
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TABLE 59 Unadjusted and confounder adjusted ORs (95% CI) for associations between maternal fasting and
post-load glucose levels and secondary outcomes for Pakistani women only (N = 4201) (continued )
Outcomes by 2-hour post-load
glucose categorya and by 1 SD
Unadjusted Confounder adjusted
OR 95% CI OR 95% CI
Secondary outcomes
Pre-eclampsia
1 reference 1.00 – 1.00 –
2 0.87 0.49 to 1.53 0.75 0.42 to 1.34
3 0.97 0.55 to 1.71 0.79 0.44 to 1.43
4 1.15 0.57 to 2.35 0.77 0.36 to 1.62
5 1.10 0.52 to 2.33 0.78 0.35 to 1.71
6 0.93 0.27 to 3.16 0.64 0.18 to 2.25
7 2.08 0.70 to 6.19 1.63 0.53 to 4.99
Per 1 SD fasting glucose 1.13 0.92 to 1.38 1.00 0.81 to 1.24
Premature delivery
1 reference 1.00 – 1.00 –
2 1.07 0.70 to 1.62 1.05 0.69 to 1.60
3 1.03 0.67 to 1.58 1.01 0.65 to 1.56
4 1.19 0.68 to 2.07 1.17 0.67 to 2.06
5 0.89 0.48 to 1.64 0.91 0.49 to 1.67
6 1.61 0.76 to 3.42 1.64 0.76 to 3.53
7 –
Per 1 SD fasting glucose 1.00 0.86 to 1.15 1.00 0.86 to 1.17
Shoulder dystociab
1 reference 1.00 – 1.00 –
2 1.24 0.40 to 3.80 1.12 0.36 to 3.46
3 2.39 0.86 to 6.68 2.29 0.79 to 6.65
4 2.07 0.55 to 7.75 2.01 0.50 to 8.04
5 3.53 1.11 to 11.22 3.45 1.04 to 11.51
6 3.13 0.60 to 16.36 3.05 0.59 to 15.73
7 5.23 0.99 to 27.58 6.18 1.09 to 34.96
Per 1 SD fasting glucose 1.58 1.14 to 2.20 1.63 1.14 to 2.34
Instrumental vaginal deliveryb
1 reference 1.00 – 1.00 –
2 0.81 0.58 to 1.12 0.79 0.56 to 1.12
3 1.02 0.74 to 1.40 1.08 0.76 to 1.52
4 1.32 0.87 to 2.00 1.56 0.99 to 2.47
5 1.05 0.68 to 1.62 1.07 0.67 to 1.73
6 1.37 0.73 to 2.57 1.82 0.94 to 3.52
7 1.81 0.88 to 3.71 1.93 0.87 to 4.26
Per 1 SD fasting glucose 1.10 0.98 to 1.24 1.16 1.02 to 1.32
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TABLE 59 Unadjusted and confounder adjusted ORs (95% CI) for associations between maternal fasting and
post-load glucose levels and secondary outcomes for Pakistani women only (N = 4201) (continued )
Outcomes by 2-hour post-load
glucose categorya and by 1 SD
Unadjusted Confounder adjusted
OR 95% CI OR 95% CI
Intensive neonatal care
1 reference 1.00 – 1.00 –
2 0.79 0.52 to 1.19 0.77 0.50 to 1.17
3 0.78 0.51 to 1.19 0.76 0.50 to 1.16
4 0.90 0.51 to 1.57 0.88 0.50 to 1.54
5 0.80 0.45 to 1.44 0.79 0.44 to 1.41
6 0.43 0.13 to 1.41 0.43 0.13 to 1.42
7 1.27 0.49 to 3.30 1.28 0.49 to 3.36
Per 1 SD fasting glucose 0.99 0.85 to 1.15 0.98 0.85 to 1.15
a Glucose categories are defined as follows: FPG level – category 1, < 4.3 mmol/l; category 2, 4.3–4.4 mmol/l; category 3,
4.5–4.7 mmol/l; category 4, 4.8–4.9 mmol/l; category 5, 5.0–5.2 mmol/l; category 6, 5.3–5.6 mmol/l; category 7,
5.7–6.0 mmol/l. Post-load plasma glucose level – category 1, < 4.7 mmol/l; category 2, 4.7–5.4 mmol/l; category 3,
5.5–6.2 mmol/l; category 4, 6.3–6.6 mmol/l; category 5, 6.7–7.2 mmol/l; category 6, 7.3–7.5 mmol/l; category 7,
7.6–7.7 mmol/l.
b These analyses exclude women who had a C-section, therefore n= 3420.
Models adjusted for gestational age at OGTT, presence or absence of family history of diabetes, previous GDM, previous
macrosomia, smoking status, mother’s age and mother’s BMI, mother’s education, baby gender and parity. BW of > 90th
percentile, sum of skinfolds > 90th percentile and preterm delivery additionally adjusted for squared BMI. Shoulder dystocia
models not adjusted for previous GDM because of small numbers.
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FIGURE 45 Frequency of secondary outcomes across glucose categories by ethnicity: WB, n= 3888; and SA, n= 4821.
(a) Pre-eclampsia; (b) premature delivery; (c) shoulder dystocia; (d) instrumental vaginal delivery; and (e) admission
to neonatal unit. Glucose categories are defined as follows: FPG level – category 1, < 4.3mmol/l; category 2,
4.3–4.4mmol/l; category 3, 4.5–4.7 mmol/l; category 4, 4.8–4.9mmol/l; category 5, 5.0–5.2mmol/l; category 6,
5.3–5.6mmol/l; category 7, 5.7–6.0 mmol/l. Post-load plasma glucose level – category 1, < 4.7 mmol/l; category 2,
4.7–5.4mmol/l; category 3, 5.5–6.2 mmol/l; category 4, 6.3–6.6mmol/l; category 5, 6.7–7.2mmol/l; category 6,
7.3–7.5mmol/l; category 7, 7.6–7.7 mmol/l. For plots of shoulder dystocia and instrumental vaginal delivery, women
who had a C-section are excluded, therefore n= 3018 for WB and n= 3914 for SA. (continued )
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FIGURE 45 Frequency of secondary outcomes across glucose categories by ethnicity: WB, n= 3888; and SA, n= 4821.
(a) Pre-eclampsia; (b) premature delivery; (c) shoulder dystocia; (d) instrumental vaginal delivery; and (e) admission
to neonatal unit. Glucose categories are defined as follows: FPG level – category 1, < 4.3mmol/l; category 2,
4.3–4.4mmol/l; category 3, 4.5–4.7mmol/l; category 4, 4.8–4.9mmol/l; category 5, 5.0–5.2mmol/l; category 6,
5.3–5.6mmol/l; category 7, 5.7–6.0mmol/l. Post-load plasma glucose level – category 1, < 4.7 mmol/l; category 2,
4.7–5.4mmol/l; category 3, 5.5–6.2mmol/l; category 4, 6.3–6.6mmol/l; category 5, 6.7–7.2mmol/l; category 6,
7.3–7.5mmol/l; category 7, 7.6–7.7mmol/l. For plots of shoulder dystocia and instrumental vaginal delivery, women
who had a C-section are excluded, therefore n= 3018 for WB and n= 3914 for SA.
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
203
1
0
2
6
4
10
8
2 3 4 5 6 7
Glucose category
Fr
eq
u
en
cy
 (
%
)
(a)
Fasting glucose
Post-load glucose
1
0
10
5
15
2 3 4 5 6 7
Glucose category
Fr
eq
u
en
cy
 (
%
)
(b)
Fasting glucose
Post-load glucose
1
0
1
3
2
5
4
2 3 4 5 6 7
Glucose category
Fr
eq
u
en
cy
 (
%
)
(c)
Fasting glucose
Post-load glucose
FIGURE 46 Frequency of secondary outcomes across glucose categories for all pregnancies (N= 9509). (a) Pre-eclampsia;
(b) premature delivery; (c) shoulder dystocia; (d) instrumental vaginal delivery; and (e) admission to neonatal unit.
Vaginal births only for shoulder dystocia and instrumental delivery. Glucose categories are defined as follows: FPG
level–category 1, < 4.3mmol/l; category 2, 4.3–4.4mmol/l; category 3, 4.5–4.7mmol/l; category 4, 4.8–4.9mmol/l;
category 5, 5.0–5.2mmol/l; category 6, 5.3–5.6mmol/l; category 7, 5.7–6.0mmol/l. Post-load plasma glucose
level–category 1, < 4.7mmol/l; category 2, 4.7–5.4mmol/l; category 3, 5.5–6.2mmol/l; category 4, 6.3–6.6mmol/l;
category 5, 6.7–7.2mmol/l; category 6, 7.3–7.5mmol/l; category 7, 7.6–7.7mmol/l. For plots of shoulder dystocia and
instrumental vaginal delivery, women who had a C-section are excluded, therefore n= 3018 for WB and n= 3914
for SA. (continued )
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FIGURE 46 Frequency of secondary outcomes across glucose categories for all pregnancies (N= 9509). (a) Pre-eclampsia;
(b) premature delivery; (c) shoulder dystocia; (d) instrumental vaginal delivery; and (e) admission to neonatal unit.
Vaginal births only for shoulder dystocia and instrumental delivery. Glucose categories are defined as follows: FPG
level–category 1, < 4.3mmol/l; category 2, 4.3–4.4mmol/l; category 3, 4.5–4.7mmol/l; category 4, 4.8–4.9mmol/l;
category 5, 5.0–5.2mmol/l; category 6, 5.3–5.6mmol/l; category 7, 5.7–6.0mmol/l. Post-load plasma glucose
level–category 1, < 4.7mmol/l; category 2, 4.7–5.4mmol/l; category 3, 5.5–6.2mmol/l; category 4, 6.3–6.6mmol/l;
category 5, 6.7–7.2mmol/l; category 6, 7.3–7.5mmol/l; category 7, 7.6–7.7mmol/l. For plots of shoulder dystocia and
instrumental vaginal delivery, women who had a C-section are excluded, therefore n= 3018 for WB and n= 3914
for SA.
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Appendix 2 Tables and figures for Chapter 3
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TABLE 61 Analysis testing for linearity of association between glucose levels and outcomes
Outcomea No. of studies Log OR of glucose squared 95% CI p-value
Fasting 75-g OGTT
C-section 6 –0.115 –0.25 to 0.02 0.1
Induction 3 –0.197 –0.52 to 0.13 0.23
Instrumental birth 3 0.107 –0.21 to 0.42 0.5
LGA 7 –0.02 –0.16 to 0.12 0.77
Macrosomia 6 –0.18 –0.39 to 0.03 0.09
Neonatal hypoglycaemia 2 0.29 0.05 to 0.53 0.02
PIH/pre-eclampsia 3 0.461 0.03 to 0.9 0.04
Pre-eclampsia 4 –0.005 –0.28 to 0.27 0.97
Preterm birth 3 0.577 0.09 to 1.07 0.02
Shoulder dystocia 4 –0.142 –1.06 to 0.78 0.76
2-hour 75-g OGTT
C-section 9 –0.016 –0.03 to 0.00 0.06
Induction 3 0.006 –0.04 to 0.05 0.81
Instrumental birth 4 –0.01 –0.05 to 0.03 0.65
LGA 11 0.004 –0.01 to 0.02 0.67
Macrosomia 7 0.006 –0.03 to 0.05 0.77
Neonatal hypoglycaemia 3 0.002 –0.02 to 0.03 0.91
PIH/pre-eclampsia 3 0.02 –0.07 to 0.11 0.67
Pre-eclampsia 4 –0.026 –0.05 to 0.00 0.05
Preterm birth 6 0.009 –0.05 to 0.07 0.78
Shoulder dystocia 5 –0.067 –0.19 to 0.06 0.29
50-g OGCT
C-section 7 –0.029 –0.07 to 0.01 0.18
Instrumental birth 2 –0.008 –0.08 to 0.07 0.84
LGA 4 –0.044 –0.1 to 0.01 0.11
Macrosomia 7 –0.004 –0.02 to 0.02 0.69
Neonatal hypoglycaemia 3 0.047 –0.18 to 0.27 0.68
Pre-eclampsia 6 –0.082 –0.15 to –0.02 0.01
Preterm birth 2 0.021 –0.05 to 0.09 0.55
Shoulder dystocia 2 –0.113 –0.25 to 0.03 0.12
a The outcomes highlighted in bold represent statistically significant results.
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TABLE 62 Chapter 3: excluded studies
Article Reason for exclusion
1 Abdel-Wareth LO, Kumari AS, Haq A, Bakir A, Sainudeen A,
Sedaghatian MR, et al. An evaluation of the latest ADA criteria
for screening and diagnosing gestational diabetes at a tertiary
care hospital in the United Arab Emirates. Int J Diabetes Metab
2006;14:55–60
Results by diagnostic criteria not by glucose levels
2 Abell DA, Beischer NA, Wood C. Routine testing for gestational
diabetes, pregnancy hypoglycemia and fetal growth
retardation, and results of treatment. J Perinatal Med
1976;4:197–212
Comparison of women with GDM and diabetes
prior to commencement of pregnancy. Treatment
was administered including admission to hospital,
dietary control and insulin therapy
3 Abell DA. The significance of abnormal glucose tolerance in
pregnancy. Aust N Z J Obstet Gynaecol 1978;18:17–20
Glucose levels were analysed in three different
groups; hypoglycaemia, normoglycaemia, and
hyperglycaemia. Glucose levels are poorly defined
4 Abell DA. The significance of abnormal glucose tolerance
(hyperglycaemia and hypoglycaemia) in pregnancy. Br J Obstet
Gynaecol 1979;86:214–21
Glucose levels were analysed in three different
groups; hypoglycaemia, normoglycaemia, and
hyperglycaemia. Glucose levels are poorly defined
5 Anazawa S, Kitamura S, Matsuoka K. Diabetologic and
obstetric analysis of abnormal glucose tolerance during
pregnancy. [Japanese]. J Japan Diabetes Soc 1985;28:747–53
Not in English
6 Anderberg E, Kallen K, Berntorp K. The impact of gestational
diabetes mellitus on pregnancy outcome comparing different
cut-off criteria for abnormal glucose tolerance. Acta Obstet
Gynecol Scand 2010;89:1532–7
Only one group without GDM, comparison of
women with GDM with women without GDM
7 Anthony R, Ikomi A, Khan R, Angala P, Kiss S. Clinical
outcomes in pregnant women newly reclassified as gestational
diabetes (GDM) using IADPSG criteria. 16th Annual
Conference of the British Maternal and Fetal Medicine Society;
April; Dublin, Ireland: Archives of Disease in Childhood: Fetal
and Neonatal Edition; 2013
Conference abstract: no relevant data
8 Atia HC, Koren Y, Weintraub AY, Novack L, Sheiner E. Is a
value of over 200mg/dL in the oral glucose tolerance test,
a marker of severity in patients with gestational diabetes
mellitus? J Matern Fetal Neonatal Med 2013;26:1259–62
Comparison of women with GDM with at least
one value over 200 mg/dl in the glucose tolerance
test and those women with GDM without any
value 200 mg/dl
Treatment consisted of diet control
9 Basu A, Bhatti N, Lee BC. Pregnancy outcome in women with
gestational diabetes: results of a four-year audit. Practical
Diabetes 2012;29:237–42
Treatment study
10 Basu A, Parghi S. Pregnancy outcome in women with
pregestational diabetes mellitus at a district general hospital in
Australia. Practical Diabetes 2012;29:372–7
Treatment study
11 Black MH, Sacks DA, Li X, Lawrence JM. Examining the
thresholds for diagnosing gestational diabetes mellitus (GDM):
How many adverse outcomes will be missed? Diabetes
2014;63:A361
Conference abstract: no relevant data
12 Breschi MC, Seghieri G, Bartolomei G, Gironi A, Baldi S,
Ferrannini E. Relation of birthweight to maternal plasma
glucose and insulin concentrations during normal pregnancy.
Diabetologia 1993;36:1315–21
Study does not present the relation between any
relevant adverse outcomes and categorical or
continuous glucose levels
Study represents a BW regression analysis only
13 Bush NC, Chandler-Laney PC, Rouse DJ, Granger WM,
Oster RA, Gower BA. Higher maternal gestational glucose
concentration is associated with lower offspring insulin
sensitivity and altered beta-cell function. J Clin Endocrinol
Metab 2011;96:E803–9
No relevant outcomes
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TABLE 62 Chapter 3: excluded studies (continued )
Article Reason for exclusion
14 Bunt JC, Tataranni PA, Salbe AD. Intrauterine exposure to
diabetes is a determinant of hemoglobin A1c and systolic
blood pressure in pima Indian children. J Clin Endocrinol Metab
2005;90:3225–9
Results not presented by glucose level and no
relevant outcomes
15 Damm P, Kühl C, Bertelsen A, Mølsted-Pedersen L. Predictive
factors for the development of diabetes in women with
previous gestational diabetes mellitus. Am J Obstet Gynecol
1992;167:607–16
Comparison of women with GDM and controls
Women with GDM were treated with diet alone,
oral hypoglycaemic agents or insulin therapy
Study also does not present categorical or
continuous glucose levels
16 Darling AM, Liu E, Aboud S, Urassa W, Spiegelman D,
Fawzi W. Maternal hyperglycemia and adverse pregnancy
outcomes in Dar es Salaam, Tanzania. Int J Gynecol Obstet
2014;125:22–7
Ineligible glucose test (RFG, repeat fasting glucose)
17 Di Cianni G, Lencioni C, Volpe L, Ghio A, Cuccuru I, Pellegrini G,
et al. C-reactive protein and metabolic syndrome in women
with previous gestational diabetes. Diabetes Metab Res Rev
2007;23:135–40
Comparison of women with GDM and controls
18 Dodd JM, Crowther CA, Antoniou G, Baghurst P, Robinson JS.
Screening for gestational diabetes: the effect of varying blood
glucose definitions in the prediction of adverse maternal
and infant health outcomes. Aust N Z J Obstet Gynaecol
2007;47:307–13
Glucose levels were analysed in three different
groups, control, mild GDM and GDM
A treatment package of dietary modification,
blood glucose monitoring and insulin therapy were
offered to those with mild GDM or GDM
19 Dong L, Liu E, Guo J, Pan L, Li B, Leng J, et al. Relationship
between maternal fasting glucose levels at 4-12 gestational
weeks and offspring growth and development in early infancy.
Diabetes Res Clin Pract 2013;102:210–7
Ineligible glucose test (FPG at 4–12 weeks)
20 Farmer G, Russell G, Hamilton-Nicol DR, Ogenbede HO,
Ross IS, Pearson DW, et al. The influence of maternal glucose
metabolism on fetal growth, development and outcome in 917
singleton pregnancies in nondiabetic women. Diabetologia
1988;31:134–41
Results not presented in glucose categories.
Presented by the following categories; summed
plasma glucose, insulin response, FPG and indices
of glucose disposal
21 Godbout A, Chastang N, Laubies A, Golmard JL,
Vauthier-Brouzes D, Jacqueminet S, et al. Gestational diabetes:
increasing therapeutic glucose level in pregnant women
without risk factors of fetal overweight. 70th Scientific Sessions
of the American Diabetes Association; 2010; Orlando, FL, USA:
Diabetes
Conference abstract: ineligible glucose test
(FBG, PPBG)
22 Godwin M, Muirhead M, Huynh J, Helt B, Grimmer J.
Prevalence of gestational diabetes mellitus among Swampy
Cree women in Moose Factory, James Bay. CMAJ
1999;16:1299–302
Comparison of women with and without GDM
only
23 Gui J, Li A, Su X, Feng L. Association between hyperglycemia
in middle and late pregnancy and maternal-fetal outcomes:
a retrospective study. BMC Pregnancy Childbirth 2014;14:34
All women had GDM or DM, and a large
proportion of women in each group received
treatment
24 Heerey AM, Carmody L, Kirwan B, Dunne FP, Egan M.
ATLANTIC DIP: Are the IADPSG criteria for GDM missing
women who would previously have been identified with GDM
using WHO criteria? Diabetes 2013;62:A376–7
Conference abstract
Only one non-GDM group reported
25 Herman G, Raimondi B. Glucose tolerance, fetal growth, and
pregnancy complications in normal women. Am J Perinatol
1988;5:168–71
Only one non-GDM group reported (by current
definition)
continued
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
213
TABLE 62 Chapter 3: excluded studies (continued )
Article Reason for exclusion
26 Herrera K, Brustman L, Foroutan J, Suffecool K, Scarpelli S,
Rosenn B. Does the number of abnormal values on the one
step 2 hour (GTT) correlate with the severity of gestational
diabetes? Reproductive Sci 2013;1:246A
Conference abstract
Examines outcomes by timing of glucose
abnormality
27 Heude B, Thiébaugeorges O, Goua V, Forhan A, Kaminski M,
Foliguet B, et al. Pre-pregnancy body mass index and weight
gain during pregnancy: relations with gestational diabetes and
hypertension, and birth outcomes. Maternal Child Health J
2012;16:355–64
No results by glucose category, no relevant
outcomes by glucose levels
28 Hill JC, Krishnaveni GV, Annamma I, Leary SD, Fall CH. Glucose
tolerance in pregnancy in South India: relationships to neonatal
anthropometry. Acta Obstet Gynecol Scand 2005;84:159–65
Comparison of women with and without GDM
only
29 Hiramatsu Y, Masuyama H, Mizutani Y, Kudo T, Oguni N,
Oguni Y. Heavy-for-date infants: their backgrounds and
relationship with gestational diabetes. J Obstet Gynaecol Res
2000;26:193–8
Study does not present the relation between any
relevant adverse outcomes and categorical or
continuous glucose levels
Study represents a BW graphical correlation
analysis
30 Jensen DM, Damm P, Sørensen B, Mølsted-Pedersen L,
Westergaard JG, Korsholm L, et al. Proposed diagnostic
thresholds for gestational diabetes mellitus according to a 75-g
oral glucose tolerance test. Maternal and perinatal outcomes in
3260 Danish women. Diabet Med 2003;20:51–7
Duplicate cohort of Jensen 200171 but without
more limited data presentation
31 Kaufmann RC, McBride P, Amankwah KS, Huffman DG. The
effect of minor degrees of glucose intolerance on the incidence
of neonatal macrosomia. Obstet Gynecol 1992;80:97–101
Comparison of women with and without GDM,
women with GDM are likely to have been treated
The glucose levels in the control group are not
reported
32 Kaymak O, Iskender CT, Ustunyurt E, Yildiz Y, Doganay M,
Danisman N. Retrospective evaluation of perinatal outcome in
women with mild gestational hyperglycemia. J Obstet Gynaecol
Res 2011;37:986–91
The number of untreated groups is unclear
It appears that there is only one group without
GDM
33 Khan MS, Kinsley BT, Daly S, McCarthy A. Increased
birthweight and shoulder dystocia with fasting plasma
glucose (FPG) levels between 5.1 and 5.7 mmol/l in screening
for gestational diabetes mellitus (GDM). Ir J Med Sci
2011;180:S507
Abstract only
Comparison of GDM definitions
34 Kim S, Min WK, Chun S, Lee W, Chung HJ, Lee PR, et al.
Quantitative risk estimation for large for gestational age using
the area under the 100-g oral glucose tolerance test curve.
J Clin Lab Analysis 2009;23:231–7
No results by glucose category
35 Korucuoglu U, Biri A, Turkyilmaz E, Doga Yildirim F, Ilhan M,
et al. Glycemic levels with glucose loading test during
pregnancy and its association with maternal and perinatal
outcomes. Diabetes Res Clin Pract 2008;80:69–74
GDM in groups 2, 3, 4 and 5 possible
36 Langhoff-Roos J, Wibell L, Gebre-Medhin M, Lindmark G.
Maternal glucose metabolism and infant birthweight: a study
in healthy pregnant women. Diabetes Res 1988;8:165–70
Used an intravenous glucose test
37 Lapolla A, Dalfra M, Ragazzi E, De Cata A, Masin M,
Bonsembiante B, et al. Analysis of pregnancies after new
IADPSG recommendation. Diabetologia 2010;53:S9–10
Conference abstract for 38
38 Lapolla A, Dalfra MG, Ragazzi E, De Cata AP, Fedele D. New
International Association of the Diabetes and Pregnancy Study
Groups (IADPSG) recommendations for diagnosing gestational
diabetes compared with former criteria. retrospective study on
pregnancy outcome. Diabet Med 2011;28:1074–7
Only one non-GDM group reported
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TABLE 62 Chapter 3: excluded studies (continued )
Article Reason for exclusion
39 Lauszus FF, Paludan J, Klebe JG. Birthweight in women with
potential gestational diabetes mellitus: an effect of obesity
rather than glucose intolerance? Acta Obstet Gynecol Scand
1999;78:520–5
Two groups glucose levels not defined, results not
presented by glucose levels
40 Leikin EL, Jenkins JH, Pomerantz GA, Klein L. Abnormal glucose
screening tests in pregnancy: a risk factor for fetal macrosomia.
Obstet Gynecol 1987;69:570–3
Women with abnormal glucose screening tests
and either one or no abnormal values on their
glucose tolerance test were compared to women
with normal glucose screening tests
41 Leung TW, Lao TT. Placental size and large-for-gestational-age
infants in women with abnormal glucose tolerance in
pregnancy. Diabet Med 2000;17:48–52
No results by glucose category, results by LGA,
AGA and SGA
42 Liao S, Mei J, Song W, Liu Y, Tan YD, Chi S, et al. The impact
of the International Association of Diabetes and Pregnancy
Study Groups (IADPSG) fasting glucose diagnostic criterion on
the prevalence and outcomes of gestational diabetes mellitus
in Han Chinese women. Diabet Med 2014;31:341–51
Compares different diagnostic criteria, groups
diagnosed with GDM
43 Lin CH, Wen SF, Wu YH, Huang MJ. Using the 100-g oral
glucose tolerance test to predict fetal and maternal outcomes
in women with gestational diabetes mellitus. Chang Gung
Med J 2009;32:283–9
Comparison of women with GDM and controls
Women with GDM were given medical nutrition
counselling, monitoring of blood glucose and, in
some cases, insulin therapy
44 Liu J, Leng J, Tang C, Liu G, Hay J, Wang J, et al. Maternal
glucose level and body mass index measured at gestational
diabetes mellitus screening and the risk of macrosomia: results
from a perinatal cohort study. BMJ Open 2014;4:e004538
Does not exclude women with positive OGTT (and
treated), therefore the association would be biased
45 Lowe LP, Metzger BE, Dyer AR, Lowe J, McCance DR,
Lappin TR, et al. Hyperglycemia and Adverse Pregnancy
Outcome (HAPO) Study: associations of maternal A1C
and glucose with pregnancy outcomes. Diabetes Care
2012;35:574–80
Does not present results by glucose categories only
present data by maternal A1C
46 Macafee CAJ, Beischer NA, Willis MM, Wood C. The
correlation of fetal, placental and maternal weight with
glucose tolerance. Aust N Z J Obstet Gynaecol 1974;14:88–94
Study does not present categorical or continuous
glucose levels
Data presented in terms of average glucose level
according to outcome
47 Mello G, Parretti E, Mecacci F, Lucchetti R, Lagazio C,
Pratesi M, et al. Risk factors for fetal macrosomia: the
importance of a positive oral glucose challenge test. Eur J
Endocrinol 1997;137:27–33
Results not presented by glucose level or
categories
48 Mello G, Parretti E, Cioni R, Lucchetti R, Carignani L, Martini E,
et al. The 75-gram glucose load in pregnancy: relation
between glucose levels and anthropometric characteristics of
infants born to women with normal glucose metabolism.
Diabetes Care 2003;26:1206–10
Study does not present the relation between any
relevant adverse outcomes and categorical or
continuous glucose levels
Study presents complicated glucose testing with a
single OR
49 Metzger BE, Lowe LP, Dyer AR, Trimble ER, Persson B,
Oats JJN, et al. The Hyperglycemia & Adverse Pregnancy
Outcome (HAPO) Study: Perinatal Outcome In Pregnancies with
GDM and Fasting Plasma Glucose (FPG) < 4.4 mmol/l. 70th
Scientific Sessions of the American Diabetes Association
Orlando, FL, USA, 2010
Conference abstract
Only one non-GDM group reported
50 Nasrat AA, Augensen K, Abushal M, Shalhoub JT. The
outcome of pregnancy following untreated impaired glucose
tolerance. Int J Gynecol Obstet 1994;47:1–6
Only one non-GDM group (reported by current
definition)
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TABLE 62 Chapter 3: excluded studies (continued )
Article Reason for exclusion
51 Negrato CA, Jovanovic L, Tambascia MA, Calderon M,
Geloneze B, Dias A, et al. Mild gestational hyperglycaemia as a
risk factor for metabolic syndrome in pregnancy and adverse
perinatal outcomes. Diabetes Metab Res Rev 2008;24:324–31
Results not presented by glucose level, metabolic
syndrome only
52 Nobile de Santis MS, Taricco E, Radaelli T, Spada E, Rigano S,
Ferrazzi E, et al. Growth of fetal lean mass and fetal fat mass
in gestational diabetes. Ultrasound Obstet Gynecol
2010;36:328–37
Comparison of women with GDM and controls
53 Nordin NM, Wei JW, Naing NN, Symonds EM. Comparison of
maternal-fetal outcomes in gestational diabetes and lesser
degrees of glucose intolerance. J Obstet Gynaecol Res
2006;32:107–14
Comparison of women with and without GDM
plus impaired glucose
Those women with GDM/impaired glucose were
treated with insulin therapy or diet control
The glucose levels in the control group were not
reported
54 Okada T, Iwashina M, Kasatani T, Kanno H, Yoshie M,
Morikawa K, et al. Clinical outcomes of pregnancies
complicated with and treated for gestational diabetes mellitus:
Consequences of screening under the IADPSG criteria.
Diabetol Int 2013;4:186–9
Only one non-GDM group reported
55 Peters CJ, Kayemba-Kays S, Geary MPP, Hindmarsh PC. Blood
glucose in multiparous women influences offspring birth size
but not size at 2 years of age. J Clin Endocrinol Metab
2013;98:4916–22
No relevant data (only correlations)
56 Peters CJ, Kayemba-Kays S, Geary MP, Hindmarsh PC. Blood
glucose in multiparous women influences offspring birth size
but not size at 2 years of age. Diabetes 2013;62:A360
Conference abstract: no relevant data
57 Pettitt DJ, Bennett PH, Knowler WC. Gestational diabetes
mellitus and impaired glucose tolerance during pregnancy.
Long-term effects on obesity and glucose tolerance in the
offspring. Diabetes 1985;34(Suppl. 2):119–22
Duplicate cohort of Pettitt 198079 but without
more limited data presentation
58 Saleh J, Machado L, Razvi Z. 2-Hour post-load serum glucose
levels and maternal blood pressure as independent predictors
of birthweight in ‘appropriate for gestational age’ neonates in
healthy nondiabetic pregnancies. Biomed Res Int 2013:757459
Did not report on required outcomes
59 Savona-Ventura C, Chircop M. Significant thresholds for the
75-g oral glucose tolerance test in pregnancy. J Diabetes
Complications 2008;22:178–80
Comparison of women with and without GDM
plus impaired glucose
Those women with GDM/impaired glucose are
likely to have been treated
The glucose levels in the control group were not
reported
60 Stuebe A. Is there a threshold OGTT value for predicting
adverse neonatal outcome? Am J Obstet Gynecol
2011;204(Suppl. 1):216
Conference abstract: no relevant data
61 Ouzilleau C, Roy MA, Leblanc L, Carpentier A, Maheux P.
An observational study comparing 2-hour 75-g oral glucose
tolerance with fasting plasma glucose in pregnant women:
both poorly predictive of birthweight. CMAJ 2003;168:403–9
No relevant outcomes, only gives average BW
percentiles (via box-and-whisker plots)
Pregnant women received ‘minimal’ treatment
when diagnosed with GDM
62 Phillipou G. The 1-h 50-g glucose challenge does not predict
large-for-gestational-age infants. Diabet Med 1992;9:81–3
Study does not present categorical or continuous
glucose levels
Data presented in terms of average glucose level
according to BW percentile
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TABLE 62 Chapter 3: excluded studies (continued )
Article Reason for exclusion
63 Sacks DA, Abu-Fadil S, Karten GJ, Forsythe AB, Hackett JR.
Screening for gestational diabetes with the one-hour 50-g
glucose test. Obstet Gynecol 1987;70:89–93
Study of prediction of GDM
64 Sacks DA, Greenspoon JS, Abu-Fadil S, Henry HM,
Wolde-Tsadik G, Yao JF. Toward universal criteria for
gestational diabetes: the 75-gram glucose tolerance test in
pregnancy. Am J Obstet Gynecol 1995;172:607–14
Study does not present the relation between any
relevant adverse outcomes and categorical or
continuous glucose levels
Study presents ROC curves and ORs and graphical
presentation of percentage with outcome as
increasing plasma glucose levels
65 Schrader HM, Jovanovic-Peterson L, Bevier WC, Peterson CM.
Fasting plasma glucose and glycosylated plasma protein at 24
to 28 weeks of gestation predict macrosomia in the general
obstetric population. Am J Perinatol 1995;12:247–51
Study does not present the relation between any
relevant adverse outcomes and categorical or
continuous glucose levels
Study represents a BW graphical correlation
analysis
66 Verma A, Mitchell BF, Demianczuk N, Flowerdew G,
Okun NB. Relationship between plasma glucose levels in
glucose-intolerant women and newborn macrosomia. J Matern
Fetal Med 1997;6:187–93
Comparison of women with GDM and ‘GCT
positive and OGCT negative’
26% of the women with GDM were treated with
insulin therapy
Case–control study presenting data by outcome
rather than glucose category
67 Willman SP, Leveno KJ, Guzick DS, Williams ML, Whalley PJ.
Glucose threshold for macrosomia in pregnancy complicated
by diabetes. Am J Obstet Gynecol 1986;154:470–5
Study includes only diabetic women, all of whom
are treated with insulin therapy
68 Yogev Y, Visser GH. Obesity, gestational diabetes and
pregnancy outcome. Semin Fetal Neonatal Med
2009;14:77–84
Narrative review
69 Yogev, Chen, Hod, Coustan, Oats, McIntyre, Metzger, Lowe,
Dyer, Dooley, Trimble, McCance, Hadden, Persson, Rogers;
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study
Cooperative Research Group. Hyperglycemia and Adverse
Pregnancy Outcome (HAPO) study: preeclampsia. Am J Obstet
Gynecol 2010;202:255.e1–7
Comparison of women with differing severity of
GDM
The women received treatment of diet or diet and
insulin
70 Zhang C, Martin K, Bowers K, Liu A, Bao W, Vaag A, et al.
Fasting glucose levels during pregnancy and long-term
childhood growth in the offspring. Am J Obstet Gynecol
2014;1:S44
Conference abstract: no relevant data
A1C, glycated haemoglobin (a retrospective estimate of blood glucose levels); AGA, appropriate for gestational age;
FBG, fasting blood glucose; PPBG, postprandial blood glucose; SGA, small for gestational age.
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FIGURE 47 Frequency of perinatal outcomes across glucose categories in the Atlantic DIP59 and BiB22 cohorts.
(a) Fasting; and (b) post load. (continued )
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FIGURE 47 Frequency of perinatal outcomes across glucose categories in the Atlantic DIP59 and BiB22 cohorts.
(a) Fasting; and (b) post load.
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OR per 1-mmol/l increase in fasting glucose
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Cohort Effect (95% CI)
C-section
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1.30 (1.18 to 1.44)
1.26 (1.17 to 1.35)
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1.80 (1.42 to 2.30)
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2.07 (1.00 to 4.30)
1.95 (1.24 to 3.06)
1.51 (1.12 to 2.04)
1.68 (1.32 to 2.13)
FIGURE 48 Odds ratios per 1-mmol/l increase in fasting glucose and perinatal outcomes in Atlantic DIP,59 BiB22 and
HAPO cohorts. Estimates for HAPO are from publications (not from IPD).
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FIGURE 49 Odds ratios per 1-mmol/l increase in 2-hour glucose and perinatal outcomes in Atlantic DIP,59 BiB22 and
HAPO cohorts. Estimates for HAPO are from publications (not from IPD).
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FIGURE 50 Odds ratios for perinatal outcomes by increasing fasting glucose category for the Atlantic DIP59 and
BiB22 cohorts. (a) C-section; (b) instrumental birth; (c) LGA; (d) macrosomia; (e) pre-eclampsia; (f) preterm birth;
and (g) shoulder dystocia.
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FIGURE 51 Odds ratios for perinatal outcomes by increasing 2-hour post-load glucose category for the Atlantic
DIP59 and BiB22 cohorts. (a) C-section; (b) instrumental birth; (c) LGA; (d) macrosomia; (e) pre-eclampsia; (f) preterm
birth; and (g) shoulder dystocia.
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FIGURE 52 Frequency of macrosomia across glucose categories by study. (a) Fasting; (b) 1 hour; and (c) 2 hours.
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FIGURE 53 Frequency of LGA across glucose categories by study. (a) Fasting; (b) 1 hour; and (c) 2 hours.
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FIGURE 54 Frequency of pre-eclampsia across glucose categories by study. (a) Fasting; (b) 1 hour; and (c) 2 hours.
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FIGURE 55 Frequency of C-section across glucose categories by study. (a) Fasting; (b) 1 hour; and (c) 2 hours.
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FIGURE 56 Frequency of instrumental birth across glucose categories by study. (a) Fasting; (b) 1 hour; and
(c) 2 hours.
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FIGURE 57 Frequency of induction of labour across glucose categories by study. (a) Fasting; (b) 1 hour; and
(c) 2 hours.
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FIGURE 58 Frequency of shoulder dystocia across glucose categories by study. (a) Fasting; (b) 1 hour; and
(c) 2 hours.
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FIGURE 59 Frequency of preterm birth across glucose categories by study. (a) Fasting; (b) 1 hour; and (c) 2 hours.
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FIGURE 60 Frequency of neonatal hypoglycaemia across glucose categories by study. (a) Fasting; (b) 1 hour; and
(c) 2 hours.
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FIGURE 61 Odds ratio for 1-mmol/l increases in 1-hour post-load glucose for 75-g OGTT and reported
perinatal outcomes.
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FIGURE 62 Adjusted ORs across categories of fasting and post-load glucose levels and macrosomia. (a) Fasting; and
(b) 1 hour.
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FIGURE 63 Adjusted ORs across categories of fasting and post-load glucose levels and LGA. (a) Fasting; (b) 1 hour;
and (c) 2 hours.
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FIGURE 64 Adjusted ORs across categories of fasting and post-load glucose levels and C-section. (a) Fasting;
(b) 1 hour; and (c) 2 hours.
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FIGURE 65 Adjusted ORs across categories of fasting and post-load glucose levels and pre-eclampsia. (a) Fasting;
(b) 1 hour; and (c) 2 hours.
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Appendix 3 Tables for Chapter 4
TABLE 64 Chapter 4: excluded studies
Excluded study Reason
Agarwal MM, Dhatt GS, Punnose J, Koster G. Gestational diabetes in a high-risk
population: Using the fasting plasma glucose to simplify the diagnostic algorithm.
Eur J Obstet Gynecol Reprod Biol 2005;120:39–44
Non-UK, United Arab Emirates and
FPG performance
Ajala O, Stenhouse E, Shaw N, Carr S, Millward A. Cardiovascular risk following
diagnosis of gestational diabetes: Diabetes in Pregnancy Mother Baby Study 3.
Diabet Med 2011;28:173
Conference abstract and incidence of
type 2 diabetes after GDM
Akhtar S, Ramanathan R, Ewins DL, Goenka N, Davies J, Joseph F. The impact of
the new International Association of Diabetes and Pregnancy Study Groups
criteria for gestational diabetes on glycaemic management. Diabet Med
2012;29:66
Conference abstract and impact of
diagnostic criteria; no usable data
Al-Ramli W, Dennedy MC, Avalos G, Dunne F. Gestational weight gain and
pregnancy outcomes in women with gestational diabetes mellitus. Ir J Med Sci
2012;181:S350–1
Conference abstract, gestational
weight gain
Anonymous. Number of women with gestational diabetes underestimated.
Medilexicon 2010
Not available at the British Library
Review of multiple countries
(estimated at 16% in nine countries)
Anthony R, Angala P, Ikomi A, Khan R, Kiss S. Resource implications of
converting from a WHO/ADA hybrid to IADPSG criteria for diagnosing
GDM in a UK University Hospital. Arch Dis Childhood Fetal Neonatal Ed
2013;98(Suppl. 1):A35
Conference abstract; impact of
diagnostic criteria
Avalos G, Owens L, Dunne F. Applying current screening tools for gestational
diabetes mellitus to a European population: Is it time for change? Ir J Med Sci
2012;181:S346
Conference abstract, full paper
already obtained
Avalos GE, Owens L, Dunne F. How many women with gestational diabetes
mellitus are missed if selective screening strategies are used? Diabetologia
2012;55:S446
Conference abstract, full paper
already obtained
Avalos GE, Owens LA, Dunne F. Applying current screening tools for gestational
diabetes mellitus to a European population: Is it time for change? Diabetes Care
2013;36:3040–4
Conference abstract
Baci Y, Ustuner I, Keskin HL, Ersoy R, Avsar AF. Effect of maternal obesity and
weight gain on gestational diabetes mellitus. Gynecol Endocrinol 2013;292:133–6
Considered for risk factors review
Beischer NA, Oats JN, Henry OA, Sheedy MT, Walstab JE. Incidence and severity
of gestational diabetes mellitus according to country of birth in women living in
Australia. Diabetes 1991;40(Suppl. 2):35–8
Australia
Bell R, Hayes L, Crowder D, Bilous M, Lewis-Barned N, Brandon H, et al. Outcome
of pregnancies complicated by gestational diabetes: a multi-centre study from the
North East of England. Arch Dis Childhood Fetal Neonatal Ed 2010;95:Fa97
Conference abstract
Bell R, Hayes L, Lewis-Barned N, Bilous M, Brandon H, Pearson S, et al. Diagnosis,
treatment and outcome of gestational diabetes: a multi-centre study in north-east
England (NorGES). Diabet Med 2010;1:15
Conference abstract, describes
characteristics of women with GDM
Bertolotto A, Volpe L, Calianno A, Pugliese MC, Lencioni C, Resi V, et al. Physical
activity and dietary habits during pregnancy: Effects on glucose tolerance.
J Maternal Fetal Neonatal Med 2010;23:1310–14
Italy
Brite J, Shiroma EJ, Bowers K, Yeung E, Laughon SK, Grewal JG, et al. Height and
the risk of gestational diabetes: Variations by race/ethnicity. Diabet Med
2014;313:332–40
Considered for risk factors review;
USA
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TABLE 64 Chapter 4: excluded studies (continued )
Excluded study Reason
Bryant M, Santorelli G, Lawlor DA, et al. A comparison of South Asian specific
and established BMI thresholds for determining obesity prevalence in pregnancy
and predicting pregnancy complications: Findings from the Born in Bradford
cohort [published online ahead of print July 20 2013). Int J Obes
BiB cohort
Buckley BS, Harreiter J, Damm P, Corcoy R, Chico A, Simmons D, et al.
Gestational diabetes mellitus in Europe: Prevalence, current screening practice
and barriers to screening. A review. Diabet Med 2012;29:844–54
Review – checked references
Buhling KJ, Elze L, Henrich W, Starr E, Stein U, Siebert G, et al. The usefulness of
glycosuria and the influence of maternal blood pressure in screening for
gestational diabetes. Eur J Obstet Gynecol Reprod Biol 2004;113:145–8
Dipstick analysis, Germany
Cairnduff V, Hill AJ, Sinclair M, Patterson C, McCance DR. Relationship between
maternal BMI, nutrient intakes and glycaemic control in third trimester of
pregnancy. Proc Nutrition Soc 2012;71:E53
Conference abstract; glycaemic
control
Chandy E, Rolph N, O’Donnell J, Scott J, Wilson J, Herlihy O. A review of oral
glucose tolerance tests at the Borders General Hospital. Pract Diabetes
2012;29:358–60a
Compares oral glucose tests, no
suitable GDM data
Chico A, Lopez-Rodo V, Rodriguez-Vaca D, Novials A. Features and outcome of
pregnancies complicated by impaired glucose tolerance and gestational diabetes
diagnosed using different criteria in a Spanish population. Diabetes Res Clin Pract
2005;68:141–6
Compares criteria; Spain
Coolen JC, Verhaeghe J. Physiology and clinical value of glycosuria after a glucose
challenge during pregnancy. Eur J Obstet Gynecol Reprod Biol 2010;150:132–6
Compares tests; Belgium
Crowe C, Noctor E, Carmody LA, Wickham B, Avalos G, Gaffney G, et al.
ATLANTIC DIP: The prevalence of pre-diabetes/type 2 diabetes in an Irish
population with gestational diabetes mellitus 1-5 years post index pregnancy.
Ir J Med Sci 2011;180:S483–4
Conference listing
Crowe C, Noctor E, Carmody LA, Wickham B, Avalos G, Gaffney G, et al.
ATLANTIC DIP: The prevalence of pre-diabetes/type 2 diabetes in an Irish
population with gestational diabetes mellitus 1-5 years post index pregnancy.
BMC Proceedings 2012;6(Suppl. 4):O35
Conference abstract
Cullinan J, Gillespie P, Owens L, Avalos G, Dunne FP, ATLANTIC DIP collaborators.
Is there a socioeconomic gradient in the prevalence of gestational diabetes
mellitus? Ir Med J 2012;105(Suppl. 5):21–3
ATLANTIC DIP,59 only data on
prevalence is reference to paper
already obtained
Davenport MH, Campbell MK, Mottola MF. Increased incidence of glucose
disorders during pregnancy is not explained by pre-pregnancy obesity in London,
Canada. BMC Pregnancy Childbirth 2010;10:85
Considered for risk factors review;
Canada
Denison FC, Norwood P, Bhattacharya S, Duffy A, Mahmood T, Morris C, et al.
Association between maternal body mass index during pregnancy, short-term
morbidity, and increased health service costs: a population-based study. BJOG
2014;121:72–81; discussion 2
No data on GDM
Di Cianni G, Volpe L, Lencioni C, Miccoli R, Cuccuru I, Ghio A, et al. Prevalence
and risk factors for gestational diabetes assessed by universal screening. Diabetes
Res Clin Pract 2003;62:131–7
Considered for risk factors review.
Italy
Fadl HE, Ostlund IKM, Magnuson AFK, Hanson USB. Maternal and neonatal
outcomes and time trends of gestational diabetes mellitus in Sweden from 1991
to 2003. Diabet Med 2010;27:436–41
Sweden
Forbes S, Reynolds RM, Patrick AW, Denison F, Norman JE. Implications of new
Scottish Intercollegiate Guidelines Network (SIGN) criteria on diagnosis of
gestational diabetes in a severely obese pregnant population. Diabet Med
2011;28:23
Conference abstract, severely obese
women only
Fox NS, Roman AS, Saltzman DH, Klauser CK, Rebarber A. Obesity and adverse
pregnancy outcomes in twin pregnancies. J Maternal Fetal Neonatal Med
2014;27:355–9
USA
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TABLE 64 Chapter 4: excluded studies (continued )
Excluded study Reason
Gayle C, Germain S, Marsh MS, Rajasingham D, Carroll P, Brackenridge A, et al.
Management of gestational diabetes using the World Health Organisation (WHO)
criteria in a diabetes antenatal clinic benefit women compared to routine care
based on European Association for the Study of Diabetes (EASD) criteria. A
comparison of treatment based on an oral glucose tolerance test 2-hour blood
glucose 7.8 - 8.9 mmol/l. Diabet Med 2010;1:35
Conference abstract, no GDM data
Gillespie P, O’Neill C, Avalos G, Dunne FP, ATLANTIC DIP Collaborators. New
estimates of the costs of universal screening for gestational diabetes mellitus in
Ireland. Ir Med J 2012;105(Suppl. 5):15–18
Costs, have AD prevalence elsewhere
ATLANTIC DIP
Gillespie P, O’Neill C, Avalos G, et al. The cost of universal screening for
gestational diabetes mellitus in Ireland. Diabet Med 2011;28:912–18
Costs
Gillespie P, O’Neill C, Cullinan J, Dunne F. The effect of Gestational Diabetes
Mellitus (GDM) on maternity care and costs in Ireland. Diabetologia
2012;55:S449
Conference abstract; no GDM data
Hall C, Going A, Moutter S, Thynne AD, Salloum M, Sengupta S, et al.
Implications of the HAPO study on diagnosis of gestational diabetes in existing
patients screened during pregnancy with a glucose tolerance test, 2009-2010.
Diabet Med 2011;28:174
Conference abstract; no GDM data
Healy GM, Vellinga A, Carmody L, Avalos G, Mustafa E, Khalil S, et al. Atlantic
DIP: Universal vs. Selective Screening for Gestational Diabetes (GDM). Diabetes
2012;61:A641
Conference abstract of Atlantic DIP
cohort
Hieronimus S, Le Meaux JP. Relevance of gestational diabetes mellitus screening
and comparison of selective with universal strategies. Diabetes Metab
2010;36(Pt 2):575–86
Considered for risk factors review;
review of screening
Jiwani A, Marseille E, Lohse N, Damm P, Hod M, Kahn JG. Gestational diabetes
mellitus: Results from a survey of country prevalence and practices. J Maternal
Fetal Neonatal Med 2012;25:600–10
Survey only reporting NICE guidelines
Kavvoura FK, Graham D, Crowley R, Simpson H, Street P, Elsheikh M. Diabetes
antenatal care at a large district general hospital: an audit from 1997 to 2010.
Diabet Med 2012;29:153
Conference abstract; insufficient data
on prevalence
Keshavarz M, Cheung NW, Babaee GR, Moghadam HK, Ajami ME, Shariati M.
Gestational diabetes in Iran: Incidence, risk factors and pregnancy outcomes.
Diabetes Res Clin Pract 2005;69:279–86
Considered for risk factors review; Iran
Kim S, Nakai H, Okabe K, Nohira T, Yoneyama K. Recurrence of gestational
diabetes mellitus: rates and risk factors from initial GDM and one abnormal GTT
value. Diabetes Res Clin Pract 2006;71:75-81
Japan
Kong M, Meakin L, Donley P, Gregory R, Scudamore I. Evidence of an ‘epidemic’
of gestational diabetes 1995–2008: Implications for service delivery. Diabet Med
2010;1:168
Conference abstract; Insufficient data
on prevalence
Kousta E, Lawrence NJ, Penny A, Millauer BA, Robinson S, Johnston DG, et al.
Women with a history of gestational diabetes of European and South Asian
origin are shorter than women with normal glucose tolerance in pregnancy.
Diabet Med 2000;17:792–7
Only data on women with previous
GDM
Lacey A, Roche J, Wheatley T. Screening for gestational diabetes: are NICE risk
factors adequate? Diabet Med 2011;28:182–3
Conference abstract; Insufficient data
on prevalence
Lappin SM, Watt P, Traub AI, Tharma S, Courtney H, McCance DR. Audit of risk
factors for Gestational Diabetes (GDM) in women diagnosed by a universal
screening programme. Diabet Med 2010;1:173–4
conference abstract
Lohse N, Marseille E, Kahn JG. Development of a model to assess the
cost-effectiveness of gestational diabetes mellitus screening and lifestyle
change for the prevention of type 2 diabetes mellitus. Int J Gynecol Obstet
2011;115(Suppl. 1):20–5
Not UK cost
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TABLE 64 Chapter 4: excluded studies (continued )
Excluded study Reason
Lowy C, Beard RW, Goldschmidt J. The UK diabetic pregnancy survey.
Acta Endocrinol Suppl (Copenh) 1986;277:86–9
Survey of GDM population
Maitland RA, Barr S, Briley A, Seed P, Poston L. Incidence of gestational diabetes
in an obese population using the International Association of Diabetes and
Pregnancy Study Groups (IADPSG) criteria in the UK Pregnancies Better Eating
and Activity Trial (UPBEAT) pilot study. Diabet Med 2012;29:152
Obese population only, small RCT
conference abstract
Maitland RA, Patel N, Rajasingham D, Brackenridge A. Trends in gestational
diabetes (GDM) prevalence over three years within a high risk inner city
population attending Guy’s and St Thomas’ NHS Foundation Trust (GSTFT).
Diabet Med 2013;30:166
Conference abstract
Mannan S, Ikomi A, Khan R, Kiss S. Implementation of the new international
guidelines in a UK university hospital: Predicted versus actual consequences. BJOG
2014;121:151
Conference abstract
Mansell A, Gouveia C, Braggins F, Claydon A, Nobeebux A, Joseph T, et al. Early
screening for gestational diabetes is essential to detect undiagnosed impaired
glucose tolerance and Type 2 diabetes in a high risk, ethnically-diverse
population. Diabet Med 2009;26:117–18
No data on prevalence conference
abstract
Marseille E, Lohse N, Jiwani A, Hod M, Seshiah V, Yajnik CS, et al. The
cost-effectiveness of gestational diabetes screening including prevention of
type 2 diabetes: application of a new model in India and Israel. J Maternal
Fetal Neonatal Med 2013;26:802–10
Cost; India and Israel
Most O, Langer O. Gestational diabetes: Maternal weight gain in relation to fetal
growth, treatment modality, BMI and glycemic control. J Maternal Fetal Neonatal
Med 2012;25:2458–63
Study of women with GDM
Munigoti SP, Davies R, Peters J. Impact of adopting the IADPSG criteria for
diagnosing gestational diabetes. Diabet Med 2011;28:170
Conference abstract; high-risk patients
only
Myagerimath R, Albert S, Nwosu EC. Outcome of glucose tolerance test in a
district general hospital. BJOG 2013;120:134
Conference abstract
Nijjar SK, Hunt KF, Rogers H, Smith C, Gayle CM, Marsh MS, et al. Clinical
outcomes of patients with gestational diabetes mellitus who do not have typical
risk factors. Diabetologia 2011;54:S479–S80
Conference abstract; all women had
GDM
Noctor E, Crowe C, Avalos G, Carmody L, Wickham B, O’Shea P, et al. ATLANTIC
DIP: Index pregnancy factors associated with progression to pre-diabetes/diabetes
up to 5 years post gestational diabetes in the west of Ireland. Diabetes
2012;61:A343
Conference abstract; abstract of
Atlantic DIP cohort
Noctor E, Crowe C, Carmody LA, Wickham B, Avalos G, Gaffney G, et al.
ATLANTIC DIP: The prevalence of pre-diabetes/diabetes up to 5 years post partum
in women with previous gestational diabetes along the Atlantic coast.
Diabetologia 2012;55:S442
Conference abstract; abstract of
Atlantic DIP cohort
O’Higgins AC, Dunne FP, Lee B, Smith D, Turner MJ. A national survey of
implementation of guidelines of screening for gestational diabetes mellitus. BJOG
2013;120:470
Conference abstract; insufficient data
on prevalence
O’Sullivan EP, Avalos G, O’Reilly MW, Dennedy C, Dunne F. ATLANTIC DIP:
Prevalence and implications of abnormal glucose tolerance in pregnancy in
Ireland. Diabetologia 2010;53:S10
Conference abstract, Abstract of
Atlantic DIP cohort
Ozumba BC, Obi SN, Oli JM. Diabetes mellitus in pregnancy in an African
population. Int J Gynecol Obstet 2004;84:114–19
Considered for risk factors review;
Nigeria
Perovic M, Garalejic E, Gojnic M, Arsic B, Pantic I, Bojovic DJ, et al. Sensitivity and
specificity of ultrasonography as a screening tool for gestational diabetes mellitus.
J Maternal Fetal Neonatal Med 2012;25:1348–53
High-risk population only
Poncet B, Touzet S, Rocher L, Berland M, Orgiazzi J, Colin C. Cost-effectiveness
analysis of gestational diabetes mellitus screening in France. Eur J Obstet Gynecol
Reprod Biol 2002;103:122–9
France; cost analysis
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TABLE 64 Chapter 4: excluded studies (continued )
Excluded study Reason
Rajab KE, Issa AA, Hasan ZA, Rajab E, Jaradat AA. Incidence of gestational
diabetes mellitus in Bahrain from 2002 to 2010. Int J Gynaecol Obstet
2012;117:74–7
Considered for risk factors review.
Bahrain
Rees G, Bennett SJ, Colleypriest O, Ellis L, Porter JM, Stenhouse E. The prevalence
of overweight and obesity in early pregnancy and the incidence of gestational
diabetes. Diabet Med 2010;1:172
Conference abstract; overweight
women only
Sayeed MA, Mahtab H, Khanam PA, Begum R, Banu A, Khan AKA. Diabetes and
hypertension in pregnancy in a rural community of Bangladesh: a population-
based study. Diabet Med 2005;22:1267–71
Considered for risk factors review;
Bangladesh
Scott-Pillai R, Spence D, Cardwell CR, Hunter A, Holmes VA. The impact of body
mass index on maternal and neonatal outcomes: a retrospective study in a UK
obstetric population, 2004-2011. BJOG 2013;120:932–9
No GDM prevalence data
Sella T, Shalev V, Elchalal U, Chovel-Sella A, Chodick G. Screening for gestational
diabetes in the 21st century: a population-based cohort study in Israel. J Maternal
Fetal Neonatal Med 2013;26:412–16
Israel
Su DF, Wang XY. Metformin vs insulin in the management of gestational
diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract
2014;104:353–7
Review
Teh WT, Teede HJ, Paul E, Harrison CL, Wallace EM, Allan C. Risk factors for
gestational diabetes mellitus: implications for the application of screening
guidelines. Aust N Z J Obstet Gynaecol 2011;51:26–30
Considered for risk factors review;
Australia
Thorpe LE, Berger D, Ellis JA, et al. Trends and racial/ethnic disparities in
gestational diabetes among pregnant women in New York City, 1990-2001.
Am J Public Health 2005;95:1536–9
Considered for risk factors review;
USA
Van Leeuwen M, Opmeer BC, Yilmaz Y, Limpens J, Serlie MJ, Mol BWJ. Accuracy
of the random glucose test as screening test for gestational diabetes mellitus: a
systematic review. Eur J Obstet Gynecol Reprod Biol 2011;154:130–5
Review
Wilson N, Ashawesh K, Smith S, Anwar A. The cost of screening for gestational
diabetes mellitus. J Med Screening 2008;15:213
Cost; no GDM prevalence data
Yang H, Wei Y, Gao X, Xu X, Fan L, He J, et al. Risk factors for gestational
diabetes mellitus in Chinese women - A prospective study of 16 286 pregnant
women in China. Diabet Med 2009;26:1099–104
Considered for risk factors review.
Chinese
Yapa M, Simmons D. Screening for gestational diabetes mellitus in a multiethnic
population in New Zealand. Diabetes Res Clin Pract 2000;48:217–23
New Zealand
Zargar AH, Sheikh MI, Bashir MI, Masoodi SR, Laway BA, Wani AI, et al.
Prevalence of gestational diabetes mellitus in Kashmiri women from the Indian
subcontinent. Diabetes Res Clin Pract 2004;66:139–45
Considered for risk factors review;
India
Zhang F, Dong L, Zhang CP, Li B, Wen J, Gao W, et al. Increasing prevalence of
gestational diabetes mellitus in Chinese women from 1999 to 2008. Diabet Med
2011;28:652–7
Considered for risk factors review;
Chinese
Zhong Y, Lin PJ, Winn A, Cohen JT, Neumann PJ. A systematic review of
cost-utility analyses in diabetes. Value Health 2013;16:A166
Conference abstract; review; no GDM
data
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Appendix 4 Tables for Chapter 5
TABLE 65 Chapter 5: excluded studies
Reference Reason for exclusion
Ahkter J, Qureshi R, Rahim F, Moosvi S, Rehman A, Jabbar A, et al. Diabetes in
pregnancy in Pakistani women: prevalence and complications in an indigenous
South Asian community. Diabet Med 1996;13:189–91
States percentage of women with
GDM with risk factors only, no other
group
Bouzari Z, Yazdani S, Samakosh MA, Mohammadnetaj M, Emamimeybodi S.
Prevalence of gestational diabetes and its risk factors in pregnant women referred
to health centers of Babol, IRAN, from September 2010 to March 2012. Iranian J
Obstet Gynecol Infert 2013;164:6–13
Not in English
Branchtein L, Schmidt MI, Matos MC, Yamashita YT, Pousada JM, Duncan BB.
Short stature and gestational diabetes in Brazil. Brazilian Gestational Diabetes
Study Group. Diabetologia 43:848–51
Reported height only
Branchtein L, Schmidt MI, Mengue SS, Reichelt AJ, Matos MC, Duncan BB. Waist
circumference and waist-to-hip ratio are related to gestational glucose tolerance.
Diabetes Care 1997;20:509–11
Waist circumference and waist to hip
ratio only
Brisson D, Perron P, Guay SP, Gaudet D, Bouchard L. The ‘hypertriglyceridemic
waist’ phenotype and glucose intolerance in pregnancy. CMAJ 2010;182:E722–5
Waist girth only, no GDM measure
Bryant M, Santorelli G, Lawlor DA, Farrar D, Tuffnell D, Bhopal R, et al.
A comparison of South Asian specific and established BMI thresholds for
determining obesity prevalence in pregnancy and predicting pregnancy
complications: Findings from the Born in Bradford cohort. Int J Obesity
2014;38:444–50
Based on the BiB cohort; already have
original raw data
Bunthalarath S, Sunsaneevithayakul P, Boriboohirunsarn D. Risk factors
for early diagnosis of gestational diabetes mellitus. J Med Assoc Thai
2004;87(Suppl. 3):50–3
Early vs. late diagnosis of GDM
Chu SY, Callaghan WM, Kim SY, Schmid CH, Lau J, England LJ, Dietz PM.
Maternal obesity and risk of gestational diabetes mellitus. Diabetes Care
2007;30:2070–6
Review
Chung JH, Melsop KA, Gilbert WM, Caughey AB, Walker CK, Main EK.
Increasing pre-pregnancy body mass index is predictive of a progressive escalation
in adverse pregnancy outcomes. J Mat Fetal Neonat Med 2012;25:1635–9
No suitable data: GDM by obesity
level, prevalence and outcomes study
Cosson E, Cussac-Pillegand C, Benbara A, Pharisien I, Jaber Y, Banu I, et al.
The diagnostic and prognostic performance of a selective screening strategy for
gestational diabetes mellitus according to ethnicity in Europe. J Clin Endocrinol
Metab 2014;99:996–1005
Ethnicity only, same cohort as 37
Dahanayaka NJ, Agampodi SB, Ranasinghe OR, Jayaweera PM, Wickramasinghe WA,
Adhikari AN, et al. Inadequacy of the risk factor based approach to detect gestational
diabetes mellitus. Ceylon Med J 2012;571:5-9
No comparison between women with
and without GDM
Detsch JCM, de Almeida ACR, Bortolini LGC, Nascimento DJ, Oliveira, Jr, FC,
Rea RR. Markers of diagnosis and treatment in 924 pregnancies with gestational
diabetes mellitus. Arq Bras Endocrinol Metabol 2011;55:389–98
Not in English
Dooley SL, Metzger BE, Cho NH. Gestational diabetes mellitus. Influence of race
on disease prevalence and perinatal outcome in a U.S. population. Diabetes
1991;40(Suppl. 2):25–9
Ethnicity only, not UK
Edwards L, Hellerstedt W, Alton I, Story M, Himes JH. Pregnancy complications
and birth outcomes in obese and normal-weight women: effects of gestational
weight change. Obstet Gynecol 1996;87:389–94
Gestational weight gain only
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TABLE 65 Chapter 5: excluded studies (continued )
Reference Reason for exclusion
Esakoff TF, Cheng YW, Caughey AB. Screening for gestational diabetes: different
cut-offs for different ethnicities? Am J Obstet Gynecol 2005;193(Pt 2):1040–4
Ethnicity only, not UK
Ezimokhai M, Joseph A, Bradley-Watson P. Audit of pregnancies complicated by
diabetes from one center five years apart with selective versus universal
screening. Ann N Y Acad Sci 2006;1084:132–40
Ethnicity only, not UK
Foster-Powell KA, Cheung NW. Recurrence of gestational diabetes. Aust N Z J
Obstet Gynaecol 1998;38:384–7
Factors for recurrence of GDM only
Gregory R, Swinn RA, Wareham N, Curling V, Dalton KJ, Edwards OM, et al. An
audit of a comprehensive screening programme for diabetes in pregnancy.
Prac Diabet Int 1998;15:45–8
No risk factors considered, audit only
Guttorm E. Practical screening for diabetes mellitus in pregnant women.
Acta Endocrinol 1974;75(Suppl. 18):11–24
Not explicitly GDM
Harder T, Franke K, Kohlhoff R, Plagemann A. Maternal and paternal family
history of diabetes in women with gestational diabetes or insulin-dependent
diabetes mellitus type I. Gynecol Obstet Invest 2001;51:160–4
Only one risk factor (maternal family
history of diabetes) considered
Hayes L, Bilous R, Bilous M, Brandon H, Crowder D, Emmerson C, et al. Universal
screening to identify gestational diabetes: a multi-centre study in the North of
England. Diabetes Res Clin Pract 2013;10:e74–7
Women with GDM only
Hedderson MM, Darbinian JA, Ferrara A. Disparities in the risk of gestational
diabetes by race-ethnicity and country of birth. Paediatr Perinat Epidemiol
2010;24:441–8
Ethnicity only, non UK
Helton MR, Arndt J, Kebede M, King M. Do low-risk prenatal patients really need
a screening glucose challenge test? J Family Pract 1997;44:556–61
No data on risk factors
Kim HS, Chang KH, Yang JI, Yang SC, Lee HJ, Ryu HS. Clinical outcomes of
pregnancy with one elevated glucose tolerance test value. Int J Gynaecol Obstet
2002;78:131–8
IGT rather than GDM
Lamberg S, Raitanen J, Rissanen P, Luoto R. Prevalence and regional differences
of gestational diabetes mellitus and oral glucose tolerance tests in Finland. Eur J
Public Health 2012;22:278–80
Insufficient risk factor data, GDM
prevalence only
McGuire V, Rauh MJ, Mueller BA, Hickock D. The risk of diabetes in a subsequent
pregnancy associated with prior history of gestational diabetes or macrosomic
infant. Paediatr Perinat Epidemiol 1996;10:64–72
insufficient data on risks
Neelakandan R, Shankar Sethu P. Early universal screening for gestational
diabetes mellitus. J Clin Diagnostic Res 2014;8:OC12–14
Insufficient data on risks, prevalence
only
Pedersen ML, Jacobsen JL, Jorgensen ME. Prevalence of gestational diabetes
mellitus among women born in Greenland: measuring the effectiveness of the
current screening procedure. Int J Circumpolar Health 2010;69:352–60
No risk factor data
Pertot T, Molyneaux L, Tan K, Ross GP, Yue DK, Wong J. Can common clinical
parameters be used to identify patients who will need insulin treatment in
gestational diabetes mellitus? Diabetes Care 2011;34:2214–6
Predicting insulin need, not GDM
Poyhonen-Alho MK, Teramo KA, Kaaja RJ, Hiilesmaa VK. 50 gram oral glucose
challenge test combined with risk factor-based screening for gestational diabetes.
Eur J Obstet Gynecol Reprod Biol 2005;121:34–7
Comparison of GCT and risk factors
Puavilai G, Kheesukapan P, Chanprasertyotin S, Chantraraprasert S,
Suwanvilaikorn S, Nitiyanant W, et al. Random capillary plasma glucose
measurement in the screening of diabetes mellitus in high-risk subjects in
Thailand. Diabetes Res Clin Pract 2001;51:125–31
Not GDM
Ray R, Heng BH, Lim C, Ling SL. Gestational diabetes in Singaporean women: use
of the glucose challenge test as a screening test and identification of high risk
factors. Ann Acad Med Singapore 1996;25:504–8
GCT results rather than GDM
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TABLE 65 Chapter 5: excluded studies (continued )
Reference Reason for exclusion
Retnakaran R, Connelly PW, Sermer M, Zinman B, Hanley AJ. The impact of
family history of diabetes on risk factors for gestational diabetes. Clin Endocrinol
2007;67:754–60
Insufficient data on risks
Rizvi JH, Rasul S, Malik S, Rehamatuallh A, Khan MA. Experience with screening
for abnormal glucose tolerance in pregnancy: maternal and perinatal outcome.
Asia Oceania J Obstet Gynaecol 1992;18:99–105
No risk factor data
Salih S, Tedd H, Gillmer M. Screening for gestational diabetes mellitus in an
indigenous Melanesian population on the islands of Vanuatu. J Obstet Gynaecol
2009;29:98–100
GCT results only, not GDM
Samuel A, Simhan HN. Clinical indications for abnormal early gestational 50-g
glucose tolerance testing. Am J Perinatol 2011;28:485–8
Examining early testing, not GDM risk
Savitz DA, Janevic TM, Engel SM, Kaufman JS, Herring AH. Ethnicity and
gestational diabetes in New York City, 1995-2003. BJOG 2008;115:969–78
Ethnicity only, non UK
Savona-Ventura C, Azzopardi J, Sant R. Risk factors for gestational diabetes
mellitus in the Maltese population: a population based study. Int J Risk Safety
Med 2000;13:1–7
Only single risk factors considered
Sepe SJ, Connell FA, Geiss LS, Teutsch SM. Gestational diabetes.
Incidence, maternal characteristics, and perinatal outcome. Diabetes
1985;34(Suppl. 2):13–16
Insufficient risk factor data, incidence
and outcomes only
Spong CY, Guillermo L, Kuboshige J, Cabalum T. Recurrence of gestational
diabetes mellitus: identification of risk factors. Am J Perinatol 1998;15:29–33
Recurrence of GDM
Sumeksri P, Wongyai S, Aimpun P. Prevalence of gestational diabetes mellitus
(GDM) in pregnant women aged 30 to 34 years old at Phramongkutklao
Hospital. J Med Assoc Thai 2006;89(Suppl. 4):94–9
Used a different set of risk factors,
combined risk factors into two
categories: positive or negative only
Tan PC, Ling LP, Omar SZ. Screening for gestational diabetes at antenatal
booking in a Malaysian university hospital: the role of risk factors and threshold
value for the 50-g glucose challenge test. Aust N Z J Obstet Gynaecol
2007;47:191–7
Compares GCT to OGTT; limited risk
factor data
Theriault S, Forest JC, Masse J, Giguere Y. Validation of early risk-prediction
models for gestational diabetes based on clinical characteristics. Diabetes Res Clin
Pract 2014;103:419–25
Secondary review of risk prediction
models
Torloni MR, Betran AP, Horta BL, Nakamura MU, Atallah AN, Moron AF, et al.
Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the
literature with meta-analysis. Obes Rev 2009;10:194–203
Review, no relevant data
Volpe L, Di Cianni G, Bottone P, Orsini P, Murru S, Casadidio I, et al. Gestational
diabetes: clinical characteristics and birthweight. Ann Ist Super Sanita
1997;33:407–10
No risk factor data presented.
Outcome data
Wein P, Dong ZG, Beischer NA, Sheedy MT. Factors predictive of recurrent
gestational diabetes diagnosed before 24 weeks’ gestation. Am J Perinatol
1995;12:352–6
Recurrence of GDM
Young C, Kuehl TJ, Sulak PJ, Allen SR. Gestational diabetes screening in
subsequent pregnancies of previously healthy patients. Am J Obstet Gynecol
2000;182:1024–6
No relevant data
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TABLE 66 Risk factors to identify women at increased risk of GDM: Conclusions of the included studies
First author Year Screening method Conclusions of the study authors
Favours risk
factor
screening?
Avalos122 2013 ADA, NICE, Irish
guideline
recommendations
Strong case for universal screening; however,
if selective screening adopted, the ADA
guideline recommendations would have
highest diagnosis rate, with lowest
proportion of missed cases
Undecided
Caliskan142 2004 Number of risk factors Population based scoring system decreases
unnecessary testing, but still diagnoses
≥ 85% of cases
Yes
Corcoy159 2004 Various risk factors Depending on the population selective
screening is reliable at identifying women at
low risk but unnecessarily complicated, as
only 7% of women were at low risk on all
factors
No
Cosson143 2013 French guideline
recommendations
One-third of women with GDM would
be missed if selectively screened; do not
support use of current French guideline
recommendations
No
Cosson163 2006 Number of risk factors Universal rather than selective screening may
improve outcomes
No
Crete160 2013 Age, BMI, prior GDM Risk factor screening to avoid need for
glucose challenge testing, may increase
glucose tolerance testing and costs
No
Cypryk144 2008 Number of risk factors Use of risk factors does not reliably identify
those at risk of GDM, therefore all pregnant
women should undergo laboratory screening
No
Danilenko-Dixon146 1999 ADA guideline
recommendations
Adherence ADA guideline recommendations
would reduce number of screens by only
10% while increasing complexity
No
Davey161 2001 ADA and ADIPS
guideline
recommendations
Selective screening can reduce need for
testing with negligible loss of diagnostic
accuracy
Yes
Göbl162 2012 Risk factors with FPG Risk factor screening with fasting plasma
glucose is accurate but needs further
evaluation
Undecided
Jensen145 2003 Number of risk factors Risk factor screening had similar performance
to OGCT or the fasting plasma glucose test;
using a risk based model could avoid OGTT
in two-thirds of women
Yes
Jiménez-Moleón93 2002 ADA and ACOG
guideline
recommendations
ADA guideline recommendations have similar
disadvantages to other selective screening
criteria, without apparent benefit
No
Marquette147 1985 Number of risk factors Testing only women over ≥ age 24 years
would reduce costs with reasonable
sensitivity in this population, but 10 of the
12 women with GDM were ≥ 24 years old
No
Moses148 1998 Age, BMI ethnicity GDM was diagnosed in 2.8% of low-risk
women (Caucasian, < 25 years of age and
< 25 kg/m2 BMI); not testing lower-risk
women requires further evaluation, but
selective testing requires testing 80% of this
population and will miss 10% of cases
No
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TABLE 66 Risk factors to identify women at increased risk of GDM: Conclusions of the included studies (continued )
First author Year Screening method Conclusions of the study authors
Favours risk
factor
screening?
Nanda149 2011 Risk model First trimester screening for GDM is possible
using a combination of maternal
characteristics and biomarkers
Yes
Naylor164 1997 Risk score Consideration of women’s clinical
characteristics can allow efficient selective
screening
Yes
Ostlund150 2003 Family history (of
diabetes), obesity, prior
macrosomic infant
> 4500 g) or prior
GDM
Using risk factors as an indicator to perform
an OGTT gives a low sensitivity to detect
GDM
No
Phaloprakam151 2009 Risk score The risk score is reliable for identifying
women likely to have an abnormal OGCT
Yes
Pintaudi152 2014 Number of risk factors Selective screening reduces the number
screened but 25% of women with GDM
without risk factors will be missed
Undecided
Sacks153 1987 Number of risk factors Risk factor screening may enhance GDM
detection, but criteria thresholds may prevent
the identification of a proportion of cases
Undecided
Savona-Ventura165 2013 Risk factors and fasting
plasma glucose
Risk factor screening with fasting plasma
glucose may be used in place of universal
glucose tolerance testing in centres facing
health-cost pressures
Undecided
Shamsuddin154 2001 Number of risk factors Universal screening appears to be the most
reliable method of diagnosing GDM
No
Shirazian155 2009 Risk score Risk factor screening does not miss a
substantial number of GDM cases
Yes
Sunsaneevithayakul156 2003 Number of risk factors Risk factor screening is appropriate Yes
Teh157 2011 NICE, ADA and ADIPS
guideline
recommendations
Selective screening criteria afford varied
performance characteristics, with generally
reasonable sensitivity but poor specificity with
no benefit over universal screening. Costs
and population characteristics should be
considered, however
Undecided
Van Leeuwen141 2010 Risk model The clinical prediction model performed
poorly, but the selective screening strategy is
satisfactory and as accurate as universal
screening with an OGCT
Yes
Van Leeuwen140 2009 Risk score Risk score has moderate discriminative
capacity but appears clinically useful
Yes
Williams158 1999 ADA guideline
recommendations
ADA guideline recommendations will ensure
90% of women are screened and will miss
only 4% of cases
Undecided
Yang139 2002 ADA and WHO
guideline
recommendations
As this population are ‘high risk due to
ethnicity’, different cut points or risk factors
are required if screening is to be useful
Undecided
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Appendix 5 Tables for Chapter 6
TABLE 67 Chapter 6: excluded studies
No. Reference Reason
1 Afaghi A, Ghanei L, Ziaee A. Effect of low glycemic load diet with and
without wheat bran on glucose control in gestational diabetes mellitus:
a randomized trial. Indian J Endocrinol Metab 2013;17:689–92
No eligible outcomes, measured the
reduction in women requiring insulin
2 Ainuddin J. Metformin: a safe alternative to insulin therapy in gestational
diabetes. Int J Gynecol Obstet 2012;119:S270
Conference abstract only, no data
3 Anjalakshi C, Balaji V, Balaji MS, Seshiah V. A prospective study comparing
insulin and glibenclamide in gestational diabetes mellitus in Asian Indian
women. Diabetes Res Clin Pract 2007;76:474–5
Letter, only one outcome
4 Ardilouze JL, Menard J, Perron P, Houde G, Moutquin JM, Hivert MF, et al.
Gestational diabetes mellitus: the first prospective randomised study of
metformin-glyburide vs insulin. Diabetologia 2014;1:S449–50
Duplicate of Ardilouze 2014214
5 Arshad R, Karim N, Hasan JA. Effects of insulin on placental, fetal and
maternal outcomes in gestational diabetes mellitus. Pak J Med Sci
2014;30:240–4
Not randomised: two groups had
different glucose levels
6 Asemi Z, Samimi M, Tabassi Z, Sabihi S-S, Esmaillzadeh A. A randomized
controlled clinical trial investigating the effect of DASH diet on insulin
resistance, inflammation, and oxidative stress in gestational diabetes.
Nutrition 2013;29:619–24
No relevant outcomes
7 Asemi Z, Tabassi Z, Samimi M, Fahiminejad T, Esmaillzadeh A. Favourable
effects of the Dietary Approaches to Stop Hypertension diet on glucose
tolerance and lipid profiles in gestational diabetes: a randomised clinical
trial. Br J Nutr 2013;109:2024–30
Duplicate of 6; no eligible outcomes
measured tolerance and lipid glucose
profiles
8 Athukorala C, Crowther CA, Willson K; Australian Carbohydrate Intolerance
Study in Pregnant Women (ACHOIS) Trial Group. Women with gestational
diabetes mellitus in the ACHOIS trial: risk factors for shoulder dystocia.
Aust N Z J Obstet Gynaecol 2007;47:37–41
ACHOIS secondary analysis; risk
factors for shoulder dystocia
9 Avery MD, Leon AS, Kopher RA. Effects of a partially home-based exercise
program for women with gestational diabetes. Obstet Gynecol
1997;1:10–15
Exercise only, no relevant outcomes
10 Bahado-Singh RO, Mele L, Landon MB, et al. Fetal male gender and the
benefits of treatment of mild gestational diabetes mellitus. Am J Obstet
Gynecol 2012;206:422.e1–5
Secondary analysis of Landon 200952
11 Balaji V, Balaji MS, Alexander C, Ashalata S, Sheela Suganthi R, Suresh S,
et al. Premixed insulin aspart 30Biasp(30) vs. premixed human insulin
30BHI(30) in gestational diabetes mellitus: a pilot study. J Assoc Phys India
2010;58:99–101
Pilot of Balaji 2012195
12 Balaji V, Balaji MS, Alexander C, Ashalata S, Suganthi RS, Suresh S, et al.
Premixed insulin aspart 30 (Biasp 30) vs premixed human insulin 30 (BHi30)
in gestational diabetes mellitus â?’ a pilot study. J Asso Phys Ind
2010;58:96–7
Duplicate of 11259
13 Bambicini JT, Soares VCM, Zanetti MRD, Torloni MR, Ribeiro MC, Mattar R.
Effects of aerobic and resistance exercises on glycemic levels of patients
with gestational diabetes: Pilot study. Int J Gynecol Obstet 2012;119:S603
Conference abstract only; no eligible
outcomes
14 Bancroft K, Tuffnell DJ, Mason GC, Rogerson LJ, Mansfield MA. Randomised
controlled pilot study of the management of gestational impaired glucose
tolerance. BJOG 2000;107:959–63
Monitoring only
15 Barakat R, Perales M, Bacchi M, Coteron J, Refoyo I. A program of exercise
throughout pregnancy. Is it safe to mother and newborn? Am J Health
Promot 2014;29:2–8
Health promotion exercise
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TABLE 67 Chapter 6: excluded studies (continued )
No. Reference Reason
16 Barrett HL, Dekker Nitert M, Jones L, O’Rourke P, Lust K, Gatford KL,
et al. Determinants of maternal triglycerides in women with gestational
diabetes mellitus in the Metformin in Gestational Diabetes (MiG) study.
Diabetes Care 2013;36:1941–6
Subgroup analysis; no relevant
outcomes
17 Barrett HL, Gatford KL, Houda CM, De Blasio MJ, McIntyre HD, Callaway LK,
et al. Maternal and neonatal circulating markers of metabolic and
cardiovascular risk in the Metformin in Gestational Diabetes (MiG) trial:
responses to maternal metformin versus insulin treatment. Diabet Care
2013;36:529–36
Subsequent analysis of data from an
included trial, perinatal outcomes
already reported in primary trial
publication
18 Battin MR, Wouldes T, Buksh M, Rowan J. Neurodevelopmental outcome at
24-months in children following a randomized trial of metformin versus
insulin treatment for gestational diabetes (MiG trial). J Paediat Child Health
2013;49:21
No relevant outcomes
19 Bonomo M, Cetin I, Pisoni MP, Faden D, Mion E, Taricco E, et al. Flexible
treatment of gestational diabetes modulated on ultrasound evaluation of
intrauterine growth: a controlled randomized clinical trial. Diabetes Metab
2004;30:237–44
Monitoring; no relevant outcomes
20 Brankston GN, Mitchell BF, Ryan EA, Okun NB. Resistance exercise
decreases the need for insulin in overweight women with gestational
diabetes mellitus. Am J Obstet Gynecol 2004:1:188–93
No relevant outcomes; need for
insulin only
21 Bung P, Bung C, Artal R, Khodiguian N, Fallenstein F, Spätling L.
Therapeutic exercise for insulin-requiring gestational diabetics: effects on
the fetus: results of a randomized prospective longitudinal study. J Perinat
Med 1993;21:125–37
Duplicate of Bung 1991204 and no
relevant data
22 Clarke P, Coleman MA, Holt RI. Alternative site self blood glucose testing is
preferred by women with gestational diabetes. Diabetes Technol Ther
2005;7:604–8
No relevant outcomes
23 Coiner J, Rowe M, DeVente J. The treatment of diabetes in pregnancy;
metformin vs glyburide and insulin–biomedical evidence of fetopathy.
Am J Obstet Gynecol 2014;1:S148
Conference abstract: no relevant
outcomes; not explicitly in GDM
24 Cordua S, Secher AL, Ringholm L, Damm P, Mathiesen ER. Real-time
continuous glucose monitoring during labour and delivery in women
with Type 1 diabetes: observations from a randomized controlled trial.
Diabet Med 2013;30:1374–81
Monitoring only
25 Cordua S, Secher AL, Ringholm L, Damm P, Mathiesen ER. Real-time
continuous glucose monitoring during delivery in women with type 1
diabetes. Diabetes Technol Ther 2013;15:A73
Glucose monitoring trial and
duplicate of 23
26 Corrado F, D’Anna R, Vieste G, Giordano D, Pintaudi B, Santamaria A,
et al. The effect of myoinositol supplementation on insulin resistance in
patients with gestational diabetes. Diabet Med 2011;8:972–5
No relevant outcomes
27 Cortez J, Tarsa M, Agent S, Chmait R, Moore T. Randomized controlled
trial of acarbose vs. placebo in the treatment of gestational diabetes.
Am J Obstet Gynecol 2006;6(Suppl. 1):S149
Abstract, insufficient data
28 Coustan DR, Lewis SB. Insulin therapy for gestational diabetes. Obstet
Gynecol 1978;51:306–10
Presentation of outcome data not
compatible
29 Coustan D. Treating mild gestational diabetes yields benefits with little or
no evidence of harms. Evid Based Med 2014;19:88
Commentary on another review
30 Crowther CA, Hague WM, Middleton PF, Baghurst PA, McPhee AJ, Tran TS,
et al. The IDEAL study: investigation of dietary advice and lifestyle for
women with borderline gestational diabetes: a randomised controlled
trial - study protocol. BMC Pregnancy Childbirth 2012;12:106
Protocol only
31 Dalfra MG, Nicolucci A, Lapolla A, TISG. The effect of telemedicine on
outcome and quality of life in pregnant women with diabetes. J Telemed
Telecare 2009;15:238–42
Telemedicine
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TABLE 67 Chapter 6: excluded studies (continued )
No. Reference Reason
32 de Barros MC, Lopes MA, Francisco RP, Sapienza AD, Zugaib M. Resistance
exercise and glycemic control in women with gestational diabetes mellitus.
Am J Obstet Gynecol 2010;203:556.e1–6
No relevant outcomes
33 Ding G, Liang P, Peng Y, Pang Y, Zheng Y. Evaluation of Continuous
Glucose Monitoring (CGM) on gestational diabetes mellitus in China.
Diabetes 2012;61:A588
Monitoring only
34 Durnwald CP, Mele L, Spong CY, Ramin SM, Varner MW, Rouse DJ, et al.
Glycemic characteristics and neonatal outcomes of women treated for mild
gestational diabetes. Obstet Gynecol 2011;117:819–27
Secondary analysis of Langdon 2008,
association between post-prandial
glucose and outcomes
35 Ehrlich S. Physical activity and gestational weight gain (GWG) in women
with GDM. Diabetes 2013;62:A18–19
No relevant outcomes
36 Ehrlich SF, Hedderson MM, Feng J, Crites Y, Quesenberry CP, Ferrara A.
Lifestyle intervention improves postpartum fasting glucose levels in women
with gestational diabetes. Diabetes 2014;63:A95
No relevant outcomes
37 Ehrlich SF, Hedderson MM, Quesenberry CP, Jr, Feng J, Brown SD, Crites Y,
et al. Post-partum weight loss and glucose metabolism in women with
gestational diabetes: the DEBI Study. Diabet Med 2014;31:862–7
No relevant outcomes
38 Ferrara A. Diet, exercise and breastfeeding intervention program for women
with gestational diabetes (DEBI Trial). ClinicalTrials.gov. URL: http://
clinicaltrials.gov/ (accessed 20 April 2015)
Ongoing trial
39 Ferrara A, Hedderson MM, Albright CL, Ehrlich SF, Quesenberry Jr CP,
Peng T, et al. A pregnancy and postpartum lifestyle intervention in women
with gestational diabetes mellitus reduces diabetes risk factors: a feasibility
randomized control trial. Diabetes Care 2011;34:1519–25
No relevant outcomes
40 Ford FA, Bruce CB, Fraser RB. Preliminary report of a randomised trial of
dietary advice in women with mild abnormalities of glucose tolerance in
pregnancy
Unpublished work cited in Alwan
review168
41 Garcia-Patterson A, Martin E, Ubeda J, Maria MA, de Leiva A, Corcoy R.
Evaluation of light exercise in the treatment of gestational diabetes.
Diabetes Care 2001;24:2006–7
No relevant outcomes
42 Gatford KL, Houda CM, Lu ZX, Coat S, Baghurst PA, Owens JA, et al.
Vitamin B12 and homocysteine status during pregnancy in the metformin in
gestational diabetes trial: responses to maternal metformin compared with
insulin treatment. Diabetes Obes Metab 2013;15:660–7
43 Gillen LJ, Tapsell LC. Advice that includes food sources of unsaturated fat
supports future risk management of gestational diabetes mellitus. J Am Diet
Assoc 2004;104:1863–7
No relevant outcomes
44 Gillman MW, Oakey H, Baghurst PA, Volkmer RE, Robinson JS,
Crowther CA. Effect of treatment of gestational diabetes mellitus on
obesity in the next generation. Diabetes Care 2010;33:964–8
Secondary analysis of Crowther
200551
45 Graham G, Johnson EB, Johnson A, Anderson R, Devine P. Cinnamon for
glycemic control in gestational diabetes: a randomized double-blind
placebo controlled pilot study. Am J Obstet Gynecol 2005;193:S91
No relevant outcomes
46 Grant SM, Wolever TM, O’Connor DL, Nisenbaum R, Josse RG. Effect of a
low glycaemic index diet on blood glucose in women with gestational
hyperglycaemia. Diabetes Res Clin Pract 2011;91:15–22
No relevant outcomes
47 Gui J, Liu Q, Feng L. Metformin vs insulin in the management of gestational
diabetes: a meta-analysis. PLOS ONE 2013;8:e64585
Systematic review
47 Han S, Crowther CA, Middleton P, Heatley E. Different types of dietary
advice for women with gestational diabetes mellitus. Cochrane Database
Syst Rev 2013;3:CD009275
Systematic review on dietary advice
for women
48 Han S, Crowther CA, Middleton PF, Tran T, Zhang Y. Women with
pregnancy hyperglycaemia: How well are lifestyle information booklets
used? J Paediatr Child Health 2013;49:93–4
Use of information lifestyle booklet
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TABLE 67 Chapter 6: excluded studies (continued )
No. Reference Reason
49 Han S, Heatley E, Middleton P, Crowther CA. Different types of dietary
advice for women with gestational diabetes mellitus: a Cochrane review.
J Paediatr Child Health 2012;48:114
Abstract on Cochrane Review on
dietary advice
50 Hartling L, Dryden DM, Guthrie A, Muise M, Vandermeer B, Donovan L.
Benefits and harms of treating gestational diabetes mellitus: a systematic
review and meta-analysis for the U.S. Preventive Services Task Force and the
National Institutes of Health Office of Medical Applications of Research.
Ann Intern Med 2013;159:123–9
Systematic review
51 Hashmi F, Malik A, Sheikh L, Ismail H. Effectiveness of metformin versus
insulin for treating diabetes in pregnancy: a retrospective cohort study to
compare maternal and perinatal outcomes. BJOG 2012;119:95
No relevant outcomes
52 Hernandez TL, Vanpelt RE, Krause MA, Reece MS, Donahoo WT, Mande A,
et al. Higher carbohydrate vs. Higher fat diet in gestational diabetes:
a randomized study. Diabetes 2012;61:A50
No relevant outcomes and a
crossover study
53 Hernandez TL, Anderson MA, Vanpelt RE, Reece MS, Reynolds R,
De La Houssaye B, et al. Women with gestational diabetes randomized
to a low-carbohydrate/ higher fat diet demonstrate greater insulin
resistance and infant adiposity. Diabetes 2013;62:A18
No relevant outcomes
54 Hernandez TL, Van Pelt RE, Anderson MA, Daniels LJ, West NA,
Donahoo WT, et al. A higher-complex carbohydrate diet in gestational
diabetes mellitus achieves glucose targets and lowers postprandial lipids:
a randomized crossover study. Diabetes Care 2014;37:1254–62
No relevant outcomes and a
crossover study
55 Hickman MA, McBride R, Boggess KA, Strauss R. Metformin compared
with insulin in the treatment of pregnant women with overt diabetes:
a randomized controlled trial. Am J Perinatol 2013;30:483–90
Includes pre-existing diabetics
56 Homko CJ, Deeb LC, Rohrbacher K, Mulla W, Mastrogiannis D, Gaughan J,
et al. Impact of a telemedicine system with automated reminders on
outcomes in women with gestational diabetes mellitus. Diabetes Technol
Ther 2012;14:624–9
Telemedicine
57 Homko CJ, Santamore WP, Whiteman V, Bower M, Berger P,
Geifman-Holtzman O, et al. Use of an internet-based telemedicine
system to manage underserved women with gestational diabetes mellitus.
Diabetes Technol Ther 2007;9:297–306
Telemedicine
58 Homko CJ, Sivan E, Reece EA. The impact of self-monitoring of blood
glucose on self-efficacy and pregnancy outcomes in women with
diet-controlled gestational diabetes. Diabetes Educ 2002;28:435–43
Monitoring
59 Hopp H, Vollert W, Ragosch V, Novak A, Weitzel HK, Glöckner E, et al.
Indication and results of insulin therapy for gestational diabetes mellitus.
J Perinat Med 1996;24:521–30
No relevant data; this trial compared
outcomes rates associated with
amniotic fluid insulin concentration
and mean blood glucose levels
60 Horvath K, Koch K, Jeitler K, Matyas E, Bender R, Bastian H, et al. Effects of
treatment in women with gestational diabetes mellitus: Systematic review
and meta-analysis. BMJ 2010;340:796
Systematic review
61 Hutchinson A, Haugabrook C, Long L, Mason L, Kipikasa J, Adair D.
A comparison between glyburide/metformin and insulin for gestational
diabetes. Am J Obstet Gynecol 2008;199:S200
No relevant outcomes
62 Ibrahim MI, Hamdy A, Shafik A, Taha S, Anwar M, Faris M. The role of
adding metformin in insulin-resistant diabetic pregnant women: a
randomized controlled trial. Archives Gynecol Obstet 2014;289:959–65
Included women with pre-pregnancy
diabetes
63 Jovanovic L, Gutierrez M, Peterson CM. Chromium supplementation for
women with gestational diabetes mellitus. J Trace Elem Exp Med
1999;12:91–7
Chromium supplementation; no
relevant outcomes
64 Jovanovic L, Howard C, Pettitt D, Zisser H, Ospina P. Insulin aspart vs.
regular human insulin in basal/bolus therapy for patients with gestational
diabetes mellitus: safety and efficacy. Diabetologia 2005;48:A317
No relevant outcomes
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TABLE 67 Chapter 6: excluded studies (continued )
No. Reference Reason
65 Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet
versus diet plus cardiovascular conditioning on glucose levels in gestational
diabetes. Am J Obstet Gynecol 1989;161:415–19
No relevant outcomes
66 Jovanovic-Peterson L, Sparks S, Palmer JP, Peterson CM. Jet-injected insulin
is associated with decreased antibody production and postprandial glucose
variability when compared with needle-injected insulin in gestational
diabetic women. Diabetes care 1993;16:1479–84
No relevant outcomes
67 Joy S, Roman A, Rebarber A, Fox N, Istwan N, Rhea D, et al. Is risk for
gestational diabetes modifiable once an obese woman is pregnant?
Am J Obstet Gynecol 2012;1:S132
No relevant outcomes
68 Kaveh M, Kiani A, Salehi M, Amouei S. Impact of education on nutrition
and exercise on the level of knowledge and metabolic control indicators
(FBS & PPBS) of gestational diabetes mellitus (GDM) patients. Iranian J
Endocrinol Met 2012;13:442–9
Non-English
69 Kavitha N, De S, Kanagasabai S. Oral hypoglycaemic agents in pregnancy.
J Obstet Gynecol India 2013;63:82–7
Review
70 Keely EJ, Malcolm JC, Hadjiyannakis S, Gaboury I, Lough G, Lawson ML.
Prevalence of metabolic markers of insulin resistance in offspring of
gestational diabetes pregnancies. Pediatr Diabetes 2008;9:53–9
Follow-up study
71 Khin MO, Vatish M, Gates S, Saravanan P. Evaluation of metformin in
gestational diabetes: Systematic review and metaanalysis. Diabet Med
2013;30:12
Abstract of systematic review
72 Klebanoff M. Treatment of gestational diabetes (GDM), weight gain and
perinatal outcome-marginal structural model (MSM) analysis. Am J
Epidemiol 2011;173:S41
Secondary analysis of Landon
2009;52 no relevant outcomes
73 Knopp RH, Magee MS, Raisys V, Benedetti T, Bonet B. Hypocaloric diets
and ketogenesis in the management of obese gestational diabetic women.
J Am Coll Nutr 1991:649–67
No relevant outcomes
74 Lain K, Garabedian M, Daftary A, Jeyabalan A. Neonatal adiposity following
maternal treatment of gestational diabetes with glyburide compared to
insulin. 2008:S34
No relevant outcomes
75 Landon MB, Thom E, Spong CY, Carpenter M, Mele L, Johnson F, et al. The
National Institute of Child Health and Human Development Maternal-Fetal
Medicine Unit Network randomized clinical trial in progress: standard
therapy versus no therapy for mild gestational diabetes. Diabetes Care
2007;30:S194–9
Trial in progress
76 Landon MB. A prospective multicenter randomized treatment trial of mild
gestational diabetes (GDM). Am J Obstet Gynecol 2008;196:S2
Abstract of Landon 200952
77 Landon MB, Thom E, Spong CY, Gabbe SG, Leindecker S, Johnson F, et al.
A planned randomized clinical trial of treatment for mild gestational
diabetes mellitus. J Matern Fetal Neonatal Med 2002:4:226–31
Planned trial
78 Landon M. Mild gestational diabetes mellitus (GDM) treatment and long
term child health. Am J Obstet Gynecol 2014;210:S408–9
Follow-up of included trial; no
relevant outcomes
79 Langer O, Anyaegbunam A, Brustman L, Divon M. Management of women
with one abnormal oral glucose tolerance test value reduces adverse
outcome in pregnancy. Am J Obstet Gynecol 1989;161:593–9
Ineligible intervention
80 Langer O, Conway D, Berkus M, Xenakis EMJ. Oral hypoglycaemic agent
is comparable to insulin in GDM management. Am J Obstet Gynecol
1999;1(Pt 2):S6
Preliminary for a subsequently
published trial
81 Langer O, Rodriguez DA, Xenakis EM, McFarland MB, Berkus MD,
Arrendondo F. Intensified versus conventional management of gestational
diabetes. Am J Obstet Gynecol 1994;4:1036–46; discussion 46–7
No relevant outcomes
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TABLE 67 Chapter 6: excluded studies (continued )
No. Reference Reason
82 Langer O, Yogev Y, Xenakis EMJ, Rosenn B. Insulin and glyburide therapy:
dosage, severity level of gestational diabetes, and pregnancy outcome.
Am J Obstet Gynecol 2005;1:134–9
Secondary analysis
83 Langer O, Yogev Y, Xenakis EM, Brustman L. Overweight and obese in
gestational diabetes: the impact on pregnancy outcome. Am J Obstet
Gynecol 2005:6:1768–76
Outcomes by BMI
84 Lauszus FF, Rasmussen OW, Henriksen JE, Klebe JG, Jensen L, Lauszus KS,
et al. Effect of a high monounsaturated fatty acid diet on blood pressure
and glucose metabolism in women with gestational diabetes mellitus.
Eur J Clin Nutr 2001:6:436–43
No relevant outcomes
85 Lepercq J, Lin J, Hall GC, Wang E, Dain M-P, Riddle MC, et al.
Meta-analysis of maternal and neonatal outcomes associated with
the use of insulin glargine versus NPH insulin during pregnancy.
Obstet Gynecol Int 2012:649070
Meta-analysis not based on RCTs
86 Lesser KB, Gruppuso PA, Terry RB, Carpenter MW. Exercise fails to improve
postprandial glycemic excursion in women with gestational diabetes.
J Matern Fetal Med 1996;4:211–17
No relevant outcomes
87 Magee MS, Knopp RH, Benedetti TJ. Metabolic effects of 1200-kcal diet in
obese pregnant women with gestational diabetes. Diabetes 1990;2:234–40
No relevant outcomes
88 Mahdian M, Behrashi M, Aliasgharzadeh A. Effects of zinc supplementation
on glycemic control and complications of gestational diabetes. Pakistan J
Med Sci 2011;27:1203–6
Ineligible treatment
89 Martinez P, Abdulhaj Martinez M, Andres Nunez P, Garcia Leon P,
Lopez Sanchez EJ, Gonzalez Ramirez AR. A randomized study comparing
metformin and insulin in the treatment of gestational diabetes mellitus.
Interim results. J Maternal Fetal Neonatal Med 2010;S1:381
No relevant outcome data
90 Maso G, Alberico S, Wiesenfeld U, Ronfani L, Erenbourg A, Hadar E, et al.
GINEXMAL RCT: Induction of labour versus expectant management in
gestational diabetes pregnancies. BMC Pregnancy Childbirth 2011;11:31
Protocol
91 Maslovitz S, Shenhav M, Bibi G, Pauzner D, Many A. Insulin combined with
metformin for glucose control of diabetes during pregnancy. Am J Obstet
Gynecol 2012;1:S132–3
Retrospective trial; abstract only
92 Mathews JE, Biswas B, Samuel P, Jana AK, Muliyil JP, Mathai M.
Retrospective cohort study comparing neonatal outcomes of women
treated with glyburide or insulin in gestational diabetes: a 5-year experience
in a South Indian teaching hospital. Indian J Med Sci 2011;65:476–81
Not an RCT
93 Mendelson SG, McNeese-Smith D, Koniak-Griffin D, Nyamathi A, Lu MC. A
community-based parish nurse intervention program for Mexican American
women with gestational diabetes. J Obstet Gynecol Neonatal Nurs
2008;4:415–25
No relevant outcomes
94 Middleton PF, Collins CT, Crowther CA, Flenady V, Makrides M,
Rumbold A, et al. Dietary influences on diabetes in pregnancy: a
systematic review. J Paediatr Child Health 2011;47:40
Systematic review
95 Moore L, Clokey D, Curet L. A randomized controlled trial of metformin
and glyburide in gestational diabetes. Am J Obstet Gynecol
2008;6(Suppl. 1):34
Abstract of Moore 2010192
96 Moore L, Clokey D, Robinson A. A randomized trial of metformin compared
to glyburide in the treatment of gestational diabetes. Am J Obstet Gynecol
2005;6(Suppl.):92
Abstract of Moore 2010192
97 Moses RG, Barker M, Winter M, Petocz P, Brand-Miller JC. Can a
low-glycemic index diet reduce the need for insulin in gestational
diabetes mellitus? A randomized trial. Diabetes Care 2009:6:996–1000
No relevant outcomes
98 Moss JR, Crowther CA, Hiller JE, McPhee AJ, Jeffries WS, Willson KJ.
Costs and consequences of treatment of gestational diabetes mellitus –
evaluation from the ACHOIS randomised trial. J Paediatr Child Health
2007;43(Suppl. 1):A28–9
Economics paper
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No. Reference Reason
99 Moss JR, Crowther CA, Hiller JE, Willson KJ, Robinson JS. Costs and
consequences of treatment for mild gestational diabetes mellitus –
evaluation from the ACHOIS randomised trial. BMC Pregnancy Childbirth
2007;7:27
Economics paper
100 Ney D, Hollingsworth DR, Cousins L. Decreased insulin requirement
and improved control of diabetes in pregnant women given a
high-carbohydrate, high-fiber, low-fat diet. Diabetes Care 1982;5:529–33
No relevant outcomes
101 Nolan CJ. Improved glucose tolerance in gestational diabetic women on a
low fat, high unrefined carbohydrate diet. Aust N Z J Obstet Gynaecol
1984;3:174–7
No relevant outcomes
102 Nor Azlin MI, Nor NA, Sufian SS, Mustafa N, Jamil MA, Kamaruddin NA.
Comparative study of two insulin regimes in pregnancy complicated by
diabetes mellitus. Acta Obstet Gynecol Scand 2007;4:407–8
No relevant outcomes
103 O’Sullivan JB, Mahan CM, Charles D, Dandrow RV. Medical treatment of
the gestational diabetic. Obstet Gynecol 1974;43:817–21
Secondary analysis of O’Sullivan
1966211
104 O’Sullivan JB, Mahan CM. Insulin treatment and high risk groups.
Diabetes Care 1980;3:482–5
No relevant outcomes; secondary
analysis of O’Sullivan 1966211
105 Page RC, Harnden KE, Walravens NK, Onslow C, Sutton P, Levy JC, et al.
‘Healthy living’ and sulphonylurea therapy have different effects on glucose
tolerance and risk factors for vascular disease in subjects with impaired
glucose tolerance. Q J Med 1993;3:145–54
Not GDM
106 Perichart-Perera O, Balas-Nakash M, Rodriguez-Cano A, Legorreta-Legorreta J,
Parra-Covarrubias A, Vadillo-Ortega F. Low glycemic index carbohydrates
versus all types of carbohydrates for treating diabetes in pregnancy:
a randomized clinical trial to evaluate the effect of glycemic control.
Int J Endocrinol 2012:296017
No relevant outcomes
107 Ong MJ, Guelfi KJ, Hunter T, Wallman KE, Fournier PA, Newnham JP.
Supervised home-based exercise may attenuate the decline of glucose
tolerance in obese pregnant women. Diabetes Metab 2009;35:418–21
Not GDM
108 Pettitt DJ, Ospina P, Howard C, Zisser H, Jovanovic L. Efficacy, safety and
lack of immunogenicity of insulin aspart compared with regular human
insulin for women with gestational diabetes mellitus. Diabet Med
2007;10:1129–35
No relevant outcome data
109 Pirc LK, Owens JA, Crowther CA, Willson K, Blasio MJ, Robinson JS. Mild
gestational diabetes in pregnancy and the adipoinsular axis in infants born
to mothers in the ACHOIS randomised controlled trial. BMC Pediatrics
2007;7:18
No relevant outcomes
110 Reader D, Splett P, Gunderson EP. Impact of gestational diabetes mellitus
nutrition practice guidelines implemented by registered dietitians on
pregnancy outcomes. J Am Diet Assoc 2006;106:1426–33
Nutrition guidelines
111 Reece EA, Hagay Z, Gay LJ, O’Connor T, DeGennaro N, Homko CJ. A
randomized clinical trial of a fiber-enriched diabetic diet vs. the standard
American Diabetes Association-recommended diet in the management of
diabetes mellitus in pregnancy. J Maternal Fetal Invest 1995;1:8–12
No relevant outcome data
112 Rosales L, Morales F, Stuardo P, Marquez J, Barria M, Martinovic C.
Metabolic profile in diet treated and glibenclamide treated gestational
diabetes. J Perinat Med 2011;39
No relevant outcome data
113 Rowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM.
Metformin in gestational diabetes: the offspring follow-up (MiG TOFU):
body composition at 2 years of age. Diabetes Care 2011;34:2279–84
No relevant outcomes
114 Rowan JA, Gao W, Hague WM, McIntyre HD. Glycemia and its relationship
to outcomes in the metformin in gestational diabetes trial. Diabetes Care
2010;1:9–16
Secondary analysis of Rowan 2008180
(MiG); no relevant outcomes
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No. Reference Reason
115 Schaefer-Graf UM, Kjos SL, Fauzan OH, Buhling KJ, Siebert G, Buhrer C.
A randomized trial evaluating a predominately fetal growth-based strategy
to guide management of gestational diabetes in Caucasian women.
Diabetes Care 2004;27:297–302
Ineligible intervention
116 Silva JC, Pacheco C, Bizato J, Souza BV, Ribeiro TE, Bertini AM. Metformin
compared with glyburide for the management of gestational diabetes.
Int J Gynaecol Obstet 2010;1:37–40
Preliminary publication of Silva
2010213 (114)
117 Macrosomia: results and preventions strategies. Rev Bras Ginecol Obstet
2005;8:461–6
Preliminary results of Silva and
non-English
118 Singh S, Mahajan S, Aswani R, Trader B, Hale S, Mullarky L. Outcome of an
Appalachian pregnant diabetics managed @perinatal diabetes center (PDC)
on modified ADA diet calorie, carbohydrate (CHO) (restricted and on either
conventional insulin therapy regular/NPH) or analog insulin novolog
(glargine or detemir) therapy. 70th Scientific Sessions of the American
Diabetes Association Orlando, FL, USA, 2010
Retrospective observational cohort
review
119 Sugiyama T, Hiramatsu Y, Sagawa N, Yaegashi N. A retrospective
multi-institutional study of the treatment of mild gestational diabetes in
Japan. 73rd Scientific Sessions of the American Diabetes Association July;
Chicago, IL, USA, 2013, A362
Not an RCT
120 Sugiyama T, Metoki H, Hamada H, Nishigori H, Saito M, Yaegashi N, et al.
A retrospective multi-institutional study of treatment for mild gestational
diabetes in Japan. Diabetes Res Clin Pract 2014;103:412–18
Not an RCT and duplicate of 118
121 Tertti, K, Laine K, Ekblad U, Rinne V, Rönnemaa T. The degree of fetal
metformin exposure does not influence fetal outcome in gestational
diabetes mellitus. Acta Diabetologica 2014;51:731–8
No relevant outcomes
122 Todorova K, Palaveev O, Petkova VB, Stefanova M, Dimitrova Z. A
pharmacoeconomical model for choice of a treatment for pregnant women
with gestational diabetes. Acta Diabetologica 2007;3:144–8
Not RCT
123 Tuuli M, Caughey A, Odibo A, Macones G, Cahill A. Glyburide versus
insulin for management of gestational diabetes: a systematic review and
meta-analysis. Am J Obstet Gynecol 2012;1:S170–1
Abstract of a systematic review
124 Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, et al.
Postprandial versus preprandial blood glucose monitoring in women with
gestational diabetes mellitus requiring insulin therapy. N Engl J Med
1995;333:1237–41
Monitoring trial
125 Yang X, Hsu-Hage BH, Dong L, Zhang H, Zhang C, Zhang Y. Postpartum
glucose intolerance in Chinese women with gestational diabetes. Diabet
Med 2003;20:687–9
Letter linked to Yang 2003199
126 Zanganeh M. The comparative study of therapeutic effects of insulin and
glibenclamide in the gestational diabetes mellitus. Iranian Registry of
Clinical Trials. URL: www.irct.ir (accessed April 2015)
No published data
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Appendix 6 Tables and figures for Chapter 7
TABLE 69 Summary of Chapter 7, with assumptions and justifications for key aspects and signposts to the
relevant sections
Key aspects Approach Assumptions/Justification Section in Chapter 7
Model Cost-effectiveness (cost–utility)
analysis using a decision tree
– Decision-analytic model
Population Obstetric population –
Time horizon Three months (third
pregnancy trimester)
l Relevant period of time where
women are expected to have
differential costs and QALYs,
depending of branch in the model
l Period includes the interval of time
in which women are usually
diagnosed and treated for GDM
¢ It was not possible to explore
alternative time frames for
screening, diagnosis and
treatment, as data
were unavailable
Adverse perinatal outcomes
Comparators (a) No intervention
(b) Screen only: screening
followed by dietary and
lifestyle advice for those who
screen positive
(c) Universal diagnostic test:
diagnostic test followed by
dietary and lifestyle advice
with pharmacological
treatment as required for
those who exceed a
diagnostic threshold
(d) Screen and diagnostic test:
screening followed by
diagnostic test in those who
screen positive, with dietary
and lifestyle advice and
pharmacological treatment as
required for those who exceed
a diagnostic threshold
(screening strategies
combined with the test using
best-performing diagnostic
threshold)
– Additional screen, diagnosis
and treatment strategies
Subgroups 1. SA and other
2. WB
Screening and
diagnostic
l Post-load glucose threshold should
be at least 0.5mmol/l higher than
the corresponding fasting glucose
¢ To restrict number of possible
combinations in the model
Blood-based tests for
hypoglycaemia in pregnancy
continued
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TABLE 69 Summary of Chapter 7, with assumptions and justifications for key aspects and signposts to the relevant
sections (continued )
Key aspects Approach Assumptions/Justification Section in Chapter 7
Clinical outcomes Perinatal adverse outcomes
with impact on costs and/or
HRQL that were available
in the BiB22 and Atlantic DIP59
cohorts, or could be modelled
by including external data:
pre-eclampsia; CS; shoulder
dystocia; instrumental delivery;
induction of labour; admission
to a neonatal care unit;
macrosomia; neonatal death;
and birth trauma
l Pre-eclampsia affects rates of
C-section
¢ Our clinical advisors agree that
pre-eclampsia has an impact
on the decision on whether or
not to perform C-section
Adverse perinatal outcomes
l Shoulder dystocia and instrumental
delivery are not possible in women
who undergo C-section
¢ Our clinical advisors
considered that it is unlikely
for either outcome to be
simultaneous with C-section
l Rates of birth trauma and neonatal
death are proportional to the rate
of shoulder dystocia
¢ Based on previous NICE
guidance18 and published
RCT data51,52
Baseline risk models were
estimated in a combined data
set with BiB and Atlantic
DIP31,59 data
l Inclusion of dummy variable
‘Centre’ (which identifies the
data set of origin), alongside
the maternal characteristics
covariables, in the risk models
controls for baseline risk
differences in the data sets
¢ Risk models include a number
of observed maternal
characteristics that explain
population risk, and any
unobserved differences are
considered to be captured in
the variable ‘Centre’
¢ Improves statistical power of
the models
Baseline probabilities of
perinatal outcomes
Missing data on outcome
models was handled with
MICE
l MICE assumes that data are
missing at random (i.e. dependent
on observable characteristics alone)
¢ This method is considered
superior to complete case
analysis in general, as it
produces less biased and
more efficient estimates40
Maternal prevalence of
undiagnosed overt type 2
diabetes and incidence if
type 2 associated to prior
GDM are included in
scenario analysis
l Prevalence of undiagnosed overt
type 2 diabetes assumed to
be 11%
¢ Based on a study of obstetric
population with similar
characteristics to the BiB
cohort233 and consistent with
other studies127,234
Incidence of type 2 diabetes
among women with a
history of gestational
diabetes mellitus
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TABLE 69 Summary of Chapter 7, with assumptions and justifications for key aspects and signposts to the relevant
sections (continued )
Key aspects Approach Assumptions/Justification Section in Chapter 7
l The proportion of women with
previous GDM at higher risk of
type 2 diabetes (because of IGT)
later in life corresponds to women
who test positive for GDM and
have a BMI ≥ 30 kg/m2 at
booking appointment
¢ This was used to circumvent
lack of data and was
considered reasonable, as it is
to be applied in a scenario
analysis
Treatment
effectiveness
RR of adverse perinatal
outcomes on treated vs.
untreated women with GDM
l Treatment in the meta-analysis
that compares diet modification or
advice, accompanied by glucose
monitoring and insulin use in some
women, to routine antenatal care
(see Chapter 6), is reflective of
current UK recommended
treatment for GDM
¢ Although the trials in the
meta-analysis did not include
metformin treatment, the
treatment review (see Chapter 6)
suggested that metformin and
insulin were generally
comparable in terms of effects
¢ Scenario analysis was
conducted with alternative
treatment effect estimates
from two high-quality trials51,52
Treatment effects
l Magnitude of the relative
treatment effect will remain
constant regardless of the mean
glucose levels in the treated groups
¢ Supporting evidence from
subgroup analysis by definition
of GDM in Chapter 6
l Treatment effect on NICU assumed
equivalent to NNU
¢ Lack of evidence for NNU
treatment effect
l In the absence of blood glucose
testing, treatment will not include
pharmacological interventions
¢ Supported by clinical
advisories input
¢ RR on treatment in the
absence of blood glucose
testing is the same as for
base-case treatment
(RR = 1.37)
¢ In the absence of data, a
conservative estimate was
applied, as base-case
treatment increases the risk of
instrumental delivery
continued
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TABLE 69 Summary of Chapter 7, with assumptions and justifications for key aspects and signposts to the relevant
sections (continued )
Key aspects Approach Assumptions/Justification Section in Chapter 7
Uptake Model includes uptake
estimates on screening,
diagnostic, treatment and
post-partum follow-up
l Uptake is not a function of the
population characteristics
¢ Lack of data; likely to be
captured within the uptake
estimates from the
studies used
Uptake of screening
diagnosis and treatment
l Risk factor screening uptake
is 100%
¢ Can easily be integrated in
current routine antenatal care
l Diagnostic test uptake differs
(increases) whether it is offered to
a population identified by
screening as high risk of GDM or
an unscreened population
¢ Based on existing evidence124,228
¢ Sensitivity analysis is used to
explore the impact of lower
uptake of diagnostic estimates
for risk factor-screened women
l Treatment uptake is 100%
¢ Reduced treatment uptake is
partially reflected on RR
estimates as they are sourced
from studies that use
intention-to-treat analysis
l Six weeks’ post-partum follow-up
uptake is similarly affected
whether it is offered to a screened
or an unscreened population, in
this case both having been
diagnosed as GDM:
¢ Based on existing, but scarce,
evidence127,233,241 lower
alternative uptake estimates
applied in exploratory analysis
HRQL QALY loss from adverse
perinatal outcomes
(pre-eclampsia, CS, shoulder
dystocia, instrumental delivery,
neonatal death, and birth
trauma)
l QALY loss from pre-eclampsia is
attributed to severe complications
of pre-eclampsia alone, and
maintained for a fixed period of
2 weeks
¢ Based on previous NICE
guidance243 and considered
reasonable by our
clinical advisors
Health-related quality of life
loss from adverse perinatal
outcomes
l QALY loss from birth trauma is
similar to that of shoulder dystocia
¢ Based on previous NICE
guidance18 and considered
reasonable by our
clinical advisors
l QALY loss from instrumental
delivery is attributed to permanent
urinary incontinence alone
¢ Based on previous NICE
guidance18 and considered
reasonable by our
clinical advisors
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TABLE 69 Summary of Chapter 7, with assumptions and justifications for key aspects and signposts to the relevant
sections (continued )
Key aspects Approach Assumptions/Justification Section in Chapter 7
QALY gain from treatment of
hyperglycaemia
l QALY gain from treatment of
hyperglycaemia is maintained for
the duration of treatment in
the model
¢ Based on previous NICE
guidance18 and considered
reasonable by our
clinical advisors
QALY gain from prevention of
type 2 diabetes
QALY gain from early
detection of overt diabetes at
post-partum follow-up
l QALY gain from treatment of
hyperglycaemia is independent of
glucose levels:
¢ Lack of evidence for HRQL
depending on mean glucose
levels; small size of benefit
(0.0050) to have differential
impact on HRQL according to
mean glucose at the diagnostic
thresholds evaluated in
the model
¢ Women who have had GDM
and who develop type 2
diabetes later in life, develop
it, on average, 15 years after
pregnancy, and would, on
average, experience 10.5 years
of asymptomatic diabetes
before progressing to
symptomatic diabetes
¢ Based on previous cost-
effectiveness study in GDM244
and considered a reasonable
approximation for scenario
analysis according to our
clinical advisors
Health-related quality of life
gains from the prevention
of maternal type 2 diabetes
Net benefit of early
detection of diabetes
l QALY loss associated with severe
hypoglycaemia is negligible
¢ Short duration unlikely to
impact on overall HRQL;
incurred by a very small
proportion of treated women
Adverse events Hypoglycaemia resulting from
treatment for GDM
l Only severe hypoglycaemia
has an impact on HRQL and costs,
and it occurs in 5% of all
hypoglycaemia events
¢ Based on assumption in
previous NICE guidance18
Treatment effects
l Only insulin can lead to
severe hypoglycaemia
¢ Supported by clinical
advisories input
continued
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TABLE 69 Summary of Chapter 7, with assumptions and justifications for key aspects and signposts to the relevant
sections (continued )
Key aspects Approach Assumptions/Justification Section in Chapter 7
Resource use and
costs
Resource use and costs
categories in the model
include blood-based tests,
adverse perinatal outcomes,
treatment of hyperglycaemia,
prevention of type 2 diabetes
and early detection of overt
diabetes
l All assumptions underlying
resource use and costs are based
on the previous NICE guidance,18
with the exception of:
¢ Cost of OGCT assumed the
same as cost of OGTT
¢ Duration of health assistant
time spent on FPG assumed to
be 10 minutes – half the time
compared with OGTT
¢ Same laboratory costs for all
blood-based tests
¢ Band 6 NHS professional
assumed to deliver advice and
instruction on all categories
where previous NICE guidance
had assumed band 7.18 Band 5
dietitian assumed to deliver
advice instead of band 7, as in
previous NICE guidance.18
Treatment bundle assumed to
be composed of 28% insulin,
35% metformin, 100% diet
and advice, based on data
reported in previous NICE
guidance.18 This was varied in
a scenario analysis
¢ ILS assumptions in terms of
composition of treatment were
based on published literature
(Diabetes Prevention Program
Research Group, 2012) and
clinical opinion
Resource use and costs
Discount rates Annual rate of 3.5% for costs
early detection of overt
diabetes post partum and
HRQL gains and losses realised
after post-partum period
No discount rate was applied to costs
which were assumed to occur within
12 months of testing (screening and/or
diagnosis) in accordance with current
guidance225
Resource use and costs
Sensitivity analysis Sensitivity analysis includes
probabilistic sensitivity analysis
and scenario analysis. The
scenarios assessed in the
analysis include:
1. inclusion of longer-
term outcomes
2. alternative estimates of
treatment effectiveness
3. alternative estimates of
treatment cost
4. alternative estimates of
diagnostic test uptake
– Sensitivity and scenario
analysis
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TABLE 70 Risk factor screening strategies applied in the model
Strategy
Screen positive determined on the basis of at least one factor: risk factor criteria
Previous
GDM
Previous
macrosomia
BMI
(kg/m2) ≥ Multiparous
Maternal
age ≥
Non-white
ethnicity
Family history
of diabetes
1 ✗
2 ✗
3 30
4 ✗
5 30
6 25
7 ✗
8 25
9 ✗ ✗
10 ✗ 30
11 ✗ ✗
12 ✗ ✗
13 ✗ 30
14 30 ✗
15 30 30
16 25 30
17 ✗ 25
18 30 ✗
19 30 25
20 25 ✗
21 25 ✗
22 25 25
23 ✗ 30 ✗
24 ✗ 30 30
25 ✗ 30 ✗
26 30 ✗ 30
27 30 30 ✗
28 ✗ 25 30
29 ✗ 30 ✗
30 25 30 ✗
31 ✗ 30 25
32 30 25 ✗
33 30 30 ✗
34 25 25 ✗
35 ✗ 25 ✗
36 25 30 ✗
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TABLE 70 Risk factor screening strategies applied in the model (continued )
Strategy
Screen positive determined on the basis of at least one factor: risk factor criteria
Previous
GDM
Previous
macrosomia
BMI
(kg/m2) ≥ Multiparous
Maternal
age ≥
Non-white
ethnicity
Family history
of diabetes
37 30 25 ✗
38 25 25 ✗
39 30 ✗ ✗
40 30 ✗ ✗
41 ✗ 30 ✗ 30
42 ✗ 30 30 ✗
43 ✗ 25 30 ✗
44 ✗ 30 25 ✗
45 ✗ 30 30 ✗
46 ✗ 25 25 ✗
47 ✗ 25 ✗ ✗
48 ✗ 25 30 ✗
49 ✗ 30 25 ✗
50 30 ✗ ✗ ✗
51 ✗
52 ✗ 25
53 25 ✗
54 ✗ 25 ✗
55 30 ✗
56 ✗ 30 ✗
57 ✗ 30 ✗ ✗
58 30 ✗ ✗
59 ✗ 30 ✗ ✗
60 30 30 ✗ ✗
61 ✗ 30 30 ✗ ✗
62 25 ✗ ✗
63 ✗ 25 ✗ ✗
64 30 ✗
65 ✗ 30 ✗
66 ✗ 25 ✗
67 30 ✗ ✗
68 ✗ 30 ✗ ✗
69 ✗ ✗ 30 ✗ ✗
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TABLE 71 Outcome criteria
Strategy Criteria
1 Previous GDM pregnancy
2 Previous macrosomic baby
3 BMI ≥ 30 kg/m2
4 Multiparous
5 Maternal age ≥ 30 years
6 Maternal age ≥ 25 years
7 Non-white ethnicity
8 BMI ≥ 25 kg/m2
9 Previous GDM pregnancy or previous macrosomic baby
10 BMI ≥ 30 kg/m2 or previous GDM pregnancy
11 Family history of diabetes mellitus or previous GDM pregnancy
12 Multiparous or previous GDM pregnancy
13 Maternal age ≥ 30 years or previous GDM pregnancy
14 BMI ≥ 30 kg/m2 or family history of diabetes
15 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2
16 Maternal age ≥ 30 years or BMI ≥ 25 kg/m2
17 Maternal age ≥ 25 years or previous GDM pregnancy
18 BMI ≥ 30 kg/m2 or non-white ethnicity
19 Maternal age ≥ 25 years or BMI ≥ 30 kg/m2
20 Maternal age ≥ 25 years or non-white ethnicity
21 BMI ≥ 25 kg/m2 or non-white ethnicity
22 Maternal age ≥ 25 years or BMI ≥ 25 kg/m2
23 BMI ≥ 30 kg/m2 or family history of diabetes mellitus or previous GDM pregnancy
24 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or previous GDM pregnancy
25 Maternal age ≥ 30 years or family history of diabetes mellitus or previous GDM pregnancy
26 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or multiparous or
27 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or family history of diabetes
28 Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or previous GDM pregnancy
29 BMI ≥ 30 kg/m2 or non-white ethnicity or previous GDM pregnancy
30 Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 family history of diabetes
31 Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or previous GDM pregnancy
32 Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or family history of diabetes
33 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or non-white ethnicity
34 Maternal age ≥ 25 years or BMI ≥ 25 kg/m2 or family history of diabetes
35 Maternal age ≥ 25 years or non-white ethnicity or previous GDM pregnancy
36 Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or non-white ethnicity
37 Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or non-white ethnicity
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TABLE 71 Outcome criteria (continued )
Strategy Criteria
38 Maternal age ≥ 25 years or BMI ≥ 25 kg/m2 or non-white ethnicity
39 BMI ≥ 30 kg/m2 or non-white ethnicity or multiparous
40 BMI ≥ 30 kg/m2 or non-white ethnicity or family history of diabetes
41 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or multiparous or previous GDM pregnancy
42 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or family history of diabetes or previous GDM pregnancy
43 Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or previous GDM pregnancy
44 Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or family history of diabetes mellitus or previous GDM pregnancy
45 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or non-white ethnicity or previous GDM pregnancy
46 Maternal age ≥ 25 years or BMI ≥ 25 kg/m2 or family history of diabetes or previous GDM pregnancy
47 Maternal age ≥ 25 years or Non-white ethnicity or family history of diabetes or previous GDM pregnancy
48 Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or non-white ethnicity or previous GDM pregnancy
49 Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or non-white ethnicity or previous GDM pregnancy
50 BMI ≥ 30 kg/m2 or non-white ethnicity or multiparous or family history of diabetes
51 Family history of diabetes
52 BMI ≥ 25 kg/m2 or previous GDM pregnancy
53 BMI ≥ 25 kg/m2 or family history of diabetes
54 BMI ≥ 25 kg/m2 or family history of diabetes or previous GDM pregnancy
55 Maternal age ≥ 30 years or non-white ethnicity
56 Maternal age ≥ 30 years or non-white ethnicity or previous GDM pregnancy
57 BMI ≥ 30 kg/m2 or non-white ethnicity or family history of diabetes or previous GDM pregnancy
58 Maternal age ≥ 30 years or non-white ethnicity or family history of diabetes
59 Maternal age ≥ 30 years or non-white ethnicity or family history of diabetes or previous GDM pregnancy
60 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or non-white ethnicity or family history of diabetes
61 Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or non-white ethnicity or family history of diabetes or previous
GDM pregnancy
62 BMI ≥ 25 kg/m2 or non-white ethnicity or family history of diabetes
63 BMI ≥ 25 kg/m2 or non-white ethnicity or family history of diabetes or previous GDM pregnancy
64 BMI ≥ 30 kg/m2 or Multiparous
65 BMI ≥ 30 kg/m2 or multiparous or previous GDM pregnancy
66 BMI ≥ 25 kg/m2 or non-white ethnicity or previous GDM pregnancy
67 BMI ≥ 30 kg/m2 or multiparous or family history of diabetes
68 BMI ≥ 30 kg/m2 or multiparous or family history of diabetes or previous GDM pregnancy
69 NICE criteria
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TABLE 73 Summary of model parameters for the base-case analysis
Variable Value Distribution Source
Uptake
Universal OGTT 62.83% Beta
α = 11,516
β = 6182
Farrar 2014124
Selective RF OGTT 89.66%
Average A (99.05%) and
B (80.26%)
Beta (A)
α = 1151 β = 11
Farrar 2014124
Beta (B)
α = 122 β = 30
Holt 2003235
6 weeks’ follow-up for
universally OGTT
52.24% Beta
α = 35
β = 32
Gregory 1998127
6 weeks’ follow-up for selective
RF OGTT
82.84% Beta
α = 985
β = 204
McClean 2010233
Preventative treatment with ILS 57.50% Deterministic DPPOS 2012251
Probabilities
Perinatal outcomes Logistic regression parameters Log-normal BiB22 and Atlantic DIP59 data
Hypoglycaemia, given
treatment with insulin
0.2020 Beta
α = 41
β = 162
Langer 2000187
Severe hypoglycaemia, given
hypoglycaemia
0.05 Deterministic Assumption
Diabetes in pregnancy, NICE
guideline 201518
Incidence of post-partum type 2
diabetes mellitus
0.1107 Beta
α = 109
β = 876
McClean 2010233
10-year risk of developing type 2
diabetes mellitus, given GDM
0.1480 Calculated Aroda 2015239
BMI ≥ 20 kg/m2, given GDM Variable across diagnostic
thresholds
Beta BiB data22
Treatment effect
NICU 0.91 Log-normal
(LNSE) = 0.197
Treatment review, Chapter 5
Shoulder dystocia 0.39 Log-normal
(LNSE) = 0.280
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TABLE 73 Summary of model parameters for the base-case analysis (continued )
Variable Value Distribution Source
C-section 0.86 Log normal
(LNSE) = 0.054
Pre-eclampsia 0.58 Log normal
(LNSE) = 0.242
Induction 1.12 Log normal
(LNSE) = 0.157
Instrumental 1.37 Log normal
(LNSE) = 0.979
Macrosomia 0.46 Log normal
(LNSE) = 0.130
Prevention of type 2 diabetes
mellitus
0.3520 – Aroda 2015239
HRQL (utilities)
C-section –0.0017 Deterministic C-section, NICE guideline
201133
Pre-eclampsia –0.0046 Deterministic Hypertension in pregnancy,
NICE guideline 2007243
Instrumental birth –0.0526 Deterministic C-section, NICE guideline
201133
Serious perinatal complications –2.0594 Deterministic Diabetes in pregnancy, NICE
guideline 2015240 Calculated
Maternal during pregnancy
untreated
0.1750 Beta
SE = 0.02
Crowther 200551
Maternal during pregnancy
treated
0.1800 Beta
SE = 0.03
Maternal post partum,
untreated
0.1975 Beta
SE = 0.02
Maternal post partum, treated 0.2000 Beta
SE = 0.02
Early treatment of type 2
diabetes mellitus QALY gain
0.045 Normal
S = 0.046
Gillies 2008238
Prevention of type 2 diabetes
mellitus with ILS
0.20 – Calculated
Type 2 diabetes mellitus
without complications
–0.0621 Gamma
SE = 0.0038
Sullivan 2011246
Type 2 diabetes mellitus with
complications
–0.0565 Gamma
SE = 0.0181
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TABLE 73 Summary of model parameters for the base-case analysis (continued )
Variable Value Distribution Source
Women in general UK
population, years
– –
25–34 0.93 Beta
SE = 0.00729325
Kind 1999245
35–44 0.91 Beta
SE = 0.008588975
45–54 0.85 Beta
SE = 0.014075771
55–64 0.81 Beta
SE = 0.015320647
65–74 0.78 Beta
SE = 0.015504342
≥ 75 0.71 Beta
SE = 0.018811791
Costs (£)
Pre-eclampsia 4656.00 Deterministic Hypertension in pregnancy,
NICE guideline 2007243
C-section 884.00 Gamma
SE = 86.00
Diabetes in pregnancy, NICE
guideline 2015240
NHS reference costs
2012–13260Induction 329.00 Gamma
SE = 72.00
NICU 1118.00 Gamma
SE = 35.00
Shoulder dystocia 1256.00 Gamma
SE = 125.00
Birth trauma 1256.00 Gamma
SE = 125.00
Neonatal death 767.00 Gamma
SE = 39.00
Diabetes in pregnancy, NICE
guideline 2015240
NHS reference costs
2005–6249
Serious perinatal complications 1221.77 – Weighted average of
shoulder dystocia, birth
trauma and neonatal death
Calculated
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TABLE 73 Summary of model parameters for the base-case analysis (continued )
Variable Value Distribution Source
Instrumental birth 1086.00 Deterministic NHS reference costs
2012–13260
Calculated
Treatment for GDM 934.66 Deterministic Calculated
Diagnostic with OGTT 22.06 Deterministic Calculated
RF screening 0.00 Deterministic Assumption
Screening with OCGT 22.06 Deterministic Calculated
Screening with FPG 20.42 Deterministic Calculated
Prevention of type 2 diabetes
mellitus with ILS
3585.17 Deterministic Calculated
Treatment of early-type DM 558.07 Gamma
SE = 478.58
Gillies 2008238
Severe hypoglycaemia 629.00 Deterministic Diabetes in pregnancy, NICE
guideline 2015240
NHS reference costs
2012–13260
LNSE, log normal standard error; RF, risk factor.
Note: It was not possible to apply multivariate (log) normal distributions to parameters taken from a regression framework
(i.e. logistic regression coefficients applied to estimate baseline risk of perinatal adverse events), which is the approach
commonly used to preserve the correlation between covariables in each regression model when the probabilistic sensitivity
analysis is performed (Brigg 2006252). The variance–covariance matrices for the perinatal adverse outcomes risk models
estimated from the observational data were not positive definite matrices. As this approach includes the decomposition of
the regression variance–covariance matrix (Cholesky decomposition; Brigg 2006252), and this decomposition requires a
positive definite matrix, it was not possible to apply a multivariate normal distribution to the regression parameters. The
variance–covariance matrices for each risk model estimated suggest that the correlations between covariables were small,
and therefore, we applied independent lognormal distributions to each parameter within the risk models. This implies
assuming that the covariables within each risk model are not correlated, i.e. completely independent).
TABLE 74 Population characteristics in base-case and subgroup analysis
Characteristics Base case, n= 10,353
Subgroup
SA and other, n= 6265 WB, n= 4088
Gestational age, weeks 26.29 26.32 26.24
Maternal age, years 27.58 27.97 26.95
BMI, kg/m2 26.05 25.56 26.81
Previous GDM 0.01 0.01 0.01
Previous macrosomic baby 0.05 0.04 0.07
Ethnicity, SA 0.52 0.86 0
Ethnicity, white 0.39 0 1
Ethnicity, other 0.08 0.14 0
No previous pregnancy 0.41 0.36 0.48
One previous pregnancy 0.29 0.27 0.317
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TABLE 74 Population characteristics in base-case and subgroup analysis (continued )
Characteristics Base case, n= 10,353
Subgroup
SA and other, n= 6265 WB, n= 4088
Two previous pregnancies 0.16 0.19 0.13
Three or more previous pregnancies 0.13 0.18 0.07
Family history of diabetes mellitus 0.25 0.34 0.13
Never smoker 0.70 0.88 0.41
Past smoker 0.16 0.07 0.25
Smoker during pregnancy 0.14 0.05 0.34
Alcohol in pregnancy 0.20 0.04 0.44
Fasting glucose, mmol/l 4.52 4.60 4.41
Post-load glucose, mmol/l 5.68 5.83 5.44
TABLE 75 Base case: cost-effectiveness summary results for non-dominated strategies, £20,000 per QALY
Screening strategy S+T+ S+T– S+ S– Cost (£) QALY NMB (£)
Multiparous or previous GDM pregnancy 0.005 0.294 0.30 0.70 480.92 –0.0360 –1201.75
Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 0.013 0.466 0.48 0.52 500.06 –0.0355 –1210.23
Previous macrosomic baby 0.05 0.95 526.72 –0.0350 –1227.14
Previous GDM pregnancy or previous macrosomic
baby
0.06 0.94 533.86 –0.0347 –1228.80
BMI ≥ 30 kg/m2 0.21 0.79 633.92 –0.0311 –1256.01
BMI ≥ 30 kg/m2 or previous GDM pregnancy 0.22 0.78 638.64 –0.0310 –1257.85
Family history of diabetes mellitus or previous GDM
pregnancy
0.26 0.74 676.20 –0.0308 –1291.88
Multiparous or previous GDM pregnancy 0.30 0.70 700.55 –0.0306 –1313.52
Maternal age ≥ 30 years 0.35 0.65 745.91 –0.0295 –1335.90
Maternal age ≥ 30 years or previous GDM pregnancy 0.36 0.64 748.51 –0.0294 –1336.40
BMI ≥ 30 kg/m2 or family history of diabetes mellitus 0.41 0.59 788.88 –0.0276 –1340.29
BMI ≥ 30 kg/m2 or family history of diabetes mellitus
or previous GDM pregnancy
0.42 0.58 791.51 –0.0275 –1341.31
BMI ≥ 30 kg/m2 or multiparous 0.45 0.55 813.69 –0.0272 –1356.89
BMI ≥ 30 kg/m2 or multiparous or previous GDM
pregnancy
0.46 0.54 817.33 –0.0270 –1358.13
Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 0.48 0.52 840.75 –0.0265 –1371.52
Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or
previous GDM pregnancy
0.48 0.52 842.32 –0.0265 –1372.00
BMI ≥ 25 kg/m2 0.50 0.50 857.99 –0.0256 –1369.57
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TABLE 75 Base case: cost-effectiveness summary results for non-dominated strategies, £20,000 per QALY
(continued )
Screening strategy S+T+ S+T– S+ S– Cost (£) QALY NMB (£)
BMI ≥ 25 kg/m2 or previous GDM pregnancy 0.51 0.49 859.94 –0.0255 –1370.68
BMI ≥ 30 kg/m2 or multiparous or family history of
diabetes mellitus
0.60 0.40 927.21 –0.0246 –1418.64
BMI ≥ 30 kg/m2 or multiparous or family history of
diabetes mellitus or previous GDM pregnancy
0.60 0.40 929.11 –0.0245 –1419.43
Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or family
history of diabetes mellitus
0.60 0.40 935.98 –0.0245 –1425.55
Maternal age ≥ 30 years or BMI ≥ 30 kg/m2 or family
history of diabetes mellitus or previous GDM
pregnancy
0.60 0.40 936.80 –0.0244 –1425.68
BMI ≥ 25 kg/m2 or family history of diabetes mellitus 0.62 0.38 950.27 –0.0237 –1424.84
BMI ≥ 25 kg/m2 or family history of diabetes mellitus
or previous GDM pregnancy
0.62 0.38 951.58 –0.0237 –1425.52
Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 0.65 0.35 971.29 –0.0233 –1438.10
Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or
previous GDM pregnancy
0.65 0.35 972.16 –0.0233 –1438.51
BMI ≥ 30 kg/m2 or non-white ethnicity 0.71 0.29 1024.46 –0.0226 –1477.45
BMI ≥ 30 kg/m2 or non-white ethnicity or previous
GDM pregnancy
0.71 0.29 1025.48 –0.0226 –1477.98
Maternal age ≥ 30 years or BMI 25 kg/m2 family
history of diabetes mellitus
0.72 0.28 1032.92 –0.0222 –1476.16
Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or
previous GDM pregnancy
0.72 0.28 1033.37 –0.0221 –1476.30
BMI ≥ 30 kg/m2 or non-white ethnicity or family
history of diabetes mellitus
0.75 0.25 1053.95 –0.0220 –1493.38
BMI ≥ 30 kg/m2 or non-white ethnicity or family
history of diabetes mellitus or previous GDM
pregnancy
0.75 0.25 1054.82 –0.0220 –1493.84
NICE criteria 0.78 0.22 1076.47 –0.0216 –1507.95
Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or family
history of diabetes mellitus
0.79 0.21 1083.72 –0.0214 –1510.84
Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or family
history of diabetes mellitus or previous GDM
pregnancy
0.79 0.21 1083.95 –0.0213 –1510.92
BMI ≥ 30 kg/m2 or non-white ethnicity or multiparous 0.81 0.19 1097.35 –0.0211 –1519.45
Maternal age ≥ 25 years or BMI ≥ 25 kg/m2 0.81 0.19 1102.07 –0.0208 –1518.73
BMI ≥ 25 kg/m2 or non-white ethnicity 0.83 0.17 1111.87 –0.0207 –1524.93
BMI ≥ 25 kg/m2 or non-white ethnicity or previous
GDM pregnancy
0.83 0.17 1112.42 –0.0206 –1525.21
BMI ≥ 25 kg/m2 or non-white ethnicity or family
history of diabetes mellitus
0.85 0.15 1128.27 –0.0203 –1534.23
BMI ≥ 25 kg/m2 or non-white ethnicity or family
history of diabetes mellitus or previous GDM
pregnancy
0.85 0.15 1128.74 –0.0203 –1534.50
Maternal age ≥ 25 years or BMI ≥ 25 kg/m2 or family
history of diabetes mellitus
0.85 0.15 1129.36 –0.0203 –1534.96
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TABLE 75 Base case: cost-effectiveness summary results for non-dominated strategies, £20,000 per QALY
(continued )
Screening strategy S+T+ S+T– S+ S– Cost (£) QALY NMB (£)
Maternal age ≥ 25 years or BMI ≥ 25 kg/m2 or family
history of diabetes mellitus or previous GDM
pregnancy or
0.85 0.15 1129.52 –0.0203 –1535.02
Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or
non-white ethnicity
0.87 0.13 1151.69 –0.0199 –1550.61
Maternal age ≥ 30 years or BMI ≥ 25 kg/m2 or
non-white ethnicity or previous GDM pregnancy
0.87 0.13 1151.84 –0.0199 –1550.67
Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or
non-white ethnicity
0.88 0.12 1159.06 –0.0199 –1557.37
Maternal age ≥ 25 years or BMI ≥ 30 kg/m2 or
non-white ethnicity or previous GDM pregnancy
0.88 0.12 1159.37 –0.0199 –1557.48
Maternal age ≥ 25 years or BMI ≥ 25 kg/m2 or
non-white ethnicity
0.92 0.08 1187.95 –0.0192 –1572.49
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Appendix 7 Search strategies
The databases and information sources searched in September
2013 and October 2014
A. September 2013 search strategies:
Source: MEDLINE In-Process & Other Non-Indexed Citations and MEDLINE
1946 to present
Interface/URL: OvidSP.
Search date: 16 September 2013.
Retrieved records: 4217.
TABLE 83 Databases and information sources searched and numbers retrieved for Chapter 3
Database/information source Interface/URL
MEDLINE® and MEDLINE In-Process & Other Non-Indexed Citations OvidSP
EMBASE OvidSP
CINAHL Plus EBSCOhost
CENTRAL The Cochrane Library/Wiley Interscience
CDSR The Cochrane Library/Wiley Interscience
DARE The Cochrane Library/Wiley Interscience
HTA database The Cochrane Library/Wiley Interscience
NHS EED The Cochrane Library/Wiley Interscience
Cochrane Methodology Register The Cochrane Library/Wiley Interscience
Records identified
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 4217
EMBASE 7873
CINAHL Plus 1097
CENTRAL 165
CDSR 41
DARE 6
HTA database 1
NHS EED 1
Cochrane Methodology Register 0
TOTAL 13,401
TOTAL after deduplication 808
DOI: 10.3310/hta20860 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 86
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Farrar et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
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Search strategy
1. (pregnancy adj4 diabetes).ti,ab. (3811)
2. (gestational adj4 diabetes).ti,ab. (7253)
3. exp DIABETES, GESTATIONAL/ (6899)
4. gdm.ti,ab. (2828)
5. (glucose adj4 (pregnan* or gestation* or natal or maternal)).ti,ab. (3314)
6. 1 or 2 or 3 or 4 or 5 (13,904)
7. macrosomia.ti,ab. (2142)
8. exp FETAL MACROSOMIA/ (1747)
9. 7 or 8 (2949)
10. exp BIRTH INJURIES/ (4780)
11. ((perinatal or labor or labour or birth) adj4 trauma).ti,ab. (1297)
12. ((perinatal or labor or labour or birth) adj4 injur*).ti,ab. (2385)
13. ((perinatal or labor or labour or birth) adj4 complication*1).ti,ab. (4130)
14. exp OBSTETRIC LABOR COMPLICATIONS/ (50,946)
15. *DYSTOCIA/ (1845)
16. (shoulder adj4 dystocia).ti,ab. (959)
17. (fracture*1 adj4 clavicle*1).ti,ab. (1123)
18. (fracture*1 adj4 humerus).ti,ab. (3203)
19. (fracture*1 adj4 shoulder*1).ti,ab. (709)
20. (fracture*1 adj4 arm*1).ti,ab. (437)
21. “erb* palsy”.ti,ab. (168)
22. neuropath*.ti,ab. (93,706)
23. exp BRACHIAL PLEXUS NEUROPATHIES/ (2692)
24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (160,801)
25. (preeclampsia or pre-eclampsia).ti,ab. (18,840)
26. exp PRE-ECLAMPSIA/ (23,296)
27. 25 or 26 (29,671)
28. (heart adj4 (disorder*1 or disease*1)).ti,ab. (135,343)
29. (cardiovascular adj4 (disorder*1 or disease*1)).ti,ab. (111,102)
30. (cardiac adj4 (disorder*1 or disease*1)).ti,ab. (25,664)
31. exp CARDIOVASCULAR DISEASES/ (1,866,094)
32. exp HEART DISEASES/ (887,858)
33. 28 or 29 or 30 or 31 or 32 (1,938,013)
34. exp HYPOGLYCEMIA/ (21,601)
35. hypoglyc*.ti,ab. (40,106)
36. 34 or 35 (46,491)
37. exp DIABETES MELLITUS, TYPE 2/ (86,196)
38. ((“type 2” or “type AND two” or “type II”) adj4 diabet*).ti,ab. (80,227)
39. 37 or 38 (113,317)
40. exp OBESITY/ (140,385)
41. (obesity or obese or bmi or “body mass” or overweight).ti,ab. (282,204)
42. 40 or 41 (312,183)
43. 9 or 24 or 27 or 33 or 36 or 39 or 42 (2,436,744)
44. (offspring or son*1 or daughter*1 or child or children or pediatric*1 or paediatric*1).ti,ab. (1,102,950)
45. exp CHILD OF IMPAIRED PARENTS/ (4216)
46. exp CHILD/ (1,547,523)
47. (maternal or mother*2).ti,ab. (275,418)
48. exp MOTHERS/ (26,220)
49. 44 or 45 or 46 or 47 or 48 (2,141,917)
50. 43 and 49 (259,112)
51. 6 and 50 (4434)
52. 51 not (animals/ not humans/) (4217)
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Source: EMBASE 1974 to 13 September 2013
Interface/URL: OvidSP.
Search date: 16 September 2013.
Retrieved records: 7873.
Search strategy
1. (pregnancy adj4 diabetes).ti,ab. (5134)
2. (gestational adj4 diabetes).ti,ab. (10,165)
3. exp DIABETES, GESTATIONAL/ (19,158)
4. gdm.ti,ab. (4151)
5. (glucose adj4 (pregnan* or gestation* or natal or maternal)).ti,ab. (4075)
6. 1 or 2 or 3 or 4 or 5 (24,428)
7. macrosomia.ti,ab. (3031)
8. exp FETAL MACROSOMIA/ (3632)
9. 7 or 8 (4445)
10. exp BIRTH INJURIES/ (5609)
11. ((perinatal or labor or labour or birth) adj4 trauma).ti,ab. (1703)
12. ((perinatal or labor or labour or birth) adj4 injur*).ti,ab. (2912)
13. ((perinatal or labor or labour or birth) adj4 complication*1).ti,ab. (5268)
14. exp OBSTETRIC LABOR COMPLICATIONS/ (131,242)
15. exp SHOULDER DYSTOCIA/ (962)
16. (shoulder adj4 dystocia).ti,ab. (1388)
17. (fracture*1 adj4 clavicle*1).ti,ab. (1321)
18. (fracture*1 adj4 humerus).ti,ab. (3994)
19. (fracture*1 adj4 shoulder*1).ti,ab. (883)
20. (fracture*1 adj4 arm*1).ti,ab. (529)
21. erb* palsy.ti,ab. (219)
22. neuropath*.ti,ab. (118,816)
23. exp BRACHIAL PLEXUS NEUROPATHIES/ (1613)
24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (267,112)
25. (preeclampsia or pre-eclampsia).ti,ab. (25,457)
26. exp PRE-ECLAMPSIA/ (35,429)
27. 25 or 26 (39,026)
28. (heart adj4 (disorder*1 or disease*1)).ti,ab. (174,985)
29. (cardiovascular adj4 (disorder*1 or disease*1)).ti,ab. (141,764)
30. (cardiac adj4 (disorder*1 or disease*1)).ti,ab. (34,098)
31. exp CARDIOVASCULAR DISEASES/ (2,920,008)
32. exp HEART DISEASES/ (1,306,554)
33. 28 or 29 or 30 or 31 or 32 (2,968,279)
34. exp HYPOGLYCEMIA/ (51,492)
35. hypoglyc*.ti,ab. (53,319)
36. 34 or 35 (72,756)
37. exp DIABETES MELLITUS, TYPE 2/ (132,330)
38. ((“type 2” or “type two” or “type II”) adj4 diabet*).ti,ab. (107,631)
39. 37 or 38 (158,436)
40. exp OBESITY/ (275,568)
41. (obesity or obese or bmi or “body mass” or overweight).ti,ab. (372,903)
42. 40 or 41 (451,582)
43. 9 or 24 or 27 or 33 or 36 or 39 or 42 (3,621,049)
44. (offspring or son*1 or daughter*1 or child or children or pediatric*1 or paediatric*1).ti,ab. (1,363,229)
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45. exp CHILD OF IMPAIRED PARENTS/ (1,789,089)
46. exp CHILD/ (1,789,089)
47. (maternal or mother*2).ti,ab. (323,775)
48. exp MOTHERS/ (80,799)
49. 44 or 45 or 46 or 47 or 48 (2,503,254)
50. 43 and 49 (401,545)
51. 6 and 50 (7873)
Source: CINAHL Plus
Interface/URL: EBSCOhost.
Search date: 17 September 2013.
Retrieved records: 1097.
Search strategy
S55 S51 not S54 (1097)
S54 S52 not S53 (44,999)
S53 (MH “Human”) (1,095,475)
S52 (MH “Animals”) (49,408)
S51 S6 AND S50 (1103)
S50 S43 AND S49 (51,638)
S49 S44 OR S45 OR S46 OR S47 OR S48 (474,583)
S48 (MH “Mothers+”) (19,731)
S47 TI (maternal or mother*) or AB (maternal or mother*) (52,862)
S46 (MH “Child+”) (379,811)
S45 (MH “Children of Impaired Parents+”) (1460)
S44 TI (offspring or son or sons or daughter* OR child OR children OR pediatric* OR paediatric*) or AB
(offspring or son or sons or daughter* OR child OR children OR pediatric* OR paediatric*) (232,624)
S43 S9 OR S24 OR S27 OR S33 OR S36 OR S39 OR S42 (431,186)
S42 S40 OR S41 (76,702)
S41 TI (obesity or obese or bmi or “body mass” or overweight) or AB (obesity or obese or bmi or “body
mass” or overweight) (57,664)
S40 (MH “Obesity+”) (48,791)
S39 S37 OR S38 (35,582)
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S38 TI ((“type 2” or “type two” or “type II”) N4 diabet*) or AB ((“type 2” or “type two” or “type II”) N4
diabet*) (21,280)
S37 (MH “Diabetes Mellitus, Type 2”) (31,041)
S36 S34 OR S35 (8255)
S35 TI (hypoglyc*) or AB (hypoglyc*) (5766)
S34 (MH “Hypoglycemia+”) (5158)
S33 S28 OR S29 OR S30 OR S31 OR S32 (324,646)
S32 (MH “Heart Diseases+”) (150,895)
S31 (MH “Cardiovascular Diseases+”) (312,990)
S30 TI (cardiac N4 (disorder* or disease*)) or AB (cardiac N4 (disorder* or disease*)) (3433)
S29 TI (cardiovascular N4 (disorder* or disease*)) or AB (cardiovascular N4 (disorder* or disease*)) (19,387)
S28 TI (heart N4 (disorder* or disease*)) or AB (heart N4 (disorder* or disease*)) (21,170)
S27 S25 OR S26 (4403)
S26 (MH “Pre-Eclampsia+”) (3600)
S25 TI (preeclampsia or pre-eclampsia) or AB (preeclampsia or pre-eclampsia) (3124)
S24 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
OR S23 (20,330)
S23 (MH “Brachial Plexus Neuropathies+”) (603)
S22 TI (neuropath*) or AB (neuropath*) (11,432)
S21 TI (erb* palsy) or AB (erb* palsy) (54)
S20 TI (fracture* N4 arm*) or AB (fracture* N4 arm*) (97)
S19 TI (fracture* N4 shoulder*) or AB (fracture* N4 shoulder*) (179)
S18 TI (fracture* N4 humerus) or AB (fracture* N4 humerus) (644)
S17 TI (fracture* N4 clavicle*) or AB (fracture* N4 clavicle*) (326)
S16 TI (shoulder N4 dystocia) or AB (shoulder N4 dystocia) (378)
S15 (MH “Shoulder Dystocia”) (329)
S14 ((MH “Labor Complications+”) (5672)
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S13 TI ((perinatal or labor or labour or birth) N4 complication*) or AB ((perinatal or labor or labour or birth)
N4 complication*) (721)
S12 TI ((perinatal or labor or labour or birth) N4 injur*) or AB ((perinatal or labor or labour or birth) N4
injur*) (407)
S11 TI ((perinatal or labor or labour or birth) N4 trauma) or AB ((perinatal or labor or labour or birth) N4
trauma) (276)
S10 (MH “Birth Injuries+”) (868)
S9 S7 OR S8 (686)
S8 (MH “Fetal Macrosomia”) (510)
S7 TI (macrosomia) OR AB (macrosomia) (387)
S6 S1 OR S2 OR S3 OR S4 OR S5 (3944)
S5 TI (glucose N4 (pregnan* or gestation* or natal or maternal)) or AB (glucose N4 (pregnan* or
gestation* or natal or maternal)) (551)
S4 TI (gdm) or AB (gdm) (715)
S3 (MH “Diabetes Mellitus, Gestational”) (2870)
S2 TI (gestational N4 diabetes) or AB (gestational N4 diabetes) (2343)
S1 TI (pregnancy N4 diabetes) or AB (pregnancy N4 diabetes) (905)
Source: Cochrane Central Register of Controlled Trials, Issue 8 of 12,
August 2013
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 18 September 2013.
Retrieved records: 165.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (635)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (483)
#3 MeSH descriptor: [Diabetes, Gestational] explode all trees (293)
#4 #1 or #2 or #3 (875)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (108)
#6 MeSH descriptor: [Fetal Macrosomia] explode all trees (61)
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#7 #5 or #6 (108)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1003)
#9 MeSH descriptor: [Birth Injuries] explode all trees (33)
#10 MeSH descriptor: [Obstetric Labor Complications] explode all trees (2143)
#11 MeSH descriptor: [Dystocia] explode all trees (77)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (323)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (3785)
#14 MeSH descriptor: [Brachial Plexus Neuropathies] explode all trees (44)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (6670)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1008)
#17 MeSH descriptor: [Pre-Eclampsia] explode all trees (558)
#18 #16 or #17 (1008)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (12,623)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (9318)
#21 MeSH descriptor: [Heart Diseases] explode all trees (34,478)
#22 MeSH descriptor: [Cardiovascular Diseases] explode all trees (69,430)
#23 #19 or #20 or #21 or #22 (77,250)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (6540)
#25 MeSH descriptor: [Hypoglycemia] explode all trees (1070)
#26 #24 or #25 (6543)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been
searched) (6726)
#28 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees (7868)
#29 #27 or #28 (9566)
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#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (18,800)
#31 MeSH descriptor: [Obesity] explode all trees (6607)
#32 #30 or #31 (18,817)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (107,317)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (73,610)
#35 MeSH descriptor: [Child] explode all trees (99)
#36 MeSH descriptor: [Child of Impaired Parents] explode all trees (109)
#37 MeSH descriptor: [Mothers] explode all trees (847)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (10,448)
#39 #34 or #35 or #36 or #37 or #38 (80,319)
#40 #33 and #39 (6929)
#41 #4 and #40 in Trials (165)
Source: Cochrane Database of Systematic Reviews, Issue 9 of 12,
September 2013
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 18 September 2013.
Retrieved records: 41.
Search strategy
#1 ((pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (635)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (483)
#3 MeSH descriptor: [Diabetes, Gestational] explode all trees (293)
#4 #1 or #2 or #3 (875)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (108)
#6 MeSH descriptor: [Fetal Macrosomia] explode all trees (61)
#7 #5 or #6 (108)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1003)
#9 MeSH descriptor: [Birth Injuries] explode all trees (33)
#10 MeSH descriptor: [Obstetric Labor Complications] explode all trees (2143)
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#11 MeSH descriptor: [Dystocia] explode all trees (77)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (323)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (3785)
#14 MeSH descriptor: [Brachial Plexus Neuropathies] explode all trees (44)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (6670)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1008)
#17 MeSH descriptor: [Pre-Eclampsia] explode all trees (558)
#18 #16 or #17 (1008)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (12,623)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (9318)
#21 MeSH descriptor: [Heart Diseases] explode all trees (34,478)
#22 MeSH descriptor: [Cardiovascular Diseases] explode all trees (69,430)
#23 #19 or #20 or #21 or #22 (77,250)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (6540)
#25 MeSH descriptor: [Hypoglycemia] explode all trees (1070)
#26 #24 or #25 (6543)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been
searched) (6726)
#28 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees (7868)
#29 #27 or #28 (9566)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (18,800)
#31 MeSH descriptor: [Obesity] explode all trees (6607)
#32 #30 or #31 (18,817)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (107,317)
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#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (73,610)
#35 MeSH descriptor: [Child] explode all trees (99)
#36 MeSH descriptor: [Child of Impaired Parents] explode all trees (109)
#37 MeSH descriptor: [Mothers] explode all trees (847)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (10,448)
#39 #34 or #35 or #36 or #37 or #38 (80,319)
#40 #33 and #39 (6929)
#41 #4 and #40 in Cochrane Reviews (Reviews and Protocols) (41)
Source: Database of Abstracts of Reviews of Effects, Issue 3 of 4, July 2013
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 18 September 2013.
Retrieved records: 6.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (635)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (483)
#3 MeSH descriptor: [Diabetes, Gestational] explode all trees (293)
#4 #1 or #2 or #3 (875)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (108)
#6 MeSH descriptor: [Fetal Macrosomia] explode all trees (61)
#7 #5 or #6 (108)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1003)
#9 MeSH descriptor: [Birth Injuries] explode all trees (33)
#10 MeSH descriptor: [Obstetric Labor Complications] explode all trees (2143)
#11 MeSH descriptor: [Dystocia] explode all trees (77)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (323)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (3785)
#14 MeSH descriptor: [Brachial Plexus Neuropathies] explode all trees (44)
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#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (6670)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1008)
#17 MeSH descriptor: [Pre-Eclampsia] explode all trees (558)
#18 #16 or #17 (1008)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (12,623)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (9318)
#21 MeSH descriptor: [Heart Diseases] explode all trees (34,478)
#22 MeSH descriptor: [Cardiovascular Diseases] explode all trees (69,430)
#23 #19 or #20 or #21 or #22 (77,250)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (6540)
#25 MeSH descriptor: [Hypoglycemia] explode all trees (1070)
#26 #24 or #25 (6543)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been
searched) (6726)
#28 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees (7868)
#29 #27 or #28 (9566)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (18,800)
#31 MeSH descriptor: [Obesity] explode all trees (6607)
#32 #30 or #31 (18,817)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (107,317)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (73,610)
#35 MeSH descriptor: [Child] explode all trees (99)
#36 MeSH descriptor: [Child of Impaired Parents] explode all trees (109)
#37 MeSH descriptor: [Mothers] explode all trees (847)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (10,448)
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#39 #34 or #35 or #36 or #37 or #38 (80,319)
#40 #33 and #39 (6929)
#41 #4 and #40 in Other Reviews (6)
Source: Health Technology Assessment database, Issue 3 of 4, July 2013
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 18 September 2013.
Retrieved records: 1.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (635)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (483)
#3 MeSH descriptor: [Diabetes, Gestational] explode all trees (293)
#4 #1 or #2 or #3 (875)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (108)
#6 MeSH descriptor: [Fetal Macrosomia] explode all trees (61)
#7 #5 or #6 (108)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1003)
#9 MeSH descriptor: [Birth Injuries] explode all trees (33)
#10 MeSH descriptor: [Obstetric Labor Complications] explode all trees (2143)
#11 MeSH descriptor: [Dystocia] explode all trees (77)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (323)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (3785)
#14 MeSH descriptor: [Brachial Plexus Neuropathies] explode all trees (44)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (6670)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1008)
#17 MeSH descriptor: [Pre-Eclampsia] explode all trees (558)
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#18 #16 or #17 (1008)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (12,623)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (9318)
#21 MeSH descriptor: [Heart Diseases] explode all trees (34,478)
#22 MeSH descriptor: [Cardiovascular Diseases] explode all trees (69,430)
#23 #19 or #20 or #21 or #22 (77,250)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (6540)
#25 MeSH descriptor: [Hypoglycemia] explode all trees (1070)
#26 #24 or #25 (6543)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been
searched) (6726)
#28 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees (7868)
#29 #27 or #28 (9566)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (18,800)
#31 MeSH descriptor: [Obesity] explode all trees (6607)
#32 #30 or #31 (18,817)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (107,317)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (73,610)
#35 MeSH descriptor: [Child] explode all trees (99)
#36 MeSH descriptor: [Child of Impaired Parents] explode all trees (109)
#37 MeSH descriptor: [Mothers] explode all trees (847)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (10,448)
#39 #34 or #35 or #36 or #37 or #38 (80,319)
#40 #33 and #39 (6929)
#41 #4 and #40 in Technology Assessments (1)
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Source: NHS Economic Evaluation Database (issue number not given)
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 18 September 2013.
Retrieved records: 1.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (635)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (483)
#3 MeSH descriptor: [Diabetes, Gestational] explode all trees (293)
#4 #1 or #2 or #3 (875)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (108)
#6 MeSH descriptor: [Fetal Macrosomia] explode all trees (61)
#7 #5 or #6 (108)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1003)
#9 MeSH descriptor: [Birth Injuries] explode all trees (33)
#10 MeSH descriptor: [Obstetric Labor Complications] explode all trees (2143)
#11 MeSH descriptor: [Dystocia] explode all trees (77)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (323)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (3785)
#14 MeSH descriptor: [Brachial Plexus Neuropathies] explode all trees (44)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (6670)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1008)
#17 MeSH descriptor: [Pre-Eclampsia] explode all trees (558)
#18 #16 or #17 (1008)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (12,623)
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#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (9318)
#21 MeSH descriptor: [Heart Diseases] explode all trees (34,478)
#22 MeSH descriptor: [Cardiovascular Diseases] explode all trees (69,430)
#23 #19 or #20 or #21 or #22 (77,250)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (6540)
#25 MeSH descriptor: [Hypoglycemia] explode all trees (1070)
#26 #24 or #25 (6543)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been
searched) (6726)
#28 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees (7868)
#29 #27 or #28 (9566)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (18,800)
#31 MeSH descriptor: [Obesity] explode all trees (6607)
#32 #30 or #31 (18,817)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (107,317)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (73,610)
#35 MeSH descriptor: [Child] explode all trees (99)
#36 MeSH descriptor: [Child of Impaired Parents] explode all trees (109)
#37 MeSH descriptor: [Mothers] explode all trees (847)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (10,448)
#39 #34 or #35 or #36 or #37 or #38 (80,319)
#40 #33 and #39 (6929)
#41 #4 and #40 in Economic Evaluations (1)
Source: Cochrane Methodology Register, Issue 3 of 4, July 2012
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 18 September 2013.
Retrieved records: 0.
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Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (635)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (483)
#3 MeSH descriptor: [Diabetes, Gestational] explode all trees (293)
#4 #1 or #2 or #3 (875)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (108)
#6 MeSH descriptor: [Fetal Macrosomia] explode all trees (61)
#7 #5 or #6 (108)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1003)
#9 MeSH descriptor: [Birth Injuries] explode all trees (33)
#10 MeSH descriptor: [Obstetric Labor Complications] explode all trees (2143)
#11 MeSH descriptor: [Dystocia] explode all trees (77)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (323)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (3785)
#14 MeSH descriptor: [Brachial Plexus Neuropathies] explode all trees (44)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (6670)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1008)
#17 MeSH descriptor: [Pre-Eclampsia] explode all trees (558)
#18 #16 or #17 (1008)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (12,623)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (9318)
#21 MeSH descriptor: [Heart Diseases] explode all trees (34,478)
#22 MeSH descriptor: [Cardiovascular Diseases] explode all trees (69,430)
#23 #19 or #20 or #21 or #22 (77,250)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (6540)
#25 MeSH descriptor: [Hypoglycemia] explode all trees (1070)
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#26 #24 or #25 (6543)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been
searched) (6726)
#28 MeSH descriptor: [Diabetes Mellitus, Type 2] explode all trees (7868)
#29 #27 or #28 (9566)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (18,800)
#31 MeSH descriptor: [Obesity] explode all trees (6607)
#32 #30 or #31 (18,817)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (107,317)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (73,610)
#35 MeSH descriptor: [Child] explode all trees (99)
#36 MeSH descriptor: [Child of Impaired Parents] explode all trees (109)
#37 MeSH descriptor: [Mothers] explode all trees (847)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (10,448)
#39 #34 or #35 or #36 or #37 or #38 (80,319)
#40 #33 and #39 (6929)
#41 #4 and #40 in Methods Studies (0)
TABLE 84 Databases and information sources searched and numbers retrieved for Chapter 3: October 2014
literature search results
Database/information source Records identified
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations 4622
EMBASE 9726
CINAHL 1261
CENTRAL 256
CDSR 42
DARE 7
HTA database 1
NHS EED 1
Cochrane Methodology Register 0
TOTAL 15,916
TOTAL after deduplication 2464
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B. October 2014 search strategies:
Source: MEDLINE In-Process & Other Non-Indexed Citations and MEDLINE
1946 to present
Interface/URL: OvidSP.
Search date: 20 October 2014.
Retrieved records: 4622.
Search strategy
1. (pregnancy adj4 diabetes).ti,ab. (4082)
2. (gestational adj4 diabetes).ti,ab. (8108)
3. exp DIABETES, GESTATIONAL/ (7439)
4. gdm.ti,ab. (3272)
5. (glucose adj4 (pregnan* or gestation* or natal or maternal)).ti,ab. (3469)
6. 1 or 2 or 3 or 4 or 5 (15,075)
7. macrosomia.ti,ab. (2314)
8. exp FETAL MACROSOMIA/ (1826)
9. 7 or 8 (3157)
10. exp BIRTH INJURIES/ (4937)
11. ((perinatal or labor or labour or birth) adj4 trauma).ti,ab. (1355)
12. ((perinatal or labor or labour or birth) adj4 injur*).ti,ab. (2542)
13. ((perinatal or labor or labour or birth) adj4 complication*1).ti,ab. (4372)
14. exp OBSTETRIC LABOR COMPLICATIONS/ (53,369)
15. *DYSTOCIA/ (1902)
16. (shoulder adj4 dystocia).ti,ab. (1021)
17. (fracture*1 adj4 clavicle*1).ti,ab. (1218)
18. (fracture*1 adj4 humerus).ti,ab. (3451)
19. (fracture*1 adj4 shoulder*1).ti,ab. (753)
20. (fracture*1 adj4 arm*1).ti,ab. (454)
21. “erb* palsy”.ti,ab. (185)
22. neuropath*.ti,ab. (97,784)
23. exp BRACHIAL PLEXUS NEUROPATHIES/ (2817)
24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (168,258)
25. (preeclampsia or pre-eclampsia).ti,ab. (20,669)
26. exp PRE-ECLAMPSIA/ (24,509)
27. 25 or 26 (31,679)
28. (heart adj4 (disorder*1 or disease*1)).ti,ab. (142,562)
29. (cardiovascular adj4 (disorder*1 or disease*1)).ti,ab. (119,950)
30. (cardiac adj4 (disorder*1 or disease*1)).ti,ab. (26,958)
31. exp CARDIOVASCULAR DISEASES/ (1,944,605)
32. exp HEART DISEASES/ (922,916)
33. 28 or 29 or 30 or 31 or 32 (2,024,083)
34. exp HYPOGLYCEMIA/ (22,500)
35. hypoglyc*.ti,ab. (42,033)
36. 34 or 35 (48,692)
37. exp DIABETES MELLITUS, TYPE 2/ (90,640)
38. ((“type 2” or “type AND two” or “type II”) adj4 diabet*).ti,ab. (87,156)
39. 37 or 38 (121,847)
40. exp OBESITY/ (152,662)
41. (obesity or obese or bmi or “body mass” or overweight).ti,ab. (311,123)
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42. 40 or 41 (343,012)
43. 9 or 24 or 27 or 33 or 36 or 39 or 42 (2,561,831)
44. (offspring or son*1 or daughter*1 or child or children or pediatric*1 or paediatric*1).ti,ab. (1,177,569)
45. exp CHILD OF IMPAIRED PARENTS/ (4392)
46. exp CHILD/ (1,595,153)
47. (maternal or mother*2).ti,ab. (288,181)
48. exp MOTHERS/ (27,857)
49. 44 or 45 or 46 or 47 or 48 (2,246,955)
50. 43 and 49 (274,768)
51. 6 and 50 (4840)
52. 51 not (animals/ not humans/) (4622)
Source: EMBASE 1974 to 17 October 2014
Interface/URL: OvidSP.
Search date: 20 October 2014.
Retrieved records: 9726.
Search strategy
1. (pregnancy adj4 diabetes).ti,ab. (5533)
2. (gestational adj4 diabetes).ti,ab. (11,687)
3. exp DIABETES, GESTATIONAL/ (20,744)
4. gdm.ti,ab. (5092)
5. (glucose adj4 (pregnan* or gestation* or natal or maternal)).ti,ab. (4355)
6. 1 or 2 or 3 or 4 or 5 (26,356)
7. macrosomia.ti,ab. (3278)
8. exp FETAL MACROSOMIA/ (4036)
9. 7 or 8 (4784)
10. exp BIRTH INJURIES/ (5520)
11. ((perinatal or labor or labour or birth) adj4 trauma).ti,ab. (1758)
12. ((perinatal or labor or labour or birth) adj4 injur*).ti,ab. (3012)
13. ((perinatal or labor or labour or birth) adj4 complication*1).ti,ab. (5608)
14. exp OBSTETRIC LABOR COMPLICATIONS/ (136,143)
15. exp SHOULDER DYSTOCIA/ (1155)
16. (shoulder adj4 dystocia).ti,ab. (1473)
17. (fracture*1 adj4 clavicle*1).ti,ab. (1389)
18. (fracture*1 adj4 humerus).ti,ab. (4150)
19. (fracture*1 adj4 shoulder*1).ti,ab. (948)
20. (fracture*1 adj4 arm*1).ti,ab. (545)
21. erb* palsy.ti,ab. (232)
22. neuropath*.ti,ab. (125,149)
23. exp BRACHIAL PLEXUS NEUROPATHIES/ (1479)
24. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 (278,656)
25. (preeclampsia or pre-eclampsia).ti,ab. (27,629)
26. exp PRE-ECLAMPSIA/ (37,874)
27. 25 or 26 (41,348)
28. (heart adj4 (disorder*1 or disease*1)).ti,ab. (180,301)
29. (cardiovascular adj4 (disorder*1 or disease*1)).ti,ab. (154,633)
30. (cardiac adj4 (disorder*1 or disease*1)).ti,ab. (35,636)
31. exp CARDIOVASCULAR DISEASES/ (3,031,448)
32. exp HEART DISEASES/ (1,365,227)
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33. 28 or 29 or 30 or 31 or 32 (3,080,008)
34. exp HYPOGLYCEMIA/ (56,246)
35. hypoglyc*.ti,ab. (57,381)
36. 34 or 35 (77,892)
37. exp DIABETES MELLITUS, TYPE 2/ (147,853)
38. ((“type 2” or “type two” or “type II”) adj4 diabet*).ti,ab. (121,802)
39. 37 or 38 (174,880)
40. exp OBESITY/ (307,381)
41. (obesity or obese or bmi or “body mass” or overweight).ti,ab. (421,534)
42. 40 or 41 (506,838)
43. 9 or 24 or 27 or 33 or 36 or 39 or 42 (3,782,413)
44. (offspring or son*1 or daughter*1 or child or children or pediatric*1 or paediatric*1).ti,ab. (1,423,835)
45. exp CHILD OF IMPAIRED PARENTS/ (2,113,745)
46. exp CHILD/ (2,113,745)
47. (maternal or mother*2).ti,ab. (337,918)
48. exp MOTHERS/ (90,011)
49. 44 or 45 or 46 or 47 or 48 (2,803,538)
50. 43 and 49 (482,980)
51. 6 and 50 (9726)
Source: CINAHL Plus
Interface/URL: EBSCOhost.
Search date: 20 October 2014.
Retrieved records: 1261.
Search strategy
S55 S51 not S54 (1261)
S54 S52 not S53 (51,441)
S53 (MH “Human”) (1,248,660)
S52 (MH “Animals”) (56,845)
S51 S6 AND S50 (1269)
S50 S43 AND S49 (57,843)
S49 S44 OR S45 OR S46 OR S47 OR S48 (520,392)
S48 (MH “Mothers+”) (21,782)
S47 TI (maternal or mother*) or AB (maternal or mother*) (58,083)
S46 (MH “Child+”) (415,087)
S45 (MH “Children of Impaired Parents+”) (1570)
S44 TI (offspring or son or sons or daughter* OR child OR children OR pediatric* OR paediatric*) or AB
(offspring or son or sons or daughter* OR child OR children OR pediatric* OR paediatric*) (255,886)
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S43 S9 OR S24 OR S27 OR S33 OR S36 OR S39 OR S42 (479,375)
S42 S40 OR S41 (87,332)
S41 TI (obesity or obese or bmi or “body mass” or overweight) or AB (obesity or obese or bmi or “body
mass” or overweight) (65,840)
S40 (MH “Obesity+”) (55,658)
S39 S37 OR S38 (39,817)
S38 TI ((“type 2” or “type two” or “type II”) N4 diabet*) or AB ((“type 2” or “type two” or “type II”) N4
diabet*) (23,906)
S37 (MH “Diabetes Mellitus, Type 2”) (34,699)
S36 S34 OR S35 (9166)
S35 TI (hypoglyc*) or AB (hypoglyc*) (6420)
S34 (MH “Hypoglycemia+”) (5725)
S33 (S28 OR S29 OR S30 OR S31 OR S32 (358,605)
S32 (MH “Heart Diseases+”) (165,936)
S31 (MH “Cardiovascular Diseases+”) (345,747)
S30 TI (cardiac N4 (disorder* or disease*)) or AB (cardiac N4 (disorder* or disease*)) (3743)
S29 TI (cardiovascular N4 (disorder* or disease*)) or AB (cardiovascular N4 (disorder* or disease*)) (21,477)
S28 TI (heart N4 (disorder* or disease*)) or AB (heart N4 (disorder* or disease*)) (22,833)
S27 S25 OR S26 (5004)
S26 (MH “Pre-Eclampsia+”) (4037)
S25 TI (preeclampsia or pre-eclampsia) or AB (preeclampsia or pre-eclampsia) (3555)
S24 S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
OR S23 (22,645)
S23 (MH “Brachial Plexus Neuropathies+”) (693)
S22 TI (neuropath*) or AB (neuropath*) (12,777)
S21 TI (erb* palsy) or AB (erb* palsy) (58)
S20 TI (fracture* N4 arm*) or AB (fracture* N4 arm*) (106)
S19 TI (fracture* N4 shoulder*) or AB (fracture* N4 shoulder*) (197)
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S18 TI (fracture* N4 humerus) or AB (fracture* N4 humerus) (748)
S17 TI (fracture* N4 clavicle*) or AB (fracture* N4 clavicle*) (367)
S16 TI (shoulder N4 dystocia) or AB (shoulder N4 dystocia) (413)
S15 (MH “Shoulder Dystocia”) (338)
S14 (MH “Labor Complications+”) (6280)
S13 TI ((perinatal or labor or labour or birth) N4 complication*) or AB ((perinatal or labor or labour or birth)
N4 complication*) (806)
S12 TI ((perinatal or labor or labour or birth) N4 injur*) or AB ((perinatal or labor or labour or birth) N4
injur*) (437)
S11 TI ((perinatal or labor or labour or birth) N4 trauma) or AB ((perinatal or labor or labour or birth) N4
trauma) (300)
S10 (MH “Birth Injuries+”) (903)
S9 S7 OR S8 (769)
S8 (MH “Fetal Macrosomia”) (552)
S7 TI (macrosomia) OR AB (macrosomia) (446)
S6 S1 OR S2 OR S3 OR S4 OR S5 (4523)
S5 TI (glucose N4 (pregnan* or gestation* or natal or maternal)) or AB (glucose N4 (pregnan* or
gestation* or natal or maternal)) (608)
S4 TI (gdm) or AB (gdm) (838)
S3 (MH “Diabetes Mellitus, Gestational”) (3293)
S2 TI (gestational N4 diabetes) or AB (gestational N4 diabetes) (2729)
S1 TI (pregnancy N4 diabetes) or AB (pregnancy N4 diabetes) (1018)
Source: Cochrane Central Register of Controlled Trials, Issue 9 of 12,
September 2014
Interface/URL: The Cochrane Library/Wiley Interscience
Search date: 20 October 2014
Retrieved records: 256
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (840)
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#2 (glucose near (pregnan* or gestation* or natal or maternal)) (588)
#3 [mh “Diabetes, Gestational”] (352)
#4 #1 or #2 or #3 (1107)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (137)
#6 [mh “Fetal Macrosomia”] (67)
#7 #5 or #6 (137)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1146)
#9 [mh “Birth Injuries”] (33)
#10 [mh “Obstetric Labor Complications”] (2336)
#11 [mh Dystocia] (88)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (441)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (4623)
#14 [mh “Brachial Plexus Neuropathies”] (47)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (7923)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1181)
#17 [mh Pre-Eclampsia] (613)
#18 #16 or #17 (1181)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (14,511)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (11,691)
#21 [mh “Heart Diseases”] (37,370)
#22 [mh “Cardiovascular Diseases”] (75,564)
#23 #19 or #20 or #21 or #22 (85,943)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (7938)
#25 [mh Hypoglycemia] (1176)
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#26 #24 or #25 (7941)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been searched)
(9096)
#28 [mh “Diabetes Mellitus, Type 2”] (8928)
#29 #27 or #28 (12,190)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (24,839)
#31 [mh Obesity] (7607)
#32 #30 or #31 (24,858)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (124,396)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (84,655)
#35 [mh Child] (116)
#36 [mh “Child of Impaired Parents”] (120)
#37 [mh Mothers] (990)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (12,225)
#39 #34 or #35 or #36 or #37 or #38 (92,429)
#40 #33 and #39 (8640)
#41 #4 and #40 in Trials (256)
Source: Cochrane Database of Systematic Reviews, Issue 10 of 12,
October 2014
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 20 October 2014.
Retrieved records: 42.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (840)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (588)
#3 [mh “Diabetes, Gestational”] (352)
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#4 #1 or #2 or #3 (1107)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (137)
#6 [mh “Fetal Macrosomia”] (67)
#7 #5 or #6 (137)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1146)
#9 [mh “Birth Injuries”] (33)
#10 [mh “Obstetric Labor Complications”] (2336)
#11 [mh Dystocia] (88)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (441)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (4623)
#14 [mh “Brachial Plexus Neuropathies”] (47)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (7923)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1181)
#17 [mh Pre-Eclampsia] (613)
#18 #16 or #17 (1181)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (14,511)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (11,691)
#21 [mh “Heart Diseases”] (37,370)
#22 [mh “Cardiovascular Diseases”] (75,564)
#23 #19 or #20 or #21 or #22 (85,943)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (7938)
#25 [mh Hypoglycemia] (1176)
#26 #24 or #25 (7941)
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#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been searched)
(9096)
#28 [mh “Diabetes Mellitus, Type 2”] (8928)
#29 #27 or #28 (12,190)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (24,839)
#31 [mh Obesity] (7607)
#32 #30 or #31 (24,858)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (124,396)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (84,655)
#35 [mh Child] (116)
#36 [mh “Child of Impaired Parents”] (120)
#37 [mh Mothers] (990)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (12,225)
#39 #34 or #35 or #36 or #37 or #38 (92,429)
#40 #33 and #39 (8640)
#41 #4 and #40 in Cochrane Reviews (Reviews and Protocols) (42)
Source: Database of Abstracts of Reviews of Effects, Issue 3 of 4, July 2014
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 20 October 2014.
Retrieved records: 7.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (840)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (588)
#3 [mh “Diabetes, Gestational”] (352)
#4 #1 or #2 or #3 (1107)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (137)
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#6 [mh “Fetal Macrosomia”] (67)
#7 #5 or #6 (137)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1146)
#9 [mh “Birth Injuries”] (33)
#10 [mh “Obstetric Labor Complications”] (2336)
#11 [mh Dystocia] (88)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (441)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (4623)
#14 [mh “Brachial Plexus Neuropathies”] (47)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (7923)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1181)
#17 [mh Pre-Eclampsia] (613)
#18 #16 or #17 (1181)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (14,511)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (11,691)
#21 [mh “Heart Diseases”] (37,370)
#22 [mh “Cardiovascular Diseases”] (75,564)
#23 #19 or #20 or #21 or #22 (85,943)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (7938)
#25 [mh Hypoglycemia] (1176)
#26 #24 or #25 (7941)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been searched)
(9096)
#28 [mh “Diabetes Mellitus, Type 2”] (8928)
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#29 #27 or #28 (12,190)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (24,839)
#31 [mh Obesity] (7607)
#32 #30 or #31 (24,858)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (124,396)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (84,655)
#35 [mh Child] (116)
#36 [mh “Child of Impaired Parents”] (120)
#37 [mh Mothers] (990)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (12,225)
#39 #34 or #35 or #36 or #37 or #38 (92,429)
#40 #33 and #39 (8640)
#41 #4 and #40 in Other Reviews (7)
Source: Health Technology Assessment database, Issue 3 of 4, July 2014
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 20 October 2014.
Retrieved records: 1.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (840)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (588)
#3 [mh “Diabetes, Gestational”] (352)
#4 #1 or #2 or #3 (1107)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (137)
#6 [mh “Fetal Macrosomia”] (67)
#7 #5 or #6 (137)
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#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1146)
#9 [mh “Birth Injuries”] (33)
#10 [mh “Obstetric Labor Complications”] (2336)
#11 [mh Dystocia] (88)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (441)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (4623)
#14 [mh “Brachial Plexus Neuropathies”] (47)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (7923)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1181)
#17 [mh Pre-Eclampsia] (613)
#18 #16 or #17 (1181)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (14,511)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (11,691)
#21 [mh “Heart Diseases”] (37,370)
#22 [mh “Cardiovascular Diseases”] (75,564)
#23 #19 or #20 or #21 or #22 (85,943)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (7938)
#25 [mh Hypoglycemia] (1176)
#26 #24 or #25 (7941)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been searched)
(9096)
#28 [mh “Diabetes Mellitus, Type 2”] (8928)
#29 #27 or #28 (12,190)
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#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (24,839)
#31 [mh Obesity] (7607)
#32 #30 or #31 (24,858)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (124,396)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (84,655)
#35 [mh Child] (116)
#36 [mh “Child of Impaired Parents”] (120)
#37 [mh Mothers] (990)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (12,225)
#39 #34 or #35 or #36 or #37 or #38 (92,429)
#40 #33 and #39 (8640)
#41 #4 and #40 in Technology Assessments (1)
Source: NHS Economic Evaluation Database, Issue 3 of 4, July 2014
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 20 October 2014.
Retrieved records: 1.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (840)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (588)
#3 [mh “Diabetes, Gestational”] (352)
#4 #1 or #2 or #3 (1107)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (137)
#6 [mh “Fetal Macrosomia”] (67)
#7 #5 or #6 (137)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1146)
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#9 [mh “Birth Injuries”] (33)
#10 [mh “Obstetric Labor Complications”] (2336)
#11 [mh Dystocia] (88)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (441)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (4623)
#14 [mh “Brachial Plexus Neuropathies”] (47)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (7923)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1181)
#17 [mh Pre-Eclampsia] (613)
#18 #16 or #17 (1181)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (14,511)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (11,691)
#21 [mh “Heart Diseases”] (37,370)
#22 [mh “Cardiovascular Diseases”] (75,564)
#23 #19 or #20 or #21 or #22 (85,943)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (7938)
#25 [mh Hypoglycemia] (1176)
#26 #24 or #25 (7941)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been searched)
(9096)
#28 [mh “Diabetes Mellitus, Type 2”] (8928)
#29 #27 or #28 (12,190)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (24,839)
#31 [mh Obesity] (7607)
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#32 #30 or #31 (24,858)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (124,396)
#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (84,655)
#35 [mh Child] (116)
#36 [mh “Child of Impaired Parents”] (120)
#37 [mh Mothers] (990)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (12,225)
#39 #34 or #35 or #36 or #37 or #38 (92,429)
#40 #33 and #39 (8640)
#41 #4 and #40 in Economic Evaluations (1)
Source: Cochrane Methodology Register, Issue 3 of 4, July 2012
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 20 October 2014.
Retrieved records: 0.
Search strategy
#1 (pregnancy near diabetes):ti,ab,kw or (gestational near diabetes):ti,ab,kw or “GDM”:ti,ab,kw or
“gestational diabetes”:ti,ab,kw or (pregnancy diabetes):ti,ab,kw (Word variations have been
searched) (840)
#2 (glucose near (pregnan* or gestation* or natal or maternal)) (588)
#3 [mh “Diabetes, Gestational”] (352)
#4 #1 or #2 or #3 (1107)
#5 Macrosomia:ti,ab,kw (Word variations have been searched) (137)
#6 [mh “Fetal Macrosomia”] (67)
#7 #5 or #6 (137)
#8 ((perinatal or labor or labour or birth) near trauma):ti,ab,kw or ((perinatal or labor or labour or birth)
near injur*):ti,ab,kw or ((perinatal or labor or labour or birth) near complication*):ti,ab,kw (Word variations
have been searched) (1146)
#9 [mh “Birth Injuries”] (33)
#10 [mh “Obstetric Labor Complications”] (2336)
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#11 [mh Dystocia] (88)
#12 (shoulder near dystocia):ti,ab,kw or (fracture* near clavicle*):ti,ab,kw or (fracture* near humerus):ti,
ab,kw or (fracture* near shoulder*):ti,ab,kw or (fracture* near arm*):ti,ab,kw (Word variations have been
searched) (441)
#13 (“erb* palsy”):ti,ab,kw or (neuropath*):ti,ab,kw (Word variations have been searched) (4623)
#14 [mh “Brachial Plexus Neuropathies”] (47)
#15 #8 or #9 or #10 or #11 or #12 or #13 or #14 (7923)
#16 “preeclampsia”:ti,ab,kw or “pre-eclampsia”:ti,ab,kw (Word variations have been searched) (1181)
#17 [mh Pre-Eclampsia] (613)
#18 #16 or #17 (1181)
#19 heart near disease*:ti,ab,kw or heart near disorder*:ti,ab,kw or cardiac near disease*:ti,ab,kw or
cardiac near disorder*:ti,ab,kw (Word variations have been searched) (14,511)
#20 cardiovascular near disease*:ti,ab,kw or cardiovascular near disorder*:ti,ab,kw (Word variations have
been searched) (11,691)
#21 [mh “Heart Diseases”] (37,370)
#22 [mh “Cardiovascular Diseases”] (75,564)
#23 #19 or #20 or #21 or #22 (85,943)
#24 hypoglyc*:ti,ab,kw (Word variations have been searched) (7938)
#25 [mh Hypoglycemia] (1176)
#26 #24 or #25 (7941)
#27 “type 2 diabetes mellitus”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw or “type 2 diabetes”:ti,ab,kw
or “type two diabetes”:ti,ab,kw or “type II diabetes mellitus”:ti,ab,kw (Word variations have been searched)
(9096)
#28 [mh “Diabetes Mellitus, Type 2”] (8928)
#29 #27 or #28 (12,190)
#30 “obese”:ti,ab,kw or “body mass”:ti,ab,kw or obesit*:ti,ab,kw or “overweigh*”:ti,ab,kw or “body
mass index”:ti,ab,kw (Word variations have been searched) (24,839)
#31 [mh Obesity] (7607)
#32 #30 or #31 (24,858)
#33 #7 or #15 or #18 or #23 or #26 or #29 or #32 (124,396)
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#34 “offspring”:ti,ab,kw or “daughter”:ti,ab,kw or “son”:ti,ab,kw or “Child”:ti,ab,kw or “paediatric” or
“pediatric”:ti,ab,kw (Word variations have been searched) (84,655)
#35 [mh Child] (116)
#36 [mh “Child of Impaired Parents”] (120)
#37 [mh Mothers] (990)
#38 mother*:ti,ab,kw or “maternal”:ti,ab,kw (Word variations have been searched) (12,225)
#39 #34 or #35 or #36 or #37 or #38 (92,429)
#40 #33 and #39 (8640)
#41 #4 and #40 in Methods Studies (0)
Searches were carried out for Chapter 4 on 16 July 2014
Source: Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid
MEDLINE <1946 to present>
Interface/URL: OvidSP.
Search date: 16 July 2014.
Retrieved records: 409.
Search strategy
1. exp great britain/ (303,828)
2. Ireland/ (13,048)
3. (“united king*” or uk or “U.K.” or “UK.” or “U.K” or britain).ti,ab. (106,466)
4. (british or english or scottish or welsh or irish).ti,ab. (121,608)
5. (scotland or ireland).ti,ab. (78,711)
6. eire.ti,ab. (175)
7. (england not “new england”).ti,ab. (30,291)
8. (wales not “new south wales”).ti,ab. (11,198)
9. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).ti,ab. (74,398)
TABLE 85 Databases and information sources searched and numbers retrieved for Chapter 4
Database/information source Interface/URL Records identified
MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations OvidSP 409
EMBASE OvidSP 1034
Maternity and Infant Care OvidSP 116
Incidence and Prevalence Database (IPD) Free version 32
TOTAL 1591
TOTAL after deduplication 1196
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10. ((london adj2 ontario) or (london adj on) or new london).ti,ab. (647)
11. (manchester adj3 (USA or massach*)).ti,ab. (8)
12. (newcastle adj4 (australia* or “new south wales” or nsw)).ti,ab. (249)
13. (liverpool adj4 (australia* or “new south wales” or nsw)).ti,ab. (16)
14. or/10-13 (920)
15. 9 not 14 (73,478)
16. (or/1-8) or 15 (567,708)
17. exp diabetes, gestational/ (7009)
18. (gestation$ adj4 diabet$).ti,ab. (8072)
19. gdm.ti,ab. (3046)
20. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).ti,ab. (3402)
21. exp Hyperglycemia/ (26,451)
22. exp Pregnancy/ (714,470)
23. 21 and 22 (1575)
24. ((hyperglycemi$ or hyperglycaemi$) adj5 (pregnan$ or gestation$ or prenatal$ or antenatal$ or
pre-natal$ or ante-natal$ or maternal$)).ti,ab. (894)
25. 17 or 18 or 19 or 20 or 23 or 24 (13,372)
26. 16 and 25 (557)
27. exp Epidemiology/ (21,538)
28. exp Epidemiologic Studies/ (1,664,350)
29. exp Incidence/ (177,085)
30. exp Prevalence/ (192,691)
31. (incidence or prevalence or occur* or frequenc* or proportion* or rate* or number* or percent*).ti,ab.
(5,612,742)
32. or/27-31 (6,466,375)
33. 26 and 32 (412)
34. limit 33 to english language (409)
Source: EMBASE <1974 to 2014 Week 28>
Interface/URL: OvidSP.
Search date: 16 July 2014.
Retrieved records: 1034.
Search strategy
1. United Kingdom/ (329,209)
2. Ireland/ (20,079)
3. (“united king*” or uk or “U.K.” or “UK.” or “U.K” or britain).ti,ab. (189,361)
4. (british or english or scottish or welsh or irish).ti,ab. (173,545)
5. (scotland or ireland).ti,ab. (160,575)
6. eire.ti,ab. (206)
7. (england not “new england”).ti,ab. (35,698)
8. (wales not “new south wales”).ti,ab. (13,659)
9. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).ti,ab. (156,936)
10. ((london adj2 ontario) or (london adj on) or new london).ti,ab. (784)
11. (manchester adj3 (USA or massach*)).ti,ab. (9)
12. (newcastle adj4 (australia* or “new south wales” or nsw)).ti,ab. (311)
13. (liverpool adj4 (australia* or “new south wales” or nsw)).ti,ab. (26)
14. or/10-13 (1130)
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15. 9 not 14 (155,806)
16. (or/1-8) or 15 (831,515)
17. exp pregnancy diabetes mellitus/ (20,129)
18. (gestation$ adj4 diabet$).ti,ab. (11,810)
19. gdm.ti,ab. (4778)
20. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).ti,ab. (4298)
21. hyperglycemia/ (61,078)
22. exp Pregnancy/ (589,193)
23. 21 and 22 (1647)
24. ((hyperglycemi$ or hyperglycaemi$) adj5 (pregnan$ or gestation$ or prenatal$ or antenatal$ or
pre-natal$ or ante-natal$ or maternal$)).ti,ab. (1171)
25. 17 or 18 or 19 or 20 or 23 or 24 (25,055)
26. 16 and 25 (1738)
27. Epidemiology/ (179,438)
28. epidemiological data/ or epidemiological monitoring/ (24,516)
29. incidence/ or familial incidence/ or standardized incidence ratio/ (213,226)
30. Prevalence/ (381,394)
31. (incidence or prevalence or occur* or frequenc* or proportion* or rate* or number* or percent*).ti,ab.
(6,756,057)
32. or/27-31 (6,980,639)
33. 26 and 32 (1040)
34. limit 33 to english language (1034)
Source: Maternity and Infant Care <1971 to June 2014>
Interface/URL: OvidSP.
Search date: 16 July 2014.
Retrieved records: 116.
Search strategy
1. (Great Britain or United Kingdom or England or Wales or Scotland or Northern Ireland).de. (10,228)
2. Ireland.de. (437)
3. (“united king*” or uk or “U.K.” or “UK.” or “U.K” or britain).ti,ab. (9318)
4. (british or english or scottish or welsh or irish).ti,ab. (4652)
5. (scotland or ireland).ti,ab. (2350)
6. eire.ti,ab. (13)
7. (england not “new england”).ti,ab. (3895)
8. (wales not “new south wales”).ti,ab. (2025)
9. (london or manchester or birmingham or leeds or sheffield or liverpool or newcastle or edinburgh or
glasgow or cardiff or oxford or bristol).ti,ab. (6179)
10. ((london adj2 ontario) or (london adj on) or new london).ti,ab. (65)
11. (manchester adj3 (USA or massach*)).ti,ab. (0)
12. (newcastle adj4 (australia* or “new south wales” or nsw)).ti,ab. (11)
13. (liverpool adj4 (australia* or “new south wales” or nsw)).ti,ab. (1)
14. or/10-13 (77)
15. 9 not 14 (6102)
16. (or/1-8) or 15 (26,375)
17. (Gestational diabetes or Diabetes - gestational).de. (1191)
18. (gestation$ adj4 diabet$).ti,ab. (2730)
19. gdm.ti,ab. (993)
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20. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).ti,ab. (811)
21. Hyperglycemia.de. (1)
22. ((hyperglycemi$ or hyperglycaemi$) adj5 (pregnan$ or gestation$ or prenatal$ or antenatal$ or
pre-natal$ or ante-natal$ or maternal$)).ti,ab. (180)
23. 17 or 18 or 19 or 20 or 21 or 22 (3251)
24. 16 and 23 (171)
25. Epidemiology.de. (128)
26. (incidence or prevalence or occur* or frequenc* or proportion* or rate* or number* or percent*).ti,ab.
(76,295)
27. 25 or 26 (76,373)
28. 24 and 27 (116)
29. limit 28 to english language [Limit not valid; records were retained] (116)
Source: Incidence and Prevalence Database
Interface/URL: free Internet version on Dialog.
Search date: 16 July 2014.
Retrieved records: 32.
Search strategy
A restricted search of this database was carried out because of its prohibitive cost. Thirty-two records were
retrieved when searches were undertaken for ‘Gestational diabetes’ or ‘gdm’ in the title.
Searches for Chapter 5 were carried out on 6 June 2014
Source: Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid
MEDLINE <1946 to present>
Interface/URL: OvidSP.
Search date: 6 June 2014.
Retrieved records: 2429.
TABLE 86 Databases and information sources searched and numbers retrieved for Chapter 5
Resource Interface/URL Records identified
MEDLINE and MEDLINE In-Process & Other Non-Indexed
Citations
OvidSP 2429
EMBASE OvidSP 2289
Maternity and Infant Care OvidSP 884
CENTRAL The Cochrane Library/Wiley
Interscience
265
TOTAL 5867
TOTAL after deduplication 3140
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Search strategy
1. risk/ (98,061)
2. risk factors/ (563,466)
3. risk$.tw. (1,321,838)
4. related.tw. (1,576,712)
5. relationship.tw. (681,818)
6. rates.tw. (688,903)
7. difference$.tw. (1,634,999)
8. prevalence.tw. (382,911)
9. associated factors.tw. (8200)
10. predict$.tw. (943,185)
11. or/1-10 (5547,109)
12. exp overweight/ (142,733)
13. (obese or obesity).tw. (175,969)
14. (overweight or over weight).tw. (38,413)
15. body mass index/ (80,128)
16. BMI.tw. (75,276)
17. body mass index.tw. (101,816)
18. exp Ethnic Groups/ (112,019)
19. (ethnicity or ethnic or multiethnic$ or race).tw. (133,942)
20. (caucasian$ or asian$ or spanish or mexican$ or hispanic$ or afrocaribbean$ or african$ or
caribbean$).tw.)
21. (237,285)
22. (middle eastern or bangladeshi$ or pakistani$).tw. (6067)
23. maternal age/ (16,131)
24. age.tw. (1,482,617)
25. (pregnan$ adj2 late$ adj2 life).tw. (41)
26. older.tw. (263,039)
27. over 35.tw. (2427)
28. over 25.tw. (3623)
29. over 30.tw. (10,584)
30. (previous adj3 (gdm or diabet$)).tw. (2130)
31. (prior adj3 (gdm or diabet$)).tw. (1392)
32. (history adj3 (gdm or diabet$)).tw. (7728)
33. (family adj3 (gdm or diabet$)).tw. (3296)
34. (relative adj3 (gdm or diabet$)).tw. (1141)
35. family history.tw. (42,205)
36. prior history.tw. (3983)
37. previous history.tw. (7267)
38. ((prior or previous or history) adj2 macrosomia).tw. (48)
39. ((prior or previous or history) adj2 macrosomic).tw. (25)
40. ((prior or previous or history) adj2 LGA).tw. (5)
41. ((prior or previous or history) adj2 large gestational age).tw. (0)
42. ((prior or previous or history) adj2 large for gestational age).tw. (1)
43. ((prior or previous or history) adj2 large bab$).tw. (3)
44. ((prior or previous or history) adj2 large infant$).tw. (2)
45. parity.tw. (21,039)
46. parity/ (20,499)
47. risk factor$.ti. (73,764)
48. or/12-46 (2,152,353)
49. 11 and 47 (1,297,220)
50. exp diabetes, gestational/ (6917)
51. (gestation$ adj4 diabet$).tw. (7955)
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52. gdm.tw. (2973)
53. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).tw.)
54. (3380)
55. exp Hyperglycemia/ (26,216)
56. exp Pregnancy/ (711,357)
57. 53 and 54 (1565)
58. ((hyperglycemi$ or hyperglycaemi$) adj5 (pregnan$ or gestation$ or prenatal$ or antenatal$ or
pre-natal$ or ante-natal$ or maternal$)).tw. (884)
59. or/49-52,55-56 (13,211)
60. 48 and 57 (5062)
61. Mass Screening/ (81,803)
62. screen$.ti. (116,932)
63. screen$.ab. /freq=2 (122,782)
64. Glucose Tolerance Test/ (29,299)
65. Blood glucose/an (47,809)
66. (glucose adj3 (test$ or measur$ or assess$ or evaluat$)).tw. (36,335)
67. ((glucose adj2 tolerance) or gtt or ogtt).tw. (33,566)
68. ((glucose adj2 challeng$) or gct or ogct).tw. (4698)
69. (fasting adj2 glucose).tw. (24,915)
70. or/59-67 (332,758)
71. Diagnosis/ (16,639)
72. Prenatal Diagnosis/ (31,200)
73. exp Diagnostic errors/ (94,398)
74. Diagnosis, Differential/ (379,054)
75. diagnos$.ti. (450,817)
76. diagnos$.ab. /freq=2 (536,082)
77. (di or du).fs. (2,229,471)
78. exp “Sensitivity and Specificity”/ (416,076)
79. (sensitivity or specificity).tw. (725,114)
80. ((pre-test or pretest) adj probabilit$).tw. (1402)
81. ((post-test or posttest) adj probabilit$).tw. (738)
82. (predictive adj3 value$).tw. (70,018)
83. (false positiv$ or false negativ$).tw. (56,289)
84. observer variation$.tw. (959)
85. roc curve$.tw. (14,358)
86. (likelihood adj3 ratio$).tw. (9220)
87. accurac$.tw. (232,990)
88. detection.tw. (591,376)
89. or/69-86 (3,919,528)
90. 68 or 87 (4,099,746)
91. 58 and 88 (2801)
92. animals/ not humans/ (3,855,883)
93. (editorial or case reports or news or letter or comment).pt. (2,995,254)
94. 89 not (90 or 91) (2665)
95. limit 92 to english language (2429)
Source: EMBASE <1974 to 2014 Week 22>
Interface/URL: OvidSP.
Search date: 6 June 2014.
Retrieved records: 2289.
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Search strategy
1. high risk infant/ or high risk patient/ or high risk population/ or high risk pregnancy/ or low risk
population/or population risk/ (159,235)
2. risk factor/ (609,961)
3. risk$.tw. (1,729,570)
4. related.tw. (1,894,574)
5. relationship.tw. (820,833)
6. rates.tw. (844,892)
7. difference$.tw. (2,006,843)
8. prevalence.tw. (488,098)
9. associated factors.tw. (10,057)
10. predict$.tw. (1,155,249)
11. or/1-10 (6,731,793)
12. exp obesity/ (292,645)
13. (obese or obesity).tw. (235,953)
14. (overweight or over weight).tw. (52,865)
15. body mass/ (185,645)
16. BMI.tw. (133,729)
17. body mass index.tw. (131,385)
18. exp “ethnic and racial groups”/ (333,104)
19. (ethnicity or ethnic or multiethnic$ or race).tw. (167,278)
20. (caucasian$ or asian$ or spanish or mexican$ or hispanic$ or afrocaribbean$ or african$ or
caribbean$).tw.)
21. (302,094)
22. (middle eastern or bangladeshi$ or pakistani$).tw. (7602)
23. maternal age/ (22,047)
24. age.tw. (2,013,347)
25. (pregnan$ adj2 late$ adj2 life).tw. (52)
26. older.tw. (329,442)
27. over 35.tw. (3025)
28. over 25.tw. (4644)
29. over 30.tw. (13,528)
30. (previous adj3 (gdm or diabet$)).tw. (3297)
31. (prior adj3 (gdm or diabet$)).tw. (2294)
32. (history adj3 (gdm or diabet$)).tw. (11,881)
33. (family adj3 (gdm or diabet$)).tw. (4461)
34. (relative adj3 (gdm or diabet$)).tw. (1363)
35. family history.tw. (60,508)
36. prior history.tw. (6224)
37. previous history.tw. (10,741)
38. ((prior or previous or history) adj2 macrosomia).tw. (78)
39. ((prior or previous or history) adj2 macrosomic).tw. (41)
40. ((prior or previous or history) adj2 LGA).tw. (9)
41. ((prior or previous or history) adj2 large gestational age).tw. (0)
42. ((prior or previous or history) adj2 large for gestational age).tw. (2)
43. ((prior or previous or history) adj2 large bab$).tw. (7)
44. ((prior or previous or history) adj2 large infant$).tw. (2)
45. parity.tw. (24,255)
46. parity/ (23,009)
47. risk factor$.ti. (93,554)
48. or/12-46 (2,962,447)
49. 11 and 47 (1,790,792)
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50. exp *pregnancy diabetes mellitus/ (11,726)
51. (gestation$ adj4 diabet$).tw. (11,561)
52. gdm.tw. (4660)
53. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).tw.)
54. (4254)
55. *hyperglycemia/ (16,323)
56. exp *pregnancy/ (160,365)
57. 53 and 54 (224)
58. ((hyperglycemi$ or hyperglycaemi$) adj5 (pregnan$ or gestation$ or prenatal$ or antenatal$ or
pre-natal$ or ante-natal$ or maternal$)).tw. (1161)
59. or/49-52,55-56 (19,285)
60. 48 and 57 (7226)
61. exp *screening/ (136,180)
62. screen$.ti. (144,840)
63. screen$.ab. /freq=2 (161,674)
64. Glucose Tolerance Test/ (21,678)
65. Blood glucose/an (16,029)
66. (glucose adj3 (test$ or measur$ or assess$ or evaluat$)).tw. (48,149)
67. ((glucose adj2 tolerance) or gtt or ogtt).tw. (44,930)
68. ((glucose adj2 challeng$) or gct or ogct).tw. (6122)
69. (fasting adj2 glucose).tw. (36,533)
70. or/59-67 (424,217)
71. *diagnosis/ (50,263)
72. *prenatal diagnosis/ (23,505)
73. *differential diagnosis/ (11,262)
74. exp *diagnostic error/ (6128)
75. *diagnostic accuracy/ (4749)
76. diagnos$.ti. (540,893)
77. diagnos$.ab. /freq=2 (750,292)
78. di.fs. (2,549,486)
79. *”sensitivity and specificity”/ (697)
80. (sensitivity or specificity).tw. (844,233)
81. ((pre-test or pretest) adj probabilit$).tw. (2063)
82. ((post-test or posttest) adj probabilit$).tw. (874)
83. (predictive adj3 value$).tw. (92,314)
84. (false positiv$ or false negativ$).tw. (69,384)
85. observer variation$.tw. (1211)
86. roc curve$.tw. (23,111)
87. (likelihood adj3 ratio$).tw. (11,254)
88. accurac$.tw. (275,387)
89. detection.tw. (703,313)
90. or/69-87 (4,429,688)
91. 68 or 88 (4,688,631)
92. 58 and 89 (3792)
93. (animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/ (3,776,825)
94. (editorial or letter).pt. or case report.ti. or (conference abstract or conference paper or conference
proceeding or conference review).pt. (3,666,517)
95. 90 not (91 or 92) (2587)
96. limit 93 to english language (2289)
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Source: Maternity and Infant Care <1971 to April 2014>
Interface/URL: OvidSP.
Search date: 6 June 2014.
Retrieved records: 884.
Search strategy
1. risk$.tw. (47,816)
2. related.tw. (16,447)
3. relationship.tw. (9690)
4. rates.tw. (16,144)
5. difference$.tw. (22,927)
6. prevalence.tw. (8332)
7. associated factors.tw. (234)
8. predict$.tw. (14,779)
9. or/1-8 (91,159)
10. obesity.de. (1257)
11. (obese or obesity).tw. (3186)
12. (overweight or over weight).tw. (1220)
13. body mass index.de. (812)
14. BMI.tw. (1988)
15. body mass index.tw. (3064)
16. Ethnic Groups.de. (2291)
17. (ethnicity or ethnic or multiethnic$ or race).tw. (6778)
18. (caucasian$ or asian$ or spanish or mexican$ or hispanic$ or afrocaribbean$ or african$ or caribbean$).tw.
(5455)
19. (middle eastern or bangladeshi$ or pakistani$).tw. (316)
20. age.tw. (39,774)
21. (pregnan$ adj2 late$ adj2 life).tw. (15)
22. older.tw. (3367)
23. over 35.tw. (148)
24. over 25.tw. (61)
25. over 30.tw. (171)
26. (previous adj3 (gdm or diabet$)).tw. (110)
27. (prior adj3 (gdm or diabet$)).tw. (61)
28. (history adj3 (gdm or diabet$)).tw. (222)
29. (family adj3 (gdm or diabet$)).tw. (83)
30. (relative adj3 (gdm or diabet$)).tw. (36)
31. family history.tw. (724)
32. prior history.tw. (83)
33. previous history.tw. (209)
34. ((prior or previous or history) adj2 macrosomia).tw. (23)
35. ((prior or previous or history) adj2 macrosomic).tw. (14)
36. ((prior or previous or history) adj2 LGA).tw. (4)
37. ((prior or previous or history) adj2 large gestational age).tw. (0)
38. ((prior or previous or history) adj2 large for gestational age).tw. (1)
39. ((prior or previous or history) adj2 large bab$).tw. (5)
40. ((prior or previous or history) adj2 large infant$).tw. (1)
41. parity.tw. (4622)
42. parity.de. (527)
43. risk factor$.ti. (2244)
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44. or/10-43 (51,430)
45. 9 and 44 (36,837)
46. Diabetes - gestational.de. (1181)
47. (gestation$ adj4 diabet$).tw. (2863)
48. gdm.tw. (965)
49. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).tw. (801)
50. Hyperglycaemia.de. (119)
51. (Pregnancy complications or Pregnancy).de. (57,381)
52. 50 and 51 (74)
53. ((hyperglycemi$ or hyperglycaemi$) adj5 (pregnan$ or gestation$ or prenatal$ or antenatal$ or
pre-natal$ or)
54. ante-natal$ or maternal$)).tw. (195)
55. or/46-49,52-53 (3225)
56. 45 and 54 (1637)
57. Screening.de. (5491)
58. screen$.tw. (15,289)
59. Mass screening.de. (705)
60. Prenatal diagnosis.de. (4440)
61. diagnos$.tw. (26,426)
62. (“Sensitivity and specificity” or “Predictive value of tests”).de. (2526)
63. Glucose tolerance test.de. (238)
64. (glucose adj3 (test$ or measur$ or assess$ or evaluat$)).tw. (1073)
65. ((glucose adj2 tolerance) or gtt or ogtt).tw. (934)
66. ((glucose adj2 challeng$) or gct or ogct).tw. (226)
67. (fasting adj2 glucose).tw. (380)
68. ((pre-test or pretest) adj probabilit$).tw. (18)
69. ((post-test or posttest) adj probabilit$).tw. (24)
70. (predictive adj3 value$).tw. (4212)
71. (false positiv$ or false negativ$).tw. (1660)
72. observer variation$.tw. (143)
73. roc curve$.tw. (356)
74. (likelihood adj3 ratio$).tw. (492)
75. accurac$.tw. (2774)
76. detection.tw. (4826)
77. or/56-75 (40,118)
78. 55 and 76 (889)
79. (correspondance or editorial or case report or case study or news or news release or news item or
letter or commentary).pt. (30,045)
80. 77 not 78 (884)
Source: Cochrane Central Register of Controlled Trials, Issue 6 of 12, June 2014
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 6 June 2014.
Retrieved records: 265.
Search strategy
#1 MeSH descriptor: [Diabetes, Gestational] explode all trees
#2 (gestation* near/4 diabet*)
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#3 gdm
#4 (glucose near/4 (pregnan* or gestation* or prenatal* or antenatal* or pre-natal* or ante-natal*
or maternal*))
#5 MeSH descriptor: [Hyperglycemia] explode all trees
#6 MeSH descriptor: [Pregnancy] explode all trees
#7 #5 and #6
#8 ((hyperglycemi* or hyperglycaemi*) near/5 (pregnan* or gestation* or prenatal* or antenatal* or
pre-natal* or ante-natal* or maternal*))
#9 #1 or #2 or #3 or #4 or #7 or #8
#10 MeSH descriptor: [Risk] this term only
#11 MeSH descriptor: [Risk Factors] this term only
#12 (related or relationship or rates or difference* or prevalence or associated or predict*)
#13 #10 or #11 or #12
#14 #9 and #13
#15 MeSH descriptor: [Mass Screening] this term only
#16 MeSH descriptor: [Blood Glucose] this term only
#17 glucose or screen*
#18 MeSH descriptor: [Diagnosis] this term only
#19 MeSH descriptor: [Prenatal Diagnosis] this term only
#20 MeSH descriptor: [Diagnostic Errors] explode all trees
#21 MeSH descriptor: [Diagnosis, Differential] this term only
#22 diagnos* or sensitivity or specificity or pre-test or pretest or post-test or posttest or predictive near/4
value* or false positive* or false negative* or observer variation* or roc curve* or likelihood near/4 ratio or
accuracy* or detection
#23 MeSH descriptor: [Sensitivity and Specificity] explode all trees
#24 #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25 #14 and #24
#26 MeSH descriptor: [Overweight] explode all trees
#27 obesity or obese or over weight or overweight or BMI or body mass index
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#28 MeSH descriptor: [Body Mass Index] this term only
#29 MeSH descriptor: [Ethnic Groups] explode all trees
#30 ethnicity or ethnic or multi-ethnic* or race or Caucasian* or Asian* or Spanish or Mexican* or
Hispanic* or afrocaribbean or African or Caribbean or middle eastern or Bangladeshi* or Pakistani*
#31 MeSH descriptor: [Maternal Age] this term only
#32 age or late near/2 life or older or over or previous or prior or history or family or relative or parity
#33 MeSH descriptor: [Parity] this term only
#34 #26 or #27 or #18 or #29 or #30 or #31 or #32 or #33
#35 #25 and #34
The September 2013 search for Chapter 6 identified 2895
records: 2226 records remained after deduplication; the
October 2014 update search identified 3555 records
TABLE 87 Databases and information sources searched and numbers retrieved for Chapter 6: September 2013 and
October 2014 combined
Database/information source Interface/URL
MEDLINE and MEDLINE In-Process & Other
Non-Indexed Citations
OvidSP
EMBASE OvidSP
CENTRAL The Cochrane Library/Wiley Interscience
Records identified in the original
2013 searches
Records identified in the 2014
update searches
MEDLINE and MEDLINE In-Process & Other
Non-Indexed Citations
864 940
EMBASE 1420 1813
CENTRAL 611 802
TOTAL 2895 3555
TOTAL after deduplication 2226 1419
Search strategies (September 2013)
Source: Cochrane Central Register of Controlled Trials, Issue 8 of 12,
August 2013
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 11 September 2013.
Retrieved records: 611.
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Search strategy
#1 MeSH descriptor: [Diabetes, Gestational] explode all trees (293)
#2 (gestation* near/4 diabet*) (563)
#3 gdm (142)
#4 (glucose near/4 (pregnan* or gestation* or prenatal* or antenatal* or pre-natal* or ante-natal* or
maternal*)) (394)
#5 #1 or #2 or #3 or #4 (785)
#6 MeSH descriptor: [Glucose Intolerance] this term only (413)
#7 MeSH descriptor: [Glucose Tolerance Test] this term only (1483)
#8 IGT (355)
#9 ((impair* or reduced) near/2 glucose) (1506)
#10 (glucose next (tolerance* or intolerance*)) (3335)
#11 (gtt or ogtt) (657)
#12 MeSH descriptor: [Prediabetic State] this term only (118)
#13 (prediabet* or pre-diabet*) (234)
#14 MeSH descriptor: [Insulin Resistance] explode all trees (2574)
#15 (metabolic next syndrome* or syndrome* next x or borderline next diabet*) (1521)
#16 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 (6512)
#17 MeSH descriptor: [Pregnancy] explode all trees (5409)
#18 (pregnan* or gestation* or prenatal* or antenatal* or pre-natal* or ante-natal* or
maternal*) (31,548)
#19 #17 or #18 (31,663)
#20 #16 and #19 (514)
#21 #5 or #20 in Trials (611)
Source: MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations
1946 to present
Interface/URL: OvidSP.
Search date: 12 September 2013.
Retrieved records: 864.
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Search strategy
1. exp diabetes, gestational/ (6899)
2. (gestation$ adj4 diabet$).ti,ab. (7705)
3. gdm.ti,ab. (2826)
4. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).ti,ab. (3366)
5. or/1-4 (12,010)
6. Glucose Intolerance/ (6367)
7. Glucose Tolerance Test/ (29,619)
8. IGT.ti,ab. (3628)
9. ((impair$ or reduced) adj2 glucose).ti,ab. (17,221)
10. (glucose adj (tolerance$ or intolerance$)).ti,ab. (36,342)
11. (gtt or ogtt).ti,ab. (6783)
12. Prediabetic State/ (3657)
13. (prediabet$ or pre-diabet$).ti,ab. (4581)
14. exp Insulin Resistance/ (54,897)
15. (metabolic syndrome$ or syndrome$ x or borderline diabet$).ti,ab. (29,541)
16. or/6-15 (114,795)
17. exp Pregnancy/ (713,514)
18. (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or maternal$).ti,ab.
(572,627)
19. or/17-18 (903,336)
20. 16 and 19 (8640)
21. 5 or 20 (16,584)
22. randomized controlled trial.pt. (385,372)
23. controlled clinical trial.pt. (89,166)
24. random$.ti,ab. (725,429)
25. placebo.ti,ab. (166,003)
26. drug therapy.fs. (1,750,436)
27. trial.ti,ab. (374,230)
28. groups.ab. (1,352,980)
29. or/22-28 (3,543,468)
30. 21 and 29 (4978)
31. (2012$ or 2013$ or 2014$).ed,dc,dp,ep,vd,yr. (2,303,896)
32. 30 and 31 (956)
33. animals/ not humans/ (3,937,252)
34. 32 not 33 (864)
Source: EMBASE 1974 to 11 September 2013
Interface/URL: OvidSP.
Search date: 12 September 2013.
Retrieved records: 1420.
Search strategy
1. exp pregnancy diabetes mellitus/ (19,149)
2. (gestation$ adj4 diabet$).ti,ab. (10,764)
3. gdm.ti,ab. (4148)
4. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).ti,ab. (4143)
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5. or/1-4 (22,936)
6. impaired glucose tolerance/ (16,945)
7. glucose intolerance/ (10,830)
8. exp glucose tolerance test/ (41,669)
9. IGT.ti,ab. (5232)
10. ((impair$ or reduced) adj2 glucose).ti,ab. (21,989)
11. (glucose adj (tolerance$ or intolerance$)).ti,ab. (46,496)
12. (gtt or ogtt).ti,ab. (10,650)
13. (prediabet$ or pre-diabet$).ti,ab. (6237)
14. insulin resistance/ (73,020)
15. metabolic syndrome X/ (43,215)
16. (metabolic syndrome$ or syndrome$ x or borderline diabet$).ti,ab. (41,778)
17. or/6-16 (175,188)
18. exp pregnancy/ (618,511)
19. (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or maternal$).ti,ab.
(679,071)
20. or/18-19 (931,013)
21. 17 and 20 (12,193)
22. 5 or 21 (28,523)
23. randomized controlled trial/ (358,223)
24. “randomized controlled trial (topic)”/ (38,557)
25. crossover procedure/ (38,413)
26. double blind procedure/ (120,036)
27. single blind procedure/ (18,230)
28. random$.ti,ab. (856,059)
29. factorial$.ti,ab. (22,209)
30. (crossover$ or cross-over$).ti,ab. (70,187)
31. placebo$.ti,ab. (200,440)
32. doubl$ blind$.ti,ab. (146,751)
33. singl$ blind$.ti,ab. (14,162)
34. assign$.ti,ab. (235,266)
35. allocat$.ti,ab. (80,922)
36. volunteer$.ti,ab. (179,039)
37. trial.ti,ab. (455,704)
38. groups.ab. (1,662,182)
39. or/23-38 (2,878,357)
40. 22 and 39 (6177)
41. (2012$ or 2013$ or 2014$).em,dp,yr. (2,472,974)
42. 40 and 41 (1503)
43. (animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/ (3,657,804)
44. 42 not 43 (1420)
Update search strategies: October 2014
Source: Cochrane Central Register of Controlled Trials, Issue 9 of 12,
September 2014
Interface/URL: The Cochrane Library/Wiley Interscience.
Search date: 14 October 2014.
Retrieved records: 802.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
344
Search strategy
#1 [mh “Diabetes, Gestational”] (352)
#2 (gestation* near/4 diabet*) (726)
#3 gdm (230)
#4 (glucose near/4 (pregnan* or gestation* or prenatal* or antenatal* or pre-natal* or ante-natal* or
maternal*)) (484)
#5 #1 or #2 or #3 or #4 (979)
#6 [mh ^”Glucose Intolerance”] (472)
#7 [mh ^”Glucose Tolerance Test”] (1593)
#8 IGT (434)
#9 ((impair* or reduced) near/2 glucose) (1905)
#10 (glucose next (tolerance* or intolerance*)) (3987)
#11 (gtt or ogtt) (778)
#12 [mh ^”Prediabetic State”] (161)
#13 (prediabet* or pre-diabet*) (351)
#14 [mh “Insulin Resistance”] (3093)
#15 (metabolic next syndrome* or syndrome* next x or borderline next diabet*) (2249)
#16 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 (8217)
#17 [mh Pregnancy] (5804)
#18 (pregnan* or gestation* or prenatal* or antenatal* or pre-natal* or ante-natal* or
maternal*) (35,893)
#19 #17 or #18 (36,019)
#20 #16 and #19 (631)
#21 #5 or #20 in Trials (802)
Source: Ovid MEDLINE In-Process & Other Non-Indexed Citations and Ovid
MEDLINE 1946 to present
Interface/URL: OvidSP.
Search date: 14 October 2013.
Retrieved records: 940.
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Search strategy
1. exp diabetes, gestational/ (7433)
2. (gestation$ adj4 diabet$).ti,ab. (8559)
3. gdm.ti,ab. (3263)
4. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).ti,ab. (3520)
5. or/1-4 (13,077)
6. Glucose Intolerance/ (6655)
7. Glucose Tolerance Test/ (30,420)
8. IGT.ti,ab. (3868)
9. ((impair$ or reduced) adj2 glucose).ti,ab. (18,095)
10. (glucose adj (tolerance$ or intolerance$)).ti,ab. (38,304)
11. (gtt or ogtt).ti,ab. (7294)
12. Prediabetic State/ (3939)
13. (prediabet$ or pre-diabet$).ti,ab. (5048)
14. exp Insulin Resistance/ (58,654)
15. (metabolic syndrome$ or syndrome$ x or borderline diabet$).ti,ab. (32,817)
16. or/6-15 (122,777)
17. exp Pregnancy/ (733,700)
18. (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or maternal$).ti,ab.
(596,979)
19. or/17-18 (936,507)
20. 16 and 19 (9233)
21. 5 or 20 (17,945)
22. randomized controlled trial.pt. (396,977)
23. controlled clinical trial.pt. (90,468)
24. random$.ti,ab. (758,589)
25. placebo.ti,ab. (167,219)
26. drug therapy.fs. (1,773,912)
27. trial.ti,ab. (390,474)
28. groups.ab. (1,427,636)
29. or/22-28 (3,672,104)
30. 21 and 29 (5452)
31. (2013$ or 2014$ or 2015$).ed,dc,dp,ep,vd,yr. (2,338,649)
32. 30 and 31 (1033)
33. animals/ not humans/ (3,981,381)
34. 32 not 33 (940)
Source: EMBASE 1974 to 2014 October 13
Interface/URL: OvidSP.
Search date: 14 October 2014.
Retrieved records: 1813.
Search strategy
1. exp pregnancy diabetes mellitus/ (20,732)
2. (gestation$ adj4 diabet$).ti,ab. (12,311)
3. gdm.ti,ab. (5089)
4. (glucose adj4 (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or
maternal$)).ti,ab. (4425)
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5. or/1-4 (24,743)
6. impaired glucose tolerance/ (19,159)
7. glucose intolerance/ (11,688)
8. exp glucose tolerance test/ (43,801)
9. IGT.ti,ab. (5676)
10. ((impair$ or reduced) adj2 glucose).ti,ab. (23,596)
11. (glucose adj (tolerance$ or intolerance$)).ti,ab. (49,570)
12. (gtt or ogtt).ti,ab. (12,028)
13. (prediabet$ or pre-diabet$).ti,ab. (7337)
14. insulin resistance/ (81,011)
15. metabolic syndrome X/ (49,311)
16. (metabolic syndrome$ or syndrome$ x or borderline diabet$).ti,ab. (47,074)
17. or/6-16 (191,349)
18. exp pregnancy/ (595,884)
19. (pregnan$ or gestation$ or prenatal$ or antenatal$ or pre-natal$ or ante-natal$ or maternal$).ti,ab.
(700,285)
20. or/18-19 (935,882)
21. 17 and 20 (13,412)
22. 5 or 21 (30,882)
23. randomized controlled trial/ (353,710)
24. “randomized controlled trial (topic)”/ (59,334)
25. crossover procedure/ (40,369)
26. double blind procedure/ (118,207)
27. single blind procedure/ (18,906)
28. random$.ti,ab. (918,458)
29. factorial$.ti,ab. (24,012)
30. (crossover$ or cross-over$).ti,ab. (72,507)
31. placebo$.ti,ab. (208,414)
32. doubl$ blind$.ti,ab. (150,493)
33. singl$ blind$.ti,ab. (14,995)
34. assign$.ti,ab. (247,571)
35. allocat$.ti,ab. (87,329)
36. volunteer$.ti,ab. (184,812)
37. trial.ti,ab. (489,194)
38. groups.ab. (1,777,499)
39. or/23-38 (3,059,904)
40. 22 and 39 (7133)
41. (2013$ or 2014$ or 2015$).em,dp,yr. (2,778,898)
42. 40 and 41 (1913)
43. (animal experiment/ or animal model/ or animal tissue/ or nonhuman/) not exp human/ (3,834,022)
44. 42 not 43 (1813)
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